

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N	A2	(11) International Publication Number: WO 00/12678 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19726 (22) International Filing Date: 31 August 1999 (31.08.99) (30) Priority Data: 60/098,964 1 September 1998 (01.09.98) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BAILEY, Camella, C. [US/US]; 1753 Kilbourne Place NW, Washington, DC 20010 (US). CHOI, Gil, H. [CN/US]; 11429 Potomac Oaks Drive, Rockville, MD 20850 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: STAPHYLOCOCCUS AUREUS GENES AND POLYPEPTIDES		
(57) Abstract <p>The present invention relates to novel genes from <i>S. aureus</i> and the polypeptides they encode. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of <i>S. aureus</i> polypeptide activity. The invention additionally relates to diagnostic methods for detecting <i>Staphylococcus</i> nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by <i>Staphylococcus</i>.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GR	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Staphylococcus aureus genes and polypeptides.

Field of the Invention

5 The present invention relates to novel *Staphylococcus aureus* genes (*S. aureus*) nucleic acids and polypeptides. Also provided are vectors, host cells and recombinant methods for producing the same. Further provided are diagnostic methods for detecting *S. aureus* using probes, primers, and antibodies to the *S. aureus* nucleic acids and polypeptides of the present invention. The invention further relates to screening methods for identifying agonists and
10 antagonists of *S. aureus* polypeptide activity and to vaccines using *S. aureus* nucleic acids and polypeptides.

Background of the Invention

15 The genus *Staphylococcus* includes at least 20 distinct species. (For a review see Novick, R. P., *The Staphylococcus as a Molecular Genetic System in MOLECULAR BIOLOGY OF THE STAPHYLOCOCCI*, 1-37 (R. Novick, Ed., VCH Publishers, New York (1990)). Species differ from one another by 80% or more, by hybridization kinetics, whereas strains within a species are at least 90% identical by the same measure.

20 The species *S. aureus*, a gram-positive, facultatively aerobic, clump-forming cocci, is among the most important etiological agents of bacterial infection in humans, as discussed briefly below.

Human Health and S. aureus

25 *Staphylococcus aureus* is a ubiquitous pathogen. See, e.g., Mims et al., *MEDICAL MICROBIOLOGY* (Mosby-Year Book Europe Limited, London, UK 1993). It is an etiological agent of a variety of conditions, ranging in severity from mild to fatal. A few of the more common conditions caused by *S. aureus* infection are burns, cellulitis, eyelid infections, food poisoning, joint infections, neonatal conjunctivitis, osteomyelitis, skin infections, surgical
30 wound infection, scalded skin syndrome and toxic shock syndrome, some of which are described further below.

Burns: Burn wounds generally are sterile initially. However, they generally compromise physical and immune barriers to infection, cause loss of fluid and electrolytes and result in local or general physiological dysfunction. After cooling, contact with viable bacteria
35 results in mixed colonization at the injury site. Infection may be restricted to the non-viable debris on the burn surface ("eschar"), it may progress into full skin infection and invade viable tissue below the eschar and it may reach below the skin, enter the lymphatic and blood circulation and develop into septicemia. *S. aureus* is among the most important pathogens typically found in burn wound infections. It can destroy granulation tissue and produce severe

septicemia.

Cellulitis: Cellulitis, an acute infection of the skin that expands from a typically superficial origin to spread below the cutaneous layer, most commonly is caused by *S. aureus* in conjunction with *S. pyrogenes*. Cellulitis can lead to systemic infection. In fact, cellulitis can be one aspect of synergistic bacterial gangrene. This condition typically is caused by a mixture of *S. aureus* and microaerophilic *Streptococci*. It causes necrosis and treatment is limited to excision of the necrotic tissue. The condition often is fatal.

Eyelid infections: *S. aureus* is the cause of styes and of "sticky eye" in neonates, among other eye infections. Typically such infections are limited to the surface of the eye, and may occasionally penetrate the surface with more severe consequences.

Food poisoning: Some strains of *S. aureus* produce one or more of five serologically distinct, heat and acid stable enterotoxins that are not destroyed by digestive process of the stomach and small intestine (enterotoxins A-E). Ingestion of the toxin, in sufficient quantities, typically results in severe vomiting, but not diarrhea. The effect does not require viable bacteria. Although the toxins are known, their mechanism of action is not understood.

Joint infections: *S. aureus* infects bone joints causing diseases such as osteomyelitis. See, e.g., R. Cunningham et al., (1996) J. Med. Microbiol. 44:157-164.

Osteomyelitis: *S. aureus* is the most common causative agent of haematogenous osteomyelitis. The disease tends to occur in children and adolescents more than adults and it is associated with non-penetrating injuries to bones. Infection typically occurs in the long end of growing bone, hence its occurrence in physically immature populations. Most often, infection is localized in the vicinity of sprouting capillary loops adjacent to epiphysis growth plates in the end of long, growing bones.

Skin infections: *S. aureus* is the most common pathogen of such minor skin infections as abscesses and boils. Such infections often are resolved by normal host response mechanisms, but they also can develop into severe internal infections. Recurrent infections of the nasal passages plague nasal carriers of *S. aureus*.

Surgical Wound Infections: Surgical wounds often penetrate far into the body. Infection of such wound thus poses a grave risk to the patient. *S. aureus* is the most important causative agent of infections in surgical wounds. *S. aureus* is unusually adept at invading surgical wounds; sutured wounds can be infected by far fewer *S. aureus* cells than are necessary to cause infection in normal skin. Invasion of surgical wound can lead to severe *S. aureus* septicemia. Invasion of the blood stream by *S. aureus* can lead to seeding and infection of internal organs, particularly heart valves and bone, causing systemic diseases, such as endocarditis and osteomyelitis.

Scalded Skin Syndrome: *S. aureus* is responsible for "scalded skin syndrome" (also called toxic epidermal necrosis, Ritter's disease and Lyell's disease). This disease occurs in older children, typically in outbreaks caused by flowering of *S. aureus* strains produce exfoliation (also called scalded skin syndrome toxin). Although the bacteria initially may infect

only a minor lesion, the toxin destroys intercellular connections, spreads epidermal layers and allows the infection to penetrate the outer layer of the skin, producing the desquamation that typifies the diseases. Shedding of the outer layer of skin generally reveals normal skin below, but fluid lost in the process can produce severe injury in young children if it is not treated properly.

Toxic Shock Syndrome: Toxic shock syndrome is caused by strains of *S. aureus* that produce the so-called toxic shock syndrome toxin. The disease can be caused by *S. aureus* infection at any site, but it is too often erroneously viewed exclusively as a disease solely of women who use tampons. The disease involves toxemia and septicemia, and can be fatal.

Nocosomal Infections: In the 1984 National Nosocomial Infection Surveillance Study ("NNIS") *S. aureus* was the most prevalent agent of surgical wound infections in many hospital services, including medicine, surgery, obstetrics, pediatrics and newborns.

Other Infections: Other types of infections, risk factors, etc. involving *S. aureus* are discussed in: A. Trilla (1995) *J. Chemotherapy* 3:37-43; F. Espersen (1995) *J. Chemotherapy* 3:11-17; D.E. Craven (1995) *J. Chemotherapy* 3:19-28; J.D. Breen et al. (1995) *Infect. Dis. Clin. North Am.* 9(1):11-24 (each incorporated herein in their entireties).

Resistance to drugs of S. aureus strains

Prior to the introduction of penicillin the prognosis for patients seriously infected with *S. aureus* was unfavorable. Following the introduction of penicillin in the early 1940s even the worst *S. aureus* infections generally could be treated successfully. The emergence of penicillin-resistant strains of *S. aureus* did not take long, however. Most strains of *S. aureus* encountered in hospital infections today do not respond to penicillin; although, fortunately, this is not the case for *S. aureus* encountered in community infections.

It is well known now that penicillin-resistant strains of *S. aureus* produce a lactamase which converts penicillin to penicilloic acid, and thereby destroys antibiotic activity. Furthermore, the lactamase gene often is propagated episomally, typically on a plasmid, and often is only one of several genes on an episomal element that, together, confer multidrug resistance.

Methicillins, introduced in the 1960s, largely overcame the problem of penicillin resistance in *S. aureus*. These compounds conserve the portions of penicillin responsible for antibiotic activity and modify or alter other portions that make penicillin a good substrate for inactivating lactamases. However, methicillin resistance has emerged in *S. aureus*, along with resistance to many other antibiotics effective against this organism, including aminoglycosides, tetracycline, chloramphenicol, macrolides and lincosamides. In fact, methicillin-resistant strains of *S. aureus* generally are multiply drug resistant.

Methicillin-resistant *S. aureus* (MRSA) has become one of the most important nosocomial pathogens worldwide and poses serious infection control problems. Today, many strains are multiresistant against virtually all antibiotics with the exception of vancomycin-type

glycopeptide antibiotics.

Recent reports that transfer of vancomycin resistance genes from enterococci to *S. aureus* has been observed in the laboratory sustain the fear that MRSA might become resistant against vancomycin, too, a situation generally considered to result in a public health disaster.

5 MRSA owe their resistance against virtually all β -lactam antibiotics to the expression of an extra penicillin binding protein (PBP) 2a, encoded by the *mecA* gene. This additional very low affinity pbp, which is found exclusively in resistant strains, appears to be the only pbp still functioning in cell wall peptidoglycan synthesis at β -lactam concentrations high enough to saturate the normal set of *S. aureus* pbp 1-4. In 1983 it was shown by insertion mutagenesis using transposon Tn551 that several additional genes independent of *mecA* are needed to sustain the high level of methicillin resistance of MRSA. Interruption of these genes did not influence the resistance level by interfering with PBP2a expression, and were therefore called *fem* (factor essential for expression of methicillin resistance) or *aux* (auxiliary genes).

10 In the meantime six *fem* genes (*femA*- through *F*) have been described and the minimal number of additional *aux* genes has been estimated to be more than 10. Interference with *femA* and *femB* results in a strong reduction of methicillin resistance, back to sensitivity of strains without PBP2a. The *fem* genes are involved in specific steps of cell wall synthesis.

Consequently, inactivation of *fem* encoded factors induce β -lactam hypersensitivity in already sensitive strains. Both *femA* and *femB* have been shown to be involved in peptidoglycan pentaglycine interpeptide bridge formation. FemA is responsible for the formation of glycines 2 and 3, and FemB is responsible for formation of glycines 4 and 5. *S. aureus* may be involved in the formation of a monoglycine mucopeptide precursors. FemC-F influence amidation of the iso-D-glutamic acid residue of the peptidoglycan stem peptide, formation of a minor mucopeptide with L-alanine instead of glycine at position 1 of the interpeptide bridge, perform a yet unknown function, or are involved in an early step of peptidoglycan precursors biosynthesis (addition of L-lysine), respectively.

Summary of the Invention

30 The present invention provides isolated *S. aureus* polynucleotides and polypeptides shown in Table 1 and SEQ ID NO:1 through SEQ ID NO:61. One aspect of the invention provides isolated nucleic acid molecules comprising or alternatively consisting of polynucleotides having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence shown in Table 1; (b) a nucleotide sequence encoding any of the amino acid sequences of the polypeptides shown in Table 1; and (c) a nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b). The invention further provides for fragments of the nucleic acid molecules of (a), (b) & (c) above.

35 Further embodiments of the invention include isolated nucleic acid molecules that comprise, or alternatively consist of, a polynucleotide having a nucleotide sequence at least

90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical, to any of the nucleotide sequences in (a), (b) or (c) above, or a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide in (a), (b) or (c) above. Additional nucleic acid embodiments of the invention relate to isolated nucleic acid molecules comprising polynucleotides which encode the amino acid sequences of epitope-bearing portions of a *S. aureus* polypeptide having an amino acid sequence in (a) above.

The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells. The present invention further relates to the use of these vectors in the production of *S. aureus* polypeptides or peptides by recombinant techniques.

The invention further provides isolated *S. aureus* polypeptides having an amino acid sequence selected from the group consisting of an amino acid sequence of any of the polypeptides described in Table 1 or fragments thereof.

The polypeptides of the present invention also include polypeptides having an amino acid sequence with at least 70% similarity, and more preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% similarity to those described in Table 1, as well as polypeptides having an amino acid sequence at least 70% identical, more preferably at least 75% identical, and still more preferably 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to those above; as well as isolated nucleic acid molecules encoding such polypeptides.

The present invention further provides a vaccine, preferably a multi-component vaccine comprising one or more of the *S. aureus* polynucleotides or polypeptides described in Table 1, or fragments thereof, together with a pharmaceutically acceptable diluent, carrier, or excipient, wherein the *S. aureus* polypeptide(s) are present in an amount effective to elicit an immune response to members of the *Staphylococcus* genus, or at least *S. aureus*, in an animal. The *S. aureus* polypeptides of the present invention may further be combined with one or more immunogens of one or more other staphylococcal or non-staphylococcal organisms to produce a multi-component vaccine intended to elicit an immunological response against members of the *Staphylococcus* genus and, optionally, one or more non-staphylococcal organisms.

The vaccines of the present invention can be administered in a DNA form, e.g., "naked" DNA, wherein the DNA encodes one or more staphylococcal polypeptides and, optionally, one or more polypeptides of a non-staphylococcal organism. The DNA encoding one or more polypeptides may be constructed such that these polypeptides are expressed as fusion proteins.

The vaccines of the present invention may also be administered as a component of a genetically engineered organism or host cell. Thus, a genetically engineered organism or host cell which expresses one or more *S. aureus* polypeptides may be administered to an animal. For example, such a genetically engineered organism or host cell may contain one or more *S. aureus* polypeptides of the present invention intracellularly, on its cell surface, or in its

periplasmic space. Further, such a genetically engineered organism or host cell may secrete one or more *S. aureus* polypeptides. The vaccines of the present invention may also be co-administered to an animal with an immune system modulator (e.g., CD86 and GM-CSF).

The invention also provides a method of inducing an immunological response in an animal to one or more members of the *Staphylococcus* genus, preferably one or more isolates of the *S. aureus* species, comprising administering to the animal a vaccine as described above.

The invention further provides a method of inducing a protective immune response in an animal, sufficient to prevent, attenuate, or control an infection by members of the *Staphylococcus* genus, preferably at least *S. aureus* species, comprising administering to the animal a composition comprising one or more of the polynucleotides or polypeptides described in Table 1, or fragments thereof. Further, these polypeptides, or fragments thereof, may be conjugated to another immunogen and/or administered in admixture with an adjuvant.

The invention further relates to antibodies elicited in an animal by the administration of one or more *S. aureus* polypeptides of the present invention and to methods for producing such antibodies and fragments thereof. The invention further relates to recombinant antibodies and fragments thereof and to methods for producing such antibodies and fragments thereof.

The invention also provides diagnostic methods for detecting the expression of the polynucleotides and polypeptides of Table 1 by members of the *Staphylococcus* genus in a biological or environmental sample. One such method involves assaying for the expression of a polynucleotide encoding *S. aureus* polypeptides in a sample from an animal. This expression may be assayed either directly (e.g., by assaying polypeptide levels using antibodies elicited in response to amino acid sequences described in Table 1) or indirectly (e.g., by assaying for antibodies having specificity for amino acid sequences described in Table 1). The expression of polynucleotides can also be assayed by detecting the nucleic acids of Table 1. An example of such a method involves the use of the polymerase chain reaction (PCR) to amplify and detect *Staphylococcus* nucleic acid sequences.

The present invention also relates to nucleic acid probes having all or part of a nucleotide sequence described in Table 1 which are capable of hybridizing under stringent conditions to *Staphylococcus* nucleic acids. The invention further relates to a method of detecting one or more *Staphylococcus* nucleic acids in a biological sample obtained from an animal, said one or more nucleic acids encoding *Staphylococcus* polypeptides, comprising: (a) contacting the sample with one or more of the above-described nucleic acid probes, under conditions such that hybridization occurs, and (b) detecting hybridization of said one or more probes to the *Staphylococcus* nucleic acid present in the biological sample.

Detailed Description

The present invention relates to recombinant antigenic *S. aureus* polypeptides and fragments thereof. The invention also relates to methods for using these polypeptides to produce immunological responses and to confer immunological protection to disease caused by

members of the genus *Staphylococcus*. The invention further relates to nucleic acid sequences which encode antigenic *S. aureus* polypeptides and to methods for detecting *Staphylococcus* nucleic acids and polypeptides in biological samples. The invention also relates to *Staphylococcus* specific antibodies and methods for detecting such antibodies produced in a host animal.

Definitions

The following definitions are provided to clarify the subject matter which the inventors consider to be the present invention.

As used herein, the phrase "pathogenic agent" means an agent which causes a disease state or affliction in an animal. Included within this definition, for examples, are bacteria, protozoans, fungi, viruses and metazoan parasites which either produce a disease state or render an animal infected with such an organism susceptible to a disease state (*e.g.*, a secondary infection). Further included are species and strains of the genus *Staphylococcus* which produce disease states in animals.

As used herein, the term "organism" means any living biological system, including viruses, regardless of whether it is a pathogenic agent.

As used herein, the term "*Staphylococcus*" means any species or strain of bacteria which is members of the genus *Staphylococcus* regardless of whether they are known pathogenic agents.

As used herein, the phrase "one or more *S. aureus* polypeptides of the present invention" means the amino acid sequence of one or more of the *S. aureus* polypeptides disclosed in Table 1. These polypeptides may be expressed as fusion proteins wherein the *S. aureus* polypeptides of the present invention are linked to additional amino acid sequences which may be of Staphylococcal or non-Staphylococcal origin. This phrase further includes fragments of the *S. aureus* polypeptides of the present invention.

As used herein, the phrase "full-length amino acid sequence" and "full-length polypeptide" refer to an amino acid sequence or polypeptide encoded by a full-length open reading frame (ORF). For purposes of the present invention, polynucleotide ORFs in Table 1 are defined by the corresponding polypeptide sequences of Table 1 encoded by said polynucleotide. Therefore, a polynucleotide ORF is defined at the 5' end by the first base coding for the initiation codon of the corresponding polypeptide sequence of Table 1 and is defined at the 3' end by the last base of the last codon of said polypeptide sequence. As discussed below for polynucleotide fragments, the ORFs of the present invention may be claimed by a 5' and 3' position of a polynucleotide sequence of the present invention wherein the first base of said sequence is position 1.

As used herein, the phrase "truncated amino acid sequence" and "truncated polypeptide" refer to a sub-sequence of a full-length amino acid sequence or polypeptide. Several criteria may also be used to define the truncated amino acid sequence or polypeptide.

For example, a truncated polypeptide may be defined as a mature polypeptide (*e.g.*, a polypeptide which lacks a leader sequence). A truncated polypeptide may also be defined as an amino acid sequence which is a portion of a longer sequence that has been selected for ease of expression in a heterologous system but retains regions which render the polypeptide useful for use in vaccines (*e.g.*, antigenic regions which are expected to elicit a protective immune response).

Additional definitions are provided throughout the specification.

Explanation of Table 1

Table 1 lists the full length *S. aureus* polynucleotide and polypeptide sequences of the present invention. Each polynucleotide and polypeptide sequence is preceded by a gene identifier. Each polynucleotide sequence is followed by at least one polypeptide sequence encoded by said polynucleotide. For some of the sequences of Table 1, a known biological activity and the name of the homolog with similar activity is listed after the gene sequence identifier.

Explanation of Table 2

Table 2 lists accession numbers for the closest matching sequences between the polypeptides of the present invention and those available through GenBank and GeneSeq databases. These reference numbers are the database entry numbers commonly used by those of skill in the art, who will be familiar with their denominations. The descriptions of the nomenclature for GenBank are available from the National Center for Biotechnology Information. Column 1 lists the polynucleotide sequence of the present invention. Column 2 lists the accession number of a "match" gene sequence in GenBank or GeneSeq databases. Column 3 lists the description of the "match" gene sequence. Columns 4 and 5 are the high score and smallest sum probability, respectively, calculated by BLAST. Polypeptides of the present invention that do not share significant identity/similarity with any polypeptide sequences of GenBank and GeneSeq are not represented in Table 2. Polypeptides of the present invention that share significant identity/similarity with more than one of the polypeptides of GenBank and GeneSeq may be represented more than once.

Explanation of Table 3.

The *S. aureus* polypeptides of the present invention may include one or more conservative amino acid substitutions from natural mutations or human manipulation as indicated in Table 3. Changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein. Residues from the following groups, as indicated in Table 3, may be substituted for one another: Aromatic, Hydrophobic, Polar, Basic, Acidic, and Small,

Explanation of Table 4

Table 4 lists residues comprising antigenic epitopes of antigenic epitope-bearing fragments present in each of the full length *S. aureus* polypeptides described in Table 1 as predicted by the inventors using the algorithm of Jameson and Wolf, (1988) Comp. Appl. Biosci. 4:181-186. The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN (Version 3.11 for the Power MacIntosh, DNASTAR, Inc., 1228 South Park Street Madison, WI). *S. aureus* polypeptides shown in Table 1 may possess one or more antigenic epitopes comprising residues described in Table 4. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. The residues and locations shown described in Table 4 correspond to the amino acid sequences for each full length polypeptide sequence shown in Table 1 and in the Sequence Listing. Polypeptides of the present invention that do not have antigenic epitopes recognized by the Jameson-Wolf algorithm are not represented in Table 2.

Nucleic Acid Molecules

Sequenced *S. aureus* genomic DNA was obtained from the *S. aureus* strain ISP3. *S. aureus* strain ISP3, has been deposited at the American Type Culture Collection, as a convenience to those of skill in the art. The *S. aureus* strain ISP3 was deposited on 7 April 1998 at the ATCC, 10801 University Blvd. Manassas, VA 20110-2209, and given accession number 202108. As discussed elsewhere herein, polynucleotides of the present invention readily may be obtained by routine application of well known and standard procedures for cloning and sequencing DNA. A wide variety of *S. aureus* strains can be used to prepare *S. aureus* genomic DNA for cloning and for obtaining polynucleotides and polypeptides of the present invention. A wide variety of *S. aureus* strains are available to the public from recognized depository institutions, such as the American Type Culture Collection (ATCC). It is recognized that minor variations in the nucleic acid and amino acid sequence may be expected from *S. aureus* strain to strain. The present invention provides for genes, including both polynucleotides and polypeptides, of the present invention from all the *S. aureus* strains.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc., Foster City, CA), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. By "nucleotide sequence" of a nucleic acid molecule or polynucleotide is

intended to mean either a DNA or RNA sequence. Using the information provided herein, such as the nucleotide sequence in Table 1, a nucleic acid molecule of the present invention encoding a *S. aureus* polypeptide may be obtained using standard cloning and screening procedures, such as those for cloning DNAs using genomic DNA as starting material. See, e.g., Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor, N.Y. 2nd ed. 1989); Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (John Wiley and Sons, N.Y. 1989). Illustrative of the invention, the nucleic acid molecule described in Table 1 was discovered in a DNA library derived from a *S. aureus* ISP3 genomic DNA.

TABLE 1. Nucleotide and Amino Acid Sequences of *S. aureus* Genes.

<p>>HGS001, fabH, 3-oxoacyl-acyl-carrier protein synthase</p> <p>ATTAAGTAGCAATATTCCTACCTCTGACTTGAGTTTAAAGAGTAATCTATGTTAAATTAATACCTGGTATTAAAAATTT TATTAAGAAGGTGTTCAACTATGAACGTGGGTATTAAGGTTTGGTGCATATGCGCCAGAAAAGATTATTGACAATGCC TATTTTGAGCAATTTTAGATACATCTGATGAATGGATTCTAAGATGACTGGAATTAAAGAAAGACATTGGGCAGATGA TGATCAAGATACTTCAGATTTAGCATATGAAGCAAGTTTAAAGCAATCGCTGACCTGGTATTTCAGCCCGAAGATATAG ATATGATAAATGTTGCCACAGCAaCTGgaGATATGCCATTTCCACTGTCGCAAAATATGTTGCAAGAAGCTTTTAGGGACG GGCAAAGTTGCTCTATGGATCAACTTCAGCATGTTCTGGATTATGTATTCAATGATTACAGCTAAACAATATGTTCA ATCTGGAGATTATCATAACATTTTAGTTGTCTGGTGCAGATAAAATATCTAAAATAACAGATTAACTGACCCGTCTACTG CAGTCTATTTGGAGATGGTGCAGGTGCGGTTATCATCGGTGAAGTTTCAGATGGCAGAGGTATTATAAGTTATGAAATG GGTCTGATGCGCACAGGTGGTAAACAATTATATTAGATAAAGATACTGGTAAACTGAAATGAATGGTCGAGAAGTATT TAAATTTGCTGTTAGAATTATGGGTGATGCATCAACACGTGTAGTTGAAAAGCGAATTTAATCATCAGATGATATAGATT TATTTATCTCTCATCAAGCTAATATTAGAATTATGGAATCAGCTAGAGAAGCGCTTAGGTATTTCAAAAGACAAAATGAGT GTTTCGTGTAATAAATATGGAATACCTTCAGCTGCGTCAATACCTTTAAGTATCGATCAAGAATTAAAAAATGGTAAAT CAAAGATGATGATACAATTTGTTCTTGTCTGGATTGCGGTGGCGGCTAACTTGGGGCGCAATGACAATAAAATGGGGAAAT AGGAGGATAACGAATGAGTCAAAATAAAGAGTAGTTATTACAGGTATGGGA</p>	<p>>HGS001, FabH, 3-oxoacyl-acyl-carrier protein synthase</p> <p>MNVGKGFAYAPEKIIDNAYFEQFLDTSDEWISKMTGKERHWADDDQDTSDLAYEASLKAIDAGIQPEDIDMIIVAT ATGDMFPPTVANMLQERLGTGKVASMDQLAACSGFMYSMITAKQYVQSGDYHNILVVGADKLSKITDLTDRSTAVLFGDG AGAVIIGEVS DGRGIISYEMGSDGTGGKHL YLDKDTGKLMNGREVFKFAVRIMGDASTRVVEKANLTSDDIDLFI PHQA NIRIMESARERLGISKDKMSVSVNKYNTSAASIPLSIDQELKNGKIKDDDTIVLVGFGGLTWGAMTIKWK</p>
<p>>HGS002, murB, UDP-N-acetylenolpyruvoylglucosamine reductase</p> <p>ATACTAATTCTAATACCTTTCTCAATTTTCGCAAAATGAATTTTAAATTTGGTATAATACTATATGATATTAAAGACAT GAGAAAGGATGTACTGAGAAGTGATAATAAAGACATCTATCAAGCTTTACAACAACCTTATCCCAATGAAAAAATTA GTTGATGAACCTTTAAACGATACACTTATACTAAACAGGTGGTAAATGCCGACTTTTACATTACCCCTACTAAAAATGA AGAAGTACAAGCAGTTGTTAAATATGCTTATCAAAATGAGATTCCGTGTTACATAATTAGGAAATGGCTCAAATATTATTA TCCGTGAAGGTGGTATTTCGGGTATTGTAATTAGTTTATTTATCACTAGATCATATCGAAGTATCTGATGATGCGATAATA GCCGGTAGCGCGCTGCAATTATTGATGTCTCAGTGTGCTCGTGATTACGCACCTTACTGGCCTTGAATTTGCATGTGG TATTCCAGGTTCAATTGGTGGTGCAGTGTATATGAATGCTGGCGCTTATGTTGGCGAAGTTAAAGATTGTATAGACTATG CGCTTTGCGTAAACGAACAAGGCTCGTTAATTAACTTACAACAAAAGAATTAGAGTTAGATTATCGTAATAGCATTATT CAAAAAGAACACTTAGTTGTATTAGAAGCTGCATTTCATTAGCTCCTGGTAAATGACTGAAATACAAGCTAAAAATGGA TGATTTAACAGAACGTAGAGAATCTAAACAACCTTTAGAGTATCCCTCATGTGGTAGTGTATTCCAAAGACCGCTGGTC ATTTTGCAGGTAAATTGATACAAGATTCTAATTTGCAAGGTACCGTATTGGCGGCGTTGAAGTTTCAACCAAACACCGCT GGTTTATGGTAAATGTAGACAATGGAAGTCTACAGATTATGAAAACCTTATTCATTATGTACAAAAGACCGTCAAAGA AAAATTTGGCATTGAATTAAATCGTGAAGTTCCGATTATTTGGTGAACATCCAAAGGAATCGTAAGTTAAGGAGCTTTGTC TATGCCTAAAGTTTATGGTTCATTAATCGATACT</p>	<p>>HGS002, MurB, UDP-N-acetylenolpyruvoylglucosamine reductase</p> <p>VINKDIYQALQQLIPNEKIKVDEPLKRYTYTKTGGNADFYITPTKNEEVQAVVKYAYQNEIPVTYLNGNSNIIIREGGIR GIVISLLSLDHEVSDDAIIAGSGAAIIDVSRVARDYALTGLEFACGIPGSI GAVVMNAGAYGGEVKDCIDYALCVNEQ GSLIKLTTKELELDYRNSIIQKEHLVLEAAFTLAPGKMTETQAKMDDLTERRESKQPLEYPCSGSVFRPPGHFAGKLI QDSNLQGHRIIGVEVSTKHAGFMVNDNGTATDYENLIHYVQKTVEKFGIELNREVRIIGHEPKES</p>

>HGS003, *fabI*, *enoyl-acyl-carrier protein reductase*

AATAGTGTATAAATGTATTGACGAATAAAAGTTAGTTAAAACIGGGATTAGATATTCTATCCGTTAAATTAATTATTAT
AAGGAGTTATCTTACATGTTAAATCTTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTT
TGGTGTGCTAAAGTTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTG
AAAAATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAATTGATGTTCAAAGCGATGAAGAGGTTATTAAT
GGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGATATCATTCAATCGCATTGCTAATATGGAAGACTT
ACCGGAGCGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTAGCTCAAGACATTAGTTCTTACTCATTAAACAATTGTGG
CTCATGAAGCTAAAAAATTAAATGCCAGAAGGTGGTAGCATTGTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAA
AACTATAATGTGATGGGTGTGCTAAAGCGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCAGATAA
TATTGCGGTTAATGCAATTTAGCTAGTCCAATCCGTACATTAAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTA
AAGAAATCGAAGAGCGTGACCTTTAAAACGTAATGTTGATCAAGTAGAAGTAGGTAAACTGCGGCTTACTTATTAAGT
GATTTCATCAAGTGGCGTTACAGGTGAAAATATTTCATGTAGATAGCGGATTCCACGCAATTAAATAATATCATTTCAACAGC
TTTGTTCACGTTATTATATATGTGAGCAAAGCTTTT

>HGS003, *FabI*, *enoyl-acyl-carrier protein reductase*

MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLBQLNQPEAHLYQIDVQSDEEVINGFEQI
GKDVGNIDGVYHSIAFANMEDLRGRFSETSRGFLAODISSYSLTIVAHEAKLMPEGGSIVATTYLGGEFVQNYNVM
GVAKASLEANVKYLLALDLGPDNIRVNAISASPIRTLSAKVGVGFTILKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSG
VTGENIHVDSGFHAIK

>HGS004, *murA*, *UDP-N-acetylglucosamine 1-carboxyvinyltransferase*

TAAAATAATTTTAAATAGGGAAATGTAAAGTAATAGGAGTTCTAAGTGGAGGATTTACGATGGATAAAATAGTAATCAA
AGGTGGAATAAATTAACGGGTGAAGTTAAAGTAGAAGGTGCTAAAATGCAGTATTACCAATATTGACAGCATCTTTAT
TAGCTTCTGATAAACCGAGCAAATTAGTTAATGTTCCAGCTTTAAGTGATGTAGAAACAATAAATAATGTATTAACTAACT
TTAAATGCTGACGTTACATACAAAAGGACGAAAATGCTGTTGTGCTGTTGATGCAACAAGAGCTCTAAATGAAGAGGCACC
ATATGAATATGTTAGTAAATGCGTGCAAGTATTTAGTTATGGGACCTCTTTAGCAAGACTAGGACATGCTATTGTTG
CATTGCTGTTGGTTGTGCAATTGGAAGTAGACCGATTGAGCAACACATTAAAGGTTTGAAGCTTTAGGCGCAGAAATT
CATCTTGAAAATGGTAATATTATGCTAATGCTAAAGATGGATTAAAAGGTACATCAATTCATTTAGATTTCCTCAAGTGT
AGGAGCAACACAAAATATTATTATGGCAGCATCATTAGCTAAGGGTAAGACTTTAATTGAAAATGCAGCTAAAGAACCCTG
AAATTTGTCGATTTAGCAAACTACATTAAATGAAATGGGTGGTGAATTAAGTGGTGTGCTGCTGACAGACACAATTACAATCAAT
GGTGTAGAATCATTACATGGTGTAGAACATGCTATCATTTCCAGATAGAATTGAAGCAGGCACATTACTAATCGCTGGTGC
TATAACGCGTGGTGATATTTTGTACGTGGTGCAATCAAAGAACATATGGCGAGTTTAGTCTATAAACTAGAAGAATGG
GCGTTGAATTGGACTATCAAGAAGATGGTATTGCTGTACGTGCTGAAGGGGAATTACAACCTGTAGACATCAAACTCTA
CCACATCCTGGATTCCCGACTGATATGCAATCACAATGATGGCATTGTTATTAACGGCAAATGGTCATAAAGTCGTAAC
CGAACTGTTTGTGAAAACCGTTTATGTCATGTTGCAGAGTTCAAACGTATGAATGCTAATATCAATGTAGAAGGTGCTA
GTGCTAAACTTGAAGGTAAAAGTCAATTGCAAGGTGCACAAGTTAAAGCGACTGATTAAAGAGCAGCAGCCGCTTAATT
TTAGCTGGATTAGTTGCTGTGTTGTAATAACAGCGTTACTGAATTAACGCACCTAGATAGAGGCTATGTTGACTTACACGG
TAAATTGAAGCAATTAGGTGCAGACATTGAACGTATTAAACGATTAAATTCAGTAAATTAATATAATGGAGGATTTCACCA
TGGAACAATTTTGA

>HGS004, *MurA*, *UDP-N-acetylglucosamine 1-carboxyvinyltransferase*

MDKIVIKGNKLTGEVKVEGAKNAVLPILTASLLASDKPSKLVNVPALSDVETINNVLTTLNADVITYKKNENAVVVDATK
TLNEAPYEVVSKMRASILVMGPLLARLGHAIIVLPGGCAIGSRPIEQHIKGFALGAIEHLENGNIYANAKDGLKGTISI
HLDFPSVGATQNIIMAAASLAKCKTLIENAAKEPEIVDLANYINEMGRITGAGTDTITINGVESLHGVEHAIIPDRIEAG
TLIIAGAITRGDIIVRGAIKEHMASLVYKLEEMGVELDYQEDGIRVRAEGELQPVDIKTLPHPGFPPTDMQSQMMALLLTA
NGHKVVVTEVFENRFMHVAEFKRMNANINVEGRSAKLEKSQLQGAQVKATDLRAAALILAGLVADGKTSVTELTDLDR
GYVDLHGKLGADIERIND

>HGS005, *rho*, *transcriptional terminator Rho*

TTTCATGTAATTAAGGTTGGGATTAGCATAATGGGATTGTGCTAGCACAGTTATTTATGCATTGTCATGCCCTATCTAT
TACTTACTAACTAAAAATAATGAAATGGGTGTAACTATATGCCTGAAAGAGAAGCTACATCTCCTCAGTATGAATCAT
TCCACGAATTGTACAAGAATCTATCTACCAAGGAAGTCACTCAAAAAGCTAAAACCTTAAGTTGACGAACCATAGTAAA
TTAAATAAAAAAGAACTTGTCTAGCTATTATGGAAGCACAATGGAAGGATGGTAACTATTATATGGAAGGTATCTT
AGATGATATACAACAGGTGGTTATGGTTTTTAAAGAACAGTGAAGTATTTCTAAAGGGGAAAAAGATATTTATATATCTG
CTAGCCAAATTCGTCGTTTTGAAATTAACAGTGGGGATAAGTAACTGGGAAAGTTAGAAAACTAAAGATAACGAAAA
TATTATGGCTTATTACAAGTTGACTTTGTCAATGACCATAACGCAGAAGAAGTGAAGAAACGTCGGCATTTCCTAAGCTTT
GACACCACTTTATCCAGATGAGCGTATTAAATTAGAGACAGAAATACAAAATTATTCAACGCGCATCATGGATTAGTAA
CACCAGATTGGTTTAGGTCAACGTGGTTAATAGTGGCGCCACCTAAAGCAGGTAAACATCGTTATTAAAGAAATAGCG
AATGCAATCAGTACGAACAAACAGATGCAAAGCTATTTATTTTGTAGTTGGCGAGCGTCTGAAGAGGTAAACAGATTT
AGAAAGCTCAGTAGAAGCTGCTGAAGTCGTTTCACTCAACGTTTGACGAACCAACAGAACCATGTTAAAGTAGCTGAAT
TATTACTTGAACGTGCAAGCGTTTAGTAGAAATGGGGAAGATGTCATTATTTTAAATGGATTCTATAACAGAGATTAGCA
CGCGCTTATAACTTAGTTATTCCACCAAGTGGTGTGATATATCAGGTGGTTTAGATCTGCATCTTTACACAAACCAA

AGCATTCTTCGGTGCAGCGAGAAATATTGAAGCGGGTGAAGTTTAACAATACCTTGCAACTGCATTAGTTGATACGGGTT
CACGTATGGACGATATGATTTACGAAGAAATTTAAAGGAACAGGTAACATGGAGTTACATTTAGATCGTAAATTTGTCTGAA
CGTCGTATCTTCCCTGCAATTGATATTGGCAGAAGTTCAACGCGTAAAGAAGAATTGTTGATAAGTAAATCTGAATTAGA
CACATTATGGCAATTAAGAAATCTATTCAGTCACTCACTGACTTTACTGAAAGATTTATTCGCAAACTTAAAGGCTTA
5 AGAATAATGAAGATTTCTTCAAGCAGCTACAAAAGTCTGCAGAAGAAAGTACTAAAACGGGTCGACCTATAATTTAATAA
ACATTATATAGGGGCTTCGGTTTTGAATTAATTTACCTTTATAATTACACAGTATTGGGTAAAAAECTCACAAATAACTCTG
TTCCAGATGGTTCAGGG

>HGS005, Rho, transcriptional terminator Rho

10 MPERERTSPQYESFHELYKNTTRELTKAKTLKL/INHSKLNKELVLAIMEAQMEKDGNYMEGILDDIQQPGYGFLRT
VNYSGEKEDIYISASQIRRFEEKRGDKVTGKVRKPKDNEKYGLLQVDFVNDHNAEEVKRPHFQALTPLYPDERIKLET
EIQNYSTRIMDLVTPIGLQGRGLIVAPPKAGKTSLLKEIANAISTNKPDAKLFILLVGERPEEVDLERSVEAAEVHST
FDEPPEHHVKVAELLERAKRLVEIGEDVIILMDSITRLARAYNLVIPPGRSLSGGLDPASLHKPKAFFGAARNIEAGG
15 SLTILATALVDGSRMDDMIYEEFKGTGNMELHLDRKLSERRIFPAIDIGRSSRKEELLISKSELDLWQLRNLFTDST
DFTERFIRKLKRSKNNEDFFKQLQKSAEESTKTGRPII

>HGS006, rnpA, ribonuclease P protein component

20 GATCTTTTTTTTCGTTTAAATTAAGAATAAATAGAAAATTTATGTTATAAGCTCAATAGAAGTTTAAATATAGCTTCAATA
AAAACGATAATAAGCGAGTGATGTTATTGGAAAAAGCTTACCGAATTTAAAAAGAATGCAGATTTTCAGAGAAATATATAAA
AAAGGTCATTCTGTAGCCAACAGACAATTTGTGTATACACTTGTAAATAATAAGAAATAGACCATTTTCGCTTAGGTAT
TAGTGTCTTCAAAAACTAGGTAATGCAGTGTAAAGAAACAAGATTAAAGAGCAATACGTGAAAAATTTCAAAGTACATA
AGTCGCATATATTGCCCAAAGATATTATTGTAATAGCAAGACAGCCAGCTAAAGATATGACGACTTTACAAATACAGAAT
AGTCTTGAGCAGCTACTTAAATTTGCCAAAGTTTAAATAAAAAGATTAAAGTAAGGATAGGGTAGGGGAAGGAAAACATT
25 AACCCTCAACACATCCCGAAGTCTTACCTCAGACAAACGTAAGACTGACCTTAGGGTTATAATAACTTACTTT

>HGS006, RnpA, ribonuclease P protein component

MLLEKAYRIKKNADFQRIYKKGHSVANRQFVVYTCNNKEIDHFRLGISVSKKLGNVLRNLIKRAIRENFKVHKSHILAK
DIIVIRAPKADMTTLQIQNSLEHVLKIAKVFNKKIK

30 >HGS007M, dnaB, replicative DNA helicase

CAGCAAAACTGGTGAAGGTGGTAAATTTGTTTGGGTCAGTAAGTACAAAACAAATTGCCGAAGCACTAAAAGCACAACAT
GATATTAAAATTGATAAACGTAAAATGGATTTACCAAATGGAATTCATTCCCTAGGATATACGAATGTACCTGTTAAAT
AGATAAAGAGTTGAAGGTACAATTCGCGTACACACAGTTGAACAATAAAGTTGGATTGAAATAAGAGGTGTAACCATTC
ATGGATAGAATGTATGAGCAAAATCAAATGCCGCATAACAATGAAGCTGAACAGTCTGTCTTAGGTTCAATTATTATAGA
35 TCCAGAATTGATTAACTACTCAGGAAGTTTTCGCTTCTTGAGTCGTTTATAGGGGTGCCCATCAACATATTTTCGGTG
CAATGATGCATTAAATGAAGATAATAAAGAAATTTGATTTGTAAACATGATGGATCAATATATCAGCGGAAGGTAGCTTG
AATGAAGCGGGTGGCCCGCAATATCTTCAGAGTTTATCTACAAATGTACCAACGACGCGAAATGTTTCAAGTATTACTGA
TATCGTTTCTAAGCATGCATTAAAACGTAGATTGATTCAAACCTGCAGATAGTATTGCCAATGATGGATATAATGATGAAC
TTGAACTAGATGCGATTTTAAGTGATGCAGAACGTGCAATTTTAGAGCTATCATCTCTCGTGAAAGCGATGGCTTTAAA
40 GACATTCGAGACGCTCTTAGGACAAGTGTATGAACAGCTGAAGAGCTTGATCAAATAGTGGTCAAACACCAGGTATACC
TACAGGATATCGAGATTTAGACCAAATGACAGCAGGGTTCAACCGAAATGATTTAATTATCCTTGCAGCGCGTCCATCTG
TAGGTAAGACTGCGTTCGCACCTTAATATTGCACAAAAGTTGCAACGCAATGAAGATATGTATACAGTTGGTATTTTCTCG
CTAGAGATGGGTGCTGATCAGTTAGCCACACGTATGATTGTAGTTCTGGAATGTTGACTCAAACCGCTTAAGAACGGG
TACTATGACTGAGGAAGATTGGAGTCGTTTACTATAGCGGTAGGTAAATTTATCAGTACGAAGATTTTATTGATGATA
45 CACCGGGTATTCGAATTAATGATTTACGTTCTAAATGTCGTCGATTAAAGCAAGACATGGCTTAGACATGATTGTGATT
GACTACTTACAGTTGATTCAAGGTAGTGGTTACGTCGCTCCGATAACAGACAACAGGAAGTTTCTGAAATCTCTCGTAC
ATTAAGACATTAGCCGTGAATTAAGTGTCCAGTTATCGCAITTAAGTCAGTTATCTCGTGGTGTGGAACAACGACAAG
ATAAAGCTCCAATGATGAGTGATATTCTGTAATCTGGTTCGATTGAGCAAGATGCCGATATCGTTGCATTCTTATACCGT
GATGATTACTATAACCGTGGCGCGATGAAGATGATGACGATGATGGTGGTTTCGAGCCACAAACGAATGATGAAAACGG
50 TGAAATTGAAATTATCATTGCTAAGCAACGTAAACGGTCCACAGGCACAGTTAAGTTACATTTTATGAAACAATATAATA
AATTTACCGATATCGATTATGCACATGCAGATATGATGTAAAAAGTTTTCGCTACAATAATCATTAGATGATAAAAT
TGTACGGTTTTTATTTTGTCTGAACGGGTTG

>HGS007M, DnaB, replicative DNA helicase

55 MDRMYEQNMPHNNEABQSVLGSIIIDPELINTTQEVLLPESFYRGHQAHIIFRAMHNLNEDNKEIDVVTLMQDQSTEGTL
NEAGGPQYLAEELSTNVPTTRNVQYTTDIVSKHALKRRIQTADSIANDGYNDELELDAILSDAERRILELSSSRESDFGFK
DIRDVLGQVYETAELDQNSGQTPGIPGTGYRDLDMTAGFNRNDLIILARPVSVGKTAFALNIAQKVATHEDMYTVGIFS
LEMGADQLATRMICSSGNVDSNRLRTGTMTEEDWSRFTIAGVGLSRTKIFIDTTPGIRINDLSKCRRLKQEHGLDMIVI
DYLQLIQSGSRASDNRRQEVSEISRTLKALARELKCPVIALSQLSRGVEQRQDKRPMMSDIRESGSIEQDADIVAFLYR
60 DDYNNRGDEDDDDGGFEPQNDENGEIEIILAKQRNGPTGTVKLHFMKQYNKFTDIDYAHADM

>HGS008, fabD, malonyl CoA-acyl carrier protein transacylase

GTGGTTCCGTATTATTAGGATTGGAAGGTACTGTAGTTAAAGCACACGGTAGTTCAAATGCTAAAGCTTTTTATTCTGCA

ATTAGACAAGCGAAAAATCGCAGGAGAACAAAATATGTACAAACAATGAAAGAGACTGTAGGTGAATCAAATGAGTAAAA
CAGCAATTATTTTCGGGACAAGGTGCCCAAAAAGTTGGTATGGCGCAAGATTTGTTTAAACAACAATGATCAAGCAACT
GAAATTTTAACTTCAGCAGCGAACACATTAGACTTTGATATTTTAGAGACAATGTTTACTGATGAAGAAGGTAATTTGGG
TGAAACTGAAACACACAACCAGCTTTATTGACGCATAGTTCGGCATTATTAGCAGCGCTAAAAAATTTGAATCCTGATT
5 TTACTATGGGCGCATAGTTTAGGTGAATATTCAAGTTTAGTTGCAGCTGACGTATTATCATTGGAAGATGCAGTTAAAATT
GTTAGAAAACGTGGTCAATTAATGGCGCAAGCATTTCTACTGGTGTAGGAAGCATGGCTGCAGTATTGGGATTAGATTT
TGATAAAGTCGATGAAATTTGTAAGTCATTATCATCTGATGACAAAATAATTGAACCAGCAAAACATTAATTGCCAGGTC
AAATTTGTTGTTTCAGGTACAAAAGCTTTAATTGATGAGCTAGTAGAAAAAGGTAATCATTAGGTGCAAAACGTGTCATG
10 CCTTTAGCAGTATCTGGACCATTCATTTCATCCCTAATGAAAGTGATTGAAGAAGATTTTCAAGTTACATTAAATCAATT
TGAATGGCGTGATGCTAAGTTTCTGTAGTTCAAAATGTAAATGCCCAAGGTGAAACTGACAAAGAAGTAATTTAAATCTA
ATATGGTCAAGCAATTAATTACCCAGTACAATTCATTAACTCAACAGAATGGCTAATAGACCAAGGTGTTGATCATTTT
ATTGAAAATTGGTCCCTGGAAAAGTTTATCTGGCTTAATTAATAAATAAATAGAGATGTTAAGTTAACATCAATTCAAAC
TTTAGAAGATGTGAAAGGATGGAATGAAAATGACTAAGAGTGCTTTAGTAACAGGTGCATCAAGAGGAATTGGACGTAGT
15 ATTGCGTTACAATTAGCAGAAGAAGGATATAATGTAGCAGTAACTATGC

>HGS008, FabD, malonyl CoA-acyl carrier protein transacylase

MSKTAIIFPGQGAQKVGMAQDLFNNDQATEILTSANLDFDILETMTDEEGLGETENTQALLTHSSALLAALKNL
NPDMFMHSLGEYSLSVAADVLSFEDAVKIVRKRQQLMAQAFPTGVGSMAAVLGLDFDKVDEICKSLSSDDKIIEPANIN
CPGQIVVSGHKALIDELVEKGKSLGAKRVMLAVSGPFHSSLMKVIIEEDFSSYINQFEWRDAKFPVVQNVNAQGETDKEV
20 IKSNMVKQLYSPVQFINSTEWLIDQVDHFIEIGPGKVLSSGLIKKINRDVKLTSIQTLEDVKGNEND

>HGS009, alf1, fructose-bisphosphate aldolase

AAATACACATTTAATCTGCAGTATTTCATGCATTGACGCTATTTTGTATATAATTACTTTGAAAAATACGTGCGTAA
GCCTCAAGGAGGAACCTTCATGCCCTTAGTTTCAATGAAAGAAATGTTAATTGATGCAAAAGAAAATGGTTATGCGGTA
25 GGTCATACAAATTAATAACCTAGAATTCATCAAGCAATTTTGAAGCGTCACAAGAAGAAAATGCACCTGTAATTTT
AGGTGTTTCTGAAGGTGCTGCTCGTTACATGAGCGGTTTCTACACAATTGTTAAAAATGGTTGAAGGTTAATGCATGACT
TAAACATCACTATTCTGTAGCAATCCATTTAGACCATGGTTCAAGCTTTGAAAAATGTAAAGAAGCTATCGATGCTGCT
TTACATCAGTAAATGATCGATGCTTCACACAGCCCATTCGAAGAAAACGTAGCAACAATAAAAAAGTTGTTGAATACGC
30 TCATGAAAAAGGTGTTTCTGTAGAAGCTGAATTTAGGTACTGTTGGTGGACAAGAAGATGATGTTGTAGCAGACGGCATCA
TTTATGCTGATCCTAAGAATGTCAAGAACTAGTTGAAAAAACTGGTATGATGCATTAGCGCCAGCATTAGGTTTCAGTT
CATGGTCCATACAAAGGTGAACCAAAATTAGGATTAAAGAAATGGAAGAAATCGGTTTATCTACAGGTTTACCATTAGT
ATTACACCGTGGTACTGGTATCCCGACTAAAGATATCCAAAAGCAATTCATTGGTACAGCTAAAAATTAACGTAACA
CTGAAAACCAATCGCTTCAGCAAAAGCAGTTCTGTACGCTTTTAAATAACGACAAGAAGTTTACGATCCTCGTAAATAC
35 TTAGGACCTGCACGTGAAGCCATCAAAGAAACAGTTAAAGGTAAATTAAGAGTTGCGTACTTCTAACCGCGCTAAATA
ATTAATATTTAGTCTTTAAGTTATTAATAACGTAGGGATATTAAATTTTAAAGAAGCAGACAAAATGGTGTGCTTCTT
TTTTATGTCGTATAAGTAATAAATAAACAGTTTGATTTT

>HGS009, Alf1, fructose-bisphosphate aldolase

MPLVSMKEMILDAKENGAVGQYNNINLEFQAILEASQEENAPVILGVSEGAARYMSGFYITVKMVEGLMHDNLNITIPV
40 AIHLHDHGSSEFEKCKEADAGFTSVMIDASHSPFEENVATTKKVVEYAHEKGVSVAEELGTGQEDDVVADGIYADPKE
CQELVEKTGIDALAPALGSVHPYKGEPLKGFKEEMEEIGLSTGLPLVLHGGTGIPKDIQKAIIPGTAKINVTENQIAS
AKAVRDVLNNDKEVYDPRKYLGPAREAIKETVKGKIKEFGTSNRK

>HGS014

GCTATAATAGGCATGGTTACAATGAGCTTGCTCATACATATTAAATATAATTACAAAAACAGTCGGAGGTACGACATGAT
TAAAAATACAATTAATAAATTTGATAGAACATAGTATATATACGACTTTTAAATTACTATCAAAATTGCCAAACAAGATC
TAATTTATTTTGAAGCTTTTCATGGTAAACAATACAGCGACAACCCCAAGCATATATGAATACTTAACTGAACATAGC
GATGCCAAATTAATATGGGGTGTGAAAAAAGGATATGAACACATATTCCAACAGCACAAATGTACCATATGTTACAAAGTT
50 TTCAATGAAATGGTTTTCAGCATGCCAAGAGCGAAAGCGTGGATGATTAAACACAGTACACCAGATTGGTTATATAAAT
CACC CGCAACGACGTACTTACAAACATGGCATGGCAGCCCAITAAAAAAGATTGGTTTGGATATTAGTAACGTTAAAAATG
CTAGGAACAAATACTCAAAATTACCAAGATGGCTTTAAAAAAGAAAGCCAACGGTGGGATTATCTAGTGTACCTAATCC
ATATTGACATCGATATTTCAAAATGCATTTTCATGTTAGTTCGAGATAAGATTTTGAACAGGTTATCCAAGAAATGATA
AATTATCACATAAAGCCATGATCTGAATATATTAAATGGTATTAAAGACAAGATTAAATATTCATTAGATAAAAAAGTG
55 ATTATGTACGCGCAACTTGGCGTGACGATGAAGCGATTTCGAGAAGGTTTCATATCAATTTAATGTTAATCTTTGATATAGA
AGCTTTGCGTCAAGCGCTGGATGATGATTATGTTATTTATTACGCATGCATTAATTTAGTTGTGACACGTTATGATGAAC
ATGATGATTTTGTGAAAGACGTTTCAGATTATGAAGACATTTTCGGATTATATCTTAATCAGCGATGCGGTTAGTTACCGCA
TACTCATCTGTCTGTTTCGACTTCGGTGTATTAAAGCGTCCGCAAAATTTCTATGCATATGACTTAGATAAATATGGCGA
TGAGCTTAGAGGTTTTCATAGGATTATAAAAAAGAGTTGCCAGGTCCAATTTGTTGAAAATCAAACAGCACTCATTTGATG
CATTAATAACAAATCGATGAGACTGCAAAATGAGTATATTGAAGCACGAACGGTATTTTATCAAAAATTTCTGTTTCATTAGAA
60 GATGGACAAGCGTCACAACGAATTTGCCAAACGATTTTAAAGTGATAACTTAAAAACAATAAAAAATTATAAATTAATTA
GTTAAGTGATATAAATAAATAACGAATGTTGCTTGTATGTTATTATTGTTGATGAAA

>HGS014

MIKNTIKKLLIEHSIYITFKLLSKLPKNLIYFESFHGQYSDNPKALYEYLTEHSDAQLIWGVKKGYEHIFQQHNPVYVT
KFSMKWFLAMPRAKAWMINTRTPDWLYKSPRTYLTQWHGTPLKKIGLDISNVKMLGTNTQNYQDGFKESSQRWDYLVSP
NPYSTSIFQNAFHVSRDKILETGYPRNDKLSHKRNDTEYINGIKTRLNIPLDKKVIMYAPTWRDDEAIREGSSYQFNVNFD
IEALRQALDDDYVILLRMHYLVVTRI DEHDDFKVDVSDYEDISDLYLISDALVTDYSSVMFDFGLVKRPQIFYAYDLDKY
5 GDELRGFYMDYKKEPPIVENQTALIDALKQIDETANEYIEARTVFYQKFCSELDGQASQRICQTFK

>HGS016, -murA, -UDP-N-acetylglucosamine-1-carboxyvinyltransferase

10 TGATTTGTAATCAAACTAGATATAATTAATAATGACTTAAATAATTTTAAATAGGGAAATGTAAAGTAATAGGAGT
TCTAAGTGGAGGATTTACGATGGATAAAATAGTAATCAAAGGTGGAATAAATTAACGGGTGAAGTTAAAGTAGAAGGTG
CTAAAAATGCAGTATTACCAATATTGACAGCATCTTTATTAGCTTCTGATAAACCGAGCAAATTAGTTAATGTTCCAGCT
TTAAGTGATGTAGAAACAATAAATAATGTATTAAACAACTTTAAATGCTGACGTTACATACAAAAAGGACGAAATGCTGT
TGTCGTTGATGCAACAAGACTCTAAATGAAGAGGCACCATATGAATATGTTAGTAAATGCGTGCAAGTATTTTAGTTA
TGGGACCTCTTTTAGCAAGACTAGGACATGCTATTGTTGCATTGCGCTGGTGGTTGTGCAATTGGAAGTAGACCGATTGAG
15 CAACACATTAAAGGTTTGAAGCTTTAGGCGCAGAAATTCATCTTGAAATGGTAATATTTATGCTAATGCTAAAGATGG
ATTAAGAGGTACATCAATTCAITTAGATTTCCTAAGTGTAGGAGCAACACAAATATTATTATGGCAGCATCATTAGCTA
AGGGTAAGACTTTAATTGAAAAATGCAGCTAAAGAACCTGAAATTTGTCGATTTAGCAAACCTACATTAAATGAAATGGGTGGT
AGAATTACTGGTGCTGGTACAGACACAATTACAATCAATGGTGTAGAATCATTACATGGTGTAGAACATGCTATCATTC
AGATAGAATTGAAGCAGGCACATTACTAATCGCTGGTCTATAACCGCTGGTGATATTTTGTACGTGGTGAATCAAG
AACATATTGGCGAGTTTAGTCTATAAACTAGAGAATAATGGCGCTTGAAATTTGGAATGGAATGATGGTATTTCGTGTACGT
20 GCTGAAGGGGAATTACAACCTGTAGACATCAAACTCTACCACATCTGGATTCCCGACTGATATGCAATCACAAATGAT
GGCATTTGTTATTAAACGGCAAATGGTCATAAAGTCGTAACCGAACTGTTTGTGAAAACCGTTTATGTCATGTTCCAGAGT
TCAAACGTATGAATGCTAATATCAATGTAGAAGGTGCTAGTGTAAACTTGAAGGTAAAAGTCAATTGCAAGGTGCACAA
GTTAAAGCGACTGATTAAAGAGCAGCAGCCGCTTAATTTTAGCTGGATTAGTTGCTGATGGTAAAACAAGCGTTACTGA
ATTAACGCACCTAGATAGAGGCTATGTTGACTTACACGGTAAATTGAAGCAATTAGGTGCAGACATTGAACGTATTAAAC
25 ATTAATTTCAGTAAATTAATATAATGGAGGATTTCACCATGGAACAATTTTGTATTATAACCAAAATTAA

>HGS016, MurA, UDP-N-acetylglucosamine 1-carboxyvinyltransferase

30 MDKIVIKGGNKLITGEVKEVGAKNVLPILTASLLASDKPSKLVNVPALSDVETINNVLTTLNADVITYKKDENAVVVDTK
TLNEEAPYEYVSKMRASILVMGPLLARLGHAI VALPGGCAIGSRPIEQHIKGFALGAEIHLNGNIYANAKDLKGTSTI
HLDFPSVGATQNI IMAASLAKGKTLIENAAKEPIVDLANYINEMGGRITGAGTDTITINGVESLHGVEHAIIPDRIEAG
TLLIAGAITRGDIFVRGAIKEHMASLVYKLEEMGVELDYQEDGIRVRAEGELQPVDIKTLPHPGFPPTMQSQMALLLTA
NGHKVVVTVFENRFMHVAEFKRMNANINVEGRSAKLEKSQLQGAQVKATDLRAAAILAGLVADGKTSVTELTHLDR
GYVDLHGKLLQLGADIERIND

35 >HGS018, dnaJ, DNA ligase

AGAAAAATGGCTCAATCGAACTAGATAATTATCTTTAAATCACAAGGGCCAAAACGTTTGTAGCGCAATTTGCACCAATT
GAAAAAAGGAGGATTAAGGGATGGCTGATTATCGTCTCGTGTGAACGAGTTACATGATTATTATAATCAATACAGTTAT
GAATACTATGTAGAGGATAATCCATCTGTACCAGATAGTAATATGACAAATTACTTCATGAAGTGAATAAAATAGAAGA
40 GGAGCATCCTGAGTATAAGACTGTAGATTCTCCAACAGTTAGAGTTGGCGGTGAAGCCCAAGCCTCTTTCAATAAAGTCA
ACCATGACACGCCAATGTTAAGTTTAGGGAATGCATTTAATGAGGATGATTGAGAAAAATTCGACCAACGCATACGTGAA
CAAAATGGCAACGTTGAAATATATGTGCGAATTAAGGATGAGTGGCTTAGCAGTATCATTGAAATATGTTGATGATAT
CGTTCAAGGTTTAAACAGTGGTGTGGAACAACAGGTGAGATATTACCGAAAAATTTAAACCAATTCATGCGGATACCTT
TGAAAAATGAAAGAACCAATTAAATGTAGAAGTTCTGGTGAAGCATATATGCCGAGACGTTTCAATTTTACGATTAAATGAA
GAAAAAGAAAAAATGATGAGCAGTTATTGCAATCCAGAAACGCTGCTGCGGGATCATTAAAGACAGTTAGATTCTAA
45 ATTAACCGGCAAAACGAAAGCTAAGCGTATTATATATAGTGTCAATGATTTCACGTGATTTCATGCGCGCTTCGCAAGTG
AAGCATTAGATGAGTTAGATAAATTAGGTTTACAACGAATAAAATAGAGCGCGTGAATTAATATCGATGGTGTGTTTA
GAGTATATTGAAAAATGGACAAGCCAAAGAGAGTCAATTACCTTATGATATTGATGGGATTGTTATTAAGGTTAATGATTT
AGATCAACAGGATGAGATGGGATTCACACAAAAATCTCCTAGATGGGCCATTGCTTATAAATTTCCAGCTGAGGAAGTAG
TAACTAAATTATTAGATATTGAATTAAGTATTGGACGAACAGGTGTAGTCACACCTACTGCTATTTTAGAACCAAGTAAAA
50 GTRGCTGGTACAACCTGTATCAAGAGCATCTTTGCACAATGAGGATTTAATTCATGACAGAGATATTGCAATTGGTGATAG
TGTTGTAGTGAAGAAAGCAGGTGACATCATACCTGAAGTTGTACGTAGTATTCCAGAACGTAGACCTGAGGATGCTGTCA
CATATCATATGCCAACCCATTGTCCAAGTTGTGGACATGAATTAGTACGTATTGAAGCGGAAGTAGCACTTCGTTGCAIT
AATCCAAAATGCCAAGACACAACCTGTTGAAGGATGATTTCACTTTGTTATCAAGACAAGCCATGAATATTGATGGTTAGG
CACTAAAATTATTCAACAGCTTTATCAAGCGAATTAATTAAGATGTTGCTGATATTTCTATTTAACAGAAGAAGATT
55 TATTACCTTTAGACAGAAATGGGGCAGAAAAAGTTGATAATTTATTAGCTGCCATTCAACAAGCTAAGGACAACCTCTTTA
GAAAAATTATTATTGTTCTAGGTATTAGGCATTTAGGTGTTAAAGCGAGCCAAGTGTAGCAGAAAAATATGAAACGAT
AGATCGATTACTAACGGTAACTGAAGCGGAATTAGTAGAAATTCATGATATAGGTGATAAAGTAGCACAACTCTGTAGTTA
CTTATTTAGAAAAATGAAGATATTGCTGCTTTAATTCAAAAATTAAGATAAACATGTTAATATGATTATATAAAGGTATC
AAAACATCAGATATTGAAGGACATCCTGAATTTAGTGGTAAACGATAGTACTGACTGGTAAAGTACATCAATCAATGACAC
60 CAATGAAGCATCTAAATGGCTTGCAATCACAAGGTGCTAAAGTTACAAGTAGCGTTACTAAAAATACAGATGTCGTTATTG
CTGGTGAAGATGCAGGTTCAAAATTAACAAAAGCACAAGTTTAGGTATTGAAATTTGGACAGAGCAACAATTTGTAGAT
AAGCAAAATGAATTAATAGTTAGAGGGGTATGTCGATGAAGCGTACATTAGTATTATTGATTACAGCTATCTTTATACT
CGCTGCTTGTGGTAAACATAAGGATGACCAGGCTGGAAAAAGATA

>HGS018, DnaJ, DNA ligase

MADLSSRVNELHDLNLQYSYEDNPSPDSEYDKLLHELKIEEEHPEYKTVDSPTVRVVGGEAQASFNKVNHDTPML
SLGNAFNEDDLRFQIRREQIGNVEYMCLEKIDGLAVSLKYVDGYFVQGLTRGDGTTGEDITENLKTTHAIPLKMKPEPL
NVEVRGEAYMPRRSFLRLNEEKEKNDQLFANPRNAAAGSLRQLDSKLTAKRKLVSFIIYSVNDFTDFNARSQSEALDELD
KLGFTTNKNRARNVNIDGVLEYIEKWTQSRESLPYDIDGIVIKVNDLDQODEMGFTQKSPRWAIAYKFPAAEVVTKLLDI
ELSIGRTGVVTPTAILEPVKVAGTTVSRLSHNEDLIHDRDIRIGDSVVVKAGDIIPEVVRISIPERRPEDAVTYHMPH
CPSCGHELVRIEGEVALRCINPKCQQLVEGLIHFVSRQAMNIDGLGTKIIQQLYQSELIKDVADIFYLTTEEDLLPLDRM
GQKQVNDLLAAIQQAKNDSLENLLFGLGIRHLGVKASQVLAEKYETIDRLLTVEAEIHDIGDKVAQSVVTYLENED
IRALIQLKDKHVNMIYKGIKTSIDIEGHPEFSKGTIVLTGKLHQMTREASKWLASQGAQVTSVTKNTDVVVIAGEDAGS
KLTKAQLSLGIEIWTQQFVDKQNELNS

>HGS019, mapM, methionine aminopeptidase

TGTCTCACTCACTTTCCAAAATACTAAAGTAACATCTTTAGTATATCAAAGAATTTTGTCTATAATAAGTTTATAATTATA
TAAAAAAGGAACGGGATAAAATGATTGTAAAAACAGAAGAATTACAAGCGTTAAAAAGAAATTGGATACATATGCGCT
AAAGTGCCTAATACAATGCAAGCTGCAACCAACAGGTATCACTACGAAAGAGCTTGATAATATTGCGAAAGAGTTATT
TGAAGAATACGGTGCTATTCTGCGCAATTCATGATGAAAAATTTCTCGTCAACCGTGTATTAGTGTCAATGAAGAGG
TGGCAGATGGGATTCCAAGTAAGCGTGTCTATCGTGAAGGAGATTAGTAAATATTGATGTATCGGCTTTGAAGAATGGC
TATTATGCAGATACAGGCATTTCATTTGTCGTTGGAGAATCAGATGATCCAATGAAACAAAAAGTATGTGACGTAGCAAC
GATGGCATTGTGAGAATGCAATTGCAAAAGTAAACCGGTACTAAGTTAAGTAACATTGGTAAAGCGGTGCATAATACAG
CTAGACAAAATGATTGAAAGTCAATTAACAACTTAACAGGTGATGGTGTGGTTTATCATTCATGAAGCACCAGCACAT
GTACTTAATTACTTTGATCCAAAAGACAAAACATTATTAAGTGAAGGTATGGTATTAGCTATTGAACCGTTTATCTCATC
AAATGCATCATTTGTTACAGAAGGTAAAAATGAATGGCTTTTGAACGAGCGGATAAAAGTTTGTGTGCTCAAATTGAGC
ATACGGTTATCGTGAATAAGGATGGTCCGATTTTAAACGACAAAGATTGAAGAAGAATAGTTCAACATATATAAGACTAA
AGTATGAACATCATTTAGTTCGGAGCCTATTCATATTGGTTTCGGAACTGTTTATAATAATTAAGAACAATCAAT

>HGS019, MapM, methionine aminopeptidase

MIVKTEELQALKEIGYICAKVRNMQAATKPGITTKELDNIAKELFEEYGAI SAPIHDFNPGQTCISVNEEVAGHIPS
KRVIREGLVNIIDVSALKNYYADTGISFVVGESDDFMKQKVCVDVATMAFENAIKVKPGTKLSNIGKAVHNTARQNDLK
VIKNTLGHGVLSLHEAPAHVLNYPDKDKTLTTEGMVLAIEPFISSNASFVTEGKNEWAFETSDKSFVAQIEHTVIVTK
DGPILTTKIEEE

>HGS022-23-24, adt, glutamyl-tRNA amidotransferase subunit a, b, and c (operon comprising three ORFs listed below)

TATACAGTTTATATGAAATTAAAGTAGCACCTCATAAATACTTAGATTTTAAATTGGAAATTTGATACAATTTAGTGATG
AATGACTTAAAGGAGGCTTTTATTAAATGACAAAAGTAACCGTGAAGAAGTTGAGCATATCGCGAATCTTGCAAGACTTC
AAATTTCTCTGAAAGAAACGGAAGAAATGGCCAAACACATTAGAAAGCATTTTAGATTTTGGCAAAACAAAATGATAGCGCT
GATACAGAAGCGCTTGAACCTACATATCACGTTTATAGATTTACAAAACGTTTACGTGAAGATAAAGCAATTAAGGTAT
TCCACAAGAATTAGCTTTGAAAAATGCCAAAGAAACAGAAGATGGACAATTTAAAGTGCCATACAATCATGAATGAGGAGG
ACGCGTAAGATGAGCATTGCTACGAATCGGTTGAGAATTTATTAACCTTTAATAAAAGACAAAAAATCAAACCATCTGA
TGTTGTTAAAGATATATATGATGCAATTAAGAGACTGATCAACAAATTAAGTCTTTCTAGCGCTGGATAAAGAAATG
CAATCAAAAAGCGCAAGAATTGGATGAATTACAAGCAAAAGATCAAAATGGATGGCAAAATTAATTTGGTATTCCAATGGGT
ATAAAGATAACATTATTACAACCGGATTAGAAACAATGTCAGTGAAGTAAATGTTAGAAGGTTTGTGCCAATTTACGA
ATCTACTGTAATGGAAAGACTACATAATGAAATGCGGTTTAAATCGGTAAATTAATATGAGTGAATTTGCAATGGGTG
GTTCAACAGAAACATCTTATTCAAAAAACAGTTAACCCATTTGACCATAAAGCAGTGCCAGGTGGTTTATCAGGTGGA
TCTGCAGCAGCAGTTGAGCTGGCTTAGTACCATTAGCTTAGGTTGAGACACAGGTGGTTCAATTAGACAACCGGCTGC
ATATTGTGGCGTTGTCTGATGAAACCAACATACGGTCTGTATCTCGATTGGATTAGTTGCTTTTGCATCTTCATTAG
ACCAAATTTGGTCCATTGACTCGAAATGTAAAGATAATGCAATCGTATTAGAAGCTATTCTGCTGAGATGTTAATGAC
TCTACAAGTGCACCGATTGATGATGTAGACTTTACATCTGAAATTTGGTAAAGATATTAAAGGATTAAAGTTGCATTACC
TAAAGAATACTTAGGTGAAGGTGATGCTGATGACGTTAAAGAAGCAGTTCAAAACGCTGTAGAACTTTAAATCTTTAG
GTGCTGTCTGTTGAGGAAGTATCATTTGCCAAATACTAAATTTGGTATTCCATCATATTACGTGATTGCAATCATCAGAAGCT
TCGTCAAACTTTCTCGTTTGTGACGGAATTCGTTATGGTTATCATTTCAAGAAGCTCATTCAATAGAAGAATTATATAA
AATGTCAAGATCTGAAGGTTTCGGTAAAGAAGTAAACCGTCTGATTTTCTTAGGTACATTTCATTAGAAGATTATATGAT
ATGATGCTTACTATAAAAAATCTCAAAAAGTTAGAACATTGATTAATAATGACTTTGATAAAGTATTGCAAAATTTATGAT
GTAGTAGTTGGTCCAAACAGCGCTCAACCTGCGTTTAAATTTAGGTGAAGAAATTTGATGATCCATTAACAATGTATGCCAA
TGATTTATTAAACAACACAGTAACTTAGCTGGATTACCTGGTATTCTGTTTCTGTTGGACAATCAAAATGGCCGACCAA
TCGGTTTACAGTTTCAATGGTAAACCATTCGATGAAAAACGTTATATCGTGTGCTTATCAATATGAACACAAATCAAT
TTACATGACGTTTATGAAAAATTTATAAGGAGTGAAATCATGCAATTTTGAACAGTTATAGGACTTGAAGTTACGTTAGA
GTTAAAAACCGACTCAAAAATGTTTTCTCCATCACCAGCGCATTTTGGAGCAGAACTAACTCAAAATACAAATGTTATCG
ACTTAGCATATCCAGGTGCTTACCAGTTGTTAATAAGCGTGCAGTAGACTGGGCAATGCGTGCTGCAATGGCACTAAAT
ATGGAATCGCAACAGCAATCAAGTTTGAACCGTAAGAATTTTCTATCCAGATAATCCAAAAGCATATCAAAATTTCTCA
ATTTGATCAACCAATTTGGTGAAGTGGATATATCGATATCGAAGTCGAGCGTGAACAAAAACGAATCGGTATTACGCTC
TTCATGGAAGAAGATGCTGGTAACTAACACATAAAGGTGAGTATTATTAGTTGACTTGAACCGTCAAGGTACACCG

CTAATTGAAATCGTATCTGAACCAGATATTCGTTACCTAAAGAAGCATATGCATATTTAGAAAAATTCGCTTCAATTAT
TCAATACACTGGTGTATCAGACGTTAAGATGGAAGAGGGATCTTTACGTTGTGATGCTAACATCTCTTTACGTTCCATATG
GTCAAGAAAAATTTGGTACTAAAGCCGAATTGAAAACTTAAACTCATTTAACTATGTACGTAAAGGTTTAGAATATGAA
5 GAAAAACGCCAAGAAGAAGATTGTTAAATGGTGGAGAAATCGGACAAGAACACGTCGATTGTATGAATCTACAGGTAA
ACAATTTTAAATGCGTGTAAAGAAGGTTCTGATGATTACCGTTACTTCCCAGAGCCCTGACATGTACCTTTATATATTG
ATGATGCTTGGAAAGAGCGGTTCCTGTCAGACAATTCCTGAATTACCAGATGAACGTAAAGCTAAGTATGTAATGAATTA
GGTTTACCTGCATACGATGCACACGTATTAACTTGAATAAGAAATGTCAGATTCTTTGAATCAACAATTGAACACGG
10 TGCAGATGTTAAATTAACATCTAACTGGTTAATGGGTGGCGTAAACGAATATTTAAATAAAAAATCAAGTAGAATTATTAG
ATACTAAATTAACACCAGAAAAATTTAGCAGGTATGATTAACTTTATCGAAGACGGAACAATGAGCAGTAAATTCGGAAG
AAAGCTTCCCAGAGTTAGCAGCTAAAGGTGGTAACTGCTAAACAGATTATGGAAGATAATGGCTTAGTTCAAATTTCTGTA
TGAAGCAACACTTCTAAAAATTTGTAATGAAGCATTAGACAATAACGAACAATCAGTTGAAGATTACAAAAATGGTAAAG
GCAAAGCTATGGGCTTCTTAGTTGGTCAAATTTATGAAAGCGCTCAAAGGTCAAGCTAATCCACAATTAGTAAATCAACTA
TTAAACAAGAATTAGATAAAAGATAATTTAAATCATCAACACTATGAAGATTTAAAAATAAACCCCTTGATTGCTGACCT
15 AGATGCAATCGAGGTTTATTTATATCTATAGAAGTCAA

>HGS022, Adt, glutamyl-tRNA amidotransferase subunit a

MSIRYESVENLLTLIKDKKIKPSDVVKDIYDAIEETDPTIKSFLALDKENAIKKAQELDELQAKDQMDGKLFIPMGIKD
NIITNGLETTCAKMLEGFVPIYESTVMEKLHNENAVLIGKLNDEFAMGGSTETSYFKKTVNPFDHKAVPGSSGSGSAA
20 AVAAGLVPPFLSGSDTGGSIQPAAYCGVGMKPTYGVRVSRFGLVAFASSLDQIGPLTRNVKDNAIVLEAISGADVNDSTS
APVDDVDFTSEIGDKIKGLKVALPKEYLGEVADDVKEAVQNAVETLKSILGAVVEEVSLEPNTKFGIPSYVVIASSEASN
LSRFDGIRYGYHSKEAHSLEELYKMSRSEGFGEVKRRIFLGTFALSSGYDAYYKKSQKVRTLIKNDFKVFENYDVVV
GPTAPITAFNLGEEIDDLPLTMYANDLLTTPVNLAGLPGISVPCQSQNGRPIGLQFIGKPFDEKTLRYVAYQYETQYNLHD
VYEKL

>HGS023, Adt, glutamyl-tRNA amidotransferase subunit b

MHFETVIGLEVHVELKTDKMFSPSPAHFGAEPNSNTNVIDLAYPGVLPVUNKRAVDWAMRAAMALNMEIATESKFDRKN
YFYPDNPAYQISQFDQPIGENGYIDIEVDGETKRIGITRLHMEEDAGKSTHKGEYSLVDLNRQGTPLIEIVSEPDIRSP
25 KEAYAYLEKLSIIQYTGVSVDVKMEEGSLRCDANI SLRPYQGEKFGTKAELKNLNSFNVRKGLYEYEEKRQEEELLNGGE
IGQETRRFDESTGKTLILMRVKEGSDDYRYFPEPDIVPLYIDDANKERVQRTIPELPDERKAKYVNELGLPAYDAHVLTIT
30 KEMSDFFESTIEHGADVLTLSNWMGCVNEYLNKNQVELLDITKLTPENLAGMIKLIEDGTMSSKIAKKVFPELAAGKGN
KQIMEDNGLVQISDEATLLKFVNEALDNNEQSVEDYKNGKGMGFLVGQIMKASKGQANPOLVNLQLLKQELDKR

>HGS024, Adt, glutamyl-tRNA amidotransferase subunit c

MTKVTRREEVHEIANLRLQISPEETEEMANTLESILDFAKQNDSDTEGVEPTYHVLDLQNVLRDKAIKGIPOELALKN
35 AKETEDGQFKVPTIMNEEDA

>HGS025, pth, peptidyl-tRNA hydrolase

CTTACTAAGCTAAAGAATAATGATAATTGATGGCAATGGCGGAAAATGGATGTTGTCATTATAATAATAATGAAACAAT
TATGTTGGAGGTAAACACGCATGAAATGTATTGTAGGCTAGGTAATATAGGTAAACGTTTGAACCTACAAGACATTAAT
40 ATCGGCTTTGAAGTCGTTGATTATATTTTAGAGAAAAATAATTTTTCATTAGATAAAACAAAGTTTAAAGGTGCATATAC
AATTGAACGAATGAACGCGGATAAAGTGTATTATTCGAACCAATGACAATGATGAATTTGTCAGGTGAAGCAGTTGCAC
CGATTATGGATTATTACAATGTTAATCCAGAAGATTAAATTTGCTTATATGATGATTAGATTAGAACAAAGGACAAGTT
CGCTTAAGACAAAAAGGAAGTGGCGGCGGTCACAATGGTATGAAATCAATTATTAATAATGCTTGGTACAGACCAATTTAA
ACGTATTTCGTATTGGTGTGGGAAGACCAACGAATGGTATGACGGTACCTGATTATGTTTACAACGCTTTTCAAATGATG
45 AAATGGTAACGATGGAAGAAAGTTATCGAACACGCGAGCAGCGCAATTGAAAAGTTTGTGTAACATCAGGATTGACCAT
GTTATGAATGAATTTAATGGTGAAGTGAATAATGACAATATTGACAACGCTTATAAAGAAGATAATCATTTTCAAGAC
CTTAATCAGGTATTGGAACAAGCAAACACTAGTAACCTGCTTTCCCGT

>HGS025, Pth, peptidyl-tRNA hydrolase

MKCTVGLGNIGKRFELTRHNIGFEVVDYILEKNFSLDKQKFKGAYTIERMNGDKVLFIEPMTMMNLSGEAVAPIMDYNN
50 VNPEDLIVLYDDLDLEQGVRLRQKGSAGGHNGMKSIIKMLGTDQFKRIRIGVGRPTNGMTVPDYVLQRFSDNDEMVTMEK
VIEHAARAIEKFVETSRFDHVMNEFNGEVK

>HGS026

55 TGATCCGATTATCTTAGTAGGTGCCAATGAAAGTTATGAGCCACGTTGTGCGCGCCACCATATCGTAGCACCTAGTGATA
ATAATAAGGAGGAATTATAGTGTATTGATCAATTAGATATTGTAGAAGAAAGATACGAACAGTTAAATGAACGTGTAAGT
GACCCAGATGTTGTAATGATTCAGATAAATACGTAAATATTCTAAAGAGCAAGCTGATTTACAAAAAACTGTAGATGT
TTATCGTAACTATAAGCTAAAAAAGAAGATTAGCTGATATTGAAGAAATGTTAAGTGAGACTGATGATAAAGAAGAAG
TAGAAATGTTAAAGAGGAGAGTAAATGTTAAAGCTGAACCTTCCAAATCTGAAGAAGAGCTTAAATATTATTTGATT
60 CCTAAAGATCCTAATGATGACAAAGACGTTATTGTAGAAATAAGAGCAGCAGCAGGTGGTATGAGGCTGCGATTTTTGC
TGGTGATTAAATGCGTATGTATTCAAAGTATGCTGAATCACAAGGATTCAAACTGAAATAGTAGAAGCGTCTGAAAGTG
ACCATGGTGGTTACAAGAAATTAGTTTCTCAGTTTCTGGTAAATGGCGCGTATAGTAAATTTGAAATTTGAAATGGTGGC
CACC CGCTTCAACGTGTGCTGAAACAGAAATCAGGTGGACGTATTCATCTTCAACAGCTACAGTGGCAGTTTACCAGA

AGTTGAAGATGTAGAAATTGAAATTAGAAATGAAGATTTAAAAATCGACACGTCATCGTTCAAGTGGTGCAGGTGGTCAGC
ACGTAAACACAACCTGACTCTGCAGTACGTATTACCCATTTACCAACTGGTGTCAATTGCAACATCTTCTGAGAAGTCTCAA
ATTCAAACCCGTGAAAAAGCAATGAAAGTGTAAAAAGCAGCTTTATACGATATGAAAGTTCAAGAAGAACACAAAAGTA
TGCCTCACAACGTAAATCAGCAGTCGGTACTGGTGATCGTTTCAAGACGTATTCCGAACCTATAATTATCCACAAAGCCGTG
5 TAACAGACCATCGTATAGGTCTAACGCTTCAAAAAATTAGGGCAAATTATGGAAGGCCATTTAGAAGAAATTATAGATGCA
CTGACTTTATCAGAGCAGACAGATAAATTGAAAGAACTTAATAATGGTGAATTATAAAGAAAAGTTAGATGAAGCAATTC
ATTTAACACAACAAAAGGGTTTGAACAAACACGAGCTGAATGGTTAATGTTAGATGTATTCAATGGACGCCGTACG

>HGS026

VFDQLDIVEERYEQNLNELLSDPDVNDSDKLRKYSKEQADLQKTVDVYRNYKAKKEELADIEEMLSETDDKEEVEMLKEE
SNGIKAEPLNLEEELKILLIPKDPNDKDVIVEIRAAAGGDEAAIFAGDLRMYSKYAESQGFKTEIVEASESDHGGYKE
ISFSVSGNGAYSKLKFENGHRVORVPETESGGRIHTSTATVAVLPEVEDVEIEIRNEDLKIDTYRSSGAGQHVNTTDS
AVRIHTLPTGVIATSSSEKSIQNRKAMKVLKARLYDMKVQEEQKYASQRKSAVGTGDRSERIRTYNPQSRVTDHRI
10 LTLQKLQIMEGHLEEIIDALTLSEQTDKLLKELNNGEL

>HGS028

ATTTCTTAACATTTGTTATTTAACAAAATTATGTTAAAAATTTAGCATTATAAAAGATGCAAATCAATGACTTGAATTGAAA
TATAAATAGGAGCGAATGCTATGGAATTATCAGAAATCAAACGAAATATAGATAAGTATAATCAAGATTTAACACAAATT
AGGGGGTCTCTTGACTTAGAGAACAAGAACTAATATTCAAGAATATGAAGAAATGATGGCAGAACCTAATTTTGGGA
20 TAACCAAACGAAAGCGCAAGATATTATAGATAAAAAATAATGCGTTAAAGCAATAGTTAATGGTTATAAAACACTACAAG
CAGAAGTAGATGACATGGATGCTACTTGGGATTTTATPACAAGAAAGAAATTGATGAAGAAATGAAAGAAGACTTAGAGCAA
GAGGTCATTAATTTTAAAGCTAAAGTGGATGAATACGAATTGCAATTATTATTAGATGGGCCTCAGCATGCCAATAACGC
AATTCTAGAGTTACATCTGGTGCAGGTGGCAGGAGTCTCAAGATTGGGCTAATATGCTATTTAGAAATGTATCAACGTT
ATTGTGAGAAGAAAGGCTTTAAAGTTGAAAGCTGTTGATTATCTACCTGGGGATGAAGCGGGGATTAAAGTGTAACATTG
25 CTCATCAAAGGCATAATGCTTATGTTTATTTAAAGCTGAAAAGGTTACACCGACTAGTACGAATTTCTCCATTTGA
TTCATCAGGACGTGCTCATACATCATTGTCATCATGCGACGTTATTCCAGATTTTAATAATGATGAAATAGAGATTGAAA
TCAATCCGGATGATATTACAGTTGATACATTCAGAGCTTCTGGTGCAAGGTGGTCAGCATATTAAACAAAACGAATCCGCA
ATACGAATTACCCACCACCCCTCAGGTATAGTTGTTAATAACCAAAATGAACGTTCTCAAATTAAAAACCGTGAAGCAGC
TATGAAATGTTAAAGTCTAAATTATATCAATTAAAAATTGGAAGAGCAGGCACGTGAAATGGCTGAAATTCGTGGCGAAC
30 AAAAAAGAAATCCGCTGGGGAAGCCAAATTAGATCATATGTTTTCATCCATACCTCAATGGTGAAAGATCATCGTACGAAC
GAAGAAACAGGTAAAGTTGATGCAGTGTGATGGAGACATTGGACCATTTATCGAATCATATTTAAGACAGACAATGTC
GCACGATTAAATATATATTTTAAACCGAGGCTCTAAAGGGCGTGGTGGTTTGGTTTAAAGGTAGCTAAATAAATT
GTAATTAGATTTTGGAAATATGATTTGTTTATGAA

>HGS028

MELSEIKRNIDKYNQDLTQIRGSLDLENKETNIQEYEMMAEPNFWDNQTKAQDIIIDKNNALKAIVNGYKTLQAEVDDMD
ATWDLQEEFDEEMKEDLBQEVINFKAKVDEYELQLLLDGPHDANNAILELHPGAGGTESQDWMNLMFRMYQRYCEKKGF
KVETVDYLPGEAGIKSVLLIKGHNAYGYLKAEGVHRLVRI SPFDSSGRHRTSFASCDVIPDFNDEIEIEINPDIT
VDTFRASGAGGQHINKTESAIRITHHPSGIVVNNQERSQIKNREAAAMKMLKSKLYQLKLEEQAREMAEIRGEQKEIGWG
40 SQIRSYVFHPYSVMVKDHRTNEETGKVDVMDGIDGPFIESYLRQTM SHD

>HGS030, Tmk, thymidylate kinase

AATAACTGAAATATGATAGAATTGGTAAATGAATATCTGGAACTGGAATGATAGTTGAAGGAATTAATAAATAAATAA
TTTTAGTTGAGGATGAATAAATGTCAGCTTTTATAACTTTTGAGGGCCAGAGGCTCTGGAAAAACAACGTGAATTAA
45 TGAAGTTTACCATAGATTAGTAAAGATTATGATGTCATTATGACTAGAGAACCAGGTGGTGTCTTACTGGTGAAGAAA
TACGTAAAATTGTATTAGAAGGCAATGATATGGACATTAGAAGTGAAGCAATGTTATTGCTGCATCTAGAAGAGAACAT
CTTGATTATAAGGTATACACAGCTTTAAAGAAGGTAAGGTTGTTGTTGTTGATCGCTATATCGATAGTTTATTAGCTTA
TCAAGGTTATGCTAGAGGGATTGGCGTTGAAGAAGTAAGAGCATTAACGAATTGCAATAAATGGATTATATCCAGACT
TGACGATTTATTTAAATGTTAGTCTGAAGTAGGTCGCGAACGTATTATTAAAAATTCAAGAGATCAAAATAGATTAGAT
50 CAAGAAGATTAAAGTTTACGAAAAAGTAATTGAAGGTTACCAAGAAATCATTCAATGAATCAACCGGTTCAAAAG
CGTTAATGCAGATCAACCTCTTGAAGTGTGTTGAAGACACGTATCAAACTATCATCAAAATTTGAAAAAGATATGAT
ATAATTGTTAGAAGAGGTGTTATAAAATGAAATGATTATAGCGATCGTACAAGATCAAGATAGTCAGGAACCTGCAGAT
CAACTGTTTAAAAATAACTTTTAGAGCAACAAAATTGGCAA

>HGS030, tmk, thymidylate kinase

MSAFITFEGPEGSGKTTVINEVHRLVKDYDVIMTREFGVPTEGEEIRKIVLEGNMDIRTEAMLFAASRREHLVLKVIP
ALKEGKVVLCDRYIDSSLAYQGYARGIGVEEVRALNEFAINGLYPDLTIYLNVAEVRERIIKNSRDQNRDLQEDLKFH
EKVIEGYQEIHNESQRFKSVNADQPLENVVEDTYQTIIKYLEKI

>HGS031, PyrH, uridylate kinase

AATGTTGCTTTTATAAATGTAATCATTTCTAATAAAACGACAACCTGTGCTCTTTTACTTGTATATGTTACATATATTC
ACGATAGAGAGGATAAGAAAAATGGCTCAAATTTCTAAATATAACAGTGTAGTTTGAAGCTAAGTGGTGAAGCGTTAGCT
GGAGAAAAAGGATTGGCATAAATCCAGTAATTATTAAAAAGTGTGCTGAGCAAGTGGCTGAAGTTGCTAAAATGGACTG

5 TGAAATCGCAGTAATCGTTGGTGGCGGAAACATTTGGAGAGGTAAAACAGGTAGTGACTTAGGTATGGACCGTGGAACGTG
CTGATTACATGGGTATGCTTGCAACTGTAATGAATGCCCTTAGCATTACAAGATAGTTTAGAACAAATGGATTGTGATACA
CGAGTATTAACATCTATTGAAATGAAGCAAGTGGCTGAACCTTATATTCGTCGTCGTCGAATTAGACACTTAGAAAAAGAA
ACGCGTAGTTATTTTGGCTGCAGGTATGGAAACCCATACCTTCTTACAGATACTACAGCGGCATTACGTGCTGCAGAAG
10 TTGAAGCAGATGTTATTTTAATGGGCAAAAATAATGTAGATGGTGTATATCTGCAGATCCTAAAGTAAACAAAGATGCG
GTAAATATGAACATTTAACGCATATTCAAATGCTTCAAGAAGGTTTACAAGTAATGGATTCAACAGCATCCTCATTTCTG
TATGGATAATAACATTCGGTTAACTGTTTCTCTATTATGGAAGAAGGAAATATTAACGTCGTGTTATGGGTGAAAAAGA
TAGGTACGTTAATTACAAAATAAATTTAGAGGTGTAAATAATGAGTGACATTATTAATGAAACTAAATCAAGAATGCAA
AAATCAATCGAAAGCTTATCACGTGAATTAGCTAACATCAGTG

15 >HGS031, pyrH, uridylylate kinase

MAQISKYKRVVLKLSGEALAGEKGFGINPVIKSVAEQVAEVAKMDCEIAVIVGGGNIWRGKTGSDLGMDRGTDYMGML
ATVMNALALQDSLEQLDCDTRVLTSEIMKQVAEPYIRRRAIRHLEKKRVVIFAAGIGNPYFSTDTTAALRAAEVEADVIL
MGKNNVDGVYSADPKVNKDAVKYEHLTHIQMLQEGLVMDSTASSFCMDNNIPLTVFSIMEEGNIKRAVMGEKIGTLITK

20 >HGS032

GATAGCATCCATGTATAGTGATAGTATTTACAACAATTATTATAACTATTTAGTTAAGTAGAGAAATAGTTAAACATTT
TGAAAGTGTGGTTTAAATGGAATGTGAGCAATAGGAACAGTTTAAAGAACATGTAAAGAACCTTTATTTAAITCAAAAGA
CTGGCTCAGTTTCAAGTTAAATTTATCAATCATAGTAACATTTTAGGTGTGGCTTGGGAATTAATTAAACCTGTATGCA
25 AATTATGGTTTACTGGATGGTTTGGATTAGGAATAAGAAGTAATGCACCAATTCATGGTGTACCTTTTGTATTATGGT
TATTGGTTGGTATCAGTATGTGGTTCTTCATCAACCAAGGTATTTAGAGGTACTAAAGCAATTACACAAAAGTTAAT
CAAGTATCGAAATGAACCTCCCGTTATCGATAATACCGACATATATTGTGACAAGTAGATTATGAGCAATTTAGGCTT
ACTTTTACTTGTGATAATGCATGTATGTTTACTGGTATTTATCCATCAATACATATCATTTCAATTATTGATATATGTAC
CGTTTGTGTTTCTTAACTGCCCTCGGTGACGTTATTAACATCAACACTCGGTGTGTTAGTTAGAGATACACAAATGTTA
30 ATGCAAGCAATATTAAGAATATTTATTTTACTTTTCCACCAATTTTGTGGCTACCAAGAACCATGGTATCAGTGGTTTAAT
TCATGAAATGATGAAATATAATCCAGTTTACTTTTATGCTGAATCATACCGTGCAGCAATTTATATACGAAATGGTATT
TCATGGATCAITGGAAATTAATGTTATACAATTTCCGTATTTGTTGCCATTTCTTTGCAATTTGGTGCCTACTTACACATG
AAATATAGAGATCAATTTGCAGACTTCTTGAATATATTTATATGACGAAACCCCGTAACCATTAATAAATGGAAGTGG
GGTTCAATTTTGTGTTATAATTTAAGTAAATAACATATTAAGTTGGTGTATTAT

35 >HGS032

MSAIGTVFKEHVKNFYLIQRLAQFQVKIINHSNYLGVAWELINPVMQIMVYVMVFLGIRSNAPIHGVFPFVYVLLVIGISM
WFFINQILEGKAITQKFNQVSKMNFPLSIIPYIVTSRFYHGLLLLLVIIACMFTGIYPSIHI IQLLIYVPFCFFLT
ASVTLTSTLGLVLRDQMLMQAILRILFYFSPILWLPKNHGISGLIHEMMKYNPVYFIAESYRAAILYHEWYFMDHWKL
40 MLYNFGIVAIFFAIGAYLHMKYRDQFADFL

>HGS033

TAACAAAATCTTCTATACACTTTACAACAGGTTTAAATTTAACTGTTGAGTAGTATATTATAATCTAGATAAATG
TGAATAAGGAAGGTCTACAAATGAACGTTTCGGTAAACATTAATAATGTAACAAAAGAAATATCGTATTATCGTACAAAT
45 AAAGAAGGTATGAAAGATGCGCTCATTCCCAACATAAAAACAAACATTTTTCGCTTTAGATGACATTAGTTTAAAGC
ATATGAAGGTGACGTATAGGGCTTGTGGCATCAATGGTCCGGCAAATCAAGTTGAGCAATATCATTTGGCGGTTCTT
TGTCCGCTACTGTTGGCAAAGTGGATCGTAATGGTGAAGTCAGCGTTATCGCAATTAGTGTGCTGGCTTGAGTGGCAACTT
ACAGGGATTGAAATATCGAATTTAAATGTTATGTATGGCTTTAAGCGAAAGAAATTAAGCGATGACACCTAAGAT
TATTGAATTTAGTGAACCTTGGTGAAGTTTATTTATCAACCAAGTTTAAAGATTTCAAGTGGTATGCGTGCAAAACCTTGGTT
50 TTTCAATTAATATCACAGTTAATCCAGATATCTTAGTCATTGACGAAGCTTTATCTGTAGGTGACCAAACTTTTGCACAA
AAATGTTTAGATAAAATTTACGAGTTTAAAGAGCAAAACAAACCATCTTTTTCGTTAGTCATAACTTAGGACAAGTGAG
ACAATTTTGTACTAAGATTGCTTGGATTGAAGGCGGAAAGTTAAAGATTACGGTGAACCTTGATGATGATTACCTAAAT
ATGAAGCTTTCCCTAACGATTTTAAAGAAATCCAAAGCCGAACAAAAGAAATTTAGAAACAAACTCGATGAGTCCCGC
TTTCGTTATTAATAAACCAGAAAAACCGAGAATCTCCATTTAAGGATTTCCCTCGGTTTATTTTGTTCATCATGATTATT
TCGCTTTTATTTTCTTTTGTCTTTGGCTATT

>HGS033

MNVSVNIKVNVTKEYRIYRTNKERMKDALIPKHKNKTFALDDISLKAYEGDVLVGLVINGSGKSTLSNIIGGSLSPVIGK
VDRNGEVSVIAISAGLSGQLTGIEINIEFKMLCMGFKRKEIKAMPKIIIEFSELGEFYQPVKKYSSGMRAKLGFSINITV
55 NPDILVIDEALSVDQTFQKCLDKIYEFKEQNKTIFFVSHNLGQVRQFCTKIAWIEGKGLKDYGELDDVLPKYEAFLND
FKKKSABEQKEFRNKLDSESRFVIR

>HGS034

ATAAGGTGAAGACACATAAAACAATATATCTTAGTAAGCATGCAACACTCTTTTGTGTTATTTCATAACAACAAAAAGA
60 ATTAAAGGAGGAGTCTTATTATGGCTCGATTACAGAGGTTCAAACTGGAAAAATCTCGTCGTTTAGGTATCTCTTTAAGC
GGTACTGGTAAAGAATTAGAAAAACGTCCTTACGCACAGGACAACATGGTCCAAACCAACGTAAAAAATTATCAGAATA
TGGTTTACAATTACGTGAAAAACAAAAATTACGTTACTTATATGGAATGACTGAAAGACAATTCGTAACACATTTGACA
TCGCTGGTAAAAAATTCGGTGTACACGGTGAAAACTTCATGATCTTATTAGCAAGTCGTTAGACGCTGTGTTATTCA

TTAGGTTTAGCTCGTACTCGTCGTCAGCACGTCGAATTAGTTAACCACGGTCATATCTTAGTAGATGGTAAACGTTGTA
TATTCCATCTTATTCTGTTAAACCTGGTCAAACAATTTTCAGTTTCGTGAAAAATCTCAAAAATTAAACATCATCGTTGAAT
CAGTTGAAATCAACAATTTTCGTACCTGAGTACTTAAACCTTTGATGCTGACAGCTTAACTGGTACTTTTCGTACGTTTACCA
GAACGTAGCGAATTACCTGCTGAAATTAACGAACAATTAATCCGTTGAGTACTACTCAAGATAATACGGTCAATACCAAC
ACCCACAATTGTGGGTGT

>HGS034

MARFRGSNWKSRRLGISLSGTGKELEKRPYAPGQHPNQKRLSEYGLQLREKQKRLRYLYGMTERQFRNTFDIAGKKFG
VHGENFMILLASRLDAVVYSLGLARTRRQARQLVNHGHLVDGKRVDI PSYSVKPGQTI SVREKSQKLNIIIVESVEINNF
VPEYLNFDADSLTGTTFVRLPERSELPAEINEQLIR

>HGS036

TGTTGATTGCACCTGCTTCAGTCATTGCTATAACTATTTTAATTTTAAATTTAACCAGTGATGCACTAAGAGATAGATTG
CTGAAACAACGGGGTGAATATGATGAGTCTCATTTGATATACAAAATTTAACAATAAAGAATACTAGTGAGAAATCTCTTTA
TTAAAGGGATTGATTTGAAAAATTTTACTCAACAGATTAAATGCCCTTGATTGGAGAGAGCGCGCTGGAAAAAGTTTGATT
GCTAAAGCTTTACTTGAATATTTACCATTTGATTTAAGCTGCACGTATGATTTCGTACCAATTTGATGGGGAAAAATGTTAG
TAGATTGAGTCAATATATGCTCATACAATTTGGCTATATTTCTCAAAATTTATGCAGAAAGTTTAAACGACCATATAAAT
TAGGTAAACAGTTAACTGCGATTTATCGTAAGCATTATAAAGGTAGTAAAGAAGAGGCTTTGTCCAAAGTTGATAAGGCT
TTGTCGTGGGTAAATTTACAAAGCAAAGATATATTAATAAATATAGTTTCCAACCTTTCTGGGGGCCAACTTGAACCGCT
ATACATAGCAAGCGTTCTCATGTTGGAGCCTAAATTAATCATTTGCAGACGAACCAAGTTGCATCATTTGGATGCTTTGAACG
GTAATCAAGTGATGGATTATTACAGCATATTGTATTAGAACATGGTCAAACATTATTTATTATCACACATAACTTAAGT
CATGTATTGAAATATTTGTCAGTACATTTATGTTTAAAGAAGGTCAAATCATTGAACGAGGTAATATTAATCATTTTCAA
GTATGAGCATTTGCATCCGTATACCTGAACGCTTAATTAATATAGAACACAATTAAGAGGGATTACTATGATTGAGTTA
AAACATGTGACTTTTGGTTATAATAAAAAGCAGATGGTCTACAAGATATCAATATTACTATACCTGATGGAGAAAATGT
TGGTATTTTAGCGCAAAGTG

>HGS036

MMSLIDIQNLTIKNTSEKSLIKGIDLKIFSQIINALIGESGAGKSLIAKALLEYLPFDLSCTYDSYQFDGENVSRLSQYY
GHTIGYISQNYAESFNDHTLKGQLTAIYRKHYKGSKEEALSKVDKALSWNLQSKDILNKYSFQLSGGQLERVYIASVL
MLEPKLIIADEPVASLDALNGNQVMDLLQHVLEHGQTLFIIITHNLSHVLKYCQYIYVLKBGQIIERGNINHFKEYEHLHP
YTERLIKVRTQLKRDDYD

>HGS040

GATGATATTTTAATTACAGAAAATGGTTGTCAAGTCTTTACTAAATGCACAAAAGACCTTATAGTTTAAACATAAGCGTG
TAAATGAGGAGGAAACTGAATGATTTCCGGTTAATGATTTTAAACAGGTTTAAACAATTTCTGTTGATAACGCTATTTGG
AAAGTTATAGACTTCCAACATGTAAGCCTGGTAAAGGTTTCAGCATTCGTTTCGTTCAAAATTTACGTAATTTAAGAACTGG
TGCAATTTCAAGAGAAAACGTTTAGAGCTGGTGAAAAAGTTGAACCAGCAATGATTGAAAAATCGTCGCATGCAATATTTAT
ATGCTGACGGRGATAATCATGTATTTATGGATAATGAAAGCTTTGAACAAACAGAACTTTCAAGTGATTACTTAAAGAA
GAATTTGAATTTACTTAAAGAAGGTATGGAAGTACAAATTTCAACATACGAAGGTGAACTATCGGTGTTGAATTTACCTAA
AACTGTTGAATTAACAGTAACTGAAACAGAACTGGTATTAAAGGTGATACTGCAACTGGTGCCACTAAATCGGCAACTG
TTGAAACTGGTTATACATTAAATGTACCTTTATTTGTAACGAAGGTGACGTTTAAATTATCAACACTGGTGATGGAAGC
TACATTTCAAGAGGATAATCTCTAATTTGTTAACAATAGCTTTGATTCACTATACTGATTTAACGTAAGANATTCTAA
TAAGTCTCATAAAGCTATTGCCTAAATGATTATAGGTTA

>HGS040

MISSVNDFKITGLTISVDNAIWKVIDFQHVKPGKGSAPVRSKLRNLRTGAIQEKTFRAGEKVEPAMIENRRMQVLYADGDNH
VFMDNESFEQTELSSDYLKEELNLYLKBGMVQIQTYEGETIGVELPKTVELTVETEPGIGKDTATGATKTSATVETGYTL
NVPLFVNEGDLVLIINTGDGSYISRG

>168153/168339, (operon comprising ORFs for five polypeptides listed below)

TTAGGATGTAAGAAAGTTCCAGTGCAAGAAATCCATGAAACACAATATTCAATTAGTACATGGCAACATAAAGTTCCATTTGGTGTGTGG
TGGGAAACGTTACAACAAGAACATCGCTTGCCATGGACTACTGAGACAAGACAAGAGCGCCATTATTACAATGTGTGATGGTGATACA
GAACAATATTGTTATACAAAAGATTAGGGCAAGCACATTTTCAAGTATGGGAAAAGGTTGTGCGCAAGTTATAGTGGTTGTTGTTCTGTA
GAGAGAATTGCACAAGGTACATATCCTTGTCTTTCTCAACAAGATGACTCATGAAGTATCAGCCATTGAGTTATAAGGAAAATTGAAGCG
GTTGTTTCATAAAGGGGAACTGTGCCAGCAGGTGTGACACGCTTTAATATTTTCAGGACGATGTCTTAATCTTCAAGTACCCTGGCAATTA
CTTAAACAAGATGATGATGTTGAACAATGCGCAATTGGAAGCAGTTTTTAGCAGATAAGTTTGCCAATATGAGATGCTATACTGAAAAAG
TATACTTGGTGGAGCAATAGTTTTACTGTGATGTTGAGGGAAATATGATGATTTAGCGTATTGATAGCGAAAAATATAATAAAACAATATA
GTGTGGAGAACTTTTGATATTTTATAAATATTGAAGTTCTCCATTTTGTATTTTGCATATAAAAATTAAATAAAATAAGGTATATTAAAG
GTAAAGTATAAAATTTTAAATAAATGGGGAATGAGTATGAGCTCAATTATAGGAAAAATAGCAATTTGGATAGGCATCGTAGCTCAAATAT
ATTTTAGTGTGCTTTTGTGTTAGGATGATATCTATTAATATTGCTGGAGGATCTGATTACGAAACAATTTTATTAGGATTAAATATTGG
CTCTTTTCACTGTTTTTACCAACCATCTTTACTGCGATTTATATGAAAGTTACTCTGTAATCGGAGGTGCACTTTTTATTGTTTATGCTTA

TTATTCGACTGTGTTTATATAATTTCCCTTCGTCATATTTATGGCTGATTTGGTGGTATTTTGCTGATTTGGAATAAACTCAAAAGATG
AATCGACAGACGAAAATGAAAAGTTGATATTGAAAGTACAGAGAATCAATTTGAATCTAAAGATAAAATCACTAAAGAATAAAGAGAAT
ATTTAAGGTAAAGTATAAATTTTAAATAAATGGGAATAGACATGGAAGAAAATGTAGAAAATCATTCATAAAGATAGGTTTATATTTT
5 CAAATAGCTTATATAGTACTCATGGCTATAACTTTATGTGGGTTTGTAAATTTGCTATGGACTAATTTTCGGCCTTTTCTATTTATATCA
GGTAGCAGAGCTGATTATTTAATAGTAACAATAGTTATATCGGCAATAATTTCTATATTTGTAATTTACTTTCAATCGTACCTGTCTATC
GTATTCGCAATCTCTGGTTTGTTCAGCCATATCTATTTAGGTAGAAAAAATTAGTAGCTGCAGCAGATACTACCACTATTCAAAAA
AGTAAAGGGAACGCAATCAAGCATCACATAAAGACACGTGTAAAAAGGAACCTTGATAGTCAAGACATGATGGAACATCTCGAGGTAAAA
10 AATCCCACGACTAAAAACCTTGAAGGATTTAACGAAGAAATACATAAAGATGAAGCTACAACCTAAAGTTGTCAGTGATTAACACGGAACCG
CCTATTTGAATCAAAAGACCATGTCTCGAAAAAGATTGATGACAACTAATCGAGAGACTTAAAAAATAATATTCAACATAAGAACCTTT
TAAAACGACATTTAAACGCATTGCGCAATCACTAATGGTAGTGGCTTTAACTATACCTTAAATATCTGAATATTTTGTAAATGGAGCTAC
CTTTGTTGTACTATTCAAAATGAAGAGGAGTAAATGTAAATTAAGGAAAGAAATTTGAGGAGTGATCTTTATGACAAACAACAAAGTAGC
ATTAGTAACTGGCGGAGCACAAGGGATTGGTTTTTAAATTCAGAACGTTTGTAGTGAAGATGGTTTTCAAAGTAGCAGTTGTTGATTTCAA
15 TGAAGAAGGGGCAAAAGCAGCTGCATTTAAATTATCAAGTGATGGTACAAAAGCTATTGCTATCAAAGCAGATGTATCAAACCGTGATGA
TGTATTTAACGCATAAGACAACTGCCGCGCAATTTGGCGGATTTCCATGTCTATGGTTAACATGCGCGCCTTGGACCAACAACACCAATC
GATACAAATTACTGAAGAACAGTTTAAACAGTATATGGCGTGAACGTTGCGAGGTGTCTATGGGGTATTCAAGCCGCACATGAACAATTT
AAAAAATTCATTCATGCGGTAATAATTATCAATGCAACATCTCAAGCAGCGTTGAGGGTAACCCAGGCTTGCTTTATATTGCAGTACA
AAATTCGCAAGTTCGAGGTTTAAACACAAGTAGCCGCAAGATTAGCGTTTGAAGGTATTACTGTGAATGCATTCGCACCTGGTATCGTT
20 CAAACACCAATGATGGAAGTATCGCAGTGGCAACAGCCGAAGAAGCAGGTAAACCTGAAGCATGGGGTGGGAACAATTTCAAGTCAG
ATTGCTTTGGGCAGAGTTTCTCAACCAGAAGATGTTTCAATGTAGTGAGCTTCTTAGCTGGTAAAGACTCTGATTACATTACTGGACAA
ACAATTTATGTAGATGGTGGTATGAGATTCCGTTAATAATCATCCACTAATGATAAATAAATCCTTATTTGTTAAGTTTAAATCACTTAGCA
GTAAGGATTTTTTGTAGTCACTTAGAAGGGAGTGATTTGGTGAAGAAATTAATAAGCGAAGTTCTTAAGTGAGTTATGATGTACAGTCTAA
25 TGCATCAGTTGAAGCATTTATTAGTATTAACACACCCAAGATATTATAAAACATCACAAAAACCACTATCTAATTTATCTCAATAAAA
ATTCACAAAGTTTATCTCATTTTATTTTATAAATAAAAAATTCGATAAAAAAGCTTACAATACTTTATGTTTTTATGATATATTTTAAAT
GTATAAATGAGGTGAAGATTGGAAAGATTGGATAACTGGTGGGCTGGTTTTATTGGGTGCGATTTAGTAGATGATTTACAACAAG
ATTTATGATGTTTTATGTTCTAGATAACTATAGAACAGGTAAACGAGAAAATATTAAAAGTTTGGCTGACGATCATGTGTTGAATTAGATA
30 TTCGTGAATATGATGCAGTTGAACAAATCATGAAGACATATCAATTTGATTATGTTATTCATTAGCAGCATTAGTTAGTGTGCTGAGT
CGGTTGAGAAACCTATCTTATCTCAAGAAATAAACGTCGTAGCAACATTAAGATTGTTAGAAATCATTAAAAAATAATAATCATATAA
AACGTTTTATCTTTGCTTCGTGAGCAGCTGTTTATGGTGAATCTTCTGATTTGCTTAAAGTGATCAATCATTAATCTTACCATTATCAC
CATATGCAATAGATAAATATTTACGCGAAGCAGGACGACATTAATTTATGTTGCTTATATAACATACCAACAGCGGTTGTTAAATTTTTTA
ATGTAATTTGGGCCAAGACAGGATCCTAAGTCACAATATTCAAGTGATGTTTCAAAGATGTTGCGATTCAATTTGAGCATAACAAGCCATTTA
CATTTTTTGGTGACGGACTGCAAACTAGAGATTTTGTATATGTATATGATGTTGTTCAATCTGTACGCTTAAATTAGGAACAACAAGATG
CAATTGGACACGGTTATAACATTGGTACAGGCATTTTACTAATTTTATTAGAGGTTTATCGTATTATTGGTGAATTATATGGAANAATCAG
35 TCGAGCATGAATTTAAAGAAGCAGCAAAAAGGAGATATTAAAGCTTCTATGCGAGATTTCTAACTTAAAGGCATTAGGATTTGTTCTTA
AATATACAGTAGAACAAGCTTAAAGGATTACTTTAATTTTGGGTAGATTAATTTGAAGAAGTTACAGCTTAAAGGAAGTGAATTTGCTG
GAAAAATGACATTGAAGCTGTCATAATAATAAGGGTTATGCTATCAAAGAAAATTAGACAACTAGAAGAAGTGAGAAAAAGCTATTAC
CCAATTAACGTCGAGATTGACTTAAATTTAAGCATTTGTTTTATTATTTTAACTTTACCGATTATGGTTATATTCCGCAATTGCTATCGTC
ATAGATTGCCAGGAAACCTTATTTATAGTCAGGTTAGAGTTGGGAAGATGGGTAAATTAATTAATAAATAACAAATTACGTTTCGATGTGC
40 AAAAAACGACAGAAAAACGGTGGCGAATGGGCTGATAAAGATGATGATCGTATAACAAATGTCGGGAAGTTTATTCGTAAACACGCATT
GATGAATTTACCACAAGCTAATTAATGTTGTTAAAGGGGAAATGAGTTTATTTGACACCGCCGGAACGTCGGGAAGTTTATGAGAATTTT
AGTTTCAGAAGTAGTAGGTTTCGAGCAAAAGATGCTTCTGTTACACAGGTTTAAACAGGACTTGCAGCAAAATTCAGGTTGATATGACTTAA
CCGCAACAAAAACTGAAATATGACATGAAATATATACATAAAGGTAGTTTAAATGATGGAACATATATATCAATTAGAACATTGATGGTT
GTTATTACAGGGGAAGGCTCAAGGTAGTCTTAATTTACTTAAATAGTTCAAATAAAGTTATATTTTAAAGATTGTGACCAATTGTTTACA
45 GTATAACGAGGAATCCCTTGAGACAGTATCAATGGCATTAGAAATATGTGCCATCATTTGATTTGCATGGCTATAAATACTATTTCATCT
GATGAGATAGCCATGTTAAGAAATGAAAGTATAGCATTAAAGGGGTTGTAACAGTTGAAATTTATATTTGATTTACTAAAGCAGACA
ATGGTGGTGCAAAACACATCTCACTCACTGCCAACCATTTTTGGGTACACAATGATGTTTATGTCATTGTAGGCAATCATGGACCAA
TGATTGAACAACATAGATGCAAGAGTTAATGTAATTTATTCGAACATTAGTAGGTCCAATTGACTTTAAACAAGATATTTTAGCTGTCA
AAGTGTTAGCACAGTTATTCTCGAAAAATTAACCTGATGTTATCCATTTACATTCTTCCAAAGCTGGAACGGTGGACGAATTTGCAAGT
50 TCATTTCGAAATCGAAAGACACAGTATAGTTTACTGACATGAGTGGGCTTTACAGAGGGTGTAAACCAGCTAAAAAATTTCTAT
ATTTAGTTATCGAAAAATTAATGTCACTTATTACAGATAGCATTATTTGTGTTTCAGATTTCGATAAACAGTTAGCGTTAAAAATATCGAT
TTAATCGATTGAATTAACCAATACATAAATGGTATTGCAGATGTTCCCGCTGTAAAGCAACGCTAAAAAGCCAAATCACATAACAATA
TTGGCGAAGTAGTTGGAATGTTGCCCTAATAACAAGATTACAGATTAAATGTCGCCGACAAAGCATCAATTTGTTATGATTGCAAGATTG
CTTATCCAAAAATGCCACAAATCTAATCGCGCAATAGAGATATTGAAATTACATAACAGTAATCATGCGCATTTTACATTATAGGCG
ATGGACCTACATTAATGATTGTGACCAACAAGTTGTACAAGCTGGGTTAGAAAAATGATGTACATTTTGGGCAATGTCAATTAATGCGA
55 GTCAATTTATATCACAAATACGATACGTTTATTTTAAATAGTAAGCATGAAGGTTTGCCAAATAGCATTATAGAAGCTATGGCTACAGGTT
TGCCCTGTTATAGCCAGTCATGTTGGCGGTATTTCAGAAATTAGTAGCTGATAATGGTATATGATGATGAACAACCAACCCGAACTATTG
CTAAAGTCTTGAAAAATATTAAATAGACAGTATTACATAAATGAGTAATCAATCTAGAAAAAGCTTATTAGAATGTTTACTGAGG
AGAAAAATGTTAAAGAGGTGGAAGACGTTTATAATGGAAGAAATCAACACAATAGTAAATTAACATGTTTACTATCGGTTTAGCGGTT
TTTATTTCAGCAATCTTCGGTTATTGCGCGGTGTGAATGTTCTATAGCTGACTTTATCACATTACTAATATTAGTTTATTACTGTTTTTC
60 GCTAACCATTTATTAAAGGCAATCATTTTTCAGTTTTCATTATTTTGTATACATATCGTATGATTATTACGCTTTGTTTGTCTATTT
TTTGATGATTGTATTTATTACGGTTAAGGAAGTTCTTCGATCTACAGTTAAATATGCATTTGTAGTCAITTTATTTCTATTAGGGATG
ATCATCTTTAAGTTAGGTAATAGCAAAAAGTGATCGTTACCTCTTATATTATAAGCAGTGTGACTATAGGTCATTTTGTATTATAGCT
GGTTTGAACAAGTCCCTTTACTAATGAATTTGTTATATTGATGAAATACGTTCAAAAGGATTAAATGAATGACCCTAACATTTTCGGC

ATGACACAGATTATTACATTGGTACTTGGCTTACAAGTATATTCATAATTACATATTTCAAGGTCCTTGCATGTGGTATTTTGGCTATGGTCT
TTAACTACAACCGGGTCTAAGACTGCGTTTATCATATTAAATCGTCTTAGCCATTTATTTCTTTTATTAAGGTTATTTAGTAGAAATGCG
GTAAGTGTGTGAGTATGTCAGTGATTATGCTGATATTACTTTGTTTTACCTTTTATAATATCAACTACTATTTTATCCAATTAAAGCGAC
CTTGATGCCCTTACCGTCATTAGATCGAATGGCGTCTATTTTGAAGAGGGCTTTGCATCATTAAATGATAGTGGGTCTGAGCGAAGTGT
5 GTATGGATAAATGCCATTTTCACTAATTAATATACACTAGGTTTTGGTGTCCGATTAGTGGATTATGTACATATTTGGCTCGCAAAATTAAT
GGTATTTTACTTTGTTGCCATAATACATATTTGCGAGATCTTTGCGGAATGGGGCATTTTATTCGGTGCATTTATTTATCATATTTATGCTT
TATTTACTGTTTGAATTATTTAGATTTTAACTTTCTGGGAAAAATGTAACAGCAATTGTTGTAATGTTGACGATGCTGATTTACTTTTAA
ACAGTATCATTTAATAACTCAAGATATGTCGCTTTTATTTTAGGAATTATCGTCTTTATTTGTTCAATATGAAAAGATGGAAAGGGATCGT
AATGAAGAGTGATTCTACTAAAAGAAAAATATTATTTATCAAGGCTATACCAATTGATTAGAACGATGACACCACTGATTACAATACCCAT
10 TATTTTACGTCATTTTGGTCCAGTGGTGTGGGTATTGTTTCATTTTCTTTCAATATCGTGCATTAATTTTGTATGATTGCAAGTGTGG
CGTTCAGTTATATTTTAAATAGATTATCGCGAAGTCCGTTTAAACGACAAACCGCAATTGTCACAGCAGTTTGGGATATCTTTGTCAGTAA
ATTATTTTATAGCGTTAACAGTTTGGGATGTATATGGTCGTAATTACTATATTTATTTGATGATTACTATCTTATTTTCTACTACAAGG
AATCTATATTATAGGTGCAGCACTCGATATTTTCATGGTTTTATGCTGGAAGTGAAGGTTAAATTTCCCTAGCCTCAGTAATATTGTTGC
GTCGTGATTATGATTAAAGTGTAGTTGTTATTTTGTCAAAGATCAATCAGATTTTATCATTTGATGTATTTACTATTTGCTATTTGACGGT
15 ATTAACCAATTAACCTTTGTTTATCTATTTAAACGATACATTAGCTTTGTTTCGGTTAATTGGATACAGCTCTGGCAATTGTTTCGTTT
GTCATTAGCATACTTATTAACCAATGGACAGCTCAACTTATATAGTATTTCTTTCGTTGTTCTTGGTTTAGTAGGTACATACCAACA
AGTTGGTATCTTTTCTAACGCATTTAATATTTTAAACGGTCGCAATCATATGATTAAATACATTTGATCTTTGTAATGATTCCGCGTATTAC
CAAAATGCTCTATCCAGCAATCACATAGTTTAACTAAAACGTTAGCTAATAATATGAATATTTCAATTGATATTAAACATACCTATGGTCTT
TGGTTTAAATGCAATTATGCCATCATTTTATTTATGGTTCTTTGGTGAGGAATTTCGCATCAACTGTCCTTATGATGACCATTTTAGCGAT
20 ACTTGTATTAAATCATTTCTTTTAAATATGTTGATAAGCAGGCAATATTATTAAATAGTGAATAAAATAAGATTATATAATGCGTCAATTAC
TATTTGGTGCAGTGATAAACCCTAGTATTATGTAATTATTTTATGATATATTTTATGGAATTTACGGTGTCTGCTATTTGCGCGTTAATTACAGA
GTTTTTCTTGTCTCATTTGGCGATTATTTGATATTTACTAAAATCAATGTGAAGTTGAATATTGTAAGTACGATTCAATGTGTCATTGCTGC
TGTTATGATGTTTATTTGCTTGGTGTGGTCAATCATTTATTTGCCCTTACAAATGATACGCTACGCTGCTATTAAATTGCGATTGGTATAGT
AGTTTATCTTTTATTAATGATGACTATGAAAAATCAATACGTATGGCAATATTGAGGCATCTTCGACATAAAACAATTTAAGTACCGGT
25 AATGCTATACCTTTAGAAAATTAAGATTAAAGAAAGAAAGCAATTTCTTATTTGAAAATGGAAGTTGCTTTTAAATTCCTTTTAAAGC
GGGAAACAAAAGCAGTTAAATGCCTTTTGCATTTCAATATTAATATTAATATCAATTTTGAATATTAAATTTTATATAATTGGATATAA
CAAATAAATAAATATTATGCAAAACACACCCAAAATTAATTATTATAAAAGTATATTTCATAAAAGGAGGAATATACTTATGGCATTTAA
ATTACCAAAATTTACCATATGCATATGATGCATTGGAACCATATATAGATCAAGAACAATGGAGTTTCATCAGGACAAACATCACAAATAC
GTACGTGACGAAATTAACCGCAACAGTTGAAGGAACAGAGTTAGAGCATCAATCACTAGCGGATATGATTGCTAACTTAGACAAGGTACC
30 GGAAGCGATGGGGTACCGAGCTCGAATTCTGTAATCATGTTCATAGCTGTTTCTCTGTG

>168153_3

GTGGAAGATTGGAAAGATTTTGATAACTGGTGGGGCTGGTTTTATTTGGGTGCGATTTAGTAGATGATTTACAACAAGATTATGATGTT
TATGTTCTAGATAACTATAGAACAGGTAAACGAGAAAAATATTAAAGTTTGGCTGACGATCATGTGTTTGAATTAGATATTCGTGAATAT
35 GATGCGATTGAACAAATCATGAAGACATATCAATTTGATTATGTTATTCATTTAGCAGCATTAGTTAGTGTGCTGAGTGGTTGAGAAA
CCTATCTTCTCAAGAAATAAACGTCGTAGCAACATTAAAGATTGTTAGAAATCAITAAAAATATAATAATCATATAAAACGTTTTATC
TTTGTCTTCTGACGAGCTGTTTATGGTGTATCTTCTGTTGCTTAAAGTGTATCAATCAATCTTACCATTTATCAATTTGATGATGCAATA
GATAAATATTACGGCGAACGGACGACATTAAATTTATGTTGCTTATATAACATACCAACAGCGGTTGTTAAATTTTAAATGATTTGGG
CCAAGACAGGATCCTAAGTCACAATATTCAGGTGTGATTTCAAAGATGTTTCGATTTCATTTGAGCATAACAAGCCATTTACATTTTGGT
40 GACGGACTGCAAACTAGAGATTTTGTATATGATATGATGTTGTTCAATCTGTACGCTTAATTTATGGAACACAAAGATGCAATTGACAC
GGTTATAACATTTGGTACAGGCATTTTACTAATTTATTAGAGGTTTATCGTATTATTTGGTGAATTATATGGAATAATCAGTCGAGCATGAA
TTTAAAGAAGCAGCAAGAGGATATTAAAGCATTTCTTATGCAGATATTCTAACTTAAAGGCATTAGGATTTGTTCTTAAATATACAGTA
GAAACAGGTTTAAAGGATTACTTTAATTTTGAAGGTAGATAATATTGAAGAAGTTACAGCTAAAGAAGTGGAAATGTCGTGA

>168153_3

VEDLERVLITGGAGFIGSHLVDDLQDDYDVYVLLDNYRTGKRENIKSLADDDHVFELDIREDYDAVEQIMKYQFDYVIHLAALVSVAESVEK
PILSQEINVVATLRLLEIKKYNHNIKRFIFASSAAVYGDLPDLPKSDQSLILPLSPYAIIDKYGERITLNYCSLYNIPTAVVKFFNVFG
PRQDPKSQYSGVISKMFDSFEHNKPFTEFGDLQTRDFVYVYDVVQSVRLIMEHKDAIGHGYNIGTGFTNLLEVYRIIGELYGKSVEHE
FKEARKGDIKHSYADISNLKALGFVPKYTVETGLKDYFNEVDNIEEVTAKREVMS

>168153_2

ATGGTTATATTGCGCATTTGCTATCGTCATAGATTGCGCCAGGAAACCCATTTATAGTCAGGTTAGAGTTGGGAAGATGGGTAAATTAATT
AAAAATATACAAATTACGTTTCGATGTGCAAAAACGAGAGAAAAACGGTGGCGAATGGGCTGATAAAGATGATGATCGTATAACAAATGTC
GGGAAGTTTATTCGTGAAACACGCAATTGATGAATTACCACTAATTAATGTTGTTAAAGGGGAAATGAGTTTATTGGACACGCCCCG
55 GAACGTCGCGAATTTGTAGAATTATTAGTTCAAGAGTGATAGGTTTCGACGCAAGAGATGCTTGTACACAGGGTTAACAGGACTTGGC
CAAAATCAAGGTGGATATGACTTAACACCGCAACAAAACTGAAATATGACATGAAATATATACATAAAGGTAGTTTAAATGATGGAACATA
TATATATCAATTAGAACATTGATGGTTGTTATTACAGGGGAAGGCTCAAGGTAG

>168153_2

LDKLEEVRSYYPIKRAIDLILSIVLFLTLPIMVIFAIAVIDSPGNPIYSQVRVGKMGKLIKIKYKLRSMCKNAEKNGA
QWADKDDDRITNVGKFIKTRIDELPOLINVVKGEMSFIGPRPERPEFVELFSSEVIGFEQRCLVTPGLTGLAQIQQGYD
LTPQQLKYDMKYIHKGSLMELYISIRTLMVVITGEGSR

>168153_1

ATGATTGAACAACTAGATGCAAGAGTTAATGTAATTATTATCGAACATTTAGTAGGTCCAATTGACTTTAAACAAGATATTTAGCTGTG
AAAGTGTTCAGCAGCTTATCTCGAAAATTAAACCTGATGTTATCCATTTACATTTCTCCAAAGCTGGAACGGTTCGACGAATTCGGAAG
TTCATTTTCGAAATCGAAAGACACACGTATAGTTTTTACTGCACATGGATGGCTTTTACAGAGGGTGTAAACCAGCTAAAAAATTTCTA
TATTTAGTTATCGAAAAATTAATGTCACCTTATTACAGATAGCATTATTTGTGTTTCAGATTTCGATAAACAGTTAGCGTTAAATATCGA
TTTAATCGATTGAAATTAACCACAATACATAATGGTATTGCAGATGTTCCCGCTGTAAAGCAAACGCTAAAAAGCCAATCACATAACAAT
ATTGGCGAAGTAGTTGGAATGTTGCCATAAACAAGATTACAGATTAAATGCCCGACAAAGCATCAATTTGTATTGATTGCAAGATTT
GCTTATCCAAAAATTCGCCAAAAATCTAATCGCGGCAATAGAGATATTGAAATTACATAACAGTAATCATGCGCATTTTACATTTATAGGC
GATGGACCTACATTAAATGATTGTGACGAACAAGTTGTACAAGCTGGGTTAGAAAAATGATGTCACATTTTGGGCAATGTCATTAAATGCG
AGTCAATTATTATCACAAATACGATACGTTTATTTTAATAAGTAAGCATGAAGGTTTGCCTAATTAGCATTTATAGAGCTATGGCTACAGGT
TTGCCCTGTTATAGCCAGTCATGTTGGCGGTATTTTCAAGATTAGTAGCTGATAATGGTATATGTATGATGAACAACCAACCGAACTATT
GCTAAAGTCTGGAAAAATATTTAATAGACAGTGATTACATCAAAATGAGTAATCAATCTAGAAAACGTTATTTAGAAATGTTTACTGAG
GAGAAAAATGATTAAAGAAGTGAAGACGTTTATAATGGAATAACACAATAG

>168153_1

LKIIYCIITKADNGGAQTHLIQLANHFVHNDVYVIVGNHGMIEQLDARVNVIIIEHLVGPIDFKQDILAVKVLQALFSK
IKPDVILHSSKAGTVGRIAKFISKSDTRIVFTAHGWAFTGVKPAKKFLYLVIKLSMLITDSIICVSDFDKQLALKY
RFNRLKLTTIHNGIADVPVAVKQTLKSQSHNNIGEVVGMPLNKQDLQINAPTKHQFVMIARFAYPKLPQNLIAAIEILKLH
NSNHAHFTFIGDGPFLNDCCQOVVQAGLENDVTF LGNVINASHLLSQYDTF ILISKHGLPI SII EAMATGLPVIASHVG
GISELVADNGICMNNQPETIAKVLEKYLIDSDYIKMSNQSRKRYLECFTEEKMIKEVEDVYNGKSTQ

>168339_1 (ORF overlaps the 3' end of 168153_1 by 20 nucleotides)

ATCGAAAATCAACACAATAGTAAATTACTAACATTGTTACTTTATCGGTTTAGCGGTTTATTCAGCAATCTTCGGTTATTGCCGGTGTG
AATGTTTCTATAGCTGACTTTATCACATTACTAATATTAGTTTATTTACTGTTTTCGCTAACCATTTATTAAGGCAAAATCAATTTTATA
CAGTTTTTTCATTATTTGTATACATATCGTATGATTATTACGCTTTGTTGCTATTTTTGTATGATTGTATTTATTACCGTTAAGGAA
GTTCTTGCATCTACAGTTAAATATGCATTGTGAGTCATTTATTTCTATTTAGGGATGATCATCTTTAAGTTAGGTAATAGCAAAAAAGTG
ATCGTTACCTCTTATATTATAAGCAGTGTGACTATAGGTCTATTTGTATTATAGCTGGTTTGAACAAGTCCCTTTACTAATGAAATTG
TTATATTTTGATGAAATACGTTCAAAAGGATTAATGAATGACCTAATCTTTCGCGATGACACAGATTATTACATTTGGTACTTGCCTTAC
AAGTATATTTCATAATTACATATTCAAGGTCCTTGCATGTGGTATTTTGCTATGGTCTTTAACTACAACGGGGTCTAAGACTGCGTTTATC
ATATTAATCGTCTTAGCCATTTATTTCTTTATTAATAAAGTTATTTAGTAGAAATGCCGTAAGTGTGTGAGTATGTCAGTGATTATGCTG
ATATTACTTTGTTTACCTTTTATAATATCAACTACTATTTATTTCCAATTAAGCGACCTTGATGCCTTACCGTCATTAGATCGAATGGCG
TCTATTTTGAAGAGGGCTTTGCATCATTAAATGATAGTGGGTCTGAGCGAAGTGTGTATGGATAAATGCCATTTAGTAATTAAATAT
ACACTAGGTTTGGGTGCGGATTAGTGGATTATGTACATATTGCTCGCAAAATTAATGGTATTTTACTTGTTCGCCATAATACATATTG
CAGATCTTTGCGGAATGGGGCATTTTATTCGGTGCATTATTTATCATATTTATGCTTTATTTACTGTTTGAATTATTTAGATTAAACATT
TCTGGGAAAAATGTAACAGCAATGTGTGAATGTTGACGATGCTGATTACTTTTAAACAGTATCATTTAATAACCAAGATATGTCGCT
TTTATTTTAGGAATTATCGTCTTTATTTGTTCAATATGAAAAGATGGAAGGGATCGTAATGAAGAGTGA

>168339_1

MENQHNSKLLTLLLLIGLAVFIQSSSVIAGVNVSIADFITLLILVYLLFFANHLKANHFLOQFFIILYTYRMIITLCLFFDLDLIFITVKE
VLASTVKYAFVVIYFYLGMIIFKLGNSKKVIVTSYIISSVTIGLFCIIAGLNKSPILLMKLLYFDEIRSKGLMNDPNYFAMTQIITLVLAY
KYIHNYIFKVLACGILLSLWLTGSKTAFIILVLAIYFFIKLFSRNAVSVMVIMLILLCTFFYNINYLFLQSLDLALPSLDMA
SIFEFGFSLNDSGFSERSVVWINAISVIKYTLGFGVGLVDYVHIGSQINGILLVAHNTYIQLFAEWGILFGALFIIFMLYLLFELFRFNI
SGKNVTAIVVMLTMLIYFLTVSFNNSRYVAFILGIIIVFIVQYKMERDRNEE

>168339_2 (ORF overlaps the 3' end of 168339_1 by 35 nucleotides)

ATGAAAAGATGGAAGGGATCGTAATGAAGAGTGATTCACTAAAAGAAAATATTATTTATCAAGGCTATACCAATTGATTAGAAGCATG
ACACCACTGATTACAATACCCATTATTTACGTCGATTTGGTCCAGTGGTGTGGGTATTGTTTCATTTTCTTTCAATATCGTGCAATAC
TTTTTGATGATTGCAAGTGTGGCGTTTCACTTATATTTTAAATAGAGTTATCGCGAAGTCCGTTAACGACAAACGGCAATTTGTCACAGCAG
TTTTGGGATATCTTTGTGAGTAAATTAATTTTACGCTTAAACAGTTTTCGCGATGATATGTTGCTGTAATTACTATATTTATTGATGATTAC
TATCTTATTTTCTTACTACAAGGAATCTATATTATAGGTGACGACTCGATATTTTCATGGTTTATGCTGGAAGTGAAGGTTTAAATTT
CCTAGCCTCAGTAATATGTTGCGCTCTGGTATTGATTAAAGTGTAGTTGTTATTTTGTCAAAGATCAATCAGATTTATCATTTGATGTA
TTTACTATTGCTATTGTGACGGTATTAAACCAATTACCTTTGTTTATCTATTTAAACGATACATTAGCTTTGTTTCGGTTAAATTTGGATA
ACGCTTGGCAATGTTTCGTTTCGTCATTAGCATACTTATTAACAAATGACAGCTCAACTTATATACATAGTATTTCTTGGCTTGTCTTT
GGTTTAGTAGGTACATACCAACAAGTTGGTATCTTTTCAACGCATTTAATATTTTAAACGGTCGCAATCATAATGATTAAATACATTTGAT
CTTGTAATGATTCCGCGTATTACCAAAATGCTATCCAGCAATCAGATGTTAACTAAAACGTTAGCTAAATATATGAATATTTCAATTTG
ATATTAAACAAATACCTATGGTCTTTGGTTTAAATGCAATTAAGCCATCATTTTATTTATGGTTCTTTGGTGAGGAATTCGCATCAACTGTC
CCATTGATGACCAATTTTACGGATACTTGTATTAAATCATTCCTTTAAATATGTTGATAAGCAGGCAATATTTATTAATAGTGAATAAAATA
AGATTATATAATGCGTCAATTACTATTGGTGCAGTGAATAACCTAGTATTATGATTTATTTTATGATATATTTTATGGAATTTACGGTGTCT
GCTATTGCGCGTTTAAATTACAGAGTTTTTCTTGTCTCATTTTGGCGATTATTTGATATTACTAAATCAATGTGAAGTTGAATATTTGTAAGT
ACGATTCAATGTGTGCTGCTGCTGTTATGATGTTTATTGTGCTTGGTGTGGTCAATCATTATTTGCCCCCTACAATGTACGCTACGCTG
CTATTAATTTGCGATTGGTATAGTAGTTTATCTTTTATTAATGATGACTATGAAAATCAATACGTATGCAAAATATTGAGGCATCTTCGA
CATAAAACAATTTAA

```

>168339_2
MKSDSLKENI IYQGLYQLIRTMTPLITPI IISRAFGPSGVGIVSFSFNIVQYFLMIASVGVQLYFNRVIAKSVNDKRQLS
QQFWDIFVSKLFLALT V FAMYMVITIFIDDDYLI FL LQGIY I IGAALDISWFYAGTEKFKIPSLSNIVASGIVLSVVVI
FVKDQSDLSLYVFTIAIVTVLNQLPLFIYLKRYISFVSVNWIHWQLFRSSLAYLLPNGQLNLYTSISCVVLGLVGTYYQ
5 VGIFSNAFNILTVAI IMINTFDLVMIPRITKMSIQQSHSLTKTLANNMNIQLILTIPMVFGLIAIMPSFYLWFFGEFAS
TVPLMTILAILVLI I PLNMLISRQYLLIVNKIRLYNASITIGAVINLVLCI ILIYFYGIYGAAIARLITEFFLLIWRFD
ITKINVKLNIVSTIQCVIAAVMMFIVLGVVNHYLPPTMYATLLLIAIGIVVYLLMMTMKNQYVWQILRLRHKT I

```

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, DNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

By "isolated" polynucleotide sequence is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. This includes segments of DNA comprising the *S. aureus* polynucleotides of the present invention isolated from the native chromosome. These fragments include both isolated fragments consisting only of *S. aureus* DNA and fragments comprising heterologous sequences such as vector sequences or other foreign DNA. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention which may be partially or substantially purified. Further examples of isolated DNA molecules include recombinant DNA molecules introduced and maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically which may be partially or substantially purified the excluded RNA or heterologous DNA. Isolated nucleic acid molecules e at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 96%, 98%, 99%, or 100% pure relative to herelogenous (*Staphylococcus* or other) (DNA or RNA) or relative to all materials and compounds other than the carrier solution. The term "isolated" does not refer to genomic or cDNA libraries, whole cell mRNA preparations, genomic DNA digests (including those gel separated by electrophoresis), whole chromosome or sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotides sequences of the present invention.

In addition, isolated nucleic acid molecules of the invention include DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode a *S. aureus* polypeptides and peptides of the present invention (e.g. polypeptides of Table 1). That is, all possible DNA sequences that encode the *S. aureus* polypeptides of the present invention. This includes the genetic code and species-specific codon preferences known in the art. Thus, it would be routine for one skilled

in the art to generate the degenerate variants described above, for instance, to optimize codon expression for a particular host (e.g., change codons in the bacteria mRNA to those preferred by a mammalian or other bacterial host such as *E. coli*).

The invention further provides isolated nucleic acid molecules having the nucleotide
5 sequence shown in Table 1 or a nucleic acid molecule having a sequence complementary to one of the above sequences. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping and for identifying *S. aureus* in a biological sample, for instance, by PCR or Northern blot analysis. In specific embodiments, the polynucleotides of the present invention are less than 300kb, 200kb, 100kb, 50kb, 10kb, 7.5kb, 5kb, 2.5kb, and 1kb. In
10 another embodiment, the polynucleotides comprising the coding sequence for polypeptides of the present invention do not contain genomic flanking gene sequences or contain only genomic flanking gene sequences having regulatory control sequences for the said polynucleotides.

The present invention is further directed to nucleic acid molecules encoding portions or fragments of the nucleotide sequences described herein. Uses for the polynucleotide fragments
15 of the present invention include probes, primers, molecular weight, markers and for expressing the polypeptide fragments of the present invention. Fragments include portions of the nucleotide sequences of Table 1, at least 10 contiguous nucleotides in length selected from any two integers, one of which representing a 5' nucleotide position and a second of which representing a 3' nucleotide position, where the first nucleotide for each nucleotide sequence in
20 Table 1 is position 1. That is, every combination of a 5' and 3' nucleotide position that a fragment at least 10 contiguous nucleotides in length could occupy is included in the invention as an individual species. "At least" means a fragment may be 10 contiguous nucleotide bases in length or any integer between 10 and the length of an entire nucleotide sequence minus 1. Therefore, included in the invention are contiguous fragments specified by any 5' and 3'
25 nucleotide base positions of a nucleotide sequences of Table 1 wherein the contiguous fragment is any integer between 10 and the length of an entire nucleotide sequence minus 1.

The polynucleotide fragment specified by 5' and 3' positions can be immediately envisaged using the clone description and are therefore not individually listed solely for the purpose of not unnecessarily lengthening the specifications.

30 Although it is particularly pointed out that each of the above described species may be included in or excluded from the present invention. The above species of polynucleotides fragments of the present invention may alternatively be described by the formula "a to b"; where "a" equals the 5' nucleotide position and "b" equals 3' nucleotide position of the polynucleotide fragment, where "a" equals an integer between 1 and the number of nucleotides
35 of the polynucleotide sequence of the present invention minus 10, where "b" equals an integer between 10 and the number of nucleotides of the polynucleotide sequence of the present invention; and where "a" is an integer smaller than "b" by at least 10.

Again, it is particularly pointed out that each species of the above formula may be specifically included in, or excluded from, the present invention. Further, the invention includes polynucleotides comprising sub-genuses of fragments specified by size, in nucleotides, rather than by nucleotide positions. The invention includes any fragment size, in contiguous nucleotides, selected from integers between 10 and the length of an entire nucleotide sequence minus 1. Preferred size of contiguous nucleotide fragments include 20 nucleotides, 30 nucleotides, 40 nucleotides, 50 nucleotides, 60 nucleotides, 70 nucleotides, 80 nucleotides, 90 nucleotides, 100 nucleotides, 125 nucleotides, 150 nucleotides, 175 nucleotides, 200 nucleotides, 250 nucleotides, 300 nucleotides, 350 nucleotides, 400 nucleotides, 450 nucleotides, 500 nucleotides, 550 nucleotides, 600 nucleotides, 650 nucleotides, 700 nucleotides, 750 nucleotides, 800 nucleotides, 850 nucleotides, 900 nucleotides, 950 nucleotides, 1000 nucleotides, 1050 nucleotides, 1100 nucleotides, and 1150 nucleotides. Other preferred sizes of contiguous polynucleotide fragments, which may be useful as diagnostic probes and primers, include fragment sizes representing each integer between 50-300. Larger fragments are also useful according to the present invention corresponding to most, if not all, of the polynucleotide sequences of the sequence listing or deposited clones. The preferred sizes are, of course, meant to exemplify not limit to present invention as all size fragments, representing any integer between 10 and the length of an entire nucleotide sequence minus 1 of the sequence listing or deposited clones, may be specifically included from the invention. Additional preferred nucleic acid fragment of the present invention include nucleic acid molecules encoding epitope-bearing portions of the polynucleotides (e.g., including but not limited to, nucleic acid molecules encoding epitope-bearing portions of the polynucleotides which are shown in Table 4).

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of a polynucleotide in a nucleic acid molecules of the invention described above, for instance, nucleotide sequences of Table 1. By "stringent hybridization conditions" is intended overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C. Hybridizing polynucleotides are useful as diagnostic probes and primers as discussed above. Portions of a polynucleotide which hybridize to a nucleotide sequence in Table 1, which can be used as probes and primers, may be precisely specified by 5' and 3' base positions or by size in nucleotide bases as described above or precisely excluded in the same manner. Preferred hybridizing polynucleotides of the present invention are those that, when labeled and used in a hybridization assay known in the art (e.g. Southern and Northern blot analysis), display the greatest signal strength with the polynucleotides of Table 1

regardless of other heterologous sequences present in equimolar amounts

The nucleic acid molecules of the present invention, which encode a *S. aureus* polypeptide, may include, but are not limited to, nucleic acid molecules encoding the full length *S. aureus* polypeptides of Table 1. Also included in the present invention are nucleic acids encoding the above full length sequences and further comprise additional sequences, such as those encoding an added secretory leader sequence, such as a pre-, or pro- or prepro- protein sequence. Further included in the present invention are nucleic acids encoding the above full length sequences and portions thereof and further comprise additional heterologous amino acid sequences encoded by nucleic acid sequences from a different source.

Also included in the present invention are nucleic acids encoding the above protein sequences together with additional, non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences. These sequences include transcribed, non-translated sequences that may play a role in transcription, and mRNA processing, for example, ribosome binding and stability of mRNA. Also included in the present invention are additional coding sequences which provide additional functionalities.

Thus, a nucleotide sequence encoding a polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. For instance, hexa-histidine provides for convenient purification of the fusion protein. See Gentz et al. (1989) Proc. Natl. Acad. Sci. 86:821-24. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein. See Wilson et al. (1984) Cell 37:767. As discussed below, other such fusion proteins include the *S. aureus* fused to Fc at the N- or C-terminus.

Variant and Mutant Polynucleotides

The present invention further relates to variants of the nucleic acid molecules which encode portions, analogs or derivatives of a *S. aureus* polypeptides of Table 1, and variant polypeptides thereof including portions, analogs, and derivatives of the *S. aureus* polypeptides. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. See, e.g., B. Lewin, Genes IV (1990). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

Such nucleic acid variants include those produced by nucleotide substitutions, deletions, or additions. The substitutions, deletions, or additions may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both.

Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of a *S. aureus* protein of the present invention or portions thereof. Also preferred in this regard are conservative
5 substitutions.

Such polypeptide variants include those produced by amino acid substitutions, deletions or additions. The substitutions, deletions, or additions may involve one or more residues. Alterations may produce conservative or non-conservative amino acid substitutions, deletions, or additions. Especially preferred among these are silent substitutions, additions and
10 deletions, which do not alter the properties and activities of a *S. aureus* protein of the present invention or portions thereof. Also especially preferred in this regard are conservative substitutions.

The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant
15 vectors, as well as to methods of making such vectors and host cells and for using them for production of *S. aureus* polypeptides or peptides by recombinant techniques.

The present application is directed to nucleic acid molecules at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleic acid sequence shown in Table 1. The above nucleic acid sequences are included irrespective of whether they encode a polypeptide having *S. aureus*
20 activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having *S. aureus* activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having *S. aureus* activity include, *inter alia*, isolating an *S. aureus* gene or allelic variants thereof from a DNA
25 library, and detecting *S. aureus* mRNA expression in biological or environmental samples, suspected of containing *S. aureus* by Northern Blot analysis or PCR.

The present invention is further directed to nucleic acid molecules having sequences at least 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in Table 1, which do, in fact, encode a polypeptide having *S. aureus* protein activity. By "a
30 polypeptide having *S. aureus* activity" is intended polypeptides exhibiting activity similar, but not necessarily identical, to an activity of the *S. aureus* protein of the invention, as measured in a particular biological assay suitable for measuring activity of the specified protein. The biological activity of some of the polypeptides of the presents invention are listed in Table 1, after the name of the closest homolog with similar activity. The biological activities were
35 determined using methods known in the art for the particular biological activity listed. For the remaining polypeptides of Table 1, the assays known in the art to measure the activity of the polypeptides of Table 2, sharing a high degree of identity, may be used to measure the activity

of the corresponding polypeptides of Table 1.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequences shown in Table 1 will encode a polypeptide having biological activity. In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having biological activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid), as further described below.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the *S. aureus* polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted, inserted, or substituted with another nucleotide. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

Other methods of determining and defining whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be done by using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. See Brutlag et al. (1990) Comp. App. Biosci. 6:237-245. In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by first converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

TABLE 2. Closest matching sequence between the polypeptides of the present invention and sequences in GenSeq and GenBank databases

Sequence ID	Antigen Accession No.	Match Gene Name	High Score	Smallest Sum Probability P (N)
<i>GenSeq</i>				
HGS001	W34207	Streptomyces fabH homologue (frenolicin gene I pro...	285	3.50E-65
HGS001	W55808	Streptomyces roseofulvus frenolicin gene cluster p...	285	3.50E-65
HGS002	W20949	H. pylori cytoplasmic protein, 29zp10241orf7.	81	5.10E-12
HGS003	W48300	Staphylococcus aureus Fab I enoyl-ACP reductase.	1271	1.90E-170
HGS003	W40806	M. bovis InhA protein.	95	1.00E-29
HGS003	R23793	Stearoyl-ACP-desaturase (from clone pDES7).	157	1.60E-28
HGS003	R66290	M. tuberculosis inhA gene.	94	7.40E-28
HGS003	R66901	M. tuberculosis InhA.	94	7.40E-28
HGS003	R66292	Mycobacterium bovis InhA.	92	4.70E-19
HGS003	R63900	M. bovis InhA.	92	4.70E-19
HGS003	W16684	Lawsonia intracellularis enoyl-(acyl carrier prote...	114	1.80E-09
HGS003	W40805	M. tuberculosis InhA protein.	96	2.60E-09
HGS003	W40807	M. smegmatis InhA protein, mc2155 inhA-1.	101	9.70E-09
HGS004	W32287	Streptococcus pneumoniae MurA protein.	643	4.00E-89
HGS004	W26786	Streptococcus pneumoniae Mur A-1.	643	4.10E-89
HGS004	W27782	UDP-N-acetylglucosamine 1-carboxyvinyltransferase.	163	1.80E-15
HGS004	W27783	UDP-N-acetylglucosamine 1-carboxyvinyltransferase.	120	1.90E-12
HGS006	W36168	Staphylococcus aureus SP protein.	584	4.30E-78
HGS006	W37468	Staphylococcus aureus RNase P.	581	1.10E-77
HGS007M	W27798	Amino acid sequence of a replicative DNA heli case	5524	6e-83.2
HGS007M	R29636	pCTD ORF 1.	241.	7e-34.3
HGS008	W27814	A malonyl coenzymeA-acyl carrier protein transacyl...	365	4.70E-46
HGS008	W19629	Streptomyces venezuelae polyketide synthase.	96	2.30E-19
HGS008	W22602	Tylactone synthase ORF2 protein.	83	2.90E-18
HGS008	W22605	Tylactone synthase ORF5 protein.	95	8.90E-17

HGS008	R44431	eryA region polypeptide module #2.	88	2.30E-14
HGS008	R42452	Enzyme involved in eicosapentaenoic acid (EPA) syn...	94	5.30E-14
HGS008	R99462	Biosynthetic enzyme of icosapentaenoic acid synthase.	94	4.60E-13
HGS008	W37050	S. putrefaciens EPO biosynthesis gene cluster ORF6...	94	4.60E-13
HGS008	R44432	eryA region polypeptide module #3.	83	6.20E-13
HGS008	W22607	Platenolide synthase ORF2 protein.	80	2.20E-12
HGS014	W34454	Racillus subtilis teichoic acid polymerase.	597	2.70E-87
HGS014	W34455	Racillus subtilis teichoic acid polymerase.	597	3.10E-87
HGS014	W27744	Amino acid sequence of teichoic acid biosynthesis p...	425	2.50E-53
HGS016	W32287	Streptococcus pneumoniae MurA protein.	643	4.00E-89
HGS016	W26786	Streptococcus pneumoniae Mur A-1.	643	4.10E-89
HGS016	W27782	UDP-N-acetylglucosamine 1-carboxyvinyltransferase.	163	1.80E-15
HGS016	W27783	UDP-N-acetylglucosamine 1-carboxyvinyltransferase.	120	1.90E-12
HGS018	R95648	Thermotable DNA-ligase.	833	3.00E-205
HGS018	R81473	Thermus aquaticus DNA ligase protein.	428	2.00E-201
HGS018	R15299	Thermotable T. aquaticus ligase (I).	428	7.40E-199
HGS018	R15694	Thermotable T. aquaticus ligase (II).	428	4.80E-196
HGS019	P70096	Met-aminopeptidase.	143	2.90E-35
HGS019	R90027	Methionine aminopeptidase sequence.	138	1.60E-20
HGS022	R12401	Enantioselective amidase of Rhodococcus.	405	4.70E-102
HGS022	R25320	Enantioselective amidase.	405	4.70E-102
HGS022	W14159	Rhodococcus rhodochrous amidase.	352	6.10E-63
HGS022	W17820	Pseudomonas putida amidase.	208	1.20E-62
HGS022	R12400	Enantioselective amidase of Brevibacterium.	353	2.90E-62
HGS022	R24529	Enantioselective amidase.	353	2.90E-62
HGS022	W10882	Comamonas acidovorans derived amidase enzyme.	261	4.00E-61
HGS022	R60155	Comamonas testosteroni NI 1 amidase.	306	5.30E-47
HGS022	R42839	Urea amidolyase.	243	1.40E-31
HGS022	R44504	Urea amide lyase.	224	8.60E-30
HGS026	W29380	S. pneumoniae peptide releasing factor RF-1.	593	3.30E-142
HGS028	W29380	S. pneumoniae peptide releasing factor RF-1.	218	1.70E-49
HGS031	W20646	H. pylori cytoplasmic protein, OZcp11822orf26.	291	5.70E-47

HGS031	W20147	H. pylori cytoplasmic protein, 14574201.aa.	75	1.50E-08
HGS033	W20861	H. pylori cell envelope transporter protein, 12gel...	100	2.30E-18
HGS033	W20101	H. pylori transporter protein 11132778.aa.	100	6.10E-17
HGS033	W25671	hABC3 protein.	111	4.20E-15
HGS033	W46761	Amino acid sequence of human ATP binding cassette ...	111	4.20E-15
HGS033	W46771	Amino acid sequence of human ATP binding cassette ...	111	4.30E-15
HGS033	W42393	Bacillus thermoleovorans phosphatase (68FY5).	96	1.90E-13
HGS033	W34202	Streptomyces efflux pump protein (frenolicin gene ...	92	5.50E-12
HGS033	W55803	Streptomyces roseofulvus frenolicin gene cluster p...	92	5.50E-12
HGS033	W20224	H. pylori transporter protein, 22265691.aa.	88	7.40E-12
HGS033	W20668	H. pylori transporter protein O3ee11215orf29.	88	8.90E-12
HGS036	W20640	H. pylori transporter protein, 02ce11022orf8.	264	2.20E-33
HGS036	W34202	Streptomyces efflux pump protein (frenolicin gene ...	184	1.30E-29
HGS036	W55803	Streptomyces roseofulvus frenolicin gene cluster p...	184	1.30E-29
HGS036	W20289	H. pylori transporter protein, 24218968.aa.	201	5.50E-21
HGS036	W20711	H. pylori transporter protein, 05cp11911orf41.	148	2.10E-19
HGS036	W20101	H. pylori transporter protein 11132778.aa.	164	3.50E-19
HGS036	W20861	H. pylori cell envelope transporter protein, 12gel...	164	4.20E-19
HGS036	W20492	H. pylori cell envelope transporter protein 433843...	148	1.60E-18
HGS036	W21019	H. pylori cell envelope transporter protein, hp5el...	144	8.30E-16
HGS036	R71091	C. jejuni PEB1A antigen from ORF3.	136	7.90E-14
168153_3	W01619	Human uridine diphosphate galactose-4-epimerase.	128	9.80E-29
168153_3	W40383	S. glaucescens acbD protein.	105	1.10E-15
168153_3	R98529	dTDP-glucose dehydratase encoded by the acbB gene.	108	4.50E-15
168153_3	R80287	galE gene of S. lividans gal operon.	88	2.60E-13
168153_3	P70275	Sequence encoded by S. lividans gal operon galE gene.	86	5.10E-13
168153_3	R41529	S. lividans UDP-4-epimerase.	86	5.10E-13
168153_3	R32195	ADP-L-glycero-D-mannoheptose-6-epimerase protein.	82	3.40E-10
168153_2	W03997	Glucosyl IP-transferase (SpsB protein).	168	8.30E-36
168153_2	W32794	Spingomonas genus microbe isolated SpsB protein.	168	8.30E-36
168153_2	W22173	S. thermophilus exopolysaccharide synthesis operon ...	141	2.20E-31
168153_2	W14074	S. thermophilus exopolysaccharide biosynthesis enzy...	141	2.20E-31
168153_2	P70458	Sequence of gpD encoded by segment of Xanthomonas ...	183	2.30E-30

168153_1	W22175	S.thermophilus exopolysaccharide synthesis operon ...	141	6.40E-35
168153_1	W14076	S.thermophilus exopolysaccharide biosynthesis enzy...	141	9.50E-35
168153_1	W22174	S.thermophilus exopolysaccharide synthesis operon ...	162	9.50E-30
168153_1	W14075	S.thermophilus exopolysaccharide biosynthesis enzy...	162	9.50E-30
168339_2	W27736	Putative O-antigen transporter protein.	820	5.70E-11.5
GenBank				
HGS001	gnllPIDle1183136	similar to 3-oxoacyl- acyl-carrier protein	569	2.20E-129
HGS001	gil151943	ORF3; putative [Rhodobacter capsulatus]	404	1.40E-92
HGS001	gil2983572	(AE000723) 3-oxoacyl-[acyl-carrier-protein	311	5.10E-92
HGS001	gil1276662	beta-ketoacyl-acyl carrier protein synthase	292	3.90E-90
HGS001	gil2313291	(AE000540) beta-ketoacyl-acyl carrier protein	269	3.50E-89
HGS001	gnllPIDle1183019	similar to 3-oxoacyl- acyl-carrier protein	373	2.00E-86
HGS001	gil1143069	3-ketoacyl carrier protein synthase III	287	3.60E-86
HGS001	gil22744	beta-ketoacyl-acyl carrier protein synthase	292	1.20E-85
HGS001	gil311686	3-ketoacyl-acyl carrier protein synthase	322	3.40E-85
HGS001	gil145898	beta-ketoacyl-acyl carrier protein synthase	366	7.30E-84
HGS002	gil142833	ORF2 [Bacillus subtilis] >gnllPIDle11851...	215	2.50E-70
HGS002	gnllPIDle1019368	hypothetical protein [Synechocystis sp.]	235	8.50E-67
HGS002	gil2983165	(AE000694) UDP-N-acetylenolpyruvoylgluco...	207	1.10E-58
HGS002	gil404010	ORF2 [Bacillus licheniformis] >pir14022...	251	1.10E-50
HGS002	gil2688520	(AE001161) UDP-N-acetylmutamate dehydrog...	197	1.80E-42
HGS002	gil1841789	UDP-N-acetylenolpyruvoylglucosamine reduc...	249	7.10E-40
HGS002	gil2983149	(AE000693) UDP-N-acetylenolpyruvoylglucos...	212	3.80E-36
HGS002	gil431730	UDP-N-acetylenolpyruvoylglucosamine redu...	119	4.50E-22
HGS002	gil1573234	UDP-N-acetylenolpyruvoylglucosamine redu...	139	6.20E-22
HGS002	gil290456	UDP-N-acetylenolpyruvoylglucosamine reductas...	123	2.90E-20
HGS003	gnllPIDle1183192	similar to enoyl- acyl-carrier protein r...	743	1.80E-97
HGS003	gil142010	Shows 70.2% similarity and 48.6% identit...	519	8.90E-80
HGS003	gnllPIDle1017769	enoyl-[acyl-carrier-protein] reductase [...]	482	2.10E-73
HGS003	gil2313282	(AE000539) enoyl-(acyl-carrier-protein) ...	449	1.70E-71
HGS003	gil145851	envM [Escherichia coli] >gil587106 enoyl...	388	3.70E-71
HGS003	gil153955	envM protein [Salmonella typhimurium] >p...	386	2.10E-69

HGS003	gil1574591	short chain alcohol dehydrogenase homolo...	362	3.10E-68
HGS003	gil2983915	(AE000745) enoyl-[acyl-carrier-protein] ...	268	1.10E-64
HGS003	gil1053075	orf1; similar to E.coli EnvM [Proteus mi...	259	2.60E-29
HGS003	gnllPIDle1188732	(AJ003124) enoyl-ACP reductase [Petunia ...	154	2.20E-28
HGS004	gnllPIDle276830	UDP-N-acetylglucosamine 1-carboxyvinyl tr...	1251	2.50E-195
HGS004	gil415662	UDP-N-acetylglucosamine 1-carboxyvinyl t...	534	1.40E-139
HGS004	gnllPIDle1010850	UDP-N-acetylglucosamine 1-carboxyvinyl tr...	732	7.50E-138
HGS004	gil41344	UDP-N-acetylglucosamine 1-carboxyvinyl tr...	537	2.90E-137
HGS004	gil1574635	UDP-N-acetylglucosamine enolpyruvyl tran...	536	4.70E-136
HGS004	gil146902	UDP-N-acetylglucosamine enolpyruvyl tran...	509	5.10E-134
HGS004	gil2983705	(AE000732) UDP-N-acetylglucosamine 1-car...	492	6.20E-121
HGS004	gnllPIDle229797	UDP-N-acetylglucosamine enolpyruvyl tran...	606	3.00E-119
HGS004	gil699337	UDP-N-acetylglucosamine 1-carboxyvinyl tr...	605	1.10E-118
HGS004	gil2313767	(AE000578) UDP-N-acetylglucosamine enolp...	440	1.90E-117
HGS005	gil143434	Rho Factor [Bacillus subtilis]	755	1.10E-190
HGS005	gil853769	transcriptional terminator Rho [Bacillus ...	746	1.80E-189
HGS005	gil2983405	(AE000711) transcriptional terminator Rho...	580	2.10E-154
HGS005	gil454859	The first ATG in the open reading frame ...	543	7.90E-150
HGS005	gil147607	transcription termination factor [Escheri...	592	9.40E-149
HGS005	gil49363	ho Factor [Salmonella typhimurium] >pirl...	592	1.70E-148
HGS005	gnllPIDle220353	Rho gene product [Streptomyces lividans] ...	575	4.90E-148
HGS005	gil1573263	transcription termination factor rho (rho...	575	5.40E-147
HGS005	gil49365	Rho factor [Neisseria gonorrhoeae] >pirl...	590	1.40E-146
HGS005	gil2313666	(AE000569) transcription termination fact...	547	8.10E-146
HGS006	gil580904	homologous to E.coli rnpA [Bacillus subt...	295	8.10E-37
HGS006	gnllPIDle1005777	protein component of ribonuclease P [Bac...	293	1.60E-36
HGS006	gnllPIDle1004132	RNaseP C5 subunit [Mycoplasma capricolum...	99	3.60E-22
HGS006	gil144147	rnpA [Buchnera aphidicola] >gil2827012 (...	97	3.90E-10
HGS006	gil511457	RNase P protein component [Coxiella burn...	117	2.30E-09
HGS007M	gnllPIDle1005718	replicative DNA helicase [Bacillus subt...	579	6.20E-169
HGS007M	gil3282821	(AF045058) DnaC replicative helicase [Ba...	536	3.60E-156
HGS007M	gnllPIDle321938	helicase [Rhodothermus marinus]	433	1.50E-123

HGS007M	gil2335167	(AF006675) DNA helicase [Rhodothermus ma...	271	2.90E-109
HGS007M	gnlPIDle211889	DNA-replication helicase [Odontella sine...	395	1.60E-108
HGS007M	gnlPIDle1263993	(AL022118) replicative DNA helicase DnaB...	235	3.20E-103
HGS007M	gnlPIDle244747	gene 40 [Bacteriophage SPP1] >gil529650 ...	477	4.40E-103
HGS007M	gil2983861	(AE000742) replicative DNA helicase [Aqu...	244	1.10E-102
HGS007M	gil2314528	(AE000636) replicative DNA helicase (dna...	246	7.70E-101
HGS007M	gnlPIDle1011167	replicative DNA helicase [Synechocystis ...	209	1.50E-100
HGS008	gnlPIDle1185181	malonyl CoA-acyl carrier protein transac...	560	4.30E-90
HGS008	gil1502420	malonyl-CoA:Acyl carrier protein transac...	391	1.40E-86
HGS008	gil3282803	(AF044668) malonyl CoA-acyl carrier prot...	308	2.50E-75
HGS008	gil2738154	malonyl-CoA:acyl carrier protein transac...	283	3.40E-75
HGS008	gil145887	malonyl coenzyme A-acyl carrier protein ...	304	6.30E-75
HGS008	gil1573113	malonyl coenzyme A-acyl carrier protein ...	270	7.60E-74
HGS008	gil2983416	(AE000712) malonyl-CoA:Acyl carrier prot...	213	2.70E-73
HGS008	gil840626	transacylase [Bacillus subtilis]	221	1.20E-66
HGS008	gil3150402	(AC004165) putative malonyl-CoA:Acyl car...	235	1.60E-57
HGS008	gnlPIDle1185300	pkcC [Bacillus subtilis] >gnlPIDle11833...	145	4.40E-38
HGS009	gil460911	fructose-bisphosphate aldolase [Bacillus...	1169	2.10E-154
HGS009	gnlPIDle1251871	fructose-1,6-bisphosphate aldolase type ...	1121	6.70E-148
HGS009	gnlPIDle1003809	hypothetical protein [Bacillus subtilis]...	467	1.50E-110
HGS009	gil2313265	(AE000538) fructose-bisphosphate aldolas...	252	6.40E-91
HGS009	gil1673788	(AE000015) Mycoplasma pneumoniae, fructo...	238	4.60E-81
HGS009	gil1045692	fructose-bisphosphate aldolase [Mycoplas...	226	6.40E-77
HGS009	gnlPIDle1016691	Tagatose-bisphosphate aldolase GatY (EC ...	279	2.30E-75
HGS009	gil599738	unknown function [Escherichia coli] >pir...	274	2.00E-74
HGS009	gil1732204	putative aldolase [Vibrio furnissii]	277	5.00E-74
HGS009	gil606077	ORF_o286 [Escherichia coli] >gil1789526 ...	264	1.30E-73
HGS014	gil40100	rodC (tag3) polypeptide (AA 1-746) [Baci...	597	1.70E-86
HGS014	gnlPIDle1169895	tasA [Streptococcus pneumoniae]	108	4.90E-27
HGS014	gil2621425	(AE000822) teichoic acid biosynthesis pr...	142	2.00E-23
HGS014	gil2621421	(AE000822) teichoic acid biosynthesis pr...	147	5.90E-22
HGS014	gil143725	putative [Bacillus subtilis] >gnlPIDle1...	114	4.60E-19

HGS014	gil547513	orf3 [Haemophilus influenzae] >pirIS4924...	106	5.60E-14
HGS014	gnlPIDle1027517	(AB009477) 395aa long hypothetical prote...	79	4.20E-12
HGS014	gil2072447	EpsI [Lactococcus lactis cremoris]	106	5.20E-10
HGS014	gil915199	ggaB [Bacillus subtilis] >gnlPIDle11844...	89	8.10E-08
HGS016	gnlPIDle276830	UDP-N-acetylglucosamine 1-carboxyvinyltr...	1251	2.50E-195
HGS016	gil415662	UDP-N-acetylglucosamine 1-carboxyvinyl t...	534	1.40E-139
HGS016	gnlPIDle1010850	UDP-N-acetylglucosamine 1-carboxyvinyltr...	732	7.50E-138
HGS016	gil41344	UDP-N-acetylglucosamine 1-carboxyvinyltr...	537	2.90E-137
HGS016	gil1574635	UDP-N-acetylglucosamine enolpyruvyl tran...	536	4.70E-136
HGS016	gil146902	UDP-N-acetylglucosamine enolpyruvyl tran...	509	5.10E-134
HGS016	gil2983705	(AE000732) UDP-N-acetylglucosamine 1-car...	492	6.20E-121
HGS016	gnlPIDle229797	UDP-N-acetylglucosamine enolpyruvyl tran...	606	3.00E-119
HGS016	gil699337	UDP-N-acetylglucosamine 1-carboxyvinyl tr...	605	1.10E-118
HGS016	gil2313767	(AE000578) UDP-N-acetylglucosamine enolp...	440	1.90E-117
HGS018	gnlPIDle1182642	similar to DNA ligase [Bacillus subtilis]	1574	9.60E-287
HGS018	gnlPIDle1017321	DNA ligase [Synecocystis sp.] >pirS744...	830	5.70E-209
HGS018	gil1574651	DNA ligase (lig) [Haemophilus influenzae]	484	1.30E-204
HGS018	gil607820	DNA ligase [Rhodothermus marinus] >spIP4...	833	1.60E-204
HGS018	gil155088	DNA ligase [Thermus aquaticus thermophil...	428	3.10E-201
HGS018	gil609276	DNA ligase [Thermus scotoductus] >pirS5...	436	1.10E-200
HGS018	gil2983242	(AE000699) DNA ligase (NAD dependent) [A...	724	1.00E-179
HGS018	gil49284	DNA ligase [Zymomonas mobilis] >pirS206...	523	1.60E-170
HGS018	gnlPIDle1237759	(AL021287) DNA ligase [Mycobacterium tub...	529	1.80E-161
HGS018	gnlPIDle349403	DNA ligase [Mycobacterium leprae]	527	7.30E-160
HGS019	dbjilD86417_12	YfiG [Bacillus subtilis] >gnlPIDle11827...	559	8.00E-72
HGS019	gil1044986	methionine aminopeptidase [Bacillus subt...	254	4.50E-58
HGS019	gil1574578	methionine aminopeptidase (map) [Haemoph...	185	5.10E-56
HGS019	gnlPIDle1172953	(AL008883) methionine aminopeptidase [My...	214	1.10E-51
HGS019	gil2982825	(AE000672) methionyl aminopeptidase [Aqu...	192	3.70E-48
HGS019	gnlPIDle1253272	(AL021958) methionine aminopeptidase [My...	130	5.20E-48
HGS019	gil2687996	(AE001123) methionine aminopeptidase (ma...	195	9.00E-48
HGS019	gnlPIDle1254451	methionine aminopeptidase [Streptomyces ...	151	2.10E-43

HGS019	gil975723	methionine aminopeptidase I [Saccharomyc...	294	3.60E-43
HGS019	gil2583129	(AC002387) putative methionine aminopept...	211	2.10E-41
HGS022	gnllPIDle1182648	alternate gene name: yedB; similar to am...	1586	2.80E-212
HGS022	gil2589195	(AF008553) Glu-tRNA Gln amidotransferase ...	1436	1.70E-198
HGS022	gnllPIDle1018331	amidase [Synechocystis sp.] >pirS77264l...	867	2.30E-178
HGS022	gil2982954	(AE000680) glutamyl-tRNA (Gln) amidotran...	1247	6.50E-176
HGS022	gil1224069	amidase [Moraxella catarrhalis] >spIQ490...	522	4.40E-158
HGS022	gil2648182	(AE000943) Glu-tRNA amidotransferase, su...	548	1.30E-145
HGS022	gnllPIDle349405	probable amidase [Mycobacterium leprae]	465	6.30E-143
HGS022	gnllPIDle1237756	(AL021287) putative Glu-tRNA-Gln amidotr...	470	1.90E-141
HGS022	gil2313964	(AE000594) amidase [Helicobacter pylori]...	550	7.30E-123
HGS022	gil2622613	(AE000910) amidase [Methanobacterium the...	524	5.80E-116
HGS023	gil1354211	PET112-like protein [Bacillus subtilis] ...	2291	2.90E-307
HGS023	gil2653657	Bacillus subtilis PET112-like protein [B...	1313	1.20E-250
HGS023	gil2589196	(AF008553) Glu-tRNA Gln amidotransferase ...	1315	4.20E-250
HGS023	gnllPIDle1182649	similar to pet112-like protein [Bacillus...	1346	7.10E-224
HGS023	gil2983123	(AE000691) glutamyl-tRNA (Gln) amidotran...	931	2.30E-165
HGS023	gnllPIDle1019042	PET112 [Synechocystis sp.] >pirS75850IS...	859	4.10E-161
HGS023	gil1224071	unknown [Moraxella catarrhalis] >spIQ490...	323	3.90E-132
HGS023	gil2313783	(AE000579) PET112-like protein [Helicoba...	664	6.80E-132
HGS023	gil2688237	(AE001140) glu-tRNA amidotransferase, su...	318	4.00E-131
HGS023	gil1590917	Glu-tRNA amidotransferase (gatB) [Methan...	263	8.60E-125
HGS024	gil2465557	(AF011545) YedA [Bacillus subtilis] >gil...	237	6.30E-27
HGS024	gnllPIDle1011444	hypothetical protein [Synechocystis sp.]...	153	8.60E-22
HGS024	gil2648183	(AE000943) Glu-tRNA amidotransferase, su...	126	1.80E-21
HGS024	gnllPIDle1237757	(AL021287) putative Glu-tRNA-Gln amidotr...	166	1.80E-17
HGS024	gil2984354	(AE000775) glutamyl-tRNA (Gln) amidotran...	102	2.70E-17
HGS024	gnllPIDle349616	hypothetical protein MLCB637.12 [Mycobac...	154	7.10E-16
HGS025	gnllPIDle1005830	stage V sporulation [Bacillus subtilis] ...	496	4.90E-69
HGS025	gnllPIDle1011124	peptidyl-tRNA hydrolase [Synechocystis s...	307	2.10E-49
HGS025	gil2983032	(AE000685) peptidyl-tRNA hydrolase [Aqui...	386	2.20E-49
HGS025	gnllPIDle304565	Pth [Mycobacterium tuberculosis] >gnllPI...	266	2.60E-43

HGS025	gil1045760	peptidyl-tRNA hydrolase homolog [Mycopla...	211	1.40E-39
HGS025	gil2314676	(AE000648) peptidyl-tRNA hydrolase (pth)...	102	3.30E-39
HGS025	gil1674312	(AE000058) Mycoplasma pneumoniae, peptid...	208	9.50E-39
HGS025	gil1127571	peptidyl-tRNA hydrolase [Chlamydia trach...	187	7.00E-37
HGS025	gil1573366	peptidyl-tRNA hydrolase (pth) [Haemophil...	201	8.50E-34
HGS025	gil581202	peptidyl-tRNA hydrolase [Escherichia col...	186	2.50E-27
HGS026	gil853776	peptide chain release factor 1 [Bacillus...	889	6.10E-160
HGS026	gnlPIDid1009421	Peptide Termination Factor [Mycoplasma c...	715	1.10E-126
HGS026	gnlPIDid1019559	peptide chain release factor [Synecocys...	539	2.70E-121
HGS026	gil2688096	(AE001130) peptide chain release factor ...	627	1.80E-115
HGS026	gnlPIDid1015453	Peptide chain release factor 1 (RF-1) [E...	467	3.90E-113
HGS026	gil968930	peptide chain release factor 1 [Escheric...	463	1.30E-112
HGS026	gil147567	peptide chain release factor 1 [Escheric...	467	3.40E-112
HGS026	gil154104	release factor 1 [Salmonella typhimurium...	460	2.90E-111
HGS026	gil1574404	polypeptide chain release factor 1 (prfA...	449	1.50E-109
HGS026	gil2313158	(AE000529) peptide chain release factor ...	576	1.20E-104
HGS028	gil2331287	(AF013188) release factor 2 [Bacillus...	769	2.50E-173
HGS028	spIP28367IRF2_BACSU	PEPTIDE CHAIN RELEASE FACTOR 2 (RF-2)...	742	3.00E-157
HGS028	gil2984119	(AE000758) peptide chain release fact...	442	2.20E-128
HGS028	gnlPIDie254636	peptide release factor 2 [Bacillus fi...	718	2.90E-125
HGS028	pirS76448IS76448	translation releasing factor RF-2 - S...	883	3.30E-116
HGS028	pirA64190IA64190	translation releasing factor RF-2 - H...	444	1.70E-110
HGS028	gil154276	peptide chain release factor 2 [Salmo...	444	1.80E-108
HGS028	gil2687953	(AE001120) peptide chain release fact...	408	3.90E-108
HGS028	gil2367172	(AE000372) peptide chain release fact...	437	1.60E-107
HGS028	gil147569	peptide chain release factor 2 [Esche...	434	4.00E-107
HGS030	gnlPIDid1005806	unknown [Bacillus subtilis] >gnlPIDie11...	283	2.60E-64
HGS030	gil3176887	(AF065312) thymidylate kinase [Yersinia ...	124	3.00E-43
HGS030	gil2983484	(AE000716) thymidylate kinase [Aquifex a...	272	2.40E-37
HGS030	gil1244710	thymidylate kinase [Escherichia coli] >g...	136	7.20E-34
HGS030	gil2650584	(AE001102) thymidylate kinase (tnk) [Arc...	71	2.60E-30
HGS030	gil1045674	thymidylate kinase [Mycoplasma genitaliu...	173	8.20E-28

HGS030	gil1673808	(AE000016) Mycoplasma pneumoniae, thymid...	171	1.70E-27
HGS030	gil1246364	thymidylate:zeocin resistance protein:ND...	136	2.20E-27
HGS030	gil1246361	thymidine:thymidylate kinase:zeocin resi...	136	4.30E-27
HGS030	gil950071	ATP-bind. pyrimidine kinase [Mycoplasma ...	80	8.70E-21
HGS031	gnllPIDle1185242	uridylate kinase [Bacillus subtilis] >pi...	920	8.40E-123
HGS031	gnllPIDid1019291	uridine monophosphate kinase [Synecocys...	530	1.70E-96
HGS031	gnllPIDle1296663	(AL023797) uridylate kinase [Streptomyce...	678	2.10E-89
HGS031	gnllPIDle248883	hypothetical protein MTCY274.14c [Mycoba...	416	6.00E-89
HGS031	gnllPIDle327783	uridylate kinase [Mycobacterium leprae]	403	7.90E-86
HGS031	gil473234	uridine 5'-monophosphate (UMP) kinase [E...	384	2.10E-72
HGS031	gil1552748	uridine 5'-monophosphate (UMP) kinase [E...	375	3.60E-71
HGS031	gil1574616	mukB suppressor protein (smbA) [Haemophi...	409	3.70E-71
HGS031	gil2983290	(AE000703) UMP kinase [Aquifex aeolicus]	452	3.70E-58
HGS031	gil1518662	UMP kinase [Chlamydia trachomatis] >spP...	323	9.10E-55
HGS032	gil755152	highly hydrophobic integral membrane pro...	297	2.40E-81
HGS032	gil1235660	RfbA [Myxococcus xanthus] >spQ50862RFB...	173	4.90E-24
HGS032	gnllPIDid1017629	ABC transporter [Synecocystis sp.] >pir...	149	1.50E-19
HGS032	gnllPIDid1029275	(AB010294) integral membrane component o...	126	6.40E-19
HGS032	gnllPIDid1008332	putative integral membrane component of ...	125	9.10E-19
HGS032	gnllPIDid1029271	(AB010293) integral membrane component o...	125	9.10E-19
HGS032	gnllPIDid1029279	(AB010295) integral membrane component o...	125	9.10E-19
HGS032	gnllPIDid1029264	(AB010150) integral membrane component o...	109	3.00E-15
HGS032	gil2983575	(AE000723) ABC transporter (ABC-2 subfam...	71	9.60E-13
HGS032	gil609595	homologous to kpsM (E.coli), bexB (H.inf...	78	2.60E-12
HGS033	gil755153	ATP-binding protein [Bacillus subtilis] ...	655	9.30E-94
HGS033	gil609596	ATP-binding protein [Serratia marcescens]	387	3.70E-69
HGS033	gil765059	ABC-transporter protein [Klebsiella pneu...	371	3.70E-69
HGS033	gil567183	ATP-binding protein [Klebsiella pneumonia...	367	1.20E-67
HGS033	gil304013	abcA [Aeromonas salmonicida] >pirA36918...	294	7.20E-59
HGS033	gnllPIDid1020415	(AB002668) ABC transport protein [Actino...	323	4.00E-57
HGS033	gil1123030	CpxA [Actinobacillus pleuropneumoniae]	190	2.40E-56
HGS033	gil3135679	(AF064070) putative ABC-2 transporter hy...	219	2.10E-53

HGS033	gil2983576	(AE000723) ABC transporter [Aquifex aeol...]	294	2.10E-53
HGS033	gil1235661	RfbB [Myxococcus xanthus] >sp Q50863 RFB...	336	6.70E-53
HGS034	gil143467	ribosomal protein S4 [Bacillus subtilis]...	798	4.50E-106
HGS034	gil2314460	(AE000633) ribosomal protein S4 (rps4) [...]	322	1.50E-62
HGS034	gil2982819	(AE000672) ribosomal protein S04 [Aquife...]	253	2.00E-62
HGS034	gil606231	30S ribosomal subunit protein S4 [Escher...]	292	2.40E-58
HGS034	gnlPIDle1234848	(AJ223236) ribosomal protein S4 [Salmon...]	292	6.10E-58
HGS034	gil1573812	ribosomal protein S4 (rps4) [Haemophilus...]	292	1.60E-57
HGS034	gil639791	ribosomal protein S4 [Mycoplasma pneumon...]	260	1.90E-56
HGS034	gil1046011	ribosomal protein S4 [Mycoplasma genital...]	245	2.10E-54
HGS034	gnlPIDle316061	RpsD [Mycobacterium tuberculosis] >gnlP...	270	1.40E-52
HGS034	gil144143	ribosomal protein S4 [Buchnera aphidicol...]	255	2.00E-51
HGS036	gil2648781	(AE000980) dipeptide ABC transporter, AT...	136	1.90E-40
HGS036	gnlPIDle1264523	(AL022121) putative peptide ABC transpor...	185	5.50E-35
HGS036	gil143607	sporulation protein [Bacillus subtilis]	191	7.70E-34
HGS036	gnlPIDle1183166	oligopeptide ABC transporter (ATP-bindin...)	191	7.70E-34
HGS036	gnlPIDle1253461	oligopeptide transport ATP-binding prote...	213	5.50E-33
HGS036	gil2313342	(AE000544) oligopeptide ABC transporter...	258	7.60E-32
HGS036	gnlPIDle1015858	Dipeptide transport ATP-binding protein ...	205	1.10E-31
HGS036	gil47346	AmiE protein [Streptococcus pneumoniae] ...	202	7.40E-31
HGS036	gil972897	DppD [Haemophilus influenzae] >gil157411...	204	1.40E-30
HGS036	gil677943	AppD [Bacillus subtilis] >gnlPIDle11831...	205	9.70E-30
HGS040	gnlPIDle1185713	elongation factor P [Bacillus subtilis] ...	702	7.00E-91
HGS040	gil1399829	elongation factor P [Synecococcus PCC79...]	541	4.90E-69
HGS040	gnlPIDle1010902	elongation factor P [Synecocystis sp.] ...	535	3.20E-68
HGS040	gil951349	ORF1; putative [Anabaena sp.] >sp Q44247...	505	3.80E-64
HGS040	gnlPIDle290977	unknown [Mycobacterium tuberculosis] >gn...	480	9.20E-61
HGS040	gnlPIDle1169516	elongation factor P [Corynebacterium glu...]	460	4.80E-58
HGS040	gil2983772	(AE000736) elongation factor P [Aquifex ...]	435	1.10E-54
HGS040	gil1658506	elongation factor P homologue; EF-P [Bac...]	203	7.20E-52
HGS040	gil2313266	(AE000538) translation elongation factor...	409	4.00E-51
HGS040	gil536991	elongation factor P [Escherichia coli] >...	362	9.40E-45

168153_3	gnlPID1d1028815	(AB009524) Vi polysaccharide biosynthes...	237	5.80E-72
168153_3	gil47961	wcdB; ORF3 in citation [1] [Salmonella ...	234	1.80E-71
168153_3	gil1590951	UDP-glucose 4-epimerase (galE) [Methano...	148	3.20E-60
168153_3	pirC69149IC69149	conserved hypothetical protein MTH380 -...	151	1.90E-50
168153_3	gil143204	ORF2; Method: conceptual translation s...	227	4.50E-47
168153_3	gnlPIDle316552	unknown [Mycobacterium tuberculosis] >g...	109	4.70E-45
168153_3	gnlPIDle1185960	similar to NDP-sugar epimerase [Bacillu...	155	1.80E-39
168153_3	gnlPIDle1289548	(AL023093) putative sugar dehydratase [M...	86	1.80E-36
168153_3	gnlPIDle288124	glucose epimerase [Bacillus thuringiensis]	95	2.70E-35
168153_3	gil1591707	capsular polysaccharide biosynthesis pr...	85	1.60E-34
168153_2	gnlPIDle1184467	alternate gene name: yvhA [Bacillus subt...	354	4.90E-45
168153_2	gil1637652	Cap8M [Staphylococcus aureus]	138	9.00E-42
168153_2	gil1773352	Cap5M [Staphylococcus aureus]	138	9.00E-42
168153_2	gnlPIDle238668	hypothetical protein [Bacillus subtilis]...	139	6.10E-39
168153_2	gil1199573	spsB [Sphingomonas sp.] >gil1314578 gluc...	168	4.40E-35
168153_2	gnlPID1d1005318	ORF14 [Klebsiella pneumoniae] >sp1Q48460...	260	5.50E-33
168153_2	gnlPID1d1020425	(AB002668) galactosyltransferase [Actino...	155	5.60E-33
168153_2	gnlPID1d1029082	(AB010415) glycosyltransferase [Actinoba...	155	2.00E-32
168153_2	gnlPID1d1019174	galactosyl-1-phosphate transferase [Syne...	139	2.30E-32
168153_2	gnlPIDle220381	structural gene [Agrobacterium radiobacter]	138	2.40E-32
168153_1	gil1276880	EpsG [Streptococcus thermophilus]	141	3.40E-34
168153_1	gil1276879	EpsF [Streptococcus thermophilus]	162	1.70E-29
168153_1	gil633699	WbcQ [Yersinia enterocolitica] >pirS512...	134	9.10E-26
168153_1	gnlPIDle238704	hypothetical protein [Bacillus subtilis]...	131	1.90E-18
168153_1	gil2983976	(AF000749) capsular polysaccharide biosy...	134	1.50E-15
168153_1	gnlPID1d1005311	ORF7 [Klebsiella pneumoniae] >sp1Q484531...	94	2.10E-12
168153_1	gil633696	WbcN [Yersinia enterocolitica] >pirS512...	123	2.50E-12
168153_1	gil755606	unknown [Bacillus subtilis]	144	5.40E-12
168153_1	gil1146237	21.4% of identity to trans-acting transc...	144	6.00E-12
168153_1	gnlPIDle238664	hypothetical protein [Bacillus subtilis]...	141	3.20E-11
168339_2	gnlPIDle1169894	putative repeating unit transporter ...	234	5.70E-57
168339_2	gil2209215	(AF004325) putative oligosaccharide ...	139	4.90E-37
168339_2	gil633692	Wzx [Yersinia enterocolitica] >pirS...	141	3.00E-31
168339_2	gil2621404	(AE000819) O-antigen transporter [Me...	129	8.90E-29

168339_2	gi2072448	EpsK [Lactococcus lactis cremoris]	199	4.00E-27
168339_2	sp P37746 RFBX_ECOLI	PUTATIVE O-ANTIGEN TRANSPORTER.	140	2.10E-23
168339_2	gn IPID I016603	Putative O-antigen transporter. [Esc...	140	2.90E-23
168339_2	gi510252	membrane protein [Escherichia coli]	140	8.10E-23
168339_2	gi2621427	(AE000822) O-antigen transporter [Me...	122	3.10E-20
168339_2	gi152778	RFBX [Shigella dysenteriae] >pir S34...	114	8.50E-19

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only nucleotides outside the 5' and 3' nucleotides of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 nucleotide subject sequence is aligned to a 100 nucleotide query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 nucleotides at 5' end. The 10 unpaired nucleotides represent 10% of the sequence (number of nucleotides at the 5' and 3' ends not matched/total number of nucleotides in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 nucleotides were perfectly matched the final percent identity would be 90%. In another example, a 90 nucleotide subject sequence is compared with a 100 nucleotide query sequence. This time the deletions are internal deletions so that there are no nucleotides on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only nucleotides 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of the present invention.

Vectors and Host Cell

The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells comprising the recombinant vectors, and the production of *S. aureus* polypeptides and peptides of the present invention expressed by the host cells.

Recombinant constructs may be introduced into host cells using well known techniques such as infection, transduction, transfection, transvection, electroporation and transformation. The vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for

propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

5 Preferred are vectors comprising *cis*-acting control regions to the polynucleotide of interest. Appropriate *trans*-acting factors may be supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.

In certain preferred embodiments in this regard, the vectors provide for specific expression, which may be inducible and/or cell type-specific. Particularly preferred among
10 such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, *e.g.*, vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses,
15 vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as cosmids and phagemids.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be
20 known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating site at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

25 As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin, or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal
30 cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE9, pQE10 available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A,
35 pNH16a, pNH18A, pNH46A available from Stratagene; pET series of vectors available from Novagen; and pTrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Among known bacterial promoters suitable for use in the present invention include the *E. coli lacI* and *lacZ* promoters, the T3, T5 and T7 promoters, the *gpt* promoter, the lambda PR and PL promoters and the *trp* promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals (for example, Davis, *et al.*, *Basic Methods In Molecular Biology* (1986)).

Transcription of DNA encoding the polypeptides of the present invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are *cis*-acting elements of DNA, usually about from 10 to 300 nucleotides that act to increase transcriptional activity of a promoter in a given host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at nucleotides 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide, for example, the amino acid sequence KDEL. The signals may be endogenous to the polypeptide or they may be heterologous signals.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the

advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery, for example, human proteins, such as, hIL5-receptor has been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See Bennett, D. et al. (1995) J. Molec. Recogn. 8:52-58 and Johanson, K. et al. (1995) J. Biol. Chem. 270 (16):9459-9471.

The *S. aureus* polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography and high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses host cells that have been engineered to delete or replace endogenous genetic material (e.g. coding sequences for the polypeptides of the present invention), and/or to include genetic material (e.g. heterologous polynucleotide sequences) that is operably associated with polynucleotides of the present invention, and which activates, alters, and/or amplifies endogenous polynucleotides of the present invention. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g. promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g. U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra, et al., Nature 342:435-438 (1989), the disclosures of each of which are hereby incorporated by reference in their entireties).

Polypeptides and Fragments

The invention further provides an isolated *S. aureus* polypeptide having an amino acid sequence in Table 1, or a peptide or polypeptide comprising a portion of the above polypeptides.

Variant and Mutant Polypeptides

To improve or alter the characteristics of *S. aureus* polypeptides of the present invention, protein engineering may be employed. Recombinant DNA technology known to those skilled in the art can be used to create novel mutant proteins or muteins including single or multiple amino acid substitutions, deletions, additions, or fusion proteins. Such modified

polypeptides can show, e.g., increased/decreased activity or increased/decreased stability. In addition, they may be purified in higher yields and show better solubility than the corresponding natural polypeptide, at least under certain purification and storage conditions. Further, the polypeptides of the present invention may be produced as multimers including dimers, trimers and tetramers. Multimerization may be facilitated by linkers or recombinantly though heterologous polypeptides such as Fc regions.

N-Terminal and C-Terminal Deletion Mutants

It is known in the art that one or more amino acids may be deleted from the N-terminus or C-terminus without substantial loss of biological function. For instance, Ron et al. J. Biol. Chem., 268:2984-2988 (1993), reported modified KGF proteins that had heparin binding activity even if 3, 8, or 27 N-terminal amino acid residues were missing. Accordingly, the present invention provides polypeptides having one or more residues deleted from the amino terminus of the polypeptides shown in Table 1.

Similarly, many examples of biologically functional C-terminal deletion mutants are known. For instance, Interferon gamma shows up to ten times higher activities by deleting 8-10 amino acid residues from the carboxy terminus of the protein *See, e.g.,* Dobeli, et al. (1988) J. Biotechnology 7:199-216. Accordingly, the present invention provides polypeptides having one or more residues from the carboxy terminus of the polypeptides shown in Table 1. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini as described below.

The present invention is further directed to polynucleotide encoding portions or fragments of the amino acid sequences described herein as well as to portions or fragments of the isolated amino acid sequences described herein. Fragments include portions of the amino acid sequences of Table 1, at least 7 contiguous amino acid in length, selected from any two integers, one of which representing a N-terminal position. The first codon of the polypeptides of Table 1 is position 1. Every combination of a N-terminal and C-terminal position that a fragment at least 7 contiguous amino acid residues in length could occupy, on any given amino acid sequence of Table 1 is included in the invention. At least means a fragment may be 7 contiguous amino acid residues in length or any integer between 7 and the number of residues in a full length amino acid sequence minus 1. Therefore, included in the invention are contiguous fragments specified by any N-terminal and C-terminal positions of amino acid sequence set forth in Table 1 wherein the contiguous fragment is any integer between 7 and the number of residues in a full length sequence minus 1.

Further, the invention includes polypeptides comprising fragments specified by size, in amino acid residues, rather than by N-terminal and C-terminal positions. The invention includes any fragment size, in contiguous amino acid residues, selected from integers between 7 and the number of residues in a full length sequence minus 1. Preferred sizes of contiguous polypeptide fragments include about 7 amino acid residues, about 10 amino acid residues,

about 20 amino acid residues, about 30 amino acid residues, about 40 amino acid residues, about 50 amino acid residues, about 100 amino acid residues, about 200 amino acid residues, about 300 amino acid residues, and about 400 amino acid residues. The preferred sizes are, of course, meant to exemplify, not limit, the present invention as all size fragments representing any integer between 7 and the number of residues in a full length sequence minus 1 are included in the invention. The present invention also provides for the exclusion of any fragments specified by N-terminal and C-terminal positions or by size in amino acid residues as described above. Any number of fragments specified by N-terminal and C-terminal positions or by size in amino acid residues as described above may be excluded.

The polypeptide fragments of the present invention can be immediately envisaged using the above description and are therefore not individually listed solely for the purpose of not unnecessarily lengthening the specification.

The above fragments need not be active since they would be useful, for example, in immunoassays, in epitope mapping, epitope tagging, to generate antibodies to a particular portion of the polypeptide, as vaccines, and as molecular weight markers.

Other Mutants

In addition to N- and C-terminal deletion forms of the protein discussed above, it also will be recognized by one of ordinary skill in the art that some amino acid sequences of the *S. aureus* polypeptides of the present invention can be varied without significant effect of the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity.

Thus, the invention further includes variations of the *S. aureus* polypeptides which show substantial *S. aureus* polypeptide activity or which include regions of *S. aureus* protein such as the protein portions discussed below. Such mutants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided. There are two main approaches for studying the tolerance of an amino acid sequence to change. See, Bowie, J. U. *et al.* (1990), Science 247:1306-1310. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality.

These studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The studies indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described by Bowie *et al.* (*supra*) and the references cited therein. Typically seen as conservative substitutions are the replacements, one for another,

among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr.

Thus, the fragment, derivative, analog, or homolog of the polypeptide of Table 1 may be, for example: (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code; or (ii) one in which one or more of the amino acid residues includes a substituent group; or (iii) one in which the *S. aureus* polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol); or (iv) one in which the additional amino acids are fused to the above form of the polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the above form of the polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

Thus, the *S. aureus* polypeptides of the present invention may include one or more amino acid substitutions, deletions, or additions, either from natural mutations or human manipulation. As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 3).

TABLE 3. Conservative Amino Acid Substitutions.

Aromatic	Phenylalanine Tryptophan Tyrosine
Hydrophobic	Leucine Isoleucine Valine
Polar	Glutamine Asparagine
Basic	Arginine Lysine Histidine
Acidic	Aspartic Acid Glutamic Acid
Small	Alanine Serine Threonine Methionine Glycine

Amino acids in the *S. aureus* proteins of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis. See, e.g., Cunningham et al. (1989) Science 244:1081-1085. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity using assays appropriate for measuring the function of the particular protein.

Of special interest are substitutions of charged amino acids with other charged or neutral amino acids which may produce proteins with highly desirable improved characteristics, such as less aggregation. Aggregation may not only reduce activity but also be problematic when preparing pharmaceutical formulations, because aggregates can be immunogenic. See, e.g., Pinckard et al., (1967) Clin. Exp. Immunol. 2:331-340; Robbins, et al., (1987) Diabetes 36:838-845; Cleland, et al., (1993) Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377.

The polypeptides of the present invention are preferably provided in an isolated form, and may partially or substantially purified. A recombinantly produced version of the *S. aureus* polypeptide can be substantially purified by the one-step method described by Smith et al. (1988) Gene 67:31-40. Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies directed against the polypeptides of the invention in methods which are well known in the art of protein purification. The purity of the polypeptide of the present invention may also specified in percent purity as relative to heterologous containing polypeptides. Preferred purities include at least 25%, 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, and 100% pure, as relative to heretologous containing polypeptides.

The invention provides for isolated *S. aureus* polypeptides comprising an the amino acid sequence of a full-length *S. aureus* polypeptide having the complete amino acid sequence shown in Table 1 and the amino acid sequence of a full-length *S. aureus* polypeptide having the complete amino acid sequence shown in Table 1 excepting the N-terminal methionine. The polypeptides of the present invention also include polypeptides having an amino acid sequence at least 80% identical, more preferably at least 90% identical, and still more preferably 95%, 96%, 97%, 98% or 99% identical to those described in (a), (b), (c), and (d) above. Further polypeptides of the present invention include polypeptides which have at least 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above.

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of a *S. aureus* polypeptide having an amino acid sequence which contains at least one conservative amino acid substitution, but not more than 50 conservative amino acid substitutions, not more than 40 conservative amino acid substitutions, not more than 30 conservative amino acid substitutions, and not more than 20 conservative amino acid

substitutions. Also provided are polypeptides which comprise the amino acid sequence of a *S. aureus* polypeptide, having at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative amino acid substitutions.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% (5 of 100) of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al., (1990) Comp. App. Biosci. 6:237-245. In a sequence alignment the query and subject sequences are both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, the results, in percent identity, must be manually corrected. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-

termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query amino acid residues outside the farthest N- and C-terminal residues of the subject sequence.

5 For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not match/align with the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query
10 sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the
15 percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected. No other manual corrections are to made for the purposes of the present invention.

The above polypeptide sequences are included irrespective of whether they have their
20 normal biological activity. This is because even where a particular polypeptide molecule does not have biological activity, one of skill in the art would still know how to use the polypeptide, for instance, as a vaccine or to generate antibodies. Other uses of the polypeptides of the present invention that do not have *S. aureus* activity include, *inter alia*, as epitope tags, in epitope mapping, and as molecular weight markers on SDS-PAGE gels or on molecular sieve
25 gel filtration columns using methods known to those of skill in the art.

As described below, the polypeptides of the present invention can also be used to raise polyclonal and monoclonal antibodies, which are useful in assays for detecting *S. aureus* protein expression or as agonists and antagonists capable of enhancing or inhibiting *S. aureus* protein function. Further, such polypeptides can be used in the yeast two-hybrid system to
30 "capture" *S. aureus* protein binding proteins which are also candidate agonists and antagonists according to the present invention. See, e.g., Fields et al. (1989) Nature 340:245-246.

Epitope-Bearing Portions

In another aspect, the invention provides peptides and polypeptides comprising
35 epitope-bearing portions of the polypeptides of the present invention. These epitopes are immunogenic or antigenic epitopes of the polypeptides of the present invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein or polypeptide is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic determinant" or "antigenic

epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. *See, e.g.,* Geysen, et al. (1983) Proc. Natl. Acad. Sci. USA 81:3998-4002. Predicted antigenic epitopes are shown in Table 4, below. It is pointed out that Table 4 only lists amino acid residues comprising epitopes predicted to have the highest degree of antigenicity by particular algorithm. The polypeptides not listed in Table 4 and portions of polypeptides not listed in Table 4 are not considered non-antigenic. This is because they may still be antigenic *in vivo* but merely not recognized as such by the particular algorithm used. Thus, Table 4 lists the amino acid residues comprising only preferred antigenic epitopes, not a complete list. In fact, all fragments of the polypeptide sequence of Table 1, at least 7 amino acids residues in length, are included in the present invention as being useful in epitope mapping and in making antibodies to particular portions of the polypeptides. Moreover, Table 4 lists only the critical residues of the epitopes determined by the Jameson-Wolf analysis. Thus, additional flanking residues on either the N-terminal, C-terminal, or both N- and C-terminal ends may be added to the sequences of Table 4 to generate a epitope-bearing portion at least 7 residues in length. Amino acid residues comprising other antigenic epitopes may be determined by algorithms similar to the Jameson-Wolf analysis or by *in vivo* testing for an antigenic response using the methods described herein or those known in the art.

TABLE 4. Residues Comprising Antigenic Epitopes

HGS001	from about Asp-47 to about Asp-50, from about Ser-128 to about Asp-130, from about Lys-265 to about Gly-267.
HGS005	from about Arg-104 to about Asp-106, from about Lys-116 to about Lys-120.
HGS007m	from about Glu-155 to about Gly-158, from about Gln-178 to about Gly-181, from about Ser-304 to about Cys-306, from about Asp-401 to about Tyr-403, from about Asn-405 to about Gly-408, from about Asp-411 to about Gly-416.
HGS009	from about Pro-257 to about Lys-259.
HGS014	from about Arg-186 to about Asp-188.
HGS019	from about Lys-98 to about Gly-100, from about Pro-187 to about Asp-189.
HGS023	from about Ser-251 to about Gly-253, from about Lys-437 to about Lys-440.
HGS025	from about Met-51 to about Gly-53.
HGS026	from about Asn-105 to about Lys-108, from about Glu-190 to about Gly-193, from about Arg-226 to about Ala-230.
HGS028	from about Ile-10 to about Tyr-13.
HGS030	from about Glu-11 to about Gly-14, from about Arg-147 to about Gln-149.
HGS033	from about Lys-143 to about Ser-145.
HGS034	from about Pro-33 to about Gln-35.
HGS036	from about Asp-64 to about Tyr-66, from about Asp-255 to about Tyr-257.
HGS040	from about Pro-30 to about Lys-32, from about Asp-76 to about Asp-78.
168153_3	from about Asn-35 to about Arg-37, from about Pro-135 to about Asp-138, from about Pro-185 to about Gln-188.
168153_2	from about Asp-54 to about Arg-56.
168153_1	from about Lys-64 to about Asp-67, from about Gln-319 to about Lys-322, from about Asn-342 to about Lys-344.
168339_2	from about Asn-82 to about Arg-85.

As to the selection of peptides or polypeptides bearing an antigenic epitope (*i.e.*, that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely
5 capable of eliciting an antiserum that reacts with the partially mimicked protein. *See, e.g.*, Sutcliffe, et al., (1983) Science 219:660-666. Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (*i.e.*, immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are
10 extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer, peptides, especially those containing proline residues, usually are effective. *See*, Sutcliffe, et al., *supra*, p. 661. For instance, 18 of 20 peptides designed according to these guidelines, containing 8-39 residues covering 75% of the sequence of the influenza virus hemagglutinin HA1 polypeptide chain, induced
15 antibodies that reacted with the HA1 protein or intact virus; and 12/12 peptides from the MuLV polymerase and 18/18 from the rabies glycoprotein induced antibodies that precipitated the respective proteins.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a
20 polypeptide of the invention. Thus, a high proportion of hybridomas obtained by fusion of spleen cells from donors immunized with an antigen epitope-bearing peptide generally secrete antibody reactive with the native protein. *See* Sutcliffe, et al., *supra*, p. 663. The antibodies raised by antigenic epitope-bearing peptides or polypeptides are useful to detect the mimicked protein, and antibodies to different peptides may be used for tracking the fate of various
25 regions of a protein precursor which undergoes post-translational processing. The peptides and anti-peptide antibodies may be used in a variety of qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (*e.g.*, about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays. *See, e.g.*, Wilson, et al., (1984) Cell 37:767-778. The
30 anti-peptide antibodies of the invention also are useful for purification of the mimicked protein, for instance, by adsorption chromatography using methods known in the art.

Antigenic epitope-bearing peptides and polypeptides of the invention designed according to the above guidelines preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about 10 to about 50 amino acids (*i.e.* any
35 integer between 7 and 50) contained within the amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of a polypeptide of the invention, containing about 50 to about 100 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are considered epitope-bearing peptides or polypeptides of the invention and also are

useful for inducing antibodies that react with the mimicked protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (*i.e.*, the sequence includes relatively hydrophilic residues and highly hydrophobic sequences are preferably avoided); and sequences containing proline residues are particularly preferred.

Non-limiting examples of antigenic polypeptides or peptides that can be used to generate an Staphylococcal-specific immune response or antibodies include fragments of the amino acid sequences of Table 1 as discussed above. Table 4 discloses a list of non-limiting residues that are involved in the antigenicity of the epitope-bearing fragments of the present invention. Therefore, also included in the present inventions are isolated and purified antigenic epitope-bearing fragments of the polypeptides of the present invention comprising a peptide sequences of Table 4. The antigenic epitope-bearing fragments comprising a peptide sequence of Table 4 preferably contain between 7 to 50 amino acids (*i.e.* any integer between 7 and 50) of a polypeptide of the present invention. Also, included in the present invention are antigenic polypeptides between the integers of 7 and the full length sequence of a polypeptide of Table 1 comprising 1 or more amino acid sequences of Table 4. Therefore, in most cases, the polypeptides of Table 4 make up only a portion of the antigenic polypeptide. All combinations of sequences between the integers of 7 and the full sequence of a polypeptide sequence of Table 1 are included. The antigenic epitope-bearing fragments may be specified by either the number of contiguous amino acid residues or by specific N-terminal and C-terminal positions as described above for the polypeptide fragments of the present invention, wherein the first codon of each polypeptide sequence of Table 1 is position 1. Any number of the described antigenic epitope-bearing fragments of the present invention may also be excluded from the present invention in the same manner.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means for making peptides or polypeptides including recombinant means using nucleic acid molecules of the invention. For instance, an epitope-bearing amino acid sequence of the present invention may be fused to a larger polypeptide which acts as a carrier during recombinant production and purification, as well as during immunization to produce anti-peptide antibodies. Epitope-bearing peptides also may be synthesized using known methods of chemical synthesis. For instance, Houghten has described a simple method for synthesis of large numbers of peptides, such as 10-20 mg of 248 different 13 residue peptides representing single amino acid variants of a segment of the HA1 polypeptide which were prepared and characterized (by ELISA-type binding studies) in less than four weeks (Houghten, R. A. Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985)). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten and coworkers (1986). In this procedure the individual resins for the solid-phase synthesis of various peptides are contained in separate solvent-permeable packets, enabling the optimal use of the many identical repetitive steps involved in solid-phase methods.

A completely manual procedure allows 500-1000 or more syntheses to be conducted simultaneously (Houghten et al. (1985) Proc. Natl. Acad. Sci. 82:5131-5135 at 5134.

Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art. *See, e.g., Sutcliffe, et al., supra;;*
5 *Wilson, et al., supra;;* and Bittle, et al. (1985) J. Gen. Virol. 66:2347-2354. Generally, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine may be coupled to carrier using a linker such as m-maleimidobenzoyl-N-hydroxysuccinimide ester
10 (MBS), while other peptides may be coupled to carrier using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg peptide or carrier protein and Freund's adjuvant. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a
15 useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

20 Immunogenic epitope-bearing peptides of the invention, *i.e.*, those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. For instance, Geysen, *et al., supra*, discloses a procedure for rapid concurrent synthesis on solid supports of hundreds of peptides of sufficient purity to react in an ELISA. Interaction of synthesized peptides with antibodies is
25 then easily detected without removing them from the support. In this manner a peptide bearing an immunogenic epitope of a desired protein may be identified routinely by one of ordinary skill in the art. For instance, the immunologically important epitope in the coat protein of foot-and-mouth disease virus was located by Geysen *et al. supra* with a resolution of seven amino acids by synthesis of an overlapping set of all 208 possible hexapeptides covering the
30 entire 213 amino acid sequence of the protein. Then, a complete replacement set of peptides in which all 20 amino acids were substituted in turn at every position within the epitope were synthesized, and the particular amino acids conferring specificity for the reaction with antibody were determined. Thus, peptide analogs of the epitope-bearing peptides of the invention can be made routinely by this method. U.S. Patent No. 4,708,781 to Geysen (1987) further
35 describes this method of identifying a peptide bearing an immunogenic epitope of a desired protein.

Further still, U.S. Patent No. 5,194,392, to Geysen (1990), describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (*i.e.*, a "mimotope") which is

complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092, also to Geysen (1989), describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent No. 5,480,971 to Houghten, R. A. *et al.* (1996) discloses linear C₁-C₇-alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs of the epitope-bearing peptides of the invention also can be made routinely by these methods. The entire disclosure of each document cited in this section on "Polypeptides and Fragments" is hereby incorporated herein by reference.

As one of skill in the art will appreciate, the polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life *in vivo*. This has been shown, *e.g.*, for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EPA 0,394,827; Traunecker *et al.* (1988) *Nature* 331:84-86. Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than a monomeric *S. aureus* polypeptide or fragment thereof alone. *See* Fountoulakis *et al.* (1995) *J. Biochem.* 270:3958-3964. Nucleic acids encoding the above epitopes of *S. aureus* polypeptides can also be recombined with a gene of interest as an epitope tag to aid in detection and purification of the expressed polypeptide.

Antibodies

S. aureus polypeptide-specific antibodies for use in the present invention can be raised against the intact polypeptides of the present invention or an antigenic polypeptide fragment thereof, which may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough, without a carrier.

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules, single chain whole antibodies, and antibody fragments. Antibody fragments of the present invention include Fab and F(ab')₂ and other fragments including single-chain Fvs (scFv) and disulfide-linked Fvs (sdFv). Also included in the present invention are chimeric and humanized monoclonal antibodies and polyclonal antibodies specific for the polypeptides of the present invention. The antibodies of the present invention may be prepared by any of a variety of methods. For example, cells expressing a polypeptide of the present invention or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. For example, a preparation of a

polypeptide of the present invention or fragment thereof is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In a preferred method, the antibodies of the present invention are monoclonal antibodies or binding fragments thereof. Such monoclonal antibodies can be prepared using hybridoma technology. See, e.g., Harlow et al., ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: MONOCLONAL ANTIBODIES AND T-CELL HYBRIDOMAS 563-681 (Elsevier, N.Y., 1981). Fab and F(ab')₂ fragments may be produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, *S. aureus* polypeptide-binding fragments, chimeric, and humanized antibodies can be produced through the application of recombinant DNA technology or through synthetic chemistry using methods known in the art.

Alternatively, additional antibodies capable of binding to the polypeptide antigen of the present invention may be produced in a two-step procedure through the use of anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and that, therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, *S. aureus* polypeptide-specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the *S. aureus* polypeptide-specific antibody can be blocked by the *S. aureus* polypeptide antigen. Such antibodies comprise anti-idiotypic antibodies to the *S. aureus* polypeptide-specific antibody and can be used to immunize an animal to induce formation of further *S. aureus* polypeptide-specific antibodies.

Antibodies and fragments thereof of the present invention may be described by the portion of a polypeptide of the present invention recognized or specifically bound by the antibody. Antibody binding fragments of a polypeptide of the present invention may be described or specified in the same manner as for polypeptide fragments discussed above, i.e., by N-terminal and C-terminal positions or by size in contiguous amino acid residues. Any number of antibody binding fragments, of a polypeptide of the present invention, specified by N-terminal and C-terminal positions or by size in amino acid residues, as described above, may also be excluded from the present invention. Therefore, the present invention includes antibodies that specifically bind a particularly described fragment of a polypeptide of the present invention and allows for the exclusion of the same.

Antibodies and fragments thereof of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies and fragments that do not bind polypeptides of any other species of *Staphylococcus* other than *S. aureus* or that only bind a particular strain of *S. aureus* are included in the present invention. Likewise, antibodies and fragments that bind only species of *Staphylococcus*, i.e. antibodies and fragments that do not

bind bacteria from any genus other than *Staphylococcus*, are included in the present invention.

Antibodies and fragments thereof of the present invention may also be described or specified in terms of their binding affinity. Preferred binding affinities include 10^{-7}M , 10^{-8}M , 10^{-9}M , 10^{-10}M , 10^{-11}M , 10^{-12}M and 10^{-13}M .

Diagnostic Assays

The present invention further relates to methods for assaying staphylococcal infection in an animal by detecting the expression of genes encoding staphylococcal polypeptides of the present invention. The methods comprise analyzing tissue or body fluid from the animal for *Staphylococcus*-specific antibodies, nucleic acids, or proteins. Analysis of nucleic acid specific to *Staphylococcus* is assayed by PCR or hybridization techniques using nucleic acid sequences of the present invention as either hybridization probes or primers. See, e.g., Sambrook et al. Molecular cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 2nd ed., 1989, page 54 reference); Ereemeeva et al. (1994) J. Clin. Microbiol. 32:803-810 (describing differentiation among spotted fever group *Rickettsiae* species by analysis of restriction fragment length polymorphism of PCR-amplified DNA) and Chen et al. 1994 J. Clin. Microbiol. 32:589-595 (detecting bacterial nucleic acids via PCR).

Where diagnosis of a disease state related to infection with *Staphylococcus* has already been made, the present invention is useful for monitoring progression or regression of the disease state by measuring the amount of *Staphylococcus* cells present in a patient or whereby patients exhibiting enhanced *Staphylococcus* gene expression will experience a worse clinical outcome relative to patients expressing these gene(s) at a lower level.

By "biological sample" is intended any biological sample obtained from an animal, cell line, tissue culture, or other source which contains *Staphylococcus* polypeptide, mRNA, or DNA. Biological samples include body fluids (such as saliva, blood, plasma, urine, mucus, synovial fluid, etc.) tissues (such as muscle, skin, and cartilage) and any other biological source suspected of containing *Staphylococcus* polypeptides or nucleic acids. Methods for obtaining biological samples such as tissue are well known in the art.

The present invention is useful for detecting diseases related to *Staphylococcus* infections in animals. Preferred animals include monkeys, apes, cats, dogs, birds, cows, pigs, mice, horses, rabbits and humans. Particularly preferred are humans.

Total RNA can be isolated from a biological sample using any suitable technique such as the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski et al. (1987) Anal. Biochem. 162:156-159. mRNA encoding *Staphylococcus* polypeptides having sufficient homology to the nucleic acid sequences identified in Table 1 to allow for hybridization between complementary sequences are then assayed using any appropriate method. These include Northern blot analysis, S1 nuclease mapping, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR), and reverse transcription in combination with the ligase chain

reaction (RT-LCR).

Northern blot analysis can be performed as described in Harada et al. (1990) Cell 63:303-312. Briefly, total RNA is prepared from a biological sample as described above. For the Northern blot, the RNA is denatured in an appropriate buffer (such as glyoxal/dimethyl sulfoxide/sodium phosphate buffer), subjected to agarose gel electrophoresis, and transferred onto a nitrocellulose filter. After the RNAs have been linked to the filter by a UV linker, the filter is prehybridized in a solution containing formamide, SSC, Denhardt's solution, denatured salmon sperm, SDS, and sodium phosphate buffer. A *S. aureus* polynucleotide sequence shown in Table 1 labeled according to any appropriate method (such as the ³²P-multiprimered DNA labeling system (Amersham)) is used as probe. After hybridization overnight, the filter is washed and exposed to x-ray film. DNA for use as probe according to the present invention is described in the sections above and will preferably be at least 15 nucleotides in length.

S1 mapping can be performed as described in Fujita et al. (1987) Cell 49:357-367. To prepare probe DNA for use in S1 mapping, the sense strand of an above-described *S. aureus* DNA sequence of the present invention is used as a template to synthesize labeled antisense DNA. The antisense DNA can then be digested using an appropriate restriction endonuclease to generate further DNA probes of a desired length. Such antisense probes are useful for visualizing protected bands corresponding to the target mRNA (i.e., mRNA encoding polypeptides of the present invention).

Levels of mRNA encoding *Staphylococcus* polypeptides are assayed, for e.g., using the RT-PCR method described in Makino et al. (1990) Technique 2:295-301. By this method, the radioactivities of the "amplicons" in the polyacrylamide gel bands are linearly related to the initial concentration of the target mRNA. Briefly, this method involves adding total RNA isolated from a biological sample in a reaction mixture containing a RT primer and appropriate buffer. After incubating for primer annealing, the mixture can be supplemented with a RT buffer, dNTPs, DTT, RNase inhibitor and reverse transcriptase. After incubation to achieve reverse transcription of the RNA, the RT products are then subject to PCR using labeled primers. Alternatively, rather than labeling the primers, a labeled dNTP can be included in the PCR reaction mixture. PCR amplification can be performed in a DNA thermal cycler according to conventional techniques. After a suitable number of rounds to achieve amplification, the PCR reaction mixture is electrophoresed on a polyacrylamide gel. After drying the gel, the radioactivity of the appropriate bands (corresponding to the mRNA encoding the *Staphylococcus* polypeptides of the present invention) are quantified using an imaging analyzer. RT and PCR reaction ingredients and conditions, reagent and gel concentrations, and labeling methods are well known in the art. Variations on the RT-PCR method will be apparent to the skilled artisan. Other PCR methods that can detect the nucleic acid of the present invention can be found in PCR PRIMER: A LABORATORY MANUAL (C.W. Dieffenbach et al. eds., Cold Spring Harbor Lab Press, 1995).

The polynucleotides of the present invention, including both DNA and RNA, may be

used to detect polynucleotides of the present invention or *Staphylococcus* species including *S. aureus* using bio chip technology. The present invention includes both high density chip arrays (>1000 oligonucleotides per cm²) and low density chip arrays (<1000 oligonucleotides per cm²). Bio chips comprising arrays of polynucleotides of the present invention may be used to

5 detect *Staphylococcus* species, including *S. aureus*, in biological and environmental samples and to diagnose an animal, including humans, with an *S. aureus* or other *Staphylococcus* infection. The bio chips of the present invention may comprise polynucleotide sequences of other pathogens including bacteria, viral, parasitic, and fungal polynucleotide sequences, in addition to the polynucleotide sequences of the present invention, for use in rapid differential

10 pathogenic detection and diagnosis. The bio chips can also be used to monitor an *S. aureus* or other *Staphylococcus* infections and to monitor the genetic changes (deletions, insertions, mismatches, etc.) in response to drug therapy in the clinic and drug development in the laboratory. The bio chip technology comprising arrays of polynucleotides of the present invention may also be used to simultaneously monitor the expression of a multiplicity of genes,

15 including those of the present invention. The polynucleotides used to comprise a selected array may be specified in the same manner as for the fragments, i.e., by their 5' and 3' positions or length in contiguous base pairs and include from. Methods and particular uses of the polynucleotides of the present invention to detect *Staphylococcus* species, including *S. aureus*, using bio chip technology include those known in the art and those of: U.S. Patent Nos.

20 5510270, 5545531, 5445934, 5677195, 5532128, 5556752, 5527681, 5451683, 5424186, 5607646, 5658732 and World Patent Nos. WO/9710365, WO/9511995, WO/9743447, WO/9535505, each incorporated herein in their entireties.

Biosensors using the polynucleotides of the present invention may also be used to detect, diagnose, and monitor *S. aureus* or other *Staphylococcus* species and infections

25 thereof. Biosensors using the polynucleotides of the present invention may also be used to detect particular polynucleotides of the present invention. Biosensors using the polynucleotides of the present invention may also be used to monitor the genetic changes (deletions, insertions, mismatches, etc.) in response to drug therapy in the clinic and drug development in the laboratory. Methods and particular uses of the polynucleotides of the present invention to detect *Staphylococcus* species, including *S. aureus*, using biosensors

30 include those known in the art and those of: U.S. Patent Nos. 5721102, 5658732, 5631170, and World Patent Nos. WO97/35011, WO/9720203, each incorporated herein in their entireties.

Thus, the present invention includes both bio chips and biosensors comprising

35 polynucleotides of the present invention and methods of their use.

Assaying *Staphylococcus* polypeptide levels in a biological sample can occur using any art-known method, such as antibody-based techniques. For example, *Staphylococcus* polypeptide expression in tissues can be studied with classical immunohistological methods. In these, the specific recognition is provided by the primary antibody (polyclonal or

monoclonal) but the secondary detection system can utilize fluorescent, enzyme, or other conjugated secondary antibodies. As a result, an immunohistological staining of tissue section for pathological examination is obtained. Tissues can also be extracted, *e.g.*, with urea and neutral detergent, for the liberation of *Staphylococcus* polypeptides for Western-blot or dot/slot assay. See, *e.g.*, Jalkanen, M. et al. (1985) J. Cell. Biol. 101:976-985; Jalkanen, M. et al. (1987) J. Cell. Biol. 105:3087-3096. In this technique, which is based on the use of cationic solid phases, quantitation of a *Staphylococcus* polypeptide can be accomplished using an isolated *Staphylococcus* polypeptide as a standard. This technique can also be applied to body fluids.

Other antibody-based methods useful for detecting *Staphylococcus* polypeptide gene expression include immunoassays, such as the ELISA and the radioimmunoassay (RIA). For example, a *Staphylococcus* polypeptide-specific monoclonal antibodies can be used both as an immunoabsorbent and as an enzyme-labeled probe to detect and quantify a *Staphylococcus* polypeptide. The amount of a *Staphylococcus* polypeptide present in the sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm. Such an ELISA is described in Iacobelli et al. (1988) Breast Cancer Research and Treatment 11:19-30. In another ELISA assay, two distinct specific monoclonal antibodies can be used to detect *Staphylococcus* polypeptides in a body fluid. In this assay, one of the antibodies is used as the immunoabsorbent and the other as the enzyme-labeled probe.

The above techniques may be conducted essentially as a "one-step" or "two-step" assay. The "one-step" assay involves contacting the *Staphylococcus* polypeptide with immobilized antibody and, without washing, contacting the mixture with the labeled antibody. The "two-step" assay involves washing before contacting the mixture with the labeled antibody. Other conventional methods may also be employed as suitable. It is usually desirable to immobilize one component of the assay system on a support, thereby allowing other components of the system to be brought into contact with the component and readily removed from the sample. Variations of the above and other immunological methods included in the present invention can also be found in Harlow et al., ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988).

Suitable enzyme labels include, for example, those from the oxidase group, which catalyze the production of hydrogen peroxide by reacting with substrate. Glucose oxidase is particularly preferred as it has good stability and its substrate (glucose) is readily available. Activity of an oxidase label may be assayed by measuring the concentration of hydrogen peroxide formed by the enzyme-labeled antibody/substrate reaction. Besides enzymes, other suitable labels include radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulphur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Further suitable labels for the *Staphylococcus* polypeptide-specific antibodies of the

present invention are provided below. Examples of suitable enzyme labels include malate dehydrogenase, Staphylococcus nuclease, delta-5-steroid isomerase, yeast-alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholine esterase.

Examples of suitable radioisotopic labels include ^3H , ^{111}In , ^{125}I , ^{131}I , ^{32}P , ^{35}S , ^{14}C , ^{51}Cr , ^{57}To , ^{58}Co , ^{59}Fe , ^{75}Se , ^{152}Eu , ^{90}Y , ^{67}Cu , ^{217}Ci , ^{211}At , ^{212}Pb , ^{47}Sc , ^{109}Pd , etc. ^{111}In is a preferred isotope where *in vivo* imaging is used since it avoids the problem of dehalogenation of the ^{125}I or ^{131}I -labeled monoclonal antibody by the liver. In addition, this radionucleotide has a more favorable gamma emission energy for imaging. See, e.g., Perkins et al. (1985) Eur. J. Nucl. Med. 10:296-301; Carasquillo et al. (1987) J. Nucl. Med. 28:281-287. For example, ^{111}In coupled to monoclonal antibodies with 1-(P-isothiocyanatobenzyl)-DPTA has shown little uptake in non-tumor tissues, particularly the liver, and therefore enhances specificity of tumor localization. See, Esteban et al. (1987) J. Nucl. Med. 28:861-870.

Examples of suitable non-radioactive isotopic labels include ^{157}Gd , ^{55}Mn , ^{162}Dy , ^{52}Tr , and ^{56}Fe .

Examples of suitable fluorescent labels include an ^{152}Eu label, a fluorescein label, an isothiocyanate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an o-phthaldehyde label, and a fluorescamine label.

Examples of suitable toxin labels include, *Pseudomonas* toxin, diphtheria toxin, ricin, and cholera toxin.

Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, and an aequorin label.

Examples of nuclear magnetic resonance contrasting agents include heavy metal nuclei such as Gd, Mn, and iron.

Typical techniques for binding the above-described labels to antibodies are provided by Kennedy et al. (1976) Clin. Chim. Acta 70:1-31, and Schurs et al. (1977) Clin. Chim. Acta 81:1-40. Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester method, all of which methods are incorporated by reference herein.

In a related aspect, the invention includes a diagnostic kit for use in screening serum containing antibodies specific against *S. aureus* infection. Such a kit may include an isolated *S. aureus* antigen comprising an epitope which is specifically immunoreactive with at least one anti-*S. aureus* antibody. Such a kit also includes means for detecting the binding of said antibody to the antigen. In specific embodiments, the kit may include a recombinantly produced or chemically synthesized peptide or polypeptide antigen. The peptide or polypeptide antigen may be attached to a solid support.

In a more specific embodiment, the detecting means of the above-described kit includes a solid support to which said peptide or polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the *S. aureus* antigen can be detected by binding of the reporter labeled antibody to the anti-*S. aureus* polypeptide antibody.

In a related aspect, the invention includes a method of detecting *S. aureus* infection in a subject. This detection method includes reacting a body fluid, preferably serum, from the subject with an isolated *S. aureus* antigen, and examining the antigen for the presence of bound antibody. In a specific embodiment, the method includes a polypeptide antigen attached to a solid support, and serum is reacted with the support. Subsequently, the support is reacted with a reporter-labeled anti-human antibody. The support is then examined for the presence of reporter-labeled antibody.

The solid surface reagent employed in the above assays and kits is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plates or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

The polypeptides and antibodies of the present invention, including fragments thereof, may be used to detect Staphylococcus species including *S. aureus* using bio chip and biosensor technology. Bio chip and biosensors of the present invention may comprise the polypeptides of the present invention to detect antibodies, which specifically recognize Staphylococcus species, including *S. aureus*. Bio chip and biosensors of the present invention may also comprise antibodies which specifically recognize the polypeptides of the present invention to detect Staphylococcus species, including *S. aureus* or specific polypeptides of the present invention. Bio chips or biosensors comprising polypeptides or antibodies of the present invention may be used to detect Staphylococcus species, including *S. aureus*, in biological and environmental samples and to diagnose an animal, including humans, with an *S. aureus* or other Staphylococcus infection. Thus, the present invention includes both bio chips and biosensors comprising polypeptides or antibodies of the present invention and methods of their use.

The bio chips of the present invention may further comprise polypeptide sequences of other pathogens including bacteria, viral, parasitic, and fungal polypeptide sequences, in addition to the polypeptide sequences of the present invention, for use in rapid differential pathogenic detection and diagnosis. The bio chips of the present invention may further comprise antibodies or fragments thereof specific for other pathogens including bacteria, viral, parasitic, and fungal polypeptide sequences, in addition to the antibodies or fragments thereof of the present invention, for use in rapid differential pathogenic detection and diagnosis. The

bio chips and biosensors of the present invention may also be used to monitor an *S. aureus* or other Staphylococcus infection and to monitor the genetic changes (amino acid deletions, insertions, substitutions, etc.) in response to drug therapy in the clinic and drug development in the laboratory. The bio chip and biosensors comprising polypeptides or antibodies of the present invention may also be used to simultaneously monitor the expression of a multiplicity of polypeptides, including those of the present invention. The polypeptides used to comprise a bio chip or biosensor of the present invention may be specified in the same manner as for the fragments, i.e., by their N-terminal and C-terminal positions or length in contiguous amino acid residue. Methods and particular uses of the polypeptides and antibodies of the present invention to detect Staphylococcus species, including *S. aureus*, or specific polypeptides using bio chip and biosensor technology include those known in the art, those of the U.S. Patent Nos. and World Patent Nos. listed above for bio chips and biosensors using polynucleotides of the present invention, and those of: U.S. Patent Nos. 5658732, 5135852, 5567301, 5677196, 5690894 and World Patent Nos. WO9729366, WO9612957, each incorporated herein in their entireties.

Treatment

Agonists and Antagonists - Assays and Molecules

The invention also provides a method of screening compounds to identify those which enhance or block the biological activity of the *S. aureus* polypeptides of the present invention. The present invention further provides where the compounds kill or slow the growth of *S. aureus*. The ability of *S. aureus* antagonists, including *S. aureus* ligands, to prophylactically or therapeutically block antibiotic resistance may be easily tested by the skilled artisan. See, e.g., Straden et al. (1997) J Bacteriol. 179(1):9-16.

An agonist is a compound which increases the natural biological function or which functions in a manner similar to the polypeptides of the present invention, while antagonists decrease or eliminate such functions. Potential antagonists include small organic molecules, peptides, polypeptides, and antibodies that bind to a polypeptide of the invention and thereby inhibit or extinguish its activity.

The antagonists may be employed for instance to inhibit peptidoglycan cross bridge formation. Antibodies against *S. aureus* may be employed to bind to and inhibit *S. aureus* activity to treat antibiotic resistance. Any of the above antagonists may be employed in a composition with a pharmaceutically acceptable carrier.

Vaccines

The present invention also provides vaccines comprising one or more polypeptides of the present invention. Heterogeneity in the composition of a vaccine may be provided by combining *S. aureus* polypeptides of the present invention. Multi-component vaccines of this type are desirable because they are likely to be more effective in eliciting protective immune

responses against multiple species and strains of the *Staphylococcus* genus than single polypeptide vaccines.

Multi-component vaccines are known in the art to elicit antibody production to numerous immunogenic components. *See, e.g.*, Decker et al. (1996) J. Infect. Dis. 174:S270-275. In addition, a hepatitis B, diphtheria, tetanus, pertussis tetravalent vaccine has recently
5 been demonstrated to elicit protective levels of antibodies in human infants against all four pathogenic agents. *See, e.g.*, Aristegui, J. et al. (1997) Vaccine 15:7-9.

The present invention in addition to single-component vaccines includes multi-component vaccines. These vaccines comprise more than one polypeptide, immunogen
10 or antigen. Thus, a multi-component vaccine would be a vaccine comprising more than one of the *S. aureus* polypeptides of the present invention.

Further within the scope of the invention are whole cell and whole viral vaccines. Such vaccines may be produced recombinantly and involve the expression of one or more of the *S. aureus* polypeptides described in Table 1. For example, the *S. aureus* polypeptides of the
15 present invention may be either secreted or localized intracellular, on the cell surface, or in the periplasmic space. Further, when a recombinant virus is used, the *S. aureus* polypeptides of the present invention may, for example, be localized in the viral envelope, on the surface of the capsid, or internally within the capsid. Whole cells vaccines which employ cells expressing heterologous proteins are known in the art. *See, e.g.*, Robinson, K. et al. (1997) Nature
20 Biotech. 15:653-657; Sirard, J. et al. (1997) Infect. Immun. 65:2029-2033; Chabalgoity, J. et al. (1997) Infect. Immun. 65:2402-2412. These cells may be administered live or may be killed prior to administration. Chabalgoity, J. et al., *supra*, for example, report the successful use in mice of a live attenuated *Salmonella* vaccine strain which expresses a portion of a platyhelminth fatty acid-binding protein as a fusion protein on its cells surface.

A multi-component vaccine can also be prepared using techniques known in the art by
25 combining one or more *S. aureus* polypeptides of the present invention, or fragments thereof, with additional non-staphylococcal components (*e.g.*, diphtheria toxin or tetanus toxin, and/or other compounds known to elicit an immune response). Such vaccines are useful for eliciting protective immune responses to both members of the *Staphylococcus* genus and non-
30 staphylococcal pathogenic agents.

The vaccines of the present invention also include DNA vaccines. DNA vaccines are currently being developed for a number of infectious diseases. *See, et al.*, Boyer, et al. (1997) Nat. Med. 3:526-532; reviewed in Spier, R. (1996) Vaccine 14:1285-1288. Such DNA vaccines contain a nucleotide sequence encoding one or more *S. aureus* polypeptides of the
35 present invention oriented in a manner that allows for expression of the subject polypeptide. For example, the direct administration of plasmid DNA encoding *B. burgdorferi* OspA has been shown to elicit protective immunity in mice against borrelial challenge. *See*, Luke et al. (1997) J. Infect. Dis. 175:91-97.

The present invention also relates to the administration of a vaccine which is

co-administered with a molecule capable of modulating immune responses. Kim et al. (1997) Nature Biotech. 15:641-646, for example, report the enhancement of immune responses produced by DNA immunizations when DNA sequences encoding molecules which stimulate the immune response are co-administered. In a similar fashion, the vaccines of the present invention may be co-administered with either nucleic acids encoding immune modulators or the immune modulators themselves. These immune modulators include granulocyte macrophage colony stimulating factor (GM-CSF) and CD86.

The vaccines of the present invention may be used to confer resistance to staphylococcal infection by either passive or active immunization. When the vaccines of the present invention are used to confer resistance to staphylococcal infection through active immunization, a vaccine of the present invention is administered to an animal to elicit a protective immune response which either prevents or attenuates a staphylococcal infection. When the vaccines of the present invention are used to confer resistance to staphylococcal infection through passive immunization, the vaccine is provided to a host animal (e.g., human, dog, or mouse), and the antisera elicited by this antisera is recovered and directly provided to a recipient suspected of having an infection caused by a member of the *Staphylococcus* genus.

The ability to label antibodies, or fragments of antibodies, with toxin molecules provides an additional method for treating staphylococcal infections when passive immunization is conducted. In this embodiment, antibodies, or fragments of antibodies, capable of recognizing the *S. aureus* polypeptides disclosed herein, or fragments thereof, as well as other *Staphylococcus* proteins, are labeled with toxin molecules prior to their administration to the patient. When such toxin derivatized antibodies bind to *Staphylococcus* cells, toxin moieties will be localized to these cells and will cause their death.

The present invention thus concerns and provides a means for preventing or attenuating a staphylococcal infection resulting from organisms which have antigens that are recognized and bound by antisera produced in response to the polypeptides of the present invention. As used herein, a vaccine is said to prevent or attenuate a disease if its administration to an animal results either in the total or partial attenuation (i.e., suppression) of a symptom or condition of the disease, or in the total or partial immunity of the animal to the disease.

The administration of the vaccine (or the antisera which it elicits) may be for either a "prophylactic" or "therapeutic" purpose. When provided prophylactically, the compound(s) are provided in advance of any symptoms of staphylococcal infection. The prophylactic administration of the compound(s) serves to prevent or attenuate any subsequent infection. When provided therapeutically, the compound(s) is provided upon or after the detection of symptoms which indicate that an animal may be infected with a member of the *Staphylococcus* genus. The therapeutic administration of the compound(s) serves to attenuate any actual infection. Thus, the *S. aureus* polypeptides, and fragments thereof, of the present invention may be provided either prior to the onset of infection (so as to prevent or attenuate an anticipated infection) or after the initiation of an actual infection.

The polypeptides of the invention, whether encoding a portion of a native protein or a functional derivative thereof, may be administered in pure form or may be coupled to a macromolecular carrier. Example of such carriers are proteins and carbohydrates. Suitable proteins which may act as macromolecular carrier for enhancing the immunogenicity of the polypeptides of the present invention include keyhole limpet hemacyanin (KLH) tetanus toxoid, pertussis toxin, bovine serum albumin, and ovalbumin. Methods for coupling the polypeptides of the present invention to such macromolecular carriers are disclosed in Harlow et al., ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988).

A composition is said to be "pharmacologically or physiologically acceptable" if its administration can be tolerated by a recipient animal and is otherwise suitable for administration to that animal. Such an agent is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.

While in all instances the vaccine of the present invention is administered as a pharmacologically acceptable compound, one skilled in the art would recognize that the composition of a pharmacologically acceptable compound varies with the animal to which it is administered. For example, a vaccine intended for human use will generally not be co-administered with Freund's adjuvant. Further, the level of purity of the *S. aureus* polypeptides of the present invention will normally be higher when administered to a human than when administered to a non-human animal.

As would be understood by one of ordinary skill in the art, when the vaccine of the present invention is provided to an animal, it may be in a composition which may contain salts, buffers, adjuvants, or other substances which are desirable for improving the efficacy of the composition. Adjuvants are substances that can be used to specifically augment a specific immune response. These substances generally perform two functions: (1) they protect the antigen(s) from being rapidly catabolized after administration and (2) they nonspecifically stimulate immune responses.

Normally, the adjuvant and the composition are mixed prior to presentation to the immune system, or presented separately, but into the same site of the animal being immunized. Adjuvants can be loosely divided into several groups based upon their composition. These groups include oil adjuvants (for example, Freund's complete and incomplete), mineral salts (for example, $\text{AlK}(\text{SO}_4)_2$, $\text{AlNa}(\text{SO}_4)_2$, $\text{AlNH}_4(\text{SO}_4)$, silica, kaolin, and carbon), polynucleotides (for example, poly IC and poly AU acids), and certain natural substances (for example, wax D from *Mycobacterium tuberculosis*, as well as substances found in *Corynebacterium parvum*, or *Bordetella pertussis*, and members of the genus *Brucella*). Other substances useful as adjuvants are the saponins such as, for example, Quil A. (Superfos A/S, Denmark). Preferred adjuvants for use in the present invention include aluminum salts, such as $\text{AlK}(\text{SO}_4)_2$, $\text{AlNa}(\text{SO}_4)_2$, and $\text{AlNH}_4(\text{SO}_4)$. Examples of materials suitable for use in

vaccine compositions are provided in REMINGTON'S PHARMACEUTICAL SCIENCES 1324-1341 (A. Osol, ed, Mack Publishing Co, Easton, PA, (1980) (incorporated herein by reference).

The therapeutic compositions of the present invention can be administered parenterally by injection, rapid infusion, nasopharyngeal absorption (intranasopharyngeally), dermoabsorption, or orally. The compositions may alternatively be administered intramuscularly, or intravenously. Compositions for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, or sweetening, flavoring, or perfuming agents.

Therapeutic compositions of the present invention can also be administered in encapsulated form. For example, intranasal immunization using vaccines encapsulated in biodegradable microsphere composed of poly(DL-lactide-co-glycolide). See, Shahin, R. et al. (1995) Infect. Immun. 63:1195-1200. Similarly, orally administered encapsulated *Salmonella typhimurium* antigens can also be used. Allaoui-Attarki, K. et al. (1997) Infect. Immun. 65:853-857. Encapsulated vaccines of the present invention can be administered by a variety of routes including those involving contacting the vaccine with mucous membranes (e.g., intranasally, intracolonicly, intraduodenally).

Many different techniques exist for the timing of the immunizations when a multiple administration regimen is utilized. It is possible to use the compositions of the invention more than once to increase the levels and diversities of expression of the immunoglobulin repertoire expressed by the immunized animal. Typically, if multiple immunizations are given, they will be given one to two months apart.

According to the present invention, an "effective amount" of a therapeutic composition is one which is sufficient to achieve a desired biological effect. Generally, the dosage needed to provide an effective amount of the composition will vary depending upon such factors as the animal's or human's age, condition, sex, and extent of disease, if any, and other variables which can be adjusted by one of ordinary skill in the art.

The antigenic preparations of the invention can be administered by either single or multiple dosages of an effective amount. Effective amounts of the compositions of the invention can vary from 0.01-1,000 µg/ml per dose, more preferably 0.1-500 µg/ml per dose, and most preferably 10-300 µg/ml per dose.

Examples

Example 1: Isolation of a Selected DNA Clone From the Deposited Sample

Three approaches can be used to isolate a *S. aureus* clone comprising a polynucleotide of the present invention from any *S. aureus* genomic DNA library. The *S. aureus* strain ISP3 has been deposited as a convenient source for obtaining a *S. aureus* strain although a wide variety of strains *S. aureus* strains can be used which are known in the art.

S. aureus genomic DNA is prepared using the following method. A 20ml overnight bacterial culture grown in a rich medium (e.g., Trypticase Soy Broth, Brain Heart Infusion broth or Super broth), pelleted, washed two times with TES (30mM Tris-pH 8.0, 25mM EDTA, 50mM NaCl), and resuspended in 5ml high salt TES (2.5M NaCl). Lysostaphin is added to final concentration of approx 50ug/ml and the mixture is rotated slowly 1 hour at 37C to make protoplast cells. The solution is then placed in incubator (or place in a shaking water bath) and warmed to 55C. Five hundred micro liter of 20% sarcosyl in TES (final concentration 2%) is then added to lyse the cells. Next, guanidine HCl is added to a final concentration of 7M (3.69g in 5.5 ml). The mixture is swirled slowly at 55C for 60-90 min (solution should clear). A CsCl gradient is then set up in SW41 ultra clear tubes using 2.0ml 5.7M CsCl and overlaying with 2.85M CsCl. The gradient is carefully overlayed with the DNA-containing GuHCl solution. The gradient is spun at 30,000 rpm, 20C for 24 hr and the lower DNA band is collected. The volume is increased to 5 ml with TE buffer. The DNA is then treated with protease K (10 ug/ml) overnight at 37 C, and precipitated with ethanol. The precipitated DNA is resuspended in a desired buffer.

In the first method, a plasmid is directly isolated by screening a plasmid *S. aureus* genomic DNA library using a polynucleotide probe corresponding to a polynucleotide of the present invention. Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (See, e.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The library is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art. See, e.g., Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor, N.Y. 2nd ed. 1989); Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (John Wiley and Sons, N.Y. 1989). The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening. See, e.g., Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor, N.Y. 2nd ed. 1989); Ausubel et al.,

CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (John Wiley and Sons, N.Y. 1989) or other techniques known to those of skill in the art.

Alternatively, two primers of 15-25 nucleotides derived from the 5' and 3' ends of a polynucleotide of Table 1 are synthesized and used to amplify the desired DNA by PCR using a *S. aureus* genomic DNA prep (e.g., the deposited *S. aureus* ISP3) as a template. PCR is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 μ g of the above DNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Finally, overlapping oligos of the DNA sequences of Table 1 can be synthesized and used to generate a nucleotide sequence of desired length using PCR methods known in the art.

Example 2(a): Expression and Purification staphylococcal polypeptides in *E. coli*

The bacterial expression vector pQE60 is used for bacterial expression in this example. (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311). pQE60 encodes ampicillin antibiotic resistance ("Ampr") and contains a bacterial origin of replication ("ori"), an IPTG inducible promoter, a ribosome binding site ("RBS"), six codons encoding histidine residues that allow affinity purification using nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin (QIAGEN, Inc., *supra*) and suitable single restriction enzyme cleavage sites. These elements are arranged such that an inserted DNA fragment encoding a polypeptide expresses that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the carboxyl terminus of that polypeptide.

The DNA sequence encoding the desired portion of a *S. aureus* protein of the present invention is amplified from *S. aureus* genomic DNA or from the deposited DNA clone using PCR oligonucleotide primers which anneal to the 5' and 3' sequences coding for the portion of the *S. aureus* polynucleotide. Additional nucleotides containing restriction sites to facilitate cloning in the pQE60 vector are added to the 5' and 3' sequences, respectively.

For cloning the mature protein, the 5' primer has a sequence containing an appropriate restriction site followed by nucleotides of the amino terminal coding sequence of the desired *S. aureus* polynucleotide sequence in Table 1. One of ordinary skill in the art would appreciate that the point in the protein coding sequence where the 5' and 3' primers begin may be varied to amplify a DNA segment encoding any desired portion of the complete protein shorter or longer than the mature form. The 3' primer has a sequence containing an appropriate

restriction site followed by nucleotides complementary to the 3' end of the desired coding sequence of Table 1, excluding a stop codon, with the coding sequence aligned with the restriction site so as to maintain its reading frame with that of the six His codons in the pQE60 vector.

5 The amplified *S. aureus* DNA fragment and the vector pQE60 are digested with restriction enzymes which recognize the sites in the primers and the digested DNAs are then ligated together. The *S. aureus* DNA is inserted into the restricted pQE60 vector in a manner which places the *S. aureus* protein coding region downstream from the IPTG-inducible promoter and in-frame with an initiating AUG and the six histidine codons.

10 The ligation mixture is transformed into competent *E. coli* cells using standard procedures such as those described by Sambrook et al., *supra*. *E. coli* strain M15/rep4, containing multiple copies of the plasmid pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kanr"), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are suitable for expressing a *S.*
15 *aureus* polypeptide, is available commercially (QIAGEN, Inc., *supra*). Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

Clones containing the desired constructs are grown overnight ("O/N") in liquid culture
20 in LB media supplemented with both ampicillin (100 µg/ml) and kanamycin (25 µg/ml). The O/N culture is used to inoculate a large culture, at a dilution of approximately 1:25 to 1:250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. Isopropyl-β-D-thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the lac repressor sensitive promoter, by inactivating the lacI
25 repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells then are harvested by centrifugation.

The cells are then stirred for 3-4 hours at 4°C in 6M guanidine-HCl, pH 8. The cell debris is removed by centrifugation, and the supernatant containing the *S. aureus* polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (QIAGEN, Inc.,
30 *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist, 1995, QIAGEN, Inc., *supra*). Briefly the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the *S. aureus* polypeptide is
35 eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions

are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

Alternatively, the polypeptides of the present invention can be produced by a non-denaturing method. In this method, after the cells are harvested by centrifugation, the cell pellet from each liter of culture is resuspended in 25 ml of Lysis Buffer A at 4°C (Lysis Buffer A = 50 mM Na-phosphate, 300 mM NaCl, 10 mM 2-mercaptoethanol, 10% Glycerol, pH 7.5 with 1 tablet of Complete EDTA-free protease inhibitor cocktail (Boehringer Mannheim #1873580) per 50 ml of buffer). Absorbance at 550 nm is approximately 10-20 O.D./ml. The suspension is then put through three freeze/thaw cycles from -70°C (using a ethanol-dry ice bath) up to room temperature. The cells are lysed via sonication in short 10 sec bursts over 3 minutes at approximately 80W while kept on ice. The sonicated sample is then centrifuged at 15,000 RPM for 30 minutes at 4°C. The supernatant is passed through a column containing 1.0 ml of CL-4B resin to pre-clear the sample of any proteins that may bind to agarose non-specifically, and the flow-through fraction is collected.

The pre-cleared flow-through is applied to a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (Quiagen, Inc., *supra*). Proteins with a 6 X His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure. Briefly, the supernatant is loaded onto the column in Lysis Buffer A at 4°C, the column is first washed with 10 volumes of Lysis Buffer A until the A280 of the eluate returns to the baseline. Then, the column is washed with 5 volumes of 40 mM Imidazole (92% Lysis Buffer A / 8% Buffer B) (Buffer B = 50 mM Na-Phosphate, 300 mM NaCl, 10% Glycerol, 10 mM 2-mercaptoethanol, 500 mM Imidazole, pH of the final buffer should be 7.5). The protein is eluted off of the column with a series of increasing Imidazole solutions made by adjusting the ratios of Lysis Buffer A to Buffer B. Three different concentrations are used: 3 volumes of 75 mM Imidazole, 3 volumes of 150 mM Imidazole, 5 volumes of 500 mM Imidazole. The fractions containing the purified protein are analyzed using 8 %, 10 % or 14% SDS-PAGE depending on the protein size. The purified protein is then dialyzed 2X against phosphate-buffered saline (PBS) in order to place it into an easily workable buffer. The purified protein is stored at 4° C or frozen at -80°

The following is another alternative method may be used to purify *S. aureus* expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells are harvested by continuous centrifugation at 15,000 rpm

(Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

5 The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 x g for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

10 The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 x g centrifugation for 15 min., the pellet is discarded and the *S. aureus* polypeptide-containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

15 Following high speed centrifugation (30,000 x g) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

20 To clarify the refolded *S. aureus* polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

30 Fractions containing the *S. aureus* polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent.

35 Fractions containing the *S. aureus* polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant *S. aureus* polypeptide exhibits greater than 95% purity after the above refolding and purification steps. No major contaminant bands are observed from Commassie

blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein is also tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

5 ***Example 2(b): Expression and Purification staphylococcal polypeptides in E. coli***

Alternatively, the vector pQE10 can be used to clone and express polypeptides of the present invention. The difference being such that an inserted DNA fragment encoding a polypeptide expresses that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the amino terminus of that polypeptide. The bacterial expression vector pQE10 (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311) is used in this example. The components of the pQE10 plasmid are arranged such that the inserted DNA sequence encoding a polypeptide of the present invention expresses the polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the amino terminus.

15 The DNA sequences encoding the desired portions of a polypeptide of Table 1 are amplified using PCR oligonucleotide primers from either genomic *S. aureus* DNA or DNA from the plasmid clones listed in Table 1 clones of the present invention. The PCR primers anneal to the nucleotide sequences encoding the desired amino acid sequence of a polypeptide of the present invention. Additional nucleotides containing restriction sites to facilitate cloning in the pQE10 vector are added to the 5' and 3' primer sequences, respectively.

For cloning a polypeptide of the present invention, the 5' and 3' primers are selected to amplify their respective nucleotide coding sequences. One of ordinary skill in the art would appreciate that the point in the protein coding sequence where the 5' and 3' primers begins may be varied to amplify a DNA segment encoding any desired portion of a polypeptide of the present invention. The 5' primer is designed so the coding sequence of the 6 X His tag is aligned with the restriction site so as to maintain its reading frame with that of *S. aureus* polypeptide. The 3' is designed to include an stop codon. The amplified DNA fragment is then cloned, and the protein expressed, as described above for the pQE60 plasmid.

25 The DNA sequences encoding the amino acid sequences of Table 1 may also be cloned and expressed as fusion proteins by a protocol similar to that described directly above, wherein the pET-32b(+) vector (Novagen, 601 Science Drive, Madison, WI 53711) is preferentially used in place of pQE10.

30 ***Example 2(c): Expression and Purification of Staphylococcus polypeptides in E. coli***

The bacterial expression vector pQE60 is used for bacterial expression in this example (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311). However, in this example, the polypeptide coding sequence is inserted such that translation of the six His codons is prevented

and, therefore, the polypeptide is produced with no 6 X His tag.

The DNA sequence encoding the desired portion of the *S. aureus* amino acid sequence is amplified from a *S. aureus* genomic DNA prep using PCR oligonucleotide primers which anneal to the 5' and 3' nucleotide sequences corresponding to the desired portion of the *S. aureus* polypeptides. Additional nucleotides containing restriction sites to facilitate cloning in the pQE60 vector are added to the 5' and 3' primer sequences.

For cloning a *S. aureus* polypeptides of the present invention, 5' and 3' primers are selected to amplify their respective nucleotide coding sequences. One of ordinary skill in the art would appreciate that the point in the protein coding sequence where the 5' and 3' primers begin may be varied to amplify a DNA segment encoding any desired portion of a polypeptide of the present invention. The 3' and 5' primers contain appropriate restriction sites followed by nucleotides complementary to the 5' and 3' ends of the coding sequence respectively. The 3' primer is additionally designed to include an in-frame stop codon.

The amplified *S. aureus* DNA fragments and the vector pQE60 are digested with restriction enzymes recognizing the sites in the primers and the digested DNAs are then ligated together. Insertion of the *S. aureus* DNA into the restricted pQE60 vector places the *S. aureus* protein coding region including its associated stop codon downstream from the IPTG-inducible promoter and in-frame with an initiating AUG. The associated stop codon prevents translation of the six histidine codons downstream of the insertion point.

The ligation mixture is transformed into competent *E. coli* cells using standard procedures such as those described by Sambrook et al. *E. coli* strain M15/rep4, containing multiple copies of the plasmid pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kanr"), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are suitable for expressing *S. aureus* polypeptide, is available commercially (QIAGEN, Inc., *supra*). Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin (100 µg/ml) and kanamycin (25 µg/ml). The O/N culture is used to inoculate a large culture, at a dilution of approximately 1:25 to 1:250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. isopropyl-b-D-thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the *lac* repressor sensitive promoter, by inactivating the lacI repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells then are harvested by centrifugation.

To purify the *S. aureus* polypeptide, the cells are then stirred for 3-4 hours at 4°C in 6M guanidine-HCl, pH 8. The cell debris is removed by centrifugation, and the supernatant

containing the *S. aureus* polypeptide is dialyzed against 50 mM Na-acetate buffer pH 6, supplemented with 200 mM NaCl. Alternatively, the protein can be successfully refolded by dialyzing it against 500 mM NaCl, 20% glycerol, 25 mM Tris/HCl pH 7.4, containing protease inhibitors. After renaturation the protein can be purified by ion exchange, hydrophobic interaction and size exclusion chromatography. Alternatively, an affinity chromatography step such as an antibody column can be used to obtain pure *S. aureus* polypeptide. The purified protein is stored at 4°C or frozen at -80°C.

The following alternative method may be used to purify *S. aureus* polypeptides expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells are harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells were then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 x g for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 x g centrifugation for 15 min., the pellet is discarded and the *S. aureus* polypeptide-containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 x g) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded *S. aureus* polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-

PAGE.

Fractions containing the *S. aureus* polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent.

Fractions containing the *S. aureus* polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant *S. aureus* polypeptide exhibits greater than 95% purity after the above refolding and purification steps. No major contaminant bands are observed from Commassie blue stained 16% SDS-PAGE gel when 5 μ g of purified protein is loaded. The purified protein is also tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 2(d): Cloning and Expression of *S. aureus* in Other Bacteria

S. aureus polypeptides can also be produced in: *S. aureus* using the methods of S. Skinner et al., (1988) Mol. Microbiol. 2:289-297 or J. I. Moreno (1996) Protein Expr. Purif. 8(3):332-340; *Lactobacillus* using the methods of C. Rush et al., 1997 Appl. Microbiol. Biotechnol. 47(5):537-542; or in *Bacillus subtilis* using the methods Chang et al., U.S. Patent No. 4,952,508.

Example 3: Cloning and Expression in COS Cells

A *S. aureus* expression plasmid is made by cloning a portion of the DNA encoding a *S. aureus* polypeptide into the expression vector pDNAI/Amp or pDNAIII (which can be obtained from Invitrogen, Inc.). The expression vector pDNAI/amp contains: (1) an *E. coli* origin of replication effective for propagation in *E. coli* and other prokaryotic cells; (2) an ampicillin resistance gene for selection of plasmid-containing prokaryotic cells; (3) an SV40 origin of replication for propagation in eukaryotic cells; (4) a CMV promoter, a polylinker, an SV40 intron; (5) several codons encoding a hemagglutinin fragment (i.e., an "HA" tag to facilitate purification) followed by a termination codon and polyadenylation signal arranged so that a DNA can be conveniently placed under expression control of the CMV promoter and operably linked to the SV40 intron and the polyadenylation signal by means of restriction sites in the polylinker. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein described by Wilson et al. 1984 Cell 37:767. The fusion of the HA tag to the target protein allows easy detection and recovery of the recombinant protein with an

antibody that recognizes the HA epitope. pDNAIII contains, in addition, the selectable neomycin marker.

A DNA fragment encoding a *S. aureus* polypeptide is cloned into the polylinker region of the vector so that recombinant protein expression is directed by the CMV promoter. The plasmid construction strategy is as follows. The DNA from a *S. aureus* genomic DNA prep is amplified using primers that contain convenient restriction sites, much as described above for construction of vectors for expression of *S. aureus* in *E. coli*. The 5' primer contains a Kozak sequence, an AUG start codon, and nucleotides of the 5' coding region of the *S. aureus* polypeptide. The 3' primer, contains nucleotides complementary to the 3' coding sequence of the *S. aureus* DNA, a stop codon, and a convenient restriction site.

The PCR amplified DNA fragment and the vector, pDNAI/Amp, are digested with appropriate restriction enzymes and then ligated. The ligation mixture is transformed into an appropriate *E. coli* strain such as SURE™ (Stratagene Cloning Systems, La Jolla, CA 92037), and the transformed culture is plated on ampicillin media plates which then are incubated to allow growth of ampicillin resistant colonies. Plasmid DNA is isolated from resistant colonies and examined by restriction analysis or other means for the presence of the fragment encoding the *S. aureus* polypeptide.

For expression of a recombinant *S. aureus* polypeptide, COS cells are transfected with an expression vector, as described above, using DEAE-dextran, as described, for instance, by Sambrook et al. (*supra*). Cells are incubated under conditions for expression of *S. aureus* by the vector.

Expression of the *S. aureus*-HA fusion protein is detected by radiolabeling and immunoprecipitation, using methods described in, for example Harlow et al., *supra*. To this end, two days after transfection, the cells are labeled by incubation in media containing ³⁵S-cysteine for 8 hours. The cells and the media are collected, and the cells are washed and the lysed with detergent-containing RIPA buffer: 150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50 mM TRIS, pH 7.5, as described by Wilson et al. (*supra*). Proteins are precipitated from the cell lysate and from the culture media using an HA-specific monoclonal antibody. The precipitated proteins then are analyzed by SDS-PAGE and autoradiography. An expression product of the expected size is seen in the cell lysate, which is not seen in negative controls.

Example 4: Cloning and Expression in CHO Cells

The vector pC4 is used for the expression of *S. aureus* polypeptide in this example. Plasmid pC4 is a derivative of the plasmid pSV2-dhfr (ATCC Accession No. 37146). The plasmid contains the mouse DHFR gene under control of the SV40 early promoter. Chinese hamster ovary cells or other cells lacking dihydrofolate activity that are transfected with these plasmids can be selected by growing the cells in a selective medium (alpha minus MEM, Life

Technologies) supplemented with the chemotherapeutic agent methotrexate. The amplification of the DHFR genes in cells resistant to methotrexate (MTX) has been well documented. See, e.g., Alt et al., 1978, J. Biol. Chem. 253:1357-1370; Hamlin et al., 1990, Biochem. et Biophys. Acta, 1097:107-143; Page et al., 1991, Biotechnology 9:64-68. Cells grown in increasing concentrations of MTX develop resistance to the drug by overproducing the target enzyme, DHFR, as a result of amplification of the DHFR gene. If a second gene is linked to the DHFR gene, it is usually co-amplified and over-expressed. It is known in the art that this approach may be used to develop cell lines carrying more than 1,000 copies of the amplified gene(s). Subsequently, when the methotrexate is withdrawn, cell lines are obtained which contain the amplified gene integrated into one or more chromosome(s) of the host cell.

Plasmid pC4 contains the strong promoter of the long terminal repeat (LTR) of the Rouse Sarcoma Virus, for expressing a polypeptide of interest, Cullen, et al. (1985) Mol. Cell. Biol. 5:438-447; plus a fragment isolated from the enhancer of the immediate early gene of human cytomegalovirus (CMV), Boshart, et al., 1985, Cell 41:521-530. Downstream of the promoter are the following single restriction enzyme cleavage sites that allow the integration of the genes: *Bam* HI, *Xba* I, and *Asp* 718. Behind these cloning sites the plasmid contains the 3' intron and polyadenylation site of the rat preproinsulin gene. Other high efficiency promoters can also be used for the expression, e.g., the human β -actin promoter, the SV40 early or late promoters or the long terminal repeats from other retroviruses, e.g., HIV and HTLV. Clontech's Tet-Off and Tet-On gene expression systems and similar systems can be used to express the *S. aureus* polypeptide in a regulated way in mammalian cells (Gossen et al., 1992, Proc. Natl. Acad. Sci. USA 89:5547-5551. For the polyadenylation of the mRNA other signals, e.g., from the human growth hormone or globin genes can be used as well. Stable cell lines carrying a gene of interest integrated into the chromosomes can also be selected upon co-transfection with a selectable marker such as gpt, G418 or hygromycin. It is advantageous to use more than one selectable marker in the beginning, e.g., G418 plus methotrexate.

The plasmid pC4 is digested with the restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel. The DNA sequence encoding the *S. aureus* polypeptide is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the desired portion of the gene. A 5' primer containing a restriction site, a Kozak sequence, an AUG start codon, and nucleotides of the 5' coding region of the *S. aureus* polypeptide is synthesized and used. A 3' primer, containing a restriction site, stop codon, and nucleotides complementary to the 3' coding sequence of the *S. aureus* polypeptides is synthesized and used. The amplified fragment is digested with the restriction endonucleases and then purified again on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC4 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene are used for transfection. Five µg of the expression plasmid pC4 is cotransfected with 0.5 µg of the plasmid pSVneo using a lipid-mediated transfection agent such as Lipofectin™ or LipofectAMINE™ (Life Technologies Gaithersburg, MD). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100-200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 5: Quantitative Murine Soft Tissue Infection Model for *S. aureus*

Compositions of the present invention, including polypeptides and peptides, are assayed for their ability to function as vaccines or to enhance/stimulate an immune response to a bacterial species (e.g., *S. aureus*) using the following quantitative murine soft tissue infection model. Mice (e.g., NIH Swiss female mice, approximately 7 weeks old) are first treated with a biologically protective effective amount, or immune enhancing/stimulating effective amount of a composition of the present invention using methods known in the art, such as those discussed above. See, e.g., Harlow et al., ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988). An example of an appropriate starting dose is 20ug per animal.

The desired bacterial species used to challenge the mice, such as *S. aureus*, is grown as an overnight culture. The culture is diluted to a concentration of 5×10^8 cfu/ml, in an appropriate media, mixed well, serially diluted, and titered. The desired doses are further diluted 1:2 with sterilized Cytodex 3 microcarrier beads preswollen in sterile PBS (3g/100ml). Mice are anesthetize briefly until docile, but still mobile and injected with 0.2 ml of the Cytodex 3 bead/bacterial mixture into each animal subcutaneously in the inguinal region. After four days, counting the day of injection as day one, mice are sacrificed and the contents of the abscess is excised and placed in a 15 ml conical tube containing 1.0ml of sterile PBS. The contents of the abscess is then enzymatically treated and plated as follows.

The abscess is first disrupted by vortexing with sterilized glass beads placed in the tubes. 3.0mls of prepared enzyme mixture (1.0ml Collagenase D (4.0 mg/ml), 1.0ml Trypsin (6.0

mg/ml) and 8.0 ml PBS) is then added to each tube followed by a 20 min. incubation at 37C. The solution is then centrifuged and the supernatant drawn off. 0.5 ml dH₂O is then added and the tubes are vortexed and then incubated for 10 min. at room temperature. 0.5 ml media is then added and samples are serially diluted and plated onto agar plates, and grown overnight at 37C. Plates with distinct and separate colonies are then counted, compared to positive and negative control samples, and quantified. The method can be used to identify composition and determine appropriate and effective doses for humans and other animals by comparing the effective doses of compositions of the present invention with compositions known in the art to be effective in both mice and humans. Doses for the effective treatment of humans and other animals, using compositions of the present invention, are extrapolated using the data from the above experiments of mice. It is appreciated that further studies in humans and other animals may be needed to determine the most effective doses using methods of clinical practice known in the art.

Example 6: Murine Systemic Neutropenic Model for *S. aureus* Infection

Compositions of the present invention, including polypeptides and peptides, are assayed for their ability to function as vaccines or to enhance/stimulate an immune response to a bacterial species (e.g., *S. aureus*) using the following qualitative murine systemic neutropenic model. Mice (e.g., NIH Swiss female mice, approximately 7 weeks old) are first treated with a biologically protective effective amount, or immune enhancing/stimulating effective amount of a composition of the present invention using methods known in the art, such as those discussed above. See, e.g., Harlow et al., ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988). An example of an appropriate starting dose is 20ug per animal. Mice are then injected with 250 - 300 mg/kg cyclophosphamide intraperitoneally. Counting the day of C.P. injection as day one, the mice are left untreated for 5 days to begin recovery of PMNL'S.

The desired bacterial species used to challenge the mice, such as *S. aureus*, is grown as an overnight culture. The culture is diluted to a concentration of 5×10^8 cfu/ml, in an appropriate media, mixed well, serially diluted, and titered. The desired doses are further diluted 1:2 in 4% Brewer's yeast in media.

Mice are injected with the bacteria/brewer's yeast challenge intraperitoneally. The Brewer's yeast solution alone is used as a control. The mice are then monitored twice daily for the first week following challenge, and once a day for the next week to ascertain morbidity and mortality. Mice remaining at the end of the experiment are sacrificed. The method can be used to identify compositions and determine appropriate and effective doses for humans and other animals by comparing the effective doses of compositions of the present invention with compositions known in the art to be effective in both mice and humans. Doses for the effective treatment of humans and other animals, using compositions of the present invention, are

extrapolated using the data from the above experiments of mice. It is appreciated that further studies in humans and other animals may be needed to determine the most effective doses using methods of clinical practice known in the art.

The disclosure of all publications (including patents, patent applications, journal
5 articles, laboratory manuals, books, or other documents) cited herein and the sequence listings are hereby incorporated by reference in their entireties.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention. Functionally equivalent methods and components are within the scope of the
10 invention, in addition to those shown and described herein and will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>9</u> , line <u>18</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>7 April 1998</u>	Accession Number <u>202108</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable)	
This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p style="text-align: center;">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received with the international application </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer </div>	<p style="text-align: center;">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer </div>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATCC Deposit No. 202108

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

ATCC Deposit No. 202108**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence encoding any one of the amino acid sequences of the polypeptides shown in Table 1;
 - (b) a nucleotide sequence complementary to any one of the nucleotide sequences in (a)
 - (c) a nucleotide sequence at least 95% identical to any one of the nucleotide sequences shown in Table 1; and
 - (d) a nucleotide sequence at least 95% identical to a nucleotide sequence complementary to any one of the nucleotide sequences shown in Table 1.
2. An isolated nucleic acid molecule of claim 1 comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a) or (b) of claim 1.
3. An isolated nucleic acid molecule of claim 1 comprising a polynucleotide which encodes an epitope-bearing portion of a polypeptide in (a) of claim 1.
4. The isolated nucleic acid molecule of claim 3, wherein said epitope-bearing portion of a polypeptide comprises an amino acid sequence listed in Table 4.
5. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.
6. A recombinant vector produced by the method of claim 5.
7. A host cell comprising the vector of claim 6.
8. A method of producing a polypeptide comprising:
 - (a) growing the host cell of claim 7 such that the protein is expressed by the cell; and
 - (b) recovering the expressed polypeptide.
9. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) a complete amino acid sequences of Table 1;
 - (b) a complete amino acid sequence of Table 1 except the N-terminal residue; and
 - (c) a fragment of a polypeptide of Table 1 having biological activity; and

- (d) a fragment of a polypeptide of Table 1 which binds to an antibody specific for a *S. aureus* polypeptide.
10. An isolated polypeptide comprising an amino acid sequence at least 95% identical to an amino acid sequence of Table 1.
11. An isolated epitope-bearing polypeptide comprising an amino acid sequence of Table 4.
12. An isolated antibody specific for the polypeptide of claim 9.
13. A host cell which produces an antibody of claim 12.
16. A vaccine, comprising:
- (1) one or more *S. aureus* polypeptides selected from the group consisting of a polypeptide of claim 9; and
 - (2) a pharmaceutically acceptable diluent, carrier, or excipient;
- wherein said polypeptide is present, in an amount effective to elicit protective antibodies in an animal to a member of the *Staphylococcus* genus.
17. A method of preventing or attenuating an infection caused by a member of the *Staphylococcus* genus in an animal, comprising administering to said animal a polypeptide of claim 9, wherein said polypeptide is administered in an amount effective to prevent or attenuate said infection.
18. A method of detecting *Staphylococcus* nucleic acids in a biological sample comprising:
- (a) contacting the sample with one or more nucleic acids of claim 1, under conditions such that hybridization occurs; and
 - (b) detecting hybridization of said nucleic acids to the one or more *Staphylococcus* nucleic acid sequences present in the biological sample.
19. A method of detecting *Staphylococcus* antibodies in a biological sample obtained from an animal, comprising
- (a) contacting the sample with a polypeptide of claim 9; and
 - (b) detecting antibody-antigen complexes.
20. A method of detecting a polypeptide of claim 9 comprising:
- (a) obtaining a biological sample suspected of containing said polypeptide;
 - (c) contacting said sample with antibody which specifically binds said polypeptide; and
 - (c) determining the presence or absence of said polypeptide in said biological sample.

SEQUENCE LISTING

<110> Human Genome Sciences, Inc. et al.

<120> Staphylococcus aureus genes and polypeptides

<130> PB484

<140> Unassigned

<141> 1999-08-31

<150> 60/098,964

<151> 1998-09-01

<160> 61

<170> PatentIn Ver. 2.0

<210> 1

<211> 1092

<212> DNA

<213> Staphylococcus aureus

<400> 1

```

attaactagt caatattcct acctctgact tgagttttaa aagtaatcta tgttaaatta 60
atacctggta ttaaaaattt tattaagaag gtgttcaact atgaacgtgg gtattaaagg 120
ttttggtgca tatgcgccag aaaagattat tgacaatgcc ttttttgagc aatttttaga 180
tacatctgat gaatggattt ctaagatgac tgggaattaaa gaaagacatt gggcagatga 240
tgatcaagat acttcagatt tagcatatga agcaagttta aaagcaatcg ctgacgctgg 300
tattcagccc gaagatatag atatgataat tgttgccaca gcaactggag atatgccatt 360
tccaactgtc gcaaataatgt tgcaagaacg tttaggggac ggcaaagttg cctctatgga 420
tcaacttgca gcatgttctg gatttatgta ttcaatgatt acagctaaac aatatgttca 480
atctggagat tatcataaca ttttagttgt cgggtgcagat aaattatcta aaataacaga 540
tttaactgac cgttctactg cagttctatt tggagatggg gcagggtcgg ttatcatcgg 600
tgaagtttca gatggcagag gtattataag ttatgaaatg ggttctgatg gcacagggtg 660
taaacattta ttttagata aagatactgg taaactgaaa atgaatggtc gagaagtatt 720
taaatttgct gttagaatta tgggtgatgc atcaacacgt gtagttgaaa aagcgaattt 780
aacatcagat gatatagatt tttttattcc tcatcaagct aatattagaa ttatggaatc 840
agctagagaa cgcttaggta tttcaaaaaga caaatgagt gtttctgtaa ataatatgg 900
aaatacttca gctgcgtcaa tacctttaag tatogatcaa gaattaaaaa atggtaaaat 960
caaagatgat gatacaattg ttcttgtcgg attcgggtggc ggcctaaact ggggcgcaat 1020
gacaataaaa tggggaaaat aggaggataa cgaatgagtc aaaataaaaag agtagttatt 1080
acaggtatgg ga                                     1092

```

<210> 2

<211> 313

<212> PRT

<213> Staphylococcus aureus

<400> 2

```

Met Asn Val Gly Ile Lys Gly Phe Gly Ala Tyr Ala Pro Glu Lys Ile
  1                      5                      10                      15

```

```

Ile Asp Asn Ala Tyr Phe Glu Gln Phe Leu Asp Thr Ser Asp Glu Trp
      20                      25                      30

```

```

Ile Ser Lys Met Thr Gly Ile Lys Glu Arg His Trp Ala Asp Asp Asp
      35                      40                      45

```

```

Gln Asp Thr Ser Asp Leu Ala Tyr Glu Ala Ser Leu Lys Ala Ile Ala
      50                      55                      60

```

Asp Ala Gly Ile Gln Pro Glu Asp Ile Asp Met Ile Ile Val Ala Thr
 65 70 75 80
 Ala Thr Gly Asp Met Pro Phe Pro Thr Val Ala Asn Met Leu Gln Glu
 85 90 95
 Arg Leu Gly Thr Gly Lys Val Ala Ser Met Asp Gln Leu Ala Cys
 100 105 110
 Ser Gly Phe Met Tyr Ser Met Ile Thr Ala Lys Gln Tyr Val Gln Ser
 115 120 125
 Gly Asp Tyr His Asn Ile Leu Val Val Gly Ala Asp Lys Leu Ser Lys
 130 135 140
 Ile Thr Asp Leu Thr Asp Arg Ser Thr Ala Val Leu Phe Gly Asp Gly
 145 150 155 160
 Ala Gly Ala Val Ile Ile Gly Glu Val Ser Asp Gly Arg Gly Ile Ile
 165 170 175
 Ser Tyr Glu Met Gly Ser Asp Gly Thr Gly Gly Lys His Leu Tyr Leu
 180 185 190
 Asp Lys Asp Thr Gly Lys Leu Lys Met Asn Gly Arg Glu Val Phe Lys
 195 200 205
 Phe Ala Val Arg Ile Met Gly Asp Ala Ser Thr Arg Val Val Glu Lys
 210 215 220
 Ala Asn Leu Thr Ser Asp Asp Ile Asp Leu Phe Ile Pro His Gln Ala
 225 230 235 240
 Asn Ile Arg Ile Met Glu Ser Ala Arg Glu Arg Leu Gly Ile Ser Lys
 245 250 255
 Asp Lys Met Ser Val Ser Val Asn Lys Tyr Gly Asn Thr Ser Ala Ala
 260 265 270
 Ser Ile Pro Leu Ser Ile Asp Gln Glu Leu Lys Asn Gly Lys Ile Lys
 275 280 285
 Asp Asp Asp Thr Ile Val Leu Val Gly Phe Gly Gly Gly Leu Thr Trp
 290 295 300
 Gly Ala Met Thr Ile Lys Trp Gly Lys
 305 310

<210> 3

<211> 1074

<212> DNA

<213> Staphylococcus aureus

<400> 3

atactaattc taatactttc ttttcaattt tcgcaaata attttaaaat tggataata 60
 ctatatgata ttaaagacat gagaaaggat gtactgagaa gtgataaata aagacatcta 120
 tcaagcttta caacaactta tcccaaatga aaaaattaaa gttgatgaac ctttaaaacg 180
 atacacttat actaaaacag gtggtaatgc cgactttttac attacccta ctaaaatga 240
 agaagtacaa gcagttgtta aatatgccta tcaaatgag attcctgtta catatttagg 300

3

```

aaatggctca aatattatta tccgtgaagg tggatttcgc ggtattgtaa ttagtttatt 360
atcactagat catatcgaag tatctgatga tgcgataata gccggtagcg gcgctgcaat 420
tattgatgtc tcacgtgttg ctogtgatta cgcacttact ggccttgaat ttgcatgtgg 480
tattccaggt tcaattgggt gtgcagtgtg tatgaatgct ggcgcttatg gtggcgaagt 540
taaagattgt atagactatg cgctttgcgt aaacgaacaa ggctcgtaa ttaaacttac 600
aacaaaagaa ttagagttag attatcgtaa tagcattatt caaaaagaac acttagttgt 660
attagaagct gcatttactt tagctcctgg taaaatgact gaaatacaag ctaaaatgga 720
tgatttaaca gaacgtagag aatctaaaca accttagag tatccttcat gtggtagtgt 780
attccaaaga ccgctgtgtc attttgcagg taaattgata caagattcta atttgcaagg 840
tcaccgtatt ggccggtgtg aagtttcaac caaacacgct ggttttatgg taaatgtaga 900
caatggaact gctacagatt atgaaaacct tattcattat gtacaaaaga ccgtcaaaga 960
aaaatttggc attgaattaa atcgtgaagt tcgcattatt ggtgaacatc caaaggaatc 1020
gtaagttaag gagctttgtc tatgcctaaa gtttatgggt cattaatcga tact 1074

```

<210> 4

<211> 307

<212> PRT

<213> *Staphylococcus aureus*

<400> 4

```

Val Ile Asn Lys Asp Ile Tyr Gln Ala Leu Gln Gln Leu Ile Pro Asn
  1                      5                      10                      15

```

```

Glu Lys Ile Lys Val Asp Glu Pro Leu Lys Arg Tyr Thr Tyr Thr Lys
          20                      25                      30

```

```

Thr Gly Gly Asn Ala Asp Phe Tyr Ile Thr Pro Thr Lys Asn Glu Glu
          35                      40                      45

```

```

Val Gln Ala Val Val Lys Tyr Ala Tyr Gln Asn Glu Ile Pro Val Thr
          50                      55                      60

```

```

Tyr Leu Gly Asn Gly Ser Asn Ile Ile Ile Arg Glu Gly Gly Ile Arg
          65                      70                      75                      80

```

```

Gly Ile Val Ile Ser Leu Leu Ser Leu Asp His Ile Glu Val Ser Asp
          85                      90                      95

```

```

Asp Ala Ile Ile Ala Gly Ser Gly Ala Ala Ile Ile Asp Val Ser Arg
          100                      105                      110

```

```

Val Ala Arg Asp Tyr Ala Leu Thr Gly Leu Glu Phe Ala Cys Gly Ile
          115                      120                      125

```

```

Pro Gly Ser Ile Gly Gly Ala Val Tyr Met Asn Ala Gly Ala Tyr Gly
          130                      135                      140

```

```

Gly Glu Val Lys Asp Cys Ile Asp Tyr Ala Leu Cys Val Asn Glu Gln
          145                      150                      155                      160

```

```

Gly Ser Leu Ile Lys Leu Thr Thr Lys Glu Leu Glu Leu Asp Tyr Arg
          165                      170                      175

```

```

Asn Ser Ile Ile Gln Lys Glu His Leu Val Val Leu Glu Ala Ala Phe
          180                      185                      190

```

```

Thr Leu Ala Pro Gly Lys Met Thr Glu Ile Gln Ala Lys Met Asp Asp
          195                      200                      205

```

```

Leu Thr Glu Arg Arg Glu Ser Lys Gln Pro Leu Glu Tyr Pro Ser Cys
          210                      215                      220

```


Gly Ser Val Phe Gln Arg Pro Pro Gly His Phe Ala Gly Lys Leu Ile
 225 230 235 240

Gln Asp Ser Asn Leu Gln Gly His Arg Ile Gly Gly Val Glu Val Ser
 245 250 255

Thr Lys His Ala Gly Phe Met Val Asn Val Asp Asn Gly Thr Ala Thr
 260 265 270

Asp Tyr Glu Asn Leu Ile His Tyr Val Gln Lys Thr Val Lys Glu Lys
 275 280 285

Phe Gly Ile Glu Leu Asn Arg Glu Val Arg Ile Ile Gly Glu His Pro
 290 295 300

Lys Glu Ser
 305

<210> 5
 <211> 916
 <212> DNA
 <213> Staphylococcus aureus

<400> 5
 aatagtgtta aaatgtattg acgaataaaa agttagttaa aactgggatt agatatttcta 60
 tccgttaaat taattattat aaggagttat cttacatggt aaatcttgaa aacaaaacat 120
 atgtcatcat ggaatcgct aataagcgtg gtattgcttt tgggtgctgct aaagtttttag 180
 atcaattagg tgctaaatta gtatttactt accgtaaaga acgtagccgt aaagagcttg 240
 aaaaattatt agaacaatta aatcaaccag aagcgcaact atatcaaatt gatgttcaaa 300
 gcgatgaaga gggtattaat ggttttgagc aaattggtaa agatgttggc aatattgatg 360
 gtgtatatca ttcaatcgca tttgctaata tggaagactt acgcggacgc ttttctgaaa 420
 cttcacgtga aggcttcttg ttagctcaag acattagttc ttactcatta acaattgtgg 480
 ctcatgaagc taaaaaatta atgccagaag gtggtagcat tgttgcaaca acatatttag 540
 gtggcgaatt cgcagttcaa aactataatg tgatgggtgt tgctaaagcg agcttagaag 600
 caaatgttaa atatttagca ttagacttag gtccagataa tattecggtt aatgcaattt 660
 cagctagtcc aatccgtaca ttaagtgcga aagggtgtggg tggtttcaat acaattctta 720
 aagaaatcga agagcgtgca cctttaaaac gtaatgttga tcaagtagaa gtaggtaaaa 780
 ctgcggttta cttattaagt gatattatcaa gtggcggtac aggtgaaaat attcatgtag 840
 atagcggatt ccacgcaatt aaataatatc attcaacagc tttgttcacg ttattatata 900
 tgtgagcaaa gctttt 916

<210> 6
 <211> 256
 <212> PRT
 <213> Staphylococcus aureus

<400> 6
 Met Leu Asn Leu Glu Asn Lys Thr Tyr Val Ile Met Gly Ile Ala Asn
 1 5 10 15

Lys Arg Ser Ile Ala Phe Gly Val Ala Lys Val Leu Asp Gln Leu Gly
 20 25 30

Ala Lys Leu Val Phe Thr Tyr Arg Lys Glu Arg Ser Arg Lys Glu Leu
 35 40 45

Glu Lys Leu Leu Glu Gln Leu Asn Gln Pro Glu Ala His Leu Tyr Gln
 50 55 60

5

Ile Asp Val Gln Ser Asp Glu Glu Val Ile Asn Gly Phe Glu Gln Ile
 65 70 75 80
 Gly Lys Asp Val Gly Asn Ile Asp Gly Val Tyr His Ser Ile Ala Phe
 85 90 95
 Ala Asn Met Glu Asp Leu Arg Gly Arg Phe Ser Glu Thr Ser Arg Glu
 100 105 110
 Gly Phe Leu Leu Ala Gln Asp Ile Ser Ser Tyr Ser Leu Thr Ile Val
 115 120 125
 Ala His Glu Ala Lys Lys Leu Met Pro Glu Gly Gly Ser Ile Val Ala
 130 135 140
 Thr Thr Tyr Leu Gly Gly Glu Phe Ala Val Gln Asn Tyr Asn Val Met
 145 150 155 160
 Gly Val Ala Lys Ala Ser Leu Glu Ala Asn Val Lys Tyr Leu Ala Leu
 165 170 175
 Asp Leu Gly Pro Asp Asn Ile Arg Val Asn Ala Ile Ser Ala Ser Pro
 180 185 190
 Ile Arg Thr Leu Ser Ala Lys Gly Val Gly Gly Phe Asn Thr Ile Leu
 195 200 205
 Lys Glu Ile Glu Glu Arg Ala Pro Leu Lys Arg Asn Val Asp Gln Val
 210 215 220
 Glu Val Gly Lys Thr Ala Ala Tyr Leu Leu Ser Asp Leu Ser Ser Gly
 225 230 235 240
 Val Thr Gly Glu Asn Ile His Val Asp Ser Gly Phe His Ala Ile Lys
 245 250 255

<210> 7

<211> 1376

<212> DNA

<213> Staphylococcus aureus

<400> 7

taaaataatt ttaaaatagg gaaatgtaaa gtaataggag ttctaagtgg aggatttacg 60
 atggataaaa tagtaatcaa aggtggaaat aaattaacgg gtgaagttaa agtagaaggt 120
 gctaaaaatg cagtattacc aatattgaca gcatctttat tagcttctga taaaccgagc 180
 aaattagtta atgttccagc tttaagtgat gtagaaacaa taaataatgt attaacaact 240
 ttaaatgctg acgttacata caaaaaggac gaaaatgctg ttgtcggtga tgcaacaaag 300
 actctaaatg aagaggcacc atatgaatat gttagtaaaa tgcgtgcaag tatttttagtt 360
 atgggacctc ttttagcaag actaggacat gctattgttg cattgcctgg tggttgtgca 420
 attggaagta gaccgattga gcaacacatt aaagggtttg aagcttttagg cgcagaaatt 480
 catcttgaaa atggtaatat ttatgctaag gctaaaagat gattaaaagg tacatcaatt 540
 catttagatt ttccaagtgt aggagcaaca caaaatatta ttatggcagc atcattagct 600
 aagggttaaga ctttaattga aaatgcagct aaagaacctg aaattgtcga tttagcaaac 660
 tacattaatg aaatgggtgg tagaattact ggtgctggta cagacacaat tacaatcaat 720
 ggtgtagaat cattacatgg tgtagaacat gctatcattc cagatagaat tgaagcaggc 780
 acattactaa tcgctgggtg tataacgcgt ggtgatattt ttgtacgtgg tgcaatcaaa 840
 gaacatatgg cgagtttagt ctataaacta gaagaaatgg gcgttgaatt ggactatcaa 900

```

gaagatggta ttcgtgtacg tgctgaaggg gaattacaac ctgtagacat caaaactcta 960
ccacatcctg gattcccgac tgatatgcaa tcacaaatga tggcattggt attaacggca 1020
aatggtcata aagtcgtaac cgaaactggt tttgaaaacc gttttatgca tgttcagag 1080
ttcaaacgta tgaatgctaa tatcaatgta gaaggtcgta gtgctaaact tgaaggtaaa 1140
agtcaattgc aagggtgcac agttaaagcg actgatttaa gagcagcagc cgccttaatt 1200
ttagctggat tagttgctga tggtaaaaca agcgttactg aattaacgca cctagataga 1260
ggctatggtg acttacacgg taaattgaag caattaggtg cagacattga acgtattaac 1320
gattaattca gtaaattaat ataatggagg atttcaacca tggaaacaat ttttga 1376

```

<210> 8

<211> 421

<212> PRT

<213> Staphylococcus aureus

<400> 8

```

Met Asp Lys Ile Val Ile Lys Gly Gly Asn Lys Leu Thr Gly Glu Val
  1             5             10             15

```

```

Lys Val Glu Gly Ala Lys Asn Ala Val Leu Pro Ile Leu Thr Ala Ser
             20             25             30

```

```

Leu Leu Ala Ser Asp Lys Pro Ser Lys Leu Val Asn Val Pro Ala Leu
             35             40             45

```

```

Ser Asp Val Glu Thr Ile Asn Asn Val Leu Thr Thr Leu Asn Ala Asp
             50             55             60

```

```

Val Thr Tyr Lys Lys Asp Glu Asn Ala Val Val Val Asp Ala Thr Lys
             65             70             75             80

```

```

Thr Leu Asn Glu Glu Ala Pro Tyr Glu Tyr Val Ser Lys Met Arg Ala
             85             90             95

```

```

Ser Ile Leu Val Met Gly Pro Leu Leu Ala Arg Leu Gly His Ala Ile
             100             105             110

```

```

Val Ala Leu Pro Gly Gly Cys Ala Ile Gly Ser Arg Pro Ile Glu Gln
             115             120             125

```

```

His Ile Lys Gly Phe Glu Ala Leu Gly Ala Glu Ile His Leu Glu Asn
             130             135             140

```

```

Gly Asn Ile Tyr Ala Asn Ala Lys Asp Gly Leu Lys Gly Thr Ser Ile
             145             150             155             160

```

```

His Leu Asp Phe Pro Ser Val Gly Ala Thr Gln Asn Ile Ile Met Ala
             165             170             175

```

```

Ala Ser Leu Ala Lys Gly Lys Thr Leu Ile Glu Asn Ala Ala Lys Glu
             180             185             190

```

```

Pro Glu Ile Val Asp Leu Ala Asn Tyr Ile Asn Glu Met Gly Gly Arg
             195             200             205

```

```

Ile Thr Gly Ala Gly Thr Asp Thr Ile Thr Ile Asn Gly Val Glu Ser
             210             215             220

```

```

Leu His Gly Val Glu His Ala Ile Ile Pro Asp Arg Ile Glu Ala Gly
             225             230             235             240

```

```

Thr Leu Leu Ile Ala Gly Ala Ile Thr Arg Gly Asp Ile Phe Val Arg

```

```
<210> 9
<211> 1537
<212> DNA
<213> Staphylococcus aureus
```

[illegible]

8

tacgaagaat ttaaaggaac aggtaacatg gagttacatt tagatcgtaa attgtctgaa 1200
 cgtcgtatct tccctgcaat tgatattggc agaagttcaa cgcgtaaaga agaattgttg 1260
 ataagtaaat ctgaattaga cacattatgg caattaagaa atctattcac tgactcaact 1320
 gactttactg aaagatttat tcgcaaactt aaaagggtcta agaataatga agatttcttc 1380
 aagcagctac aaaagtctgc agaagaaagt actaaaacgg gtcgacctat aatttaataa 1440
 acattatata ggggcttgcg ttttgaatta attaccttta taattacaca gtattgggta 1500
 aaaactcaca aataactctg ttccagatgg ttcaggg 1537

<210> 10

<211> 438

<212> PRT

<213> Staphylococcus aureus

<400> 10

Met	Pro	Glu	Arg	Glu	Arg	Thr	Ser	Pro	Gln	Tyr	Glu	Ser	Phe	His	Glu
1				5					10					15	
Leu	Tyr	Lys	Asn	Tyr	Thr	Thr	Lys	Glu	Leu	Thr	Gln	Lys	Ala	Lys	Thr
			20					25					30		
Leu	Lys	Leu	Thr	Asn	His	Ser	Lys	Leu	Asn	Lys	Lys	Glu	Leu	Val	Leu
		35					40					45			
Ala	Ile	Met	Glu	Ala	Gln	Met	Glu	Lys	Asp	Gly	Asn	Tyr	Tyr	Met	Glu
	50					55					60				
Gly	Ile	Leu	Asp	Asp	Ile	Gln	Pro	Gly	Gly	Tyr	Gly	Phe	Leu	Arg	Thr
65					70					75				80	
Val	Asn	Tyr	Ser	Lys	Gly	Glu	Lys	Asp	Ile	Tyr	Ile	Ser	Ala	Ser	Gln
				85					90					95	
Ile	Arg	Arg	Phe	Glu	Ile	Lys	Arg	Gly	Asp	Lys	Val	Thr	Gly	Lys	Val
			100					105					110		
Arg	Lys	Pro	Lys	Asp	Asn	Glu	Lys	Tyr	Tyr	Gly	Leu	Leu	Gln	Val	Asp
		115					120					125			
Phe	Val	Asn	Asp	His	Asn	Ala	Glu	Glu	Val	Lys	Lys	Arg	Pro	His	Phe
	130					135						140			
Gln	Ala	Leu	Thr	Pro	Leu	Tyr	Pro	Asp	Glu	Arg	Ile	Lys	Leu	Glu	Thr
145					150					155				160	
Glu	Ile	Gln	Asn	Tyr	Ser	Thr	Arg	Ile	Met	Asp	Leu	Val	Thr	Pro	Ile
			165						170					175	
Gly	Leu	Gly	Gln	Arg	Gly	Leu	Ile	Val	Ala	Pro	Pro	Lys	Ala	Gly	Lys
			180					185					190		
Thr	Ser	Leu	Leu	Lys	Glu	Ile	Ala	Asn	Ala	Ile	Ser	Thr	Asn	Lys	Pro
		195					200					205			
Asp	Ala	Lys	Leu	Phe	Ile	Leu	Leu	Val	Gly	Glu	Arg	Pro	Glu	Glu	Val
	210					215					220				
Thr	Asp	Leu	Glu	Arg	Ser	Val	Glu	Ala	Ala	Glu	Val	Val	His	Ser	Thr
225					230					235				240	
Phe	Asp	Glu	Pro	Pro	Glu	His	His	Val	Lys	Val	Ala	Glu	Leu	Leu	Leu
			245						250					255	

Glu Arg Ala Lys Arg Leu Val Glu Ile Gly Glu Asp Val Ile Ile Leu
 260 265 270

Met Asp Ser Ile Thr Arg Leu Ala Arg Ala Tyr Asn Leu Val Ile Pro
 275 280 285

Pro Ser Gly Arg Thr Leu Ser Gly Gly Leu Asp Pro Ala Ser Leu His
 290 295 300

Lys Pro Lys Ala Phe Phe Gly Ala Ala Arg Asn Ile Glu Ala Gly Gly
 305 310 315 320

Ser Leu Thr Ile Leu Ala Thr Ala Leu Val Asp Thr Gly Ser Arg Met
 325 330 335

Asp Asp Met Ile Tyr Glu Glu Phe Lys Gly Thr Gly Asn Met Glu Leu
 340 345 350

His Leu Asp Arg Lys Leu Ser Glu Arg Arg Ile Phe Pro Ala Ile Asp
 355 360 365

Ile Gly Arg Ser Ser Thr Arg Lys Glu Glu Leu Leu Ile Ser Lys Ser
 370 375 380

Glu Leu Asp Thr Leu Trp Gln Leu Arg Asn Leu Phe Thr Asp Ser Thr
 385 390 395 400

Asp Phe Thr Glu Arg Phe Ile Arg Lys Leu Lys Arg Ser Lys Asn Asn
 405 410 415

Glu Asp Phe Phe Lys Gln Leu Gln Lys Ser Ala Glu Glu Ser Thr Lys
 420 425 430

Thr Gly Arg Pro Ile Ile
 435

<210> 11

<211> 554

<212> DNA

<213> Staphylococcus aureus

<400> 11

gatctttttt ttcgttttaa ttaagaataa atagaaattt atgttataag ctcaatagaa 60
 gtttaaataat agcttcaata aaaacgataa taagcgagtg atgttattgg aaaaagctta 120
 ccgaattaaa aagaatgcag attttcagag aatatataaa aaaggtcatt ctgtagccaa 180
 cagacaattt gttgtataca cttgtaataa taaagaaata gaccattttc gcttaggtat 240
 tagtgtttct aaaaaactag gtaatgcagt gttaagaaac aagattaaaa gagcaatagc 300
 tgaaaatttc aaagtacata agtcgcataat attggccaaa gatattattg taatagcaag 360
 acagccagct aaagatatga cgactttaca aatacagaat agtcttgagc acgtacttaa 420
 aattgccaaa gtttttaata aaaagattaa gtaaggatag ggtaggggaa ggaaaacatt 480
 aaccactcaa cacatcccga agtcttacct cagacaaacg taagactgac cttagggtta 540
 taataactta cttt 554

<210> 12

<211> 117

<212> PRT

<213> Staphylococcus aureus

<400> 12

10
 Met Leu Leu Glu Lys Ala Tyr Arg Ile Lys Lys Asn Ala Asp Phe Gln
 1 5 10 15
 Arg Ile Tyr Lys Lys Gly His Ser Val Ala Asn Arg Gln Phe Val Val
 20 25 30
 Tyr Thr Cys Asn Asn Lys Glu Ile Asp His Phe Arg Leu Gly Ile Ser
 35 40 45
 Val Ser Lys Lys Leu Gly Asn Ala Val Leu Arg Asn Lys Ile Lys Arg
 50 55 60
 Ala Ile Arg Glu Asn Phe Lys Val His Lys Ser His Ile Leu Ala Lys
 65 70 75 80
 Asp Ile Ile Val Ile Ala Arg Gln Pro Ala Lys Asp Met Thr Thr Leu
 85 90 95
 Gln Ile Gln Asn Ser Leu Glu His Val Leu Lys Ile Ala Lys Val Phe
 100 105 110
 Asn Lys Lys Ile Lys
 115

<210> 13

<211> 1712

<212> DNA

<213> Staphylococcus aureus

<400> 13

cagcaaaaac tggatgaagg ggtaaattgt ttgggtcagt aagtacaaaa caaattgccg 60
 aagcactaaa agcacaacat gatattaaaa ttgataaacg taaaatggat ttaccaaagt 120
 gaattcattc cctaggatat acgaatgtac ctgttaaatt agataaagaa gttgaaggta 180
 caattcgcgt acacacagtt gaacaataaa gttggattga aataagagggt gtaaccattc 240
 atggatagaa tgtatgagca aaatcaaatg ccgcataaca atgaagctga acagtctgtc 300
 ttaggttcaa ttattataga tccagaattg attaatacta cttaggaagt tttgcttctc 360
 gagtcgtttt ataggggtgc ccatcaacat attttccgtg caatgatgca cttaaagtga 420
 gataataaag aaattgatgt tgtaacattg atggatcaat tatcgacgga aggtacgttg 480
 aatgaagcgg gtggcccgca atatcttgca gagttatcta caaatgtacc aacgacgca 540
 aatgttcagt attatactga tatcgtttct aagcatgcat taaaacgtag attgattcaa 600
 actgcagata gtattgcaa tgatggataa aatgatgaac ttgaactaga tgcgatttta 660
 agtgatgcag aacgtcgaat ttttagacta tcatcttctc gtgaaagcga tggcttttaa 720
 gacattcgag acgtcttagg acaagtgtat gaaacagctg aagagcttga tcaaaatagt 780
 ggtcaaacac caggtatacc tacaggatat cgagatttag accaaatgac agcagggttc 840
 aaccgaaatg atttaattat ccttgacgag cgtccatctg taggtaagac tgcgttcgca 900
 cttaatatgg cacaataaag tgcaacgcac gaagatatgt atacagttgg tattttctcg 960
 ctagagatgg gtgctgatca gttagccaca cgtatgattt gtagttctgg aaatgttgac 1020
 tcaaaccgct taagaacggg tactatgact gaggaagatt ggagtcgttt tactatagcg 1080
 gtaggtaaat tatcacgtac gaagattttt attgatgata caccgggtat tcgaattaa 1140
 gatttacgtt ctaaatgtcg tcgattaaag caagaacatg gcttagacat gattgtgatt 1200
 gactacttac agttgattca aggtagtggg tcacgtgcgt ccgataacag acaacaggaa 1260
 gtttctgaaa tctctcgta attaaaagca ttagcccggtg aattaaaatg tccagttatc 1320
 gcattaagtc agttatctcg tgggtgtgaa caacgacaag ataaacgtcc aatgatgagt 1380
 gatattcgtg aatctgggtc gattgagcaa gatgccgata tcgttgcat cttataccgt 1440
 gatgattact ataaccgtgg cggcgatgaa gatgatgacg atgatgggtg tttcgagcca 1500
 caaacgaatg atgaaaacgg tgaaattgaa attatcattg ctaagcaacg taacgggtcca 1560
 acaggcacag ttaagttaca ttttatgaaa caatataata aatttaccga tatcgattat 1620
 gcacatgcag atatgatgta aaaaagtttt tccgtacaat aatcattaag atgataaaat 1680
 tgtacgggtt ttattttgtt ctgaacgggt tg 1712

<210> 14

<211> 466

<212> PRT

<213> Staphylococcus aureus

<400> 14

Met Asp Arg Met Tyr Glu Gln Asn Gln Met Pro His Asn Asn Glu Ala
 1 5 10 15

Glu Gln Ser Val Leu Gly Ser Ile Ile Ile Asp Pro Glu Leu Ile Asn
 20 25 30

Thr Thr Gln Glu Val Leu Leu Pro Glu Ser Phe Tyr Arg Gly Ala His
 35 40 45

Gln His Ile Phe Arg Ala Met Met His Leu Asn Glu Asp Asn Lys Glu
 50 55 60

Ile Asp Val Val Thr Leu Met Asp Gln Leu Ser Thr Glu Gly Thr Leu
 65 70 75 80

Asn Glu Ala Gly Gly Pro Gln Tyr Leu Ala Glu Leu Ser Thr Asn Val
 85 90 95

Pro Thr Thr Arg Asn Val Gln Tyr Tyr Thr Asp Ile Val Ser Lys His
 100 105 110

Ala Leu Lys Arg Arg Leu Ile Gln Thr Ala Asp Ser Ile Ala Asn Asp
 115 120 125

Gly Tyr Asn Asp Glu Leu Glu Leu Asp Ala Ile Leu Ser Asp Ala Glu
 130 135 140

Arg Arg Ile Leu Glu Leu Ser Ser Ser Arg Glu Ser Asp Gly Phe Lys
 145 150 155 160

Asp Ile Arg Asp Val Leu Gly Gln Val Tyr Glu Thr Ala Glu Glu Leu
 165 170 175

Asp Gln Asn Ser Gly Gln Thr Pro Gly Ile Pro Thr Gly Tyr Arg Asp
 180 185 190

Leu Asp Gln Met Thr Ala Gly Phe Asn Arg Asn Asp Leu Ile Ile Leu
 195 200 205

Ala Ala Arg Pro Ser Val Gly Lys Thr Ala Phe Ala Leu Asn Ile Ala
 210 215 220

Gln Lys Val Ala Thr His Glu Asp Met Tyr Thr Val Gly Ile Phe Ser
 225 230 235 240

Leu Glu Met Gly Ala Asp Gln Leu Ala Thr Arg Met Ile Cys Ser Ser
 245 250 255

Gly Asn Val Asp Ser Asn Arg Leu Arg Thr Gly Thr Met Thr Glu Glu
 260 265 270

Asp Trp Ser Arg Phe Thr Ile Ala Val Gly Lys Leu Ser Arg Thr Lys
 275 280 285

Ile Phe Ile Asp Asp Thr Pro Gly Ile Arg Ile Asn Asp Leu Arg Ser

12

290 295 300
 Lys Cys Arg Arg Leu Lys Gln Glu His Gly Leu Asp Met Ile Val Ile
 305 310 315 320
 Asp Tyr Leu Gln Leu Ile Gln Gly Ser Gly Ser Arg Ala Ser Asp Asn
 325 330 335
 Arg Gln Gln Glu Val Ser Glu Ile Ser Arg Thr Leu Lys Ala Leu Ala
 340 345 350
 Arg Glu Leu Lys Cys Pro Val Ile Ala Leu Ser Gln Leu Ser Arg Gly
 355 360 365
 Val Glu Gln Arg Gln Asp Lys Arg Pro Met Met Ser Asp Ile Arg Glu
 370 375 380
 Ser Gly Ser Ile Glu Gln Asp Ala Asp Ile Val Ala Phe Leu Tyr Arg
 385 390 395 400
 Asp Asp Tyr Tyr Asn Arg Gly Gly Asp Glu Asp Asp Asp Asp Asp Gly
 405 410 415
 Gly Phe Glu Pro Gln Thr Asn Asp Glu Asn Gly Glu Ile Glu Ile Ile
 420 425 430
 Ile Ala Lys Gln Arg Asn Gly Pro Thr Gly Thr Val Lys Leu His Phe
 435 440 445
 Met Lys Gln Tyr Asn Lys Phe Thr Asp Ile Asp Tyr Ala His Ala Asp
 450 455 460

Met Met
465

<210> 15

<211> 1170

<212> DNA

<213> Staphylococcus aureus

<400> 15

gtggttccgt attattagga ttggaaggta ctgtagttaa agcacacggt agttcaaagt 60
 ctaaagcttt ttattctgca attagacaag cgaaaatcgc aggagaacaa aatattgtac 120
 aaacaatgaa agagactgta ggtgaatcaa atgagtaaaa cagcaattat ttttccggga 180
 caaggtgccc aaaaagttgg tatggcgcaa gatttggtta acaacaatga tcaagcaact 240
 gaaattttta cttcagcagc gaacacatta gactttgata ttttagagac aatgtttact 300
 gatgaagaag gtaaattggg tgaaactgaa aacacacaac cagctttatt gacgcatagt 360
 tcggcattat tagcagcgt aaaaaatttg aatcctgatt ttactatggg gcatagttta 420
 ggtgaatatt caagtttagt tgcagctgac gtattatcat ttgaagatgc agttaaaatt 480
 gttagaaaac gtggtcaatt aatggcgcaa gcatttcccta ctggtgtagg aagcatggct 540
 gcagtattgg gattagattt tgataaagtc gatgaaattt gtaagtcatt atcatctgat 600
 gacaaaataa ttgaaccagc aaacattaat tgcccagggtc aaattgttgt ttcaggtcac 660
 aaagctttta ttgatgagct agtagaaaaa ggtaaatacat taggtgcaaa acgtgtcatg 720
 cttttagcag tatctggacc attccattca tcgctaataa aagtgtattga agaagatttt 780
 tcaagttaca ttaatcaatt tgaatggcgt gatgctaagt ttctgtagt tcaaaatgta 840
 aatgcgcaag gtgaaactga caaagaagta attaaatcta atatgggtcaa gcaattatat 900
 tcaccagtac aattcattaa ctcaacagaa tggctaatag accaaggtgt tgatcatttt 960
 attgaaattg gtcttgaaa agttttatct ggcttaatta aaaaaataaa tagagatgtt 1020
 aagttaacat caattcaaac tttagaagat gtgaaaggat ggaatgaaaa tgactaagag 1080
 tgcttttagta acaggtgcat caagaggaat tggacgtagt attgcgttac aattagcaga 1140

13

agaaggatat aatgtagcag taaactatgc

1170

<210> 16

<211> 308

<212> PRT

<213> Staphylococcus aureus

<400> 16

Met Ser Lys Thr Ala Ile Ile Phe Pro Gly Gln Gly Ala Gln Lys Val
 1 5 10 15

Gly Met Ala Gln Asp Leu Phe Asn Asn Asn Asp Gln Ala Thr Glu Ile
 20 25 30

Leu Thr Ser Ala Ala Asn Thr Leu Asp Phe Asp Ile Leu Glu Thr Met
 35 40 45

Phe Thr Asp Glu Glu Gly Lys Leu Gly Glu Thr Glu Asn Thr Gln Pro
 50 55 60

Ala Leu Leu Thr His Ser Ser Ala Leu Leu Ala Ala Leu Lys Asn Leu
 65 70 75 80

Asn Pro Asp Phe Thr Met Gly His Ser Leu Gly Glu Tyr Ser Ser Leu
 85 90 95

Val Ala Ala Asp Val Leu Ser Phe Glu Asp Ala Val Lys Ile Val Arg
 100 105 110

Lys Arg Gly Gln Leu Met Ala Gln Ala Phe Pro Thr Gly Val Gly Ser
 115 120 125

Met Ala Ala Val Leu Gly Leu Asp Phe Asp Lys Val Asp Glu Ile Cys
 130 135 140

Lys Ser Leu Ser Ser Asp Asp Lys Ile Ile Glu Pro Ala Asn Ile Asn
 145 150 155 160

Cys Pro Gly Gln Ile Val Val Ser Gly His Lys Ala Leu Ile Asp Glu
 165 170 175

Leu Val Glu Lys Gly Lys Ser Leu Gly Ala Lys Arg Val Met Pro Leu
 180 185 190

Ala Val Ser Gly Pro Phe His Ser Ser Leu Met Lys Val Ile Glu Glu
 195 200 205

Asp Phe Ser Ser Tyr Ile Asn Gln Phe Glu Trp Arg Asp Ala Lys Phe
 210 215 220

Pro Val Val Gln Asn Val Asn Ala Gln Gly Glu Thr Asp Lys Glu Val
 225 230 235 240

Ile Lys Ser Asn Met Val Lys Gln Leu Tyr Ser Pro Val Gln Phe Ile
 245 250 255

Asn Ser Thr Glu Trp Leu Ile Asp Gln Gly Val Asp His Phe Ile Glu
 260 265 270

Ile Gly Pro Gly Lys Val Leu Ser Gly Leu Ile Lys Lys Ile Asn Arg
 275 280 285

Asp Val Lys Leu Thr Ser Ile Gln Thr Leu Glu Asp Val Lys Gly Trp
 290 295 300

Asn Glu Asn Asp
 305

<210> 17
 <211> 1080
 <212> DNA
 <213> Staphylococcus aureus

<400> 17
 aaatacacat ttaatctgca gtatttcaat gcattgacgc tatttttttg atataattac 60
 tttgaaaaat acgtgcgtaa gcactcaagg aggaactttc atgccttttag tttcaatgaa 120
 agaaatgtta attgatgcaa aagaaaatgg ttatgcggtta ggtcaatata atattaataa 180
 cctagaattc actcaagcaa ttttagaagc gtcacaagaa gaaaatgcac ctgtaatttt 240
 aggtgtttct gaagtgctg ctcgtttacat gagcgggttc tacacaattg ttaaaatggt 300
 tgaagggtta atgcatgact taaacatcac tattcctgta gcaatccatt tagaccatgg 360
 ttcaagcttt gaaaaatgta aagaagctat cgatgctggg ttcacatcag taatgatcga 420
 tgcttcacac agcccattcg aagaaaacgt agcaacaact aaaaaagttg ttgaatacgc 480
 tcatgaaaaa ggtgtttctg tagaagctga attagggtact gttggtggac aagaagatga 540
 tggtgttagca gacggcatca tttatgctga tcctaaagaa tgtcaagaac tagttgaaaa 600
 aactggtatt gatgcattag cgccagcatt aggttcagtt catggtccat acaaagggtga 660
 accaaaatta ggtatttaaag aaatggaaga aatcggttta tctacagggt taccattagt 720
 attacacggt ggtactggta tcccgaactaa agatatccaa aaagcaattc catttggtac 780
 agctaaaatt aacgtaaaca ctgaaaacca aatcgcttca gcaaaagcag ttcgtgacgt 840
 tttaaataac gacaaagaag tttacgatcc tcgtaaatac ttaggacctg cacgtgaagc 900
 catcaaagaa acagtttaaag gtaaaattaa agagttcggg acttctaacc gcgctaaata 960
 attaataatt agtctttaag ttattaataa cgtagggata ttaattttta aagaagcaga 1020
 caaatgggtg tttgcttctt ttttatgtcg tataagtaat aaataaaaca gtttgatttt 1080

<210> 18
 <211> 286
 <212> PRT
 <213> Staphylococcus aureus

<400> 18
 Met Pro Leu Val Ser Met Lys Glu Met Leu Ile Asp Ala Lys Glu Asn
 1 5 10 15
 Gly Tyr Ala Val Gly Gln Tyr Asn Ile Asn Asn Leu Glu Phe Thr Gln
 20 25 30
 Ala Ile Leu Glu Ala Ser Gln Glu Asn Ala Pro Val Ile Leu Gly
 35 40 45
 Val Ser Glu Gly Ala Ala Arg Tyr Met Ser Gly Phe Tyr Thr Ile Val
 50 55 60
 Lys Met Val Glu Gly Leu Met His Asp Leu Asn Ile Thr Ile Pro Val
 65 70 75 80
 Ala Ile His Leu Asp His Gly Ser Ser Phe Glu Lys Cys Lys Glu Ala
 85 90 95
 Ile Asp Ala Gly Phe Thr Ser Val Met Ile Asp Ala Ser His Ser Pro
 100 105 110
 Phe Glu Glu Asn Val Ala Thr Thr Lys Lys Val Val Glu Tyr Ala His

15

115 120 125
 Glu Lys Gly Val Ser Val Glu Ala Glu Leu Gly Thr Val Gly Gly Gln
 130 135 140

 Glu Asp Asp Val Val Ala Asp Gly Ile Ile Tyr Ala Asp Pro Lys Glu
 145 150 155 160
 Cys Gln Glu Leu Val Glu Lys Thr Gly Ile Asp Ala Leu Ala Pro Ala
 165 170 175
 Leu Gly Ser Val His Gly Pro Tyr Lys Gly Glu Pro Lys Leu Gly Phe
 180 185 190
 Lys Glu Met Glu Glu Ile Gly Leu Ser Thr Gly Leu Pro Leu Val Leu
 195 200 205
 His Gly Gly Thr Gly Ile Pro Thr Lys Asp Ile Gln Lys Ala Ile Pro
 210 215 220
 Phe Gly Thr Ala Lys Ile Asn Val Asn Thr Glu Asn Gln Ile Ala Ser
 225 230 235 240
 Ala Lys Ala Val Arg Asp Val Leu Asn Asn Asp Lys Glu Val Tyr Asp
 245 250 255
 Pro Arg Lys Tyr Leu Gly Pro Ala Arg Glu Ala Ile Lys Glu Thr Val
 260 265 270
 Lys Gly Lys Ile Lys Glu Phe Gly Thr Ser Asn Arg Ala Lys
 275 280 285

<210> 19

<211> 1340

<212> DNA

<213> Staphylococcus aureus

<400> 19

gctataatag gcatggttac aatgagcttg ctcatacata ttaatataat tacaaaaaca 60
 cgctggaggt acgacatgat taaaaataca attaaaaaat tgatagaaca tagtatatat 120
 acgactttta aattactatc aaaattgcc aacaagaatc taatttattt tgaagcttt 180
 catggttaac aatacagcga caaccccaaa gcattatatg aatacttaac tgaacatagc 240
 gatgcccaat taatatgggg tgtgaaaaaa ggatatgaac acatattcca acagcacaat 300
 gtaccatatg ttacaaagt ttcaatgaaa tggtttttag cgatgccaa agcgaaaagcg 360
 tggatgatta acacacgtac accagattgg ttatataaat caccgcgaac gacgtactta 420
 caaacatggc atggcacgcc attaaaaaag attggtttgg atattagtaa cgtaaagt 480
 ctaggaaaca atactcaaaa ttaccaagat ggctttaaaa aagaaagcca acggtgggat 540
 tatctagtgt cacctaattc atattcgaca tcgatatttc aaaatgcatt tcatgttagt 600
 cgagataaga ttttggaac aggttatcca agaaatgata aattatcaca taaacgcaat 660
 gatactgaat atattaatgg tattaagaca agattaaata ttccattaga taaaaaagt 720
 attatgtacg cgccaacttg gcgtgacgat gaagcgattc gagaagggtc atatcaattt 780
 aatgtaact ttgatataga agctttgcgt caagcgctgg atgatgatta tgttatttta 840
 ttacgatgc attatttagt tgtgacacgt attgatgaac atgatgattt tgtgaaagac 900
 gtttcagatt atgaagacat ttccgattta tacttaatca gcatgctgtt agttaccgac 960
 tactcatctg tcatgttcga cttcgggtga ttaaagcgtc cgcaaatttt ctatgcatat 1020
 gacttagata aatatggcga tgagcttaga ggtttttaca tggattataa aaaagagttg 1080
 ccaggtccaa ttgttgaaaa tcaaacagca ctcatgatg cattaaaca aatcgatgag 1140
 actgcaaag agtatattga agcacgaac gtattttatc aaaaattctg ttcattagaa 1200
 gatggacaag cgtcacaacg aatttgccaa acgattttta agtgataact taaaaacaat 1260
 aaaaaattat aaattaatta gtttaagtgt ataaataata aacgaaatgt ttgcttgtat 1320

16

gttattattt gtgtatgaaa

1340

<210> 20

<211> 389

<212> PRT

<213> Staphylococcus aureus

<400> 20

Met Ile Lys Asn Thr Ile Lys Lys Leu Ile Glu His Ser Ile Tyr Thr
 1 5 10 15

Thr Phe Lys Leu Leu Ser Lys Leu Pro Asn Lys Asn Leu Ile Tyr Phe
 20 25 30

Glu Ser Phe His Gly Lys Gln Tyr Ser Asp Asn Pro Lys Ala Leu Tyr
 35 40 45

Glu Tyr Leu Thr Glu His Ser Asp Ala Gln Leu Ile Trp Gly Val Lys
 50 55 60

Lys Gly Tyr Glu His Ile Phe Gln Gln His Asn Val Pro Tyr Val Thr
 65 70 75 80

Lys Phe Ser Met Lys Trp Phe Leu Ala Met Pro Arg Ala Lys Ala Trp
 85 90 95

Met Ile Asn Thr Arg Thr Pro Asp Trp Leu Tyr Lys Ser Pro Arg Thr
 100 105 110

Thr Tyr Leu Gln Thr Trp His Gly Thr Pro Leu Lys Lys Ile Gly Leu
 115 120 125

Asp Ile Ser Asn Val Lys Met Leu Gly Thr Asn Thr Gln Asn Tyr Gln
 130 135 140

Asp Gly Phe Lys Lys Glu Ser Gln Arg Trp Asp Tyr Leu Val Ser Pro
 145 150 155 160

Asn Pro Tyr Ser Thr Ser Ile Phe Gln Asn Ala Phe His Val Ser Arg
 165 170 175

Asp Lys Ile Leu Glu Thr Gly Tyr Pro Arg Asn Asp Lys Leu Ser His
 180 185 190

Lys Arg Asn Asp Thr Glu Tyr Ile Asn Gly Ile Lys Thr Arg Leu Asn
 195 200 205

Ile Pro Leu Asp Lys Lys Val Ile Met Tyr Ala Pro Thr Trp Arg Asp
 210 215 220

Asp Glu Ala Ile Arg Glu Gly Ser Tyr Gln Phe Asn Val Asn Phe Asp
 225 230 235 240

Ile Glu Ala Leu Arg Gln Ala Leu Asp Asp Asp Tyr Val Ile Leu Leu
 245 250 255

Arg Met His Tyr Leu Val Val Thr Arg Ile Asp Glu His Asp Asp Phe
 260 265 270

Val Lys Asp Val Ser Asp Tyr Glu Asp Ile Ser Asp Leu Tyr Leu Ile
 275 280 285

Ser Asp Ala Leu Val Thr Asp Tyr Ser Ser Val Met Phe Asp Phe Gly
290 295 300

Val Leu Lys Arg Pro Gln Ile Phe Tyr Ala Tyr Asp Leu Asp Lys Tyr
305 310 315 320

Gly Asp Glu Leu Arg Gly Phe Tyr Met Asp Tyr Lys Lys Glu Leu Pro
325 330 335

Gly Pro Ile Val Glu Asn Gln Thr Ala Leu Ile Asp Ala Leu Lys Gln
340 345 350

Ile Asp Glu Thr Ala Asn Glu Tyr Ile Glu Ala Arg Thr Val Phe Tyr
355 360 365

Gln Lys Phe Cys Ser Leu Glu Asp Gly Gln Ala Ser Gln Arg Ile Cys
370 375 380

Gln Thr Ile Phe Lys
385

<210> 21

<211> 1430

<212> DNA

<213> Staphylococcus aureus

<400> 21

```

tgatttgttaa tcaaaactag atataattaa ataatgactt aaaataattt taaaataggg 60
aaatgtaaag taataggagt tctaagtga ggatttacga tggataaaat agtaatcaaa 120
ggtggaata aattaacggg tgaagttaa gtagaagggt ctaaaaatgc agtattacca 180
atattgacag catctttatt agcttctgat aaaccgagca aattagttaa tgttccagct 240
ttaagtgat tagaaacaat aaataatgta ttaacaactt taaatgctga cgttacatac 300
aaaaaggacg aaaatgctgt tgtcgttgat gcaacaaaga ctctaaatga agaggcacca 360
tatgaatatg ttagtaaaat gcgtgcaagt attttagtta tgggacctct tttagcaaga 420
ctaggacatg ctattgttgc attgcctggt gggtgtgcaa ttggaagtag accgattgag 480
caacacatta aaggttttga agcttttaggc gcagaaattc atcttgaaaa tggtaatatt 540
tatgctaattg ctaaagatgg attaaaaggt acatcaattc atttagattt tccaagtgtg 600
ggagcaacac aaaatattat tatggcagca tcattagcta agggtaagac ttttaattgaa 660
aatgcagcta aagaacctga aattgtcgat ttagcaaact acattaatga aatgggtggt 720
agaattactg gtgctggtac agacacaatt acaatcaatg gtgtagaatc attacatggg 780
gtagaacatg ctatcattcc agatagaatt gaagcaggca cattactaat cgctggtgct 840
ataacgcgtg gtgatatttt tgtacgtggt gcaatcaaag aacatatggc gagtttagtc 900
tataaactag aagaaatggg cgttgaattg gactatcaag aagatgggtat tcgtgtacgt 960
gctgaagggg aattacaacc tgtagacatc aaaactctac cacatcctgg attcccgact 1020
gatatgcaat cacaatgat ggcattgtta ttaacggcaa atggtcataa agtcgtaacc 1080
gaaactgttt ttgaaaaccg ttttatgcat gttgcagagt tcaaacgtat gaatgcta 1140
atcaatgtag aaggtcgtag tgctaaactt gaaggtaaaa gtcaattgca aggtgcacaa 1200
gttaaagcga ctgatttaag agcagcagcc gccttaattt tagctggatt agttgctgat 1260
ggtaaaacaa gcgttactga attaacgcac ctagatagag gctatgttga cttacacggt 1320
aaattgaagc aattaggtgc agacattgaa cgtattaacg attaatcag taaattaata 1380
taatggagga tttcaaccat ggaaacaatt tttgattata accaaattaa 1430

```

<210> 22

<211> 421

<212> PRT

<213> Staphylococcus aureus

<400> 22

Met Asp Lys Ile Val Ile Lys Gly Gly Asn Lys Leu Thr Gly Glu Val

1 5 10 15 18
 Lys Val Glu Gly Ala Lys Asn Ala Val Leu Pro Ile Leu Thr Ala Ser
 20 25 30
 Leu Leu Ala Ser Asp Lys Pro Ser Lys Leu Val Asn Val Pro Ala Leu
 35 40 45
 Ser Asp Val Glu Thr Ile Asn Asn Val Leu Thr Thr Leu Asn Ala Asp
 50 55 60
 Val Thr Tyr Lys Lys Asp Glu Asn Ala Val Val Val Asp Ala Thr Lys
 65 70 75 80
 Thr Leu Asn Glu Glu Ala Pro Tyr Glu Tyr Val Ser Lys Met Arg Ala
 85 90 95
 Ser Ile Leu Val Met Gly Pro Leu Leu Ala Arg Leu Gly His Ala Ile
 100 105 110
 Val Ala Leu Pro Gly Gly Cys Ala Ile Gly Ser Arg Pro Ile Glu Gln
 115 120 125
 His Ile Lys Gly Phe Glu Ala Leu Gly Ala Glu Ile His Leu Glu Asn
 130 135 140
 Gly Asn Ile Tyr Ala Asn Ala Lys Asp Gly Leu Lys Gly Thr Ser Ile
 145 150 155 160
 His Leu Asp Phe Pro Ser Val Gly Ala Thr Gln Asn Ile Ile Met Ala
 165 170 175
 Ala Ser Leu Ala Lys Gly Lys Thr Leu Ile Glu Asn Ala Ala Lys Glu
 180 185 190
 Pro Glu Ile Val Asp Leu Ala Asn Tyr Ile Asn Glu Met Gly Gly Arg
 195 200 205
 Ile Thr Gly Ala Gly Thr Asp Thr Ile Thr Ile Asn Gly Val Glu Ser
 210 215 220
 Leu His Gly Val Glu His Ala Ile Ile Pro Asp Arg Ile Glu Ala Gly
 225 230 235 240
 Thr Leu Leu Ile Ala Gly Ala Ile Thr Arg Gly Asp Ile Phe Val Arg
 245 250 255
 Gly Ala Ile Lys Glu His Met Ala Ser Leu Val Tyr Lys Leu Glu Glu
 260 265 270
 Met Gly Val Glu Leu Asp Tyr Gln Glu Asp Gly Ile Arg Val Arg Ala
 275 280 285
 Glu Gly Glu Leu Gln Pro Val Asp Ile Lys Thr Leu Pro His Pro Gly
 290 295 300
 Phe Pro Thr Asp Met Gln Ser Gln Met Met Ala Leu Leu Leu Thr Ala
 305 310 315 320
 Asn Gly His Lys Val Val Thr Glu Thr Val Phe Glu Asn Arg Phe Met
 325 330 335

His Val Ala Glu Phe Lys Arg Met Asn Ala Asn Ile Asn Val Glu Gly
340 345 350

Arg Ser Ala Lys Leu Glu Gly Lys Ser Gln Leu Gln Gly Ala Gln Val
355 360 365

Lys Ala Thr Asp Leu Arg Ala Ala Ala Leu Ile Leu Ala Gly Leu
370 375 380

Val Ala Asp Gly Lys Thr Ser Val Thr Glu Leu Thr His Leu Asp Arg
385 390 395 400

Gly Tyr Val Asp Leu His Gly Lys Leu Lys Gln Leu Gly Ala Asp Ile
405 410 415

Glu Arg Ile Asn Asp
420

<210> 23

<211> 2204

<212> DNA

<213> Staphylococcus aureus

<400> 23

```

agaaaaatgg ctcaatcgaa ctagatatta tctttaaatc acaagggcca aaacgtttgt 60
tagcgcaatt tgcaccaatt gaaaaaagga ggattaaggg atggctgatt tatcgtctcg 120
tgtgaacgag ttacatgatt tattaatatc atacagttat gaatactatg tagaggataa 180
tccatctgta ccagatagtg aatatgacaa attacttcat gaactgatta aaatagaaga 240
ggagcatcct gagtataaga ctgtagattc tccaacagtt agagttggcg gtgaagccca 300
agcctctttc aataaagtca accatgacac gccaatgtta agtttaggga atgcatttaa 360
tgaggatgat ttgagaaaat tgcaccaacg catacgtgaa caaatgggca acgttgaata 420
tatgtgcgaa ttaaaaaattg atggcttagc agtatcattg aaatatgttg atggatactt 480
cgttcaaggt ttaacacgtg gtgatggaac aacaggtgaa gatattaccg aaaattttaa 540
aacaattcat gcgatacctt tgaaaaatgaa agaaccatta aatgtagaag ttcgtggtga 600
agcatatatg ccgagacgtt cattttttacg attaaatgaa gaaaaagaaa aaaatgatga 660
gcagttatatt gcaaatccaa gaaacgctgc tgcgggatca ttaagacagt tagattctaa 720
attaacggca aaacgaaagc taagcgtatt tatatatagt gtcaatgatt tcaactgatt 780
caatgcgcgt tcgcaaagtg aagcattaga tgagttagat aaattaggtt ttacaacgaa 840
taaaaaataga gcgcgtgtaa ataatatcga tgggtgttta gagtatatg aaaaatggac 900
aagcacaaga gatcattac cttatgatag tgatgggatt gttattaagg ttaattgatt 960
agatcaacag gatgagatgg gattcacaca aaaatctcct agatgggcca ttgcttataa 1020
atttccagct gaggaagtag taactaaatt attagatatt gaattaagta ttggacgaac 1080
aggtgtagtc acacctactg ctatttttaga accagtaaaa gtrgctggta caactgtatc 1140
aagagcatct ttgcacaatg aggatttaat tcatgacaga gatattcgaa ttggtgatag 1200
tgttgtagtg aaaaaagcag gtgacatcat acctgaagtt gtacgtagta ttccagaacg 1260
tagacctgag gatgctgtca catatcatat gccaacccat tgtccaagtt gtggacatga 1320
attagtagct attgaaggcg aagtagcact tcggttgcat aatccaaaat gccaaacaca 1380
acttggtgaa ggattgatgc actttgtatc aagacaagcc atgaatattg atggtttagg 1440
cactaaaatt attcaacagc tttatcaaag cgaattaatt aaagatgttg ctgatatttt 1500
ctattttaaca gaagaagatt tattaccttt agacagaaat gggcagaaaa aagttgataa 1560
tttatttagct gccattcaac aagctaagga caactcttta gaaaatttat tatttggctc 1620
aggtattagg ctttaggtg ttaaagcgag ccaagtgtta gcagaaaaat atgaaacgat 1680
agatcgatta ctaacggtaa ctgaagcgga attagtagaa attcatgata taggtgataa 1740
agtagcacia tctgtagtta cttattttaga aaatgaagat attcgtgctt taattcaaaa 1800
attaaaagat aaacatgtta atatgattta taaaggtatc aaacatcag atattgaagg 1860
acatcctgaa ttttagtggt aaacgatagt actgactggg aagytcacatc aaatgacacg 1920
caatgaagca tctaaatggc ttgcatcaca aggtgctaaa gttacaagta gcgttactaa 1980
aaatacagat gtcgtttatt ctggtgaaga tgcaggttca aaattaacaa aagcacaag 2040
tttaggtatt gaaatttgga cagagcaaca atttgtagat aagcaaaatg aattaaatag 2100

```


20

ttagaggggt atgtcgatga agcgtacatt agtattattg attacageta tctttatact 2160
 cgctgcttgt ggtaaccata aggatgacca ggctggaaaa gata 2204

<210> 24

<211> 667

<212> PRT

<213> Staphylococcus aureus

<400> 24

Met Ala Asp Leu Ser Ser Arg Val Asn Glu Leu His Asp Leu Leu Asn
 1 5 10 15

Gln Tyr Ser Tyr Glu Tyr Tyr Val Glu Asp Asn Pro Ser Val Pro Asp
 20 25 30

Ser Glu Tyr Asp Lys Leu Leu His Glu Leu Ile Lys Ile Glu Glu Glu
 35 40 45

His Pro Glu Tyr Lys Thr Val Asp Ser Pro Thr Val Arg Val Gly Gly
 50 55 60

Glu Ala Gln Ala Ser Phe Asn Lys Val Asn His Asp Thr Pro Met Leu
 65 70 75 80

Ser Leu Gly Asn Ala Phe Asn Glu Asp Asp Leu Arg Lys Phe Asp Gln
 85 90 95

Arg Ile Arg Glu Gln Ile Gly Asn Val Glu Tyr Met Cys Glu Leu Lys
 100 105 110

Ile Asp Gly Leu Ala Val Ser Leu Lys Tyr Val Asp Gly Tyr Phe Val
 115 120 125

Gln Gly Leu Thr Arg Gly Asp Gly Thr Thr Gly Glu Asp Ile Thr Glu
 130 135 140

Asn Leu Lys Thr Ile His Ala Ile Pro Leu Lys Met Lys Glu Pro Leu
 145 150 155 160

Asn Val Glu Val Arg Gly Glu Ala Tyr Met Pro Arg Arg Ser Phe Leu
 165 170 175

Arg Leu Asn Glu Glu Lys Glu Lys Asn Asp Glu Gln Leu Phe Ala Asn
 180 185 190

Pro Arg Asn Ala Ala Ala Gly Ser Leu Arg Gln Leu Asp Ser Lys Leu
 195 200 205

Thr Ala Lys Arg Lys Leu Ser Val Phe Ile Tyr Ser Val Asn Asp Phe
 210 215 220

Thr Asp Phe Asn Ala Arg Ser Gln Ser Glu Ala Leu Asp Glu Leu Asp
 225 230 235 240

Lys Leu Gly Phe Thr Thr Asn Lys Asn Arg Ala Arg Val Asn Asn Ile
 245 250 255

Asp Gly Val Leu Glu Tyr Ile Glu Lys Trp Thr Ser Gln Arg Glu Ser
 260 265 270

Leu Pro Tyr Asp Ile Asp Gly Ile Val Ile Lys Val Asn Asp Leu Asp

21

275		280		285
Gln Gln Asp Glu Met Gly Phe Thr Gln Lys Ser Pro Arg Trp Ala Ile				
290		295		300
Ala Tyr Lys Phe Pro Ala Glu Glu Val Val Thr Lys Leu Leu Asp Ile				
305		310		315
				320
Glu Leu Ser Ile Gly Arg Thr Gly Val Val Thr Pro Thr Ala Ile Leu				
		325		330
				335
Glu Pro Val Lys Val Ala Gly Thr Thr Val Ser Arg Ala Ser Leu His				
		340		345
				350
Asn Glu Asp Leu Ile His Asp Arg Asp Ile Arg Ile Gly Asp Ser Val				
		355		360
				365
Val Val Lys Lys Ala Gly Asp Ile Ile Pro Glu Val Val Arg Ser Ile				
		370		375
				380
Pro Glu Arg Arg Pro Glu Asp Ala Val Thr Tyr His Met Pro Thr His				
		385		390
				395
				400
Cys Pro Ser Cys Gly His Glu Leu Val Arg Ile Glu Gly Glu Val Ala				
		405		410
				415
Leu Arg Cys Ile Asn Pro Lys Cys Gln Ala Gln Leu Val Glu Gly Leu				
		420		425
				430
Ile His Phe Val Ser Arg Gln Ala Met Asn Ile Asp Gly Leu Gly Thr				
		435		440
				445
Lys Ile Ile Gln Gln Leu Tyr Gln Ser Glu Leu Ile Lys Asp Val Ala				
		450		455
				460
Asp Ile Phe Tyr Leu Thr Glu Glu Asp Leu Leu Pro Leu Asp Arg Met				
		465		470
				475
				480
Gly Gln Lys Lys Val Asp Asn Leu Leu Ala Ala Ile Gln Gln Ala Lys				
		485		490
				495
Asp Asn Ser Leu Glu Asn Leu Leu Phe Gly Leu Gly Ile Arg His Leu				
		500		505
				510
Gly Val Lys Ala Ser Gln Val Leu Ala Glu Lys Tyr Glu Thr Ile Asp				
		515		520
				525
Arg Leu Leu Thr Val Thr Glu Ala Glu Leu Val Glu Ile His Asp Ile				
		530		535
				540
Gly Asp Lys Val Ala Gln Ser Val Val Thr Tyr Leu Glu Asn Glu Asp				
		545		550
				555
				560
Ile Arg Ala Leu Ile Gln Lys Leu Lys Asp Lys His Val Asn Met Ile				
		565		570
				575
Tyr Lys Gly Ile Lys Thr Ser Asp Ile Glu Gly His Pro Glu Phe Ser				
		580		585
				590
Gly Lys Thr Ile Val Leu Thr Gly Lys Leu His Gln Met Thr Arg Asn				
		595		600
				605

Glu Ala Ser Lys Trp Leu Ala Ser Gln Gly Ala Lys Val Thr Ser Ser
 610 615 620

Val Thr Lys Asn Thr Asp Val Val Ile Ala Gly Glu Asp Ala Gly Ser
 625 630 635 640

Lys Leu Thr Lys Ala Gln Ser Leu Gly Ile Glu Ile Trp Thr Glu Gln
 645 650 655

Gln Phe Val Asp Lys Gln Asn Glu Leu Asn Ser
 660 665

<210> 25

<211> 959

<212> DNA

<213> Staphylococcus aureus

<400> 25

tgtctcactc acttttccaaa atactaaagt aacatcttta gtatatcaaa gaatttttgc 60
 tataataagt tataattata taaaaaagga acgggataaa atgattgtaa aaacagaaga 120
 agaattacaa gcgttaaaag aaattggata catatgcgct aaagtgcgca atacaatgca 180
 agctgcaacc aaaccaggta tcactacgaa agagcttgat aatattgcga aagagttatt 240
 tgaagaatac ggtgctatct ctgcgccaat tcatgatgaa aattttctctg gtcaaactgtg 300
 tattagtgtc aatgaagagg tggcacatgg gattccaagt aagcgtgtca ttcgtgaagg 360
 agatttagta aatattgatg tatcggcttt gaagaatggc tattatgcag atacaggcat 420
 ttcatttgtc gttggagaat cagatgatcc aatgaaacaa aaagtatgtg acgtagcaac 480
 gatggcattt gagaatgcaa ttgcaaaagt aaaaccgggt actaagttaa gtaacattgg 540
 taaagcgggt cataatacag ctgacacaaa tgatttgaaa gtcattaaaa acttaacagg 600
 tcatggtgtt ggtttatcat tacatgaagc accagcacat gtacttaatt actttgatcc 660
 aaaagacaaa acattattaa ctgaaggatg ggtattagct attgaaccgt ttatctcatc 720
 aaatgcatca tttgttacag aaggtaaaaa tgaatgggct tttgaaacga gcgataaaag 780
 ttttgttgct caaattgagc atacggttat cgtgactaag gatgggtccga ttttaacgac 840
 aaagattgaa gaagaatagt tcaacatata ctaagactaa agtatgaaca tcatttagtt 900
 ccggagccta ttcattattg tttcgggaact gttttataat aattaagaac acaatcaat 959

<210> 26

<211> 252

<212> PRT

<213> Staphylococcus aureus

<400> 26

Met Ile Val Lys Thr Glu Glu Glu Leu Gln Ala Leu Lys Glu Ile Gly
 1 5 10 15

Tyr Ile Cys Ala Lys Val Arg Asn Thr Met Gln Ala Ala Thr Lys Pro
 20 25 30

Gly Ile Thr Thr Lys Glu Leu Asp Asn Ile Ala Lys Glu Leu Phe Glu
 35 40 45

Glu Tyr Gly Ala Ile Ser Ala Pro Ile His Asp Glu Asn Phe Pro Gly
 50 55 60

Gln Thr Cys Ile Ser Val Asn Glu Glu Val Ala His Gly Ile Pro Ser
 65 70 75 80

Lys Arg Val Ile Arg Glu Gly Asp Leu Val Asn Ile Asp Val Ser Ala
 85 90 95

23

Leu Lys Asn Gly Tyr Tyr Ala Asp Thr Gly Ile Ser Phe Val Val Gly
 100 105 110

Glu Ser Asp Asp Pro Met Lys Gln Lys Val Cys Asp Val Ala Thr Met
 115 120 125

Ala Phe Glu Asn Ala Ile Ala Lys Val Lys Pro Gly Thr Lys Leu Ser
 130 135 140

Asn Ile Gly Lys Ala Val His Asn Thr Ala Arg Gln Asn Asp Leu Lys
 145 150 155 160

Val Ile Lys Asn Leu Thr Gly His Gly Val Gly Leu Ser Leu His Glu
 165 170 175

Ala Pro Ala His Val Leu Asn Tyr Phe Asp Pro Lys Asp Lys Thr Leu
 180 185 190

Leu Thr Glu Gly Met Val Leu Ala Ile Glu Pro Phe Ile Ser Ser Asn
 195 200 205

Ala Ser Phe Val Thr Glu Gly Lys Asn Glu Trp Ala Phe Glu Thr Ser
 210 215 220

Asp Lys Ser Phe Val Ala Gln Ile Glu His Thr Val Ile Val Thr Lys
 225 230 235 240

Asp Gly Pro Ile Leu Thr Thr Lys Ile Glu Glu Glu
 245 250

<210> 27

<211> 3400

<212> DNA

<213> Staphylococcus aureus

<400> 27

tatacagttt atatgaaatt aaagtagcac ctcataaata cttagatttt taattggaaa 60
 ttgatacaaa tttagtgatg aatgacttaa aggaggcttt tattaatgac aaaagtaaca 120
 cgtgaagaag ttgagcatat cgcgaaatctt gcaagacttc aaatttctcc tgaagaaacg 180
 gaagaaatgg ccaacacatt agaaagcatt ttagattttg caaaacaaaa tgatagecgt 240
 gatacagaag gcgttgaacc tacatatcac gtttttagatt tacaacacgt tttacgtgaa 300
 gataaagcaa tttaaaggat tccacaagaa ttagctttga aaaatgccaa agaaacagaa 360
 gatggacaat ttaaagtggc tacaatcatg aatgaggagg acgcgtaaga tgagcattcg 420
 ctacgaatcg gttgagaatt tattaacttt aataaaagac aaaaaaatca aaccatctga 480
 tggttgtaaa gatatatatg atgcaattga agagactgat ccaacaatta agtcttttct 540
 agcgctggat aaagaaaatg caatcaaaaa agcgcaagaa ttggatgaat tacaagcaaa 600
 agatcaaatg gatggcaaat tatttggtat tccaatgggt ataaaagata acattattac 660
 aaacggatta gaaacaacat gtgcaagtaa aatgtagtaa ggttttgtgc caatttacga 720
 atctactgta atggaaaaac tacataatga aaatgccgtt ttaatcggtg aattaaatat 780
 ggatgagttt gcaatgggtg gttcaacaga aacatcttat ttcaaaaaaa cagttaaccc 840
 atttgaccat aaagcagtg cagggtggtc atcaggtgga tctgcagcag cagttgcagc 900
 tggcttagta ccatttagct taggttcaga cacaggtggg tcaattagac aaccggtgc 960
 atattgtggc gttgtcggta tgaaaccaac atacgggtcgt gtatctcgat ttggattagt 1020
 tgcttttgca tcttcattag accaaattgg tccattgact cgaaatgtaa aagataatgc 1080
 aatcgattta gaagctatct cgtgtgcaga tggttaatgac tctacaagtg caccagttga 1140
 tgatgtagac tttacatctg aaattggtaa agatattaaa ggattaaaag ttgcattacc 1200
 taaagaatac ttaggtgaag gtgtagctga tgacgtaaaa gaagcagttc aaaacgctgt 1260
 agaaacttta aaatctttag gtgctgtcgt tgaggaagta tcattgccaa atactaaatt 1320
 tggattacca tcatattacg tgattgcac atcagaagct tcgtcaaac tttctcggtt 1380
 tgacggaatt cggtatgggt atcattctaa agaagctcat tcattagaag aattatataa 1440

24

```

aatgtcaaga tctgaagggt tccggtaaaga agtaaaacgt cgtatcttct taggtacatt 1500
tgcattaagt tcagggttact atgatgctta ctataaaaaa tctcaaaaag ttagaacatt 1560
gattaaaaat gacttttgata aagtattcga aaattatgat gtagtagttg gtccaacagc 1620
gcctacaact gcgttttaatt taggtgaaga aattgatgat ccattaacaa tgtatgcca 1680
tgatttatta acaacaccag taaacttagc tggattacct ggtatctctg ttccttgtgg 1740
acaatcaaat ggccgaccaa tcggtttaca gttcattggt aaaccattcg atgaaaaaac 1800
gttatatcgt gtcgcttatc aatatgaaac acaatacaat ttacatgacg tttatgaaaa 1860
attataagga gtggaaatca tgcattttga aacagttata ggacttgaag ttcacgtaga 1920
gttaaaaaac gactcaaaaa tgttttctcc atcaccagcg cattttggag cagaacctaa 1980
ctcaaataca aatgttatcg acttagcata tccagggtgc ttaccagttg ttaataagcg 2040
tgcagtagac tgggcaatgc gtgctgcaat ggcactaaat atggaaatcg caacagaatc 2100
taagtttgac cgtaagaact atttctatcc agataatcca aaagcatatc aaatttctca 2160
atttgatcaa ccaattggtg aaaatggata tatcgatgc gaagtcgacg gtgaaacaaa 2220
acgaatcggg attactcgtc ttcacatgga agaagatgct ggtaagtcaa cacataaagg 2280
tgagtattca ttagttgact tgaaccgtca aggtacaccg ctaattgaaa tcgtatctga 2340
accagatatt cgttcacctt aagaagcata tgcataatta gaaaaattgc gttcaattat 2400
tcaatacact ggtgtatcag acgttaagat ggaagaggga tctttacgtt gtgatgctaa 2460
catctcttta cgtccatag gtcaagaaaa atttggtact aaagccgaat tgaaaaactt 2520
aaactcattt aactatgtac gtaaagggtt agaatatgaa gaaaaacgcc aagaagaaga 2580
attgttaaat ggtggagaaa tcggacaaga aacacgtcga tttgatgaat ctacaggtaa 2640
aacaatttta atgctgttta aagaagggtc tgatgattac cgttacttcc cagagcctga 2700
cattgtacct ttatatattg atgatgcttg gaaagagcgt gttcgtcaga caattcctga 2760
attaccagat gaacgttaaag ataagtatgt aaatgaatta ggtttacctg catacgatgc 2820
acacgtatta acattgacta aagaaatgtc agatttcttt gaatcaacaa ttgaacacgg 2880
tgcagatggt aaattaacat ctaactggtt aatgggtggc gtaaacgaat atttaataa 2940
aatcaagta gaattattag atactaaatt aacaccagaa aatttagcag gtatgattaa 3000
acttatcgaa gacggaacaa tgagcagtaa aattgccaag aaagtccttc cagagttagc 3060
agctaaagggt ggtaatgcta aacagattat ggaagataat ggcttagttc aaatttctga 3120
tgaagcaaca cttctaaaat ttgtaaatga agcattagac aataacgaac aatcagttga 3180
agattacaaa aatggtaaaag gcaaagctat gggcttctta gttggtcaaa ttatgaaagc 3240
gtctaaagggt caagctaata cacaattagt aaatcaacta ttaaaacaag aattagataa 3300
aagataattt aaatcatcaa actatgaaga tttaaaaaat aaacccttga ttgctgactt 3360
agatgcaatc gaggggttat ttatatctat agaagtcaaa 3400

```

<210> 28

<211> 485

<212> PRT

<213> Staphylococcus aureus

<400> 28

```

Met Ser Ile Arg Tyr Glu Ser Val Glu Asn Leu Leu Thr Leu Ile Lys
  1             5             10             15

```

```

Asp Lys Lys Ile Lys Pro Ser Asp Val Val Lys Asp Ile Tyr Asp Ala
      20             25             30

```

```

Ile Glu Glu Thr Asp Pro Thr Ile Lys Ser Phe Leu Ala Leu Asp Lys
      35             40             45

```

```

Glu Asn Ala Ile Lys Lys Ala Gln Glu Leu Asp Glu Leu Gln Ala Lys
      50             55             60

```

```

Asp Gln Met Asp Gly Lys Leu Phe Gly Ile Pro Met Gly Ile Lys Asp
      65             70             75             80

```

```

Asn Ile Ile Thr Asn Gly Leu Glu Thr Thr Cys Ala Ser Lys Met Leu
      85             90             95

```

```

Glu Gly Phe Val Pro Ile Tyr Glu Ser Thr Val Met Glu Lys Leu His
      100            105            110

```

25

Asn Glu Asn Ala Val Leu Ile Gly Lys Leu Asn Met Asp Glu Phe Ala
 115 120 125

Met Gly Gly Ser Thr Glu Thr Ser Tyr Phe Lys Lys Thr Val Asn Pro
 130 135 140

Phe Asp His Lys Ala Val Pro Gly Gly Ser Ser Gly Gly Ser Ala Ala
 145 150 155 160

Ala Val Ala Ala Gly Leu Val Pro Phe Ser Leu Gly Ser Asp Thr Gly
 165 170 175

Gly Ser Ile Arg Gln Pro Ala Ala Tyr Cys Gly Val Val Gly Met Lys
 180 185 190

Pro Thr Tyr Gly Arg Val Ser Arg Phe Gly Leu Val Ala Phe Ala Ser
 195 200 205

Ser Leu Asp Gln Ile Gly Pro Leu Thr Arg Asn Val Lys Asp Asn Ala
 210 215 220

Ile Val Leu Glu Ala Ile Ser Gly Ala Asp Val Asn Asp Ser Thr Ser
 225 230 235 240

Ala Pro Val Asp Asp Val Asp Phe Thr Ser Glu Ile Gly Lys Asp Ile
 245 250 255

Lys Gly Leu Lys Val Ala Leu Pro Lys Glu Tyr Leu Gly Glu Gly Val
 260 265 270

Ala Asp Asp Val Lys Glu Ala Val Gln Asn Ala Val Glu Thr Leu Lys
 275 280 285

Ser Leu Gly Ala Val Val Glu Glu Val Ser Leu Pro Asn Thr Lys Phe
 290 295 300

Gly Ile Pro Ser Tyr Tyr Val Ile Ala Ser Ser Glu Ala Ser Ser Asn
 305 310 315 320

Leu Ser Arg Phe Asp Gly Ile Arg Tyr Gly Tyr His Ser Lys Glu Ala
 325 330 335

His Ser Leu Glu Glu Leu Tyr Lys Met Ser Arg Ser Glu Gly Phe Gly
 340 345 350

Lys Glu Val Lys Arg Arg Ile Phe Leu Gly Thr Phe Ala Leu Ser Ser
 355 360 365

Gly Tyr Tyr Asp Ala Tyr Tyr Lys Lys Ser Gln Lys Val Arg Thr Leu
 370 375 380

Ile Lys Asn Asp Phe Asp Lys Val Phe Glu Asn Tyr Asp Val Val Val
 385 390 395 400

Gly Pro Thr Ala Pro Thr Thr Ala Phe Asn Leu Gly Glu Glu Ile Asp
 405 410 415

Asp Pro Leu Thr Met Tyr Ala Asn Asp Leu Leu Thr Thr Pro Val Asn
 420 425 430

Leu Ala Gly Leu Pro Gly Ile Ser Val Pro Cys Gly Gln Ser Asn Gly

26

435 440 445
 Arg Pro Ile Gly Leu Gln Phe Ile Gly Lys Pro Phe Asp Glu Lys Thr
 450 455 460
 Leu Tyr Arg Val Ala Tyr Gln Tyr Glu Thr Gln Tyr Asn Leu His Asp
 465 470 475 480
 Val Tyr Glu Lys Leu
 485

 <210> 29
 <211> 475
 <212> PRT
 <213> Staphylococcus aureus

 <400> 29
 Met His Phe Glu Thr Val Ile Gly Leu Glu Val His Val Glu Leu Lys
 1 5 10 15
 Thr Asp Ser Lys Met Phe Ser Pro Ser Pro Ala His Phe Gly Ala Glu
 20 25 30
 Pro Asn Ser Asn Thr Asn Val Ile Asp Leu Ala Tyr Pro Gly Val Leu
 35 40 45
 Pro Val Val Asn Lys Arg Ala Val Asp Trp Ala Met Arg Ala Ala Met
 50 55 60
 Ala Leu Asn Met Glu Ile Ala Thr Glu Ser Lys Phe Asp Arg Lys Asn
 65 70 75 80
 Tyr Phe Tyr Pro Asp Asn Pro Lys Ala Tyr Gln Ile Ser Gln Phe Asp
 85 90 95
 Gln Pro Ile Gly Glu Asn Gly Tyr Ile Asp Ile Glu Val Asp Gly Glu
 100 105 110
 Thr Lys Arg Ile Gly Ile Thr Arg Leu His Met Glu Glu Asp Ala Gly
 115 120 125
 Lys Ser Thr His Lys Gly Glu Tyr Ser Leu Val Asp Leu Asn Arg Gln
 130 135 140
 Gly Thr Pro Leu Ile Glu Ile Val Ser Glu Pro Asp Ile Arg Ser Pro
 145 150 155 160
 Lys Glu Ala Tyr Ala Tyr Leu Glu Lys Leu Arg Ser Ile Ile Gln Tyr
 165 170 175
 Thr Gly Val Ser Asp Val Lys Met Glu Glu Gly Ser Leu Arg Cys Asp
 180 185 190
 Ala Asn Ile Ser Leu Arg Pro Tyr Gly Gln Glu Lys Phe Gly Thr Lys
 195 200 205
 Ala Glu Leu Lys Asn Leu Asn Ser Phe Asn Tyr Val Arg Lys Gly Leu
 210 215 220
 Glu Tyr Glu Glu Lys Arg Gln Glu Glu Glu Leu Leu Asn Gly Gly Glu

27

225 230 235 240
 Ile Gly Gln Glu Thr Arg Arg Phe Asp Glu Ser Thr Gly Lys Thr Ile
 245 250 255

 Leu Met Arg Val Lys Glu Gly Ser Asp Asp Tyr Arg Tyr Phe Pro Glu
 260 265 270
 Pro Asp Ile Val Pro Leu Tyr Ile Asp Asp Ala Trp Lys Glu Arg Val
 275 280 285
 Arg Gln Thr Ile Pro Glu Leu Pro Asp Glu Arg Lys Ala Lys Tyr Val
 290 295 300
 Asn Glu Leu Gly Leu Pro Ala Tyr Asp Ala His Val Leu Thr Leu Thr
 305 310 315 320
 Lys Glu Met Ser Asp Phe Phe Glu Ser Thr Ile Glu His Gly Ala Asp
 325 330 335
 Val Lys Leu Thr Ser Asn Trp Leu Met Gly Gly Val Asn Glu Tyr Leu
 340 345 350
 Asn Lys Asn Gln Val Glu Leu Leu Asp Thr Lys Leu Thr Pro Glu Asn
 355 360 365
 Leu Ala Gly Met Ile Lys Leu Ile Glu Asp Gly Thr Met Ser Ser Lys
 370 375 380
 Ile Ala Lys Lys Val Phe Pro Glu Leu Ala Ala Lys Gly Gly Asn Ala
 385 390 395 400
 Lys Gln Ile Met Glu Asp Asn Gly Leu Val Gln Ile Ser Asp Glu Ala
 405 410 415
 Thr Leu Leu Lys Phe Val Asn Glu Ala Leu Asp Asn Asn Glu Gln Ser
 420 425 430
 Val Glu Asp Tyr Lys Asn Gly Lys Gly Lys Ala Met Gly Phe Leu Val
 435 440 445
 Gly Gln Ile Met Lys Ala Ser Lys Gly Gln Ala Asn Pro Gln Leu Val
 450 455 460

 Asn Gln Leu Leu Lys Gln Glu Leu Asp Lys Arg
 465 470 475

 <210> 30
 <211> 100
 <212> PRT
 <213> Staphylococcus aureus

 <400> 30
 Met Thr Lys Val Thr Arg Glu Glu Val Glu His Ile Ala Asn Leu Ala
 1 5 10 15
 Arg Leu Gln Ile Ser Pro Glu Glu Thr Glu Glu Met Ala Asn Thr Leu
 20 25 30
 Glu Ser Ile Leu Asp Phe Ala Lys Gln Asn Asp Ser Ala Asp Thr Glu

28

35

40

45

Gly Val Glu Pro Thr Tyr His Val Leu Asp Leu Gln Asn Val Leu Arg
 50 55 60

Glu Asp Lys Ala Ile Lys Gly Ile Pro Gln Glu Leu Ala Leu Lys Asn
 65 70 75 80

Ala Lys Glu Thr Glu Asp Gly Gln Phe Lys Val Pro Thr Ile Met Asn
 85 90 95

Glu Glu Asp Ala
 100

<210> 31

<211> 772

<212> DNA

<213> Staphylococcus aureus

<400> 31

cttactaagc taaagaataa tgataattga tggcaatggc ggaaaatgga tgttgtcatt 60
 ataataataa atgaaacaat tatgttggag gtaaaccacgc atgaaatgta ttgtaggctc 120
 aggtaataata ggtaaactgt ttgaacttac aagacataat atcggctttg aagtcgttga 180
 ttataatttta gagaaaaata atttttcatt agataaacia aagtttaaaag gtgcatatac 240
 aattgaaagg atgaacggcg ataaagtgtt atttatcgaa ccaatgacaa tgatgaattt 300
 gtcaggtgaa gcagttgcac cgattatgga ttattacaat gttaatccag aagatttaat 360
 tgtcttatat gatgatttag atttagaaca aggacaagtt cgcttaagac aaaaaggaag 420
 tgcgggcggt cacaatggta tgaaatcaat tattaaaatg cttggtacag accaatttaa 480
 acgtattcgt attgggtgtg gaagaccaac gaatggtatg acggtacctg attatgtttt 540
 acaacgcttt tcaaatgatg aaatggtaac gatggaaaaa gttatcgaac acgcagcacg 600
 cgcaattgaa aagtttggtg aaacatcacg atttgaccat gttatgaatg aatttaatgg 660
 tgaagtgaat taatgacaat attgacaacg cttataaaaag aagataatca ttttcaagac 720
 cttaatcagg tatttggaac agcaaacaca ctagtaactg gtctttcccc gt 772

<210> 32

<211> 190

<212> PRT

<213> Staphylococcus aureus

<400> 32

Met Lys Cys Ile Val Gly Leu Gly Asn Ile Gly Lys Arg Phe Glu Leu
 1 5 10 15

Thr Arg His Asn Ile Gly Phe Glu Val Val Asp Tyr Ile Leu Glu Lys
 20 25 30

Asn Asn Phe Ser Leu Asp Lys Gln Lys Phe Lys Gly Ala Tyr Thr Ile
 35 40 45

Glu Arg Met Asn Gly Asp Lys Val Leu Phe Ile Glu Pro Met Thr Met
 50 55 60

Met Asn Leu Ser Gly Glu Ala Val Ala Pro Ile Met Asp Tyr Tyr Asn
 65 70 75 80

Val Asn Pro Glu Asp Leu Ile Val Leu Tyr Asp Asp Leu Asp Leu Glu
 85 90 95

Gln Gly Gln Val Arg Leu Arg Gln Lys Gly Ser Ala Gly Gly His Asn
 100 105 110

Gly Met Lys Ser Ile Ile Lys Met Leu Gly Thr Asp Gln Phe Lys Arg
 115 120 125

Ile Arg Ile Gly Val Gly Arg Pro Thr Asn Gly Met Thr Val Pro Asp
 130 135 140

Tyr Val Leu Gln Arg Phe Ser Asn Asp Glu Met Val Thr Met Glu Lys
 145 150 155 160

Val Ile Glu His Ala Ala Arg Ala Ile Glu Lys Phe Val Glu Thr Ser
 165 170 175

Arg Phe Asp His Val Met Asn Glu Phe Asn Gly Glu Val Lys
 180 185 190

<210> 33

<211> 1277

<212> PRT

<213> Staphylococcus aureus

<400> 33

Thr Gly Ala Thr Cys Cys Gly Ala Thr Thr Ala Thr Cys Thr Thr Ala
 1 5 10 15

Gly Thr Ala Gly Gly Thr Gly Cys Cys Ala Ala Thr Gly Ala Ala Ala
 20 25 30

Gly Thr Thr Ala Thr Gly Ala Gly Cys Cys Ala Cys Gly Thr Thr Gly
 35 40 45

Thr Cys Gly Cys Gly Cys Gly Cys Ala Cys Cys Ala Thr Ala Thr Cys
 50 55 60

Gly Thr Ala Gly Cys Ala Cys Cys Thr Ala Gly Thr Gly Ala Thr Ala
 65 70 75 80

Ala Thr Ala Ala Thr Ala Ala Gly Gly Ala Gly Gly Ala Ala Thr Thr
 85 90 95

Ala Thr Ala Ala Gly Thr Gly Thr Thr Thr Gly Ala Thr Cys Ala Ala
 100 105 110

Thr Thr Ala Gly Ala Thr Ala Thr Thr Gly Thr Ala Gly Ala Ala Gly
 115 120 125

Ala Ala Ala Gly Ala Thr Ala Cys Gly Ala Ala Cys Ala Gly Thr Thr
 130 135 140

Ala Ala Ala Thr Gly Ala Ala Cys Thr Gly Thr Thr Ala Ala Gly Thr
 145 150 155 160

Gly Ala Cys Cys Cys Ala Gly Ala Thr Gly Thr Thr Gly Thr Ala Ala
 165 170 175

Ala Thr Gly Ala Thr Thr Cys Ala Gly Ala Thr Ala Ala Ala Thr Thr
 180 185 190

Ala Cys Gly Thr Ala Ala Ala Thr Ala Thr Thr Cys Thr Ala Ala Ala
 195 200 205

Gly Ala Gly Cys Ala Ala Gly Cys Thr Gly Ala Thr Thr Thr Ala Cys
 210 215 220
 Ala Ala Ala Ala Ala Cys Thr Gly Thr Ala Gly Ala Thr Gly Thr
 225 230 235 240
 Thr Thr Ala Thr Cys Gly Thr Ala Ala Cys Thr Ala Thr Ala Ala Ala
 245 250 255
 Gly Cys Thr Ala Ala Ala Ala Ala Gly Ala Ala Gly Ala Ala Thr
 260 265 270
 Thr Ala Gly Cys Thr Gly Ala Thr Ala Thr Thr Gly Ala Ala Gly Ala
 275 280 285
 Ala Ala Thr Gly Thr Thr Ala Ala Gly Thr Gly Ala Gly Ala Cys Thr
 290 295 300
 Gly Ala Thr Gly Ala Thr Ala Ala Ala Gly Ala Ala Gly Ala Ala Gly
 305 310 315 320
 Thr Ala Gly Ala Ala Ala Thr Gly Thr Thr Ala Ala Ala Ala Gly Ala
 325 330 335
 Gly Gly Ala Gly Ala Gly Thr Ala Ala Thr Gly Gly Thr Ala Thr Thr
 340 345 350
 Ala Ala Ala Gly Cys Thr Gly Ala Ala Cys Thr Thr Cys Cys Ala Ala
 355 360 365
 Ala Thr Cys Thr Thr Gly Ala Ala Gly Ala Ala Gly Ala Gly Cys Thr
 370 375 380
 Thr Ala Ala Ala Ala Thr Ala Thr Thr Ala Thr Thr Gly Ala Thr Thr
 385 390 395 400
 Cys Cys Thr Ala Ala Ala Gly Ala Thr Cys Cys Thr Ala Ala Thr Gly
 405 410 415
 Ala Thr Gly Ala Cys Ala Ala Ala Gly Ala Cys Gly Thr Thr Ala Thr
 420 425 430
 Thr Gly Thr Ala Gly Ala Ala Ala Thr Ala Ala Gly Ala Gly Cys Ala
 435 440 445
 Gly Cys Ala Gly Cys Ala Gly Gly Thr Gly Gly Thr Gly Ala Thr Gly
 450 455 460
 Ala Gly Gly Cys Thr Gly Cys Gly Ala Thr Thr Thr Thr Thr Gly Cys
 465 470 475 480
 Thr Gly Gly Thr Gly Ala Thr Thr Thr Ala Ala Thr Gly Cys Gly Thr
 485 490 495
 Ala Thr Gly Thr Ala Thr Thr Cys Ala Ala Ala Gly Thr Ala Thr Gly
 500 505 510
 Cys Thr Gly Ala Ala Thr Cys Ala Cys Ala Ala Gly Gly Ala Thr Thr
 515 520 525

Cys Ala Ala Ala Ala Cys Thr Gly Ala Ala Ala Thr Ala Gly Thr Ala
 530 535 540
 Gly Ala Ala Gly Cys Gly Thr Cys Thr Gly Ala Ala Ala Gly Thr Gly
 545 550 555 560
 Ala Cys Cys Ala Thr Gly Gly Thr Gly Gly Thr Thr Ala Cys Ala Ala
 565 570 575
 Ala Gly Ala Ala Ala Thr Thr Ala Gly Thr Thr Thr Cys Thr Cys Ala
 580 585 590
 Gly Thr Thr Thr Cys Thr Gly Gly Thr Ala Ala Thr Gly Gly Cys Gly
 595 600 605
 Cys Gly Thr Ala Thr Ala Gly Thr Ala Ala Ala Thr Thr Gly Ala Ala
 610 615 620
 Ala Thr Thr Thr Gly Ala Ala Ala Ala Thr Gly Gly Thr Gly Cys Gly
 625 630 635 640
 Cys Ala Cys Cys Gly Cys Gly Thr Thr Cys Ala Ala Cys Gly Thr Gly
 645 650 655
 Thr Gly Cys Cys Thr Gly Ala Ala Ala Cys Ala Gly Ala Ala Thr Cys
 660 665 670
 Ala Gly Gly Thr Gly Gly Ala Cys Gly Thr Ala Thr Thr Cys Ala Thr
 675 680 685
 Ala Cys Thr Thr Cys Ala Ala Cys Ala Gly Cys Thr Ala Cys Ala Gly
 690 695 700
 Thr Gly Gly Cys Ala Gly Thr Thr Thr Thr Ala Cys Cys Ala Gly Ala
 705 710 715 720
 Ala Gly Thr Thr Gly Ala Ala Gly Ala Thr Gly Thr Ala Gly Ala Ala
 725 730 735
 Ala Thr Thr Gly Ala Ala Ala Thr Thr Ala Gly Ala Ala Ala Thr Gly
 740 745 750
 Ala Ala Gly Ala Thr Thr Thr Ala Ala Ala Ala Ala Thr Cys Gly Ala
 755 760 765
 Cys Ala Cys Gly Thr Ala Thr Cys Gly Thr Thr Cys Ala Ala Gly Thr
 770 775 780
 Gly Gly Thr Gly Cys Ala Gly Gly Thr Gly Gly Thr Cys Ala Gly Cys
 785 790 795 800
 Ala Cys Gly Thr Ala Ala Ala Cys Ala Cys Ala Ala Cys Thr Gly Ala
 805 810 815
 Cys Thr Cys Thr Gly Cys Ala Gly Thr Ala Cys Gly Thr Ala Thr Thr
 820 825 830
 Ala Cys Cys Cys Ala Thr Thr Thr Ala Cys Cys Ala Ala Cys Thr Gly
 835 840 845
 Gly Thr Gly Thr Cys Ala Thr Thr Gly Cys Ala Ala Cys Ala Thr Cys

850	855	860
Thr Thr Cys Thr Gly Ala Gly Ala Ala Gly Thr Cys Thr Cys Ala Ala		
865	870	875 880
Ala Thr Thr Cys Ala Ala Ala Ala Cys Cys Gly Thr Gly Ala Ala Ala		
	885	890 895
Ala Ala Gly Cys Ala Ala Thr Gly Ala Ala Ala Gly Thr Gly Thr Thr		
	900	905 910
Ala Ala Ala Ala Gly Cys Ala Cys Gly Thr Thr Thr Ala Thr Ala Cys		
	915	920 925
Gly Ala Thr Ala Thr Gly Ala Ala Ala Gly Thr Thr Cys Ala Ala Gly		
	930	935 940
Ala Ala Gly Ala Ala Cys Ala Ala Cys Ala Ala Ala Ala Gly Thr Ala		
	945	950 955 960
Thr Gly Cys Gly Thr Cys Ala Cys Ala Ala Cys Gly Thr Ala Ala Ala		
	965	970 975
Thr Cys Ala Gly Cys Ala Gly Thr Cys Gly Gly Thr Ala Cys Thr Gly		
	980	985 990
Gly Thr Gly Ala Thr Cys Gly Thr Thr Cys Ala Gly Ala Ala Cys Gly		
	995	1000 1005
Thr Ala Thr Thr Cys Gly Ala Ala Cys Thr Thr Ala Thr Ala Ala Thr		
	1010	1015 1020
Thr Ala Thr Cys Cys Ala Cys Ala Ala Ala Gly Cys Cys Gly Thr Gly		
	1025	1030 1035 1040
Thr Ala Ala Cys Ala Gly Ala Cys Cys Ala Thr Cys Gly Thr Ala Thr		
	1045	1050 1055
Ala Gly Gly Thr Cys Thr Ala Ala Cys Gly Cys Thr Thr Cys Ala Ala		
	1060	1065 1070
Ala Ala Ala Thr Thr Ala Gly Gly Gly Cys Ala Ala Ala Thr Thr Ala		
	1075	1080 1085
Thr Gly Gly Ala Ala Gly Gly Cys Cys Ala Thr Thr Thr Ala Gly Ala		
	1090	1095 1100
Ala Gly Ala Ala Ala Thr Thr Ala Thr Ala Gly Ala Thr Gly Cys Ala		
	1105	1110 1115 1120
Cys Thr Gly Ala Cys Thr Thr Thr Ala Thr Cys Ala Gly Ala Gly Cys		
	1125	1130 1135
Ala Gly Ala Cys Ala Gly Ala Thr Ala Ala Ala Thr Thr Gly Ala Ala		
	1140	1145 1150
Ala Gly Ala Ala Cys Thr Thr Ala Ala Thr Ala Ala Thr Gly Gly Thr		
	1155	1160 1165
Gly Ala Ala Thr Thr Ala Thr Ala Ala Ala Gly Ala Ala Ala Ala Gly		
	1170	1175 1180

Thr Thr Ala Gly Ala Thr Gly Ala Ala Gly Cys Ala Ala Thr Thr Cys
 1185 1190 1195 1200

Ala Thr Thr Thr Ala Ala Cys Ala Cys Ala Ala Cys Ala Ala Ala Ala
 1205 1210 1215

Ala Gly Gly Gly Thr Thr Thr Gly Ala Ala Cys Ala Ala Ala Cys Ala
 1220 1225 1230

Cys Gly Ala Gly Cys Thr Gly Ala Ala Thr Gly Gly Thr Thr Ala Ala
 1235 1240 1245

Thr Gly Thr Thr Ala Gly Ala Thr Gly Thr Ala Thr Thr Thr Cys Ala
 1250 1255 1260

Ala Thr Gly Gly Ala Cys Gly Cys Gly Thr Ala Cys Gly
 1265 1270 1275

<210> 34

<211> 358

<212> PRT

<213> Staphylococcus aureus

<400> 34

Val Phe Asp Gln Leu Asp Ile Val Glu Glu Arg Tyr Glu Gln Leu Asn
 1 5 10 15

Glu Leu Leu Ser Asp Pro Asp Val Val Asn Asp Ser Asp Lys Leu Arg
 20 25 30

Lys Tyr Ser Lys Glu Gln Ala Asp Leu Gln Lys Thr Val Asp Val Tyr
 35 40 45

Arg Asn Tyr Lys Ala Lys Lys Glu Glu Leu Ala Asp Ile Glu Glu Met
 50 55 60

Leu Ser Glu Thr Asp Asp Lys Glu Glu Val Glu Met Leu Lys Glu Glu
 65 70 75 80

Ser Asn Gly Ile Lys Ala Glu Leu Pro Asn Leu Glu Glu Glu Leu Lys
 85 90 95

Ile Leu Leu Ile Pro Lys Asp Pro Asn Asp Asp Lys Asp Val Ile Val
 100 105 110

Glu Ile Arg Ala Ala Ala Gly Gly Asp Glu Ala Ala Ile Phe Ala Gly
 115 120 125

Asp Leu Met Arg Met Tyr Ser Lys Tyr Ala Glu Ser Gln Gly Phe Lys
 130 135 140

Thr Glu Ile Val Glu Ala Ser Glu Ser Asp His Gly Gly Tyr Lys Glu
 145 150 155 160

Ile Ser Phe Ser Val Ser Gly Asn Gly Ala Tyr Ser Lys Leu Lys Phe
 165 170 175

Glu Asn Gly Ala His Arg Val Gln Arg Val Pro Glu Thr Glu Ser Gly
 180 185 190

Gly Arg Ile His Thr Ser Thr Ala Thr Val Ala Val Leu Pro Glu Val
 195 200 205
 Glu Asp Val Glu Ile Glu Ile Arg Asn Glu Asp Leu Lys Ile Asp Thr
 210 215 220
 Tyr Arg Ser Ser Gly Ala Gly Gly Gln His Val Asn Thr Thr Asp Ser
 225 230 235 240
 Ala Val Arg Ile Thr His Leu Pro Thr Gly Val Ile Ala Thr Ser Ser
 245 250 255
 Glu Lys Ser Gln Ile Gln Asn Arg Glu Lys Ala Met Lys Val Leu Lys
 260 265 270
 Ala Arg Leu Tyr Asp Met Lys Val Gln Glu Glu Gln Gln Lys Tyr Ala
 275 280 285
 Ser Gln Arg Lys Ser Ala Val Gly Thr Gly Asp Arg Ser Glu Arg Ile
 290 295 300
 Arg Thr Tyr Asn Tyr Pro Gln Ser Arg Val Thr Asp His Arg Ile Gly
 305 310 315 320
 Leu Thr Leu Gln Lys Leu Gly Gln Ile Met Glu Gly His Leu Glu Glu
 325 330 335
 Ile Ile Asp Ala Leu Thr Leu Ser Glu Gln Thr Asp Lys Leu Lys Glu
 340 345 350
 Leu Asn Asn Gly Glu Leu
 355

<210> 35

<211> 1315

<212> DNA

<213> *Staphylococcus aureus*

<400> 35

```

atctcttaac attgttattt aacaaaatta tgttaaaatt tagcattata aaagatgcaa 60
atcaatgact tgaattgaaa tataaatagg agcgaatgct atggaattat cagaaatcaa 120
acgaaatata gataagtata atcaagattt aacacaaatt aggggggtctc ttgacttaga 180
gaacaaaagaa actaatattc aagaatatga agaaatgatg gcagaacctt atttttggga 240
taaccaaacg aaagcgcaag atattataga taaaaataat gcgttaaaag caatagttaa 300
tggttataaa acactacaag cagaagtaga tgacatggat gctacttggg atttattaca 360
agaagaattht gatgaagaaa tgaaagaaga cttagagcaa gaggtcatta attttaaggc 420
taaagtggat gaatacgaat tgcaattatt attagatggg cctcacgatg ccaataacgc 480
aattctagag ttacatcctg gtgcaggtgg cacggagtct caagattggg ctaatatgct 540
atthagaatg tatcaacgtt attgtgagaa gaaaggcttt aaagttgaaa ctggttgatta 600
tctacctggg gatgaagcgg ggattaaaag tgtaacattg ctcatacaag gccataatgc 660
ttatgggtat ttaaaagctg aaaaagggtg acaccgacta gtacgaattt ctccatttga 720
ttcatcagga cgctgctcata catcatttgc atcatgcgac gttattccag attttaataa 780
tgatgaaata gagattgaaa tcaatccgga tgatattaca gttgatacat tcagagcttc 840
tggtgcaggt ggtcagcata ttaacaaaac tgaatcggca atacgaatta cccaccaccc 900
ctcaggtata gttgttaata accaaaatga acgttctcaa attaaaaacc gtgaagcagc 960
tatgaaaatg ttaaaagtcta aattatatca attaaaattg gaagagcagg cacgtgaaat 1020
ggctgaaatt cgtggcgcaac aaaaagaaat cggctgggga agccaaatta gatcatatgt 1080
tttccatcca tactcaatgg tgaaagatca tcgtacgaac gaagaaacag gtaaggttga 1140
tgcatgtatg gatggagaca ttggaccatt tatcgaatca tattaagac agacaatgtc 1200

```

35

gcacgattaa tatatatattt aaaaccgagg ctctaaaagg gcgtcggttt ttgggttttt 1260
 taaaggtagc taaataaatt gtaaattaga ttttggaata tgatttgttt atgaa 1315

<210> 36

<211> 369

<212> PRT

<213> Staphylococcus aureus

<400> 36

Met Glu Leu Ser Glu Ile Lys Arg Asn Ile Asp Lys Tyr Asn Gln Asp
 1 5 10 15

Leu Thr Gln Ile Arg Gly Ser Leu Asp Leu Glu Asn Lys Glu Thr Asn
 20 25 30

Ile Gln Glu Tyr Glu Glu Met Met Ala Glu Pro Asn Phe Trp Asp Asn
 35 40 45

Gln Thr Lys Ala Gln Asp Ile Ile Asp Lys Asn Asn Ala Leu Lys Ala
 50 55 60

Ile Val Asn Gly Tyr Lys Thr Leu Gln Ala Glu Val Asp Asp Met Asp
 65 70 75 80

Ala Thr Trp Asp Leu Leu Gln Glu Glu Phe Asp Glu Glu Met Lys Glu
 85 90 95

Asp Leu Glu Gln Glu Val Ile Asn Phe Lys Ala Lys Val Asp Glu Tyr
 100 105 110

Glu Leu Gln Leu Leu Leu Asp Gly Pro His Asp Ala Asn Asn Ala Ile
 115 120 125

Leu Glu Leu His Pro Gly Ala Gly Gly Thr Glu Ser Gln Asp Trp Ala
 130 135 140

Asn Met Leu Phe Arg Met Tyr Gln Arg Tyr Cys Glu Lys Lys Gly Phe
 145 150 155 160

Lys Val Glu Thr Val Asp Tyr Leu Pro Gly Asp Glu Ala Gly Ile Lys
 165 170 175

Ser Val Thr Leu Leu Ile Lys Gly His Asn Ala Tyr Gly Tyr Leu Lys
 180 185 190

Ala Glu Lys Gly Val His Arg Leu Val Arg Ile Ser Pro Phe Asp Ser
 195 200 205

Ser Gly Arg Arg His Thr Ser Phe Ala Ser Cys Asp Val Ile Pro Asp
 210 215 220

Phe Asn Asn Asp Glu Ile Glu Ile Glu Ile Asn Pro Asp Asp Ile Thr
 225 230 235 240

Val Asp Thr Phe Arg Ala Ser Gly Ala Gly Gly Gln His Ile Asn Lys
 245 250 255

Thr Glu Ser Ala Ile Arg Ile Thr His His Pro Ser Gly Ile Val Val
 260 265 270

Asn Asn Gln Asn Glu Arg Ser Gln Ile Lys Asn Arg Glu Ala Ala Met

36

275

280

285

Lys Met Leu Lys Ser Lys Leu Tyr Gln Leu Lys Leu Glu Glu Gln Ala
 290 295 300

Arg Glu Met Ala Glu Ile Arg Gly Glu Gln Lys Glu Ile Gly Trp Gly
 305 310 315 320

Ser Gln Ile Arg Ser Tyr Val Phe His Pro Tyr Ser Met Val Lys Asp
 325 330 335

His Arg Thr Asn Glu Glu Thr Gly Lys Val Asp Ala Val Met Asp Gly
 340 345 350

Asp Ile Gly Pro Phe Ile Glu Ser Tyr Leu Arg Gln Thr Met Ser His
 355 360 365

Asp

<210> 37

<211> 840

<212> DNA

<213> Staphylococcus aureus

<400> 37

aataactgaa aatatgatag aattggtaaa tgaatatctg gaaactggaa tgatagttga 60
 aggaattaaa aataataaaa ttttagttga ggatgaataa aatgtcagct ttataaactt 120
 ttgagggccc agaaggctct ggaaaaacaa ctgtaattaa tgaagttac catagattag 180
 taaaagatta tgatgtcatt atgactagag aaccaggtgg tgctcctact ggtgaagaaa 240
 tacgtaaaaat tgtattagaa ggcaatgata tggacattag aactgaagca atgttatttg 300
 ctgcattctag aagagaacat cttgtattaa aggtcatacc agctttaaaa gaaggtaagg 360
 ttgtgtttgt tgatcgctat atcgatagtt cattagctta tcaaggttat gctagaggga 420
 ttggcggttga agaagtaaga gcattaaacg aatttgcaat aaatggatta tatccagact 480
 tgacgattta tttaaatgtt agtgctgaag taggtcgcga acgtattatt aaaaattcaa 540
 gagatcaaaa tagattagat caagaagatt taaagtttca cgaaaaagta attgaaggtt 600
 accaagaaat cattcataat gaatcacacac ggttcaaaaag cgtaaatgca gatcaacctc 660
 ttgaaaatgt tgttgaagac acgtatcaaa ctatcatcaa atatttagaa aagatatgat 720
 ataattgtta gaagaggtgt tataaaaatga aaatgattat agcgatcgta caagatcaag 780
 atagtcagga acttgcagat caacttgta aaaataactt tagagcaaca aaattggcaa 840

<210> 38

<211> 205

<212> PRT

<213> Staphylococcus aureus

<400> 38

Met Ser Ala Phe Ile Thr Phe Glu Gly Pro Glu Gly Ser Gly Lys Thr
 1 5 10 15

Thr Val Ile Asn Glu Val Tyr His Arg Leu Val Lys Asp Tyr Asp Val
 20 25 30

Ile Met Thr Arg Glu Pro Gly Gly Val Pro Thr Gly Glu Glu Ile Arg
 35 40 45

Lys Ile Val Leu Glu Gly Asn Asp Met Asp Ile Arg Thr Glu Ala Met
 50 55 60

Leu Phe Ala Ala Ser Arg Arg Glu His Leu Val Leu Lys Val Ile Pro

<210> 39
<211> 923
<212> DNA
<213> Staphylococcus aureus

```
<210> 40
<211> 240
<212> PRT
<213> Staphylococcus aureus
```

```

<400> 40
Met Ala Gln Ile Ser Lys Tyr Lys Arg Val Val Leu Lys Leu Ser Gly
  1             5             10             15
Glu Ala Leu Ala Gly Glu Lys Gly Phe Gly Ile Asn Pro Val Ile Ile
      20             25             30

```

Lys Ser Val Ala Glu Gln Val Ala Glu Val Ala Lys Met Asp Cys Glu
 35 40 45
 Ile Ala Val Ile Val Gly Gly Gly Asn Ile Trp Arg Gly Lys Thr Gly
 50 55 60
 Ser Asp Leu Gly Met Asp Arg Gly Thr Ala Asp Tyr Met Gly Met Leu
 65 70 75 80
 Ala Thr Val Met Asn Ala Leu Ala Leu Gln Asp Ser Leu Glu Gln Leu
 85 90 95
 Asp Cys Asp Thr Arg Val Leu Thr Ser Ile Glu Met Lys Gln Val Ala
 100 105 110
 Glu Pro Tyr Ile Arg Arg Arg Ala Ile Arg His Leu Glu Lys Lys Arg
 115 120 125
 Val Val Ile Phe Ala Ala Gly Ile Gly Asn Pro Tyr Phe Ser Thr Asp
 130 135 140
 Thr Thr Ala Ala Leu Arg Ala Ala Glu Val Glu Ala Asp Val Ile Leu
 145 150 155 160
 Met Gly Lys Asn Asn Val Asp Gly Val Tyr Ser Ala Asp Pro Lys Val
 165 170 175
 Asn Lys Asp Ala Val Lys Tyr Glu His Leu Thr His Ile Gln Met Leu
 180 185 190
 Gln Glu Gly Leu Gln Val Met Asp Ser Thr Ala Ser Ser Phe Cys Met
 195 200 205
 Asp Asn Asn Ile Pro Leu Thr Val Phe Ser Ile Met Glu Glu Gly Asn
 210 215 220
 Ile Lys Arg Ala Val Met Gly Glu Lys Ile Gly Thr Leu Ile Thr Lys
 225 230 235 240

<210> 41

<211> 1013

<212> DNA

<213> Staphylococcus aureus

<400> 41

gatagcatcc atgtatagtg atagtattta caacaattat tataatacta tttagttaag 60
 tagagaaata gttaaacatt tgaaagtgtg gtttaattgga atgtcagcaa taggaacagt 120
 ttttaaagaa catgtaaaga acttttattt aattcaaaga ctggctcagt ttcaagttaa 180
 aattatcaat catagtaact atttaggtgt ggcttgggaa ttaattaacc ctgttatgca 240
 aattatgggt tactggatgg tttttggatt aggaataaga agtaatgcac caattcatgg 300
 tgtacctttt gtttattggt tattgggttg tatcagtatg tggttcttca tcaaccaagg 360
 tatttttagaa ggtactaaag caattacaca aaagtttaat caagtatcga aaatgaactt 420
 cccgttatcg ataataccga catatattgt gacaagtaga ttttatggac atttaggctt 480
 acttttactt gtgataattg catgtatgtt tactgggtatt tatccatcaa tacatatcat 540
 tcaattattg atatatgtac cgttttggtt tttcttaact gcctcgggtga cgttattaac 600
 atcaacactc ggtgtggttag ttagagatac acaaagtgtta atgcaagcaa tattaagaat 660

39

attatttttac ttttcaccaa ttttggtggt accaaagaac catggtatca gtggtttaat 720
 tcatgaaatg atgaaatata atccagttta ctttattgct gaatcatacc gtgcagcaat 780
 tttatatcac gaatggtatt tcatggatca ttggaaatta atgttatata atttcggtat 840
 tgttgccatt ttctttgcaa ttggtgcgta cttacacatg aaatatagag atcaatttgc 900
 agacttcttg taatatattt atatgacgaa accccgctaa ccattaataa atggaagtgg 960
 ggttcatttt tgtttataat ttaagtaa aacatattaa gttggtgtat tat 1013

<210> 42

<211> 270

<212> PRT

<213> Staphylococcus aureus

<400> 42

Met Ser Ala Ile Gly Thr Val Phe Lys Glu His Val Lys Asn Phe Tyr
 1 5 10 15

Leu Ile Gln Arg Leu Ala Gln Phe Gln Val Lys Ile Ile Asn His Ser
 20 25 30

Asn Tyr Leu Gly Val Ala Trp Glu Leu Ile Asn Pro Val Met Gln Ile
 35 40 45

Met Val Tyr Trp Met Val Phe Gly Leu Gly Ile Arg Ser Asn Ala Pro
 50 55 60

Ile His Gly Val Pro Phe Val Tyr Trp Leu Leu Val Gly Ile Ser Met
 65 70 75 80

Trp Phe Phe Ile Asn Gln Gly Ile Leu Glu Gly Thr Lys Ala Ile Thr
 85 90 95

Gln Lys Phe Asn Gln Val Ser Lys Met Asn Phe Pro Leu Ser Ile Ile
 100 105 110

Pro Thr Tyr Ile Val Thr Ser Arg Phe Tyr Gly His Leu Gly Leu Leu
 115 120 125

Leu Leu Val Ile Ile Ala Cys Met Phe Thr Gly Ile Tyr Pro Ser Ile
 130 135 140

His Ile Ile Gln Leu Leu Ile Tyr Val Pro Phe Cys Phe Phe Leu Thr
 145 150 155 160

Ala Ser Val Thr Leu Leu Thr Ser Thr Leu Gly Val Leu Val Arg Asp
 165 170 175

Thr Gln Met Leu Met Gln Ala Ile Leu Arg Ile Leu Phe Tyr Phe Ser
 180 185 190

Pro Ile Leu Trp Leu Pro Lys Asn His Gly Ile Ser Gly Leu Ile His
 195 200 205

Glu Met Met Lys Tyr Asn Pro Val Tyr Phe Ile Ala Glu Ser Tyr Arg
 210 215 220

Ala Ala Ile Leu Tyr His Glu Trp Tyr Phe Met Asp His Trp Lys Leu
 225 230 235 240

Met Leu Tyr Asn Phe Gly Ile Val Ala Ile Phe Phe Ala Ile Gly Ala
 245 250 255

40

Tyr Leu His Met Lys Tyr Arg Asp Gln Phe Ala Asp Phe Leu
 260 265 270

<210> 43

<211> 995

<212> DNA

<213> Staphylococcus aureus

<400> 43

```

taacaaaatc ttctatacac tttacaacag gttttaaaat ttaacaactg ttgagtagta 60
tattataatc tagataaatg tgaataagga aggtctacaa atgaacgttt cggtaaacaat 120
taaaaatgta acaaaagaat atcgtattta tcgtacaaat aaagaacgta tgaaagatgc 180
gtcattccc aaacataaaa acaaaacatt ttctgcttta gatgacatta gtttaaaagc 240
atatgaagggt gacgtcatag ggcttggttg catcaatggt tccggcaa atcaacgttgag 300
caatatcatt ggcgggttctt tgtcgccctac tgttgccaaa gtggatcgta atggatgaagt 360
cagcgttatc gcaattagtg ctggcttgag tggacaactt acaggggattg aaaatatcga 420
attttaaaatg ttatgtatgg gctttaagcg aaaagaaatt aaagcgatga cacctaagat 480
tattgaattt agtgaacttg gtgagtttat ttatcaacca gttaaaaagt attcaagtgg 540
tatgcgtgca aaacttggtt tttcaattaa tatcacagtt aatccagata tcttagtcat 600
tgacgaagct ttatctgtag gtgaccaaac ttttgcacaa aaatgttttag ataaaattta 660
cgagtttaaa gagcaaaaaca aaaccatctt ttctggttag cataacttag gacaagtga 720
acaattttgt actaagattg cttggattga aggcggaaag ttaaaagatt acgggtgaact 780
tgatgatgta ttacctaat atgaagcttt ccttaacgat tttaaaaaga aatccaaagc 840
cgaacaaaaa gaatttagaa acaaaactcga tgagtccgcg ttcgttatta aataaaccga 900
aaaaaccgag aatctccatt taaggatttc ctcggtttta tttttgtcat catgattatt 960
tcgccttttt tatttttctt tttgctttgg ctatt 995

```

<210> 44

<211> 264

<212> PRT

<213> Staphylococcus aureus

<400> 44

```

Met Asn Val Ser Val Asn Ile Lys Asn Val Thr Lys Glu Tyr Arg Ile
  1           5           10           15

Tyr Arg Thr Asn Lys Glu Arg Met Lys Asp Ala Leu Ile Pro Lys His
      20           25           30

Lys Asn Lys Thr Phe Phe Ala Leu Asp Asp Ile Ser Leu Lys Ala Tyr
      35           40           45

Glu Gly Asp Val Ile Gly Leu Val Gly Ile Asn Gly Ser Gly Lys Ser
      50           55           60

Thr Leu Ser Asn Ile Ile Gly Gly Ser Leu Ser Pro Thr Val Gly Lys
      65           70           75           80

Val Asp Arg Asn Gly Glu Val Ser Val Ile Ala Ile Ser Ala Gly Leu
      85           90           95

Ser Gly Gln Leu Thr Gly Ile Glu Asn Ile Glu Phe Lys Met Leu Cys
      100          105          110

Met Gly Phe Lys Arg Lys Glu Ile Lys Ala Met Thr Pro Lys Ile Ile
      115          120          125

Glu Phe Ser Glu Leu Gly Glu Phe Ile Tyr Gln Pro Val Lys Lys Tyr
      130          135          140

```

41

Ser Ser Gly Met Arg Ala Lys Leu Gly Phe Ser Ile Asn Ile Thr Val
145 150 155 160

Asn Pro Asp Ile Leu Val Ile Asp Glu Ala Leu Ser Val Gly Asp Gln
165 170 175

Thr Phe Ala Gln Lys Cys Leu Asp Lys Ile Tyr Glu Phe Lys Glu Gln
180 185 190

Asn Lys Thr Ile Phe Phe Val Ser His Asn Leu Gly Gln Val Arg Gln
195 200 205

Phe Cys Thr Lys Ile Ala Trp Ile Glu Gly Gly Lys Leu Lys Asp Tyr
210 215 220

Gly Glu Leu Asp Asp Val Leu Pro Lys Tyr Glu Ala Phe Leu Asn Asp
225 230 235 240

Phe Lys Lys Lys Ser Lys Ala Glu Gln Lys Glu Phe Arg Asn Lys Leu
245 250 255

Asp Glu Ser Arg Phe Val Ile Lys
260

<210> 45

<211> 738

<212> DNA

<213> Staphylococcus aureus

<400> 45

ataaggtgaa gacacataaa acaatatatc ttagtaagca tgcaacactc ttttttgttt 60
attcataaca acaaaaaaga attaaaggag gagtcttatt atggctcgat tcagaggttc 120
aaactggaaa aaatctcgtc gtttaggtat ctctttaagc ggtactggta aagaattaga 180
aaaacgtcct tacgcaccag gacaacatgg tccaaaccaa cgtaaaaaat tatcagaata 240
tggtttacaa ttacgtgaaa aacaaaaatt acgttactta tatggaatga ctgaaagaca 300
attccgtaac acatttgaca tcgctggtaa aaaattcggg gtacacgggtg aaaacttcat 360
gatcttatta gcaagtcggt tagacgctgt tgtttattca ttaggttag ctgctactcg 420
tcgtcaagca cgtcaattag ttaaccacgg tcatatctta gtagatggtg aacgtgttga 480
tattccatct tattctgtta aacctgggtc aacaatttca gttcgtgaaa aatctcaaaa 540
attaaacatc atcgttgaat cagttgaaat caacaatttc gtacctgagt acttaaactt 600
tgatgctgac agcttaactg gtactttcgt acgtttacca gaacgtagcg aattacctgc 660
tgaaattaac gaacaattaa tccgttgagt actactcaag ataatacggg caataccaac 720
accacaatt gtgggtgt 738

<210> 46

<211> 195

<212> PRT

<213> Staphylococcus aureus

<400> 46

Met Ala Arg Phe Arg Gly Ser Asn Trp Lys Lys Ser Arg Arg Leu Gly
1 5 10 15

Ile Ser Leu Ser Gly Thr Gly Lys Glu Leu Glu Lys Arg Pro Tyr Ala
20 25 30

Pro Gly Gln His Gly Pro Asn Gln Arg Lys Lys Leu Ser Glu Tyr Gly
35 40 45

Leu Gln Leu Arg Glu Lys Gln Lys Leu Arg Tyr Leu Tyr Gly Met Thr

<210> 47
<211> 980
<212> DNA
<213> Staphylococcus aureus

```
<210> 48
<211> 258
<212> PRT
<213> Staphylococcus aureus
```

<400> 48
Met Met Ser Leu Ile Asp Ile Gln Asn Leu Thr Ile Lys Asn Thr Ser

1 5 43 10 15
 Glu Lys Ser Leu Ile Lys Gly Ile Asp Leu Lys Ile Phe Ser Gln Gln
 20 25 30
 Ile Asn Ala Leu Ile Gly Glu Ser Gly Ala Gly Lys Ser Leu Ile Ala
 35 40 45
 Lys Ala Leu Leu Glu Tyr Leu Pro Phe Asp Leu Ser Cys Thr Tyr Asp
 50 55 60
 Ser Tyr Gln Phe Asp Gly Glu Asn Val Ser Arg Leu Ser Gln Tyr Tyr
 65 70 75 80
 Gly His Thr Ile Gly Tyr Ile Ser Gln Asn Tyr Ala Glu Ser Phe Asn
 85 90 95
 Asp His Thr Lys Leu Gly Lys Gln Leu Thr Ala Ile Tyr Arg Lys His
 100 105 110
 Tyr Lys Gly Ser Lys Glu Glu Ala Leu Ser Lys Val Asp Lys Ala Leu
 115 120 125
 Ser Trp Val Asn Leu Gln Ser Lys Asp Ile Leu Asn Lys Tyr Ser Phe
 130 135 140
 Gln Leu Ser Gly Gly Gln Leu Glu Arg Val Tyr Ile Ala Ser Val Leu
 145 150 155 160
 Met Leu Glu Pro Lys Leu Ile Ile Ala Asp Glu Pro Val Ala Ser Leu
 165 170 175
 Asp Ala Leu Asn Gly Asn Gln Val Met Asp Leu Leu Gln His Ile Val
 180 185 190
 Leu Glu His Gly Gln Thr Leu Phe Ile Ile Thr His Asn Leu Ser His
 195 200 205
 Val Leu Lys Tyr Cys Gln Tyr Ile Tyr Val Leu Lys Glu Gly Gln Ile
 210 215 220
 Ile Glu Arg Gly Asn Ile Asn His Phe Lys Tyr Glu His Leu His Pro
 225 230 235 240
 Tyr Thr Glu Arg Leu Ile Lys Tyr Arg Thr Gln Leu Lys Arg Asp Tyr
 245 250 255
 Tyr Asp

<210> 49

<211> 760

<212> DNA

<213> Staphylococcus aureus

<400> 49

gatgatattt taattacaga aaatggttgt caagtcttta cttaatgcac aaaagacctt 60
 atagttttta cataagcgtg taaatgagg aggaaactga atgatttcgg ttaatgattt 120
 taaaacaggt ttaacaattt ctgttgataa cgctatttgg aaagttatag acttccaaca 180
 tgtaaagcct ggtaaagggt cagcattcgt tcgttcaaaa ttacgtaatt taagaactgg 240

44

```

tgcaattcaa gagaaaacgt ttagagctgg tgaaaaagtt gaaccagcaa tgattgaaaa 300
tcgtcgcatg caatatttat atgctgacgg rgataatcat gtatttatgg ataagaaaag 360
ctttgaacaa acagaacttt caagtgatta cttaaaagaa gaattgaatt acttaaaaga 420
aggtatggaa gtacaaattc aaacatacga aggtgaaact atcgggtgttg aattacctaa 480
aactgttgaa ttaacagtaa ctgaaacaga acctggtatt aaagggtgata ctgcaactgg 540
tgccactaaa tcggcaactg ttgaaactgg ttatacatta aatgtacctt tatttgtaaa 600
cgaaggtgac gttttaatta tcaacactgg tgatggaagc tacatttcaa gaggataatc 660
tctaatttgt taacaaatag cttgtattca ctatactgat ttaacgtaag anattctaaa 720
taagtctcat aaagctattg cctaaaatga ttataggtta 760

```

<210> 50

<211> 185

<212> PRT

<213> *Staphylococcus aureus*

<400> 50

```

Met Ile Ser Val Asn Asp Phe Lys Thr Gly Leu Thr Ile Ser Val Asp
  1                      5                      10                      15

```

```

Asn Ala Ile Trp Lys Val Ile Asp Phe Gln His Val Lys Pro Gly Lys
      20                      25                      30

```

```

Gly Ser Ala Phe Val Arg Ser Lys Leu Arg Asn Leu Arg Thr Gly Ala
      35                      40                      45

```

```

Ile Gln Glu Lys Thr Phe Arg Ala Gly Glu Lys Val Glu Pro Ala Met
      50                      55                      60

```

```

Ile Glu Asn Arg Arg Met Gln Tyr Leu Tyr Ala Asp Gly Asp Asn His
      65                      70                      75                      80

```

```

Val Phe Met Asp Asn Glu Ser Phe Glu Gln Thr Glu Leu Ser Ser Asp
      85                      90                      95

```

```

Tyr Leu Lys Glu Glu Leu Asn Tyr Leu Lys Glu Gly Met Glu Val Gln
      100                      105                      110

```

```

Ile Gln Thr Tyr Glu Gly Glu Thr Ile Gly Val Glu Leu Pro Lys Thr
      115                      120                      125

```

```

Val Glu Leu Thr Val Thr Glu Thr Glu Pro Gly Ile Lys Gly Asp Thr
      130                      135                      140

```

```

Ala Thr Gly Ala Thr Lys Ser Ala Thr Val Glu Thr Gly Tyr Thr Leu
      145                      150                      155                      160

```

```

Asn Val Pro Leu Phe Val Asn Glu Gly Asp Val Leu Ile Ile Asn Thr
      165                      170                      175

```

```

Gly Asp Gly Ser Tyr Ile Ser Arg Gly
      180                      185

```

<210> 51

<211> 9326

<212> DNA

<213> *Staphylococcus aureus*

<400> 51


```

ttaggatgta agaaagtcc agtgcaagaa atccatgaaa cacaatatcc aattagtaca 60
tggcaacata aagttccatt tgggtgtgtg tgggaaacgt tacaacaaga acatcgcttg 120

```

ccatggacta ctgagacaag acaagaagcg ccatattatta caatgtgtca tgggtgataca 180
 gaacaatatt tgtatacaaaa agatttaggc gaagcacatt ttcaagtatg ggaaaagggtt 240
 gtcgcaagtt atagtgggtg ttgttctgta gagagaattg cacaaggtag atatccttgt 300
 ctttctcaac aagatgtact catgaagtat cagccattga gttataagga aattgaagcg 360
 gttgttcata aaggggaaac tgtgccagca ggtgtgacac gctttaatat ttcaggacga 420
 tgtcttaatc ttcaagtacc actggcatta cttaacaag atgatgatgt tgaacaatgc 480
 gcaattggaa gcagttttta gcagataagt ttgccaatat gagatgctat actgaaaaag 540
 tatacttggg ggagcaatag ttttactgtg atgttgaggg aaatatgatg atttagcgta 600
 ttgatagcga aaatataata aaacaatata gtgtggagaa cttttgatat ttataaata 660
 ttgaagtctt ccatttttgt attttgcata taaaaattaa ataaaaataag gtatattaag 720
 gtaaagtata aatttttaaat aaatggggaa tgagtatgag ctcaattata ggaaaaatag 780
 caatttggat aggcacgtga gctcaaatat atttttagtgt cgttttttgtt aggatgatat 840
 ctattaatat tgctggagga tctgattacg aaacaatttt tttatttagga ttaatatagg 900
 ctcttttcac tgttttacca accatcttta ctgcgattta tatggaaagt tactctgtaa 960
 tcggaggtgc acttttttatt gttttctgta ttattgcact gtgtttatat aatttctttt 1020
 cgtcaatttt atggctgatt ggtgggtatt tgcgtatttg gaataaatac tcaaaagatg 1080
 aatcgacaga cgaaaatgaa aaagttgata ttgaaagtac agagaatcaa tttgaatcta 1140
 aagataaaat cactaaagaa taaagagaat atttaaggta aagtataaat tttaaataaa 1200
 tggggaatag acatggaaaa aaatgtagaa aaatcattca taaagatagg tttatatttt 1260
 caaatagctt atatatgtact catggctata actttatgtg ggtttgtaat ttgctatgga 1320
 ctaattttcg gcccttttcta tttattatca ggtagcagag ctgattattt aatagtaaca 1380
 atagtttatat cggcaataat ttctatatatt gtaattatata tttcaatcgt acctgtcatt 1440
 gtattggcat ctgacttatt taaagaaagg atttcaaaaag gtgtcatatt aattgtattg 1500
 gctattatcg ctttagtatt atgcaacttt gtatctgcaa tactctggtt tgtttcagcc 1560
 atatctattt taggtagaaa aaaattagta gctgcagcag atactaccac tattcaaaaa 1620
 agtaaaggga acgcaaatca agcatcacat aaagacacgt gtaaaaaagga acttgatagt 1680
 caagacatga ttgaacatcc tgagggttaa aatcccacga ctaaaaacct tgaaggattt 1740
 aacgaagaaa tacaataaga tgaagctaca actaaagttg tcagtgataa caccggaaccg 1800
 cctattgaat caaaagacca tgtctcgaaa aaagattgat gacaaactaa tcgagagact 1860
 taaaaaaata atattcaaca taagaacttt taaaacgaca tttaaacgca ttgccaatca 1920
 ctaatggtag tgcgtttaac tataccttaa atatctgaat attttgttaa atggagctac 1980
 ctttggtgta ctattcaaat gaagaggagt aaaatgtaat taaaggaaaag aaatttgagg 2040
 agtgatcttt atgacaaaaca acaaagtagc attagtaact ggcggagcac aagggtattg 2100
 ttttaaaatt gcagaacggt tagtggaaga tgggttcaaa gttagcagttg ttgatttcaa 2160
 tgaagaaggg gcaaaagcag ctgcacttaa attatcaagt gatggtacaa aagctattgc 2220
 tatcaaagca gatgtatcaa accgtgatga tgtatttaac gcataagaca aactgccgag 2280
 caatttggcg atttccatgt catgggtaac aatgccggcc ttggaccac aacaccaatc 2340
 gatacaatta ctgaagaaca gtttaaaaca gtatatggcg tgaacgttgc aggtgtgcta 2400
 tggggtattc aagccgcaca tgaacaattt aaaaaattca atcatggcgg taaaattatc 2460
 aatgcaacat ctcaagcagg cgttgagggt aaccagcgt tgtctttata ttgcagtaca 2520
 aaatttcgag tgcgaggtt aacacaagta gccgcacaag atttagcgtc tgaaggattt 2580
 actgtgaatg cattcgcacc tgggtatcgtt caaacaccaa tgatggaaag tatcgcagt 2640
 gcaacagccg aagaagcagg taaacctgaa gcatggggtt ggggaacaatt tacaagtcag 2700
 attgcttttg gcagagtttc tcaaccagaa gatgtttcaa atgtagtgag cttcttagct 2760
 ggtaaagact ctgattacat tactggacaa acaattattg tagatggttg tatgagattc 2820
 cgtaataat catccactaa tgataaataa atccttattg ttaagtttaa tcacttagca 2880
 gtaaggattt tttagtgcac ttagaaggga gtgtattggt agaaaattaa taagcgaagt 2940
 tcttaagtga gttatgatgt cacagtctaa tgcattcagtt gaaagcatta ttagtattaa 3000
 cacaccaag atattataaa acatcacaaa aacaccacta tctaatttat ctcaataaaa 3060
 attcacaag ttatctcatt ttatttttat aaataaaaaa tatcgataaa aagcttaca 3120
 tactttatgt ttttatgata tttttttaat gtataaatga ggtggaagat ttggaagag 3180
 ttttgataac tgggtgggct ggttttattg ggtcgcatt agtagatgat ttacaacaag 3240
 attatgatgt ttatgttcta gataactata gaacaggtaa acgagaaaat attaaagtt 3300
 tggctgacga tcatgtgttt gaattagata ttctgtaata tgatgcagtt gaacaaatca 3360
 tgaagacata tcaatttgat tatgttatc atttagcagc attagttagt gttgctgagt 3420
 cggttgagaa acctatctta tctcaagaaa taaacgtcgt agcaacatta agattgttag 3480
 aaatcattaa aaaatataat aatcatataa aacgttttat ctttgcttcg tcagcagctg 3540
 tttatgggtga tcttctgat ttgcctaaaa gtgatcaatc attaatctta ccattatcag 3600
 catatgcaat agataaatat tacggcgaac aaattattgt tcgttatata 3660
 acataccaac agcgggtgtt aaatttttta atgtatttgg gccaaagacag gatcctaagt 3720
 cacaatatc aggtgtgatt tcaaagatgt tcgattcatt tgagcataac aagccattta 3780

catttttttg	tgacggactg	caaaactagag	attttgtata	tgtatatgat	gttgttcaat	3840
ctgtacgctt	aattatggaa	cacaaagatg	caattggaca	cggttataac	attggtacag	3900
gcacttttac	taatttatta	gagggtttatc	gtattatttg	tgaattatat	ggaaaatcag	3960
tcgagcatga	atttaaagaa	gcacgaaaag	gagatattaa	gcattcttat	gcagatattt	4020
ctaacttaaa	ggcattagga	tttgttccta	aatatacagt	agaaacaggt	ttaaaggatt	4080
actttaattt	tgaggtagat	aatattgaag	aagttacagc	taaagaagtg	gaaatgtcgt	4140
gaaaatgaca	ttgaagctgt	ccataataat	aagggttatg	cctatcaaag	aaaattagac	4200
aaactagaag	aagtggagaaa	aagctattac	ccaattaaac	gtgcgattga	cttaatttta	4260
agcattgttt	tattattttt	aactttaccg	attatgggta	tattcgccat	tgctatcgte	4320
atagattcgc	caggaaaccc	tatttatagt	cagggttagag	ttgggaagat	gggtaaatta	4380
attaaaatat	acaaattacg	ttcgatgtgc	aaaaacgcag	agaaaaacgg	tgcgcaatgg	4440
gctgataaag	atgatgatcg	tataacaaat	gtcgggaagt	ttattcgtaa	aacacgcatt	4500
gatgaattac	cacaactaat	taatgttgtt	aaaggggaaa	tgagttttat	tggaaccacg	4560
cggaaacgtc	cgaatttgtt	agaatttatt	agttcagaag	tgatagggtt	cgagcaaaga	4620
tgtcttggtt	caccaggggt	aacaggactt	gcgcaaatc	aagggtggata	tgacttaaca	4680
ccgcaacaaa	aactgaaata	tgacatgaaa	tatatacata	aaggtagtgt	aatgatggaa	4740
ctatatatat	caattagaac	attgatgggt	gttattacag	gggaaggctc	aaggtagtct	4800
taatttactt	aataagttca	aataaaaagt	atatttttaa	gattgtgacc	aattgttaca	4860
gtataacgag	gaatcccttg	agacagtatc	aatgggcatt	aagaaatatg	tgccatcatt	4920
gatttgcata	gctataaata	ctatttcatt	gatgagatag	ccatgttaag	aaattgaaag	4980
tatagcatga	aaggggtttg	taacagttga	aaattatata	ttgtattact	aaagcagaca	5040
atgggtgtgc	acaaacacat	ctcattcaac	tcgccaacca	tttttgcgta	cacaatgatg	5100
tttatgtcat	tgtaggcaat	catggacca	tgattgaaca	actagatgca	agagttaatg	5160
taattattat	cgaacattta	gtaggtccaa	ttgacttta	acaagatatt	ttagctgtca	5220
aagtgttagc	acagttattc	tcgaaaatta	aacctgatgt	tatccattta	cattcttcca	5280
aagctggaac	ggtcggacga	attgcgaagt	tcatttcgaa	atcgaaagac	acacgtatag	5340
tttttactgc	accatggatg	gcttttacag	aggggtgtta	accagctaaa	aaatttctat	5400
atttaggtat	cgaaaaatta	atgtcactta	ttacagatag	cattatttgt	gtttcagatt	5460
tcgataaaca	gttagcggtt	aaatatcgat	ttaatcgatt	gaaattaaac	acaatacata	5520
atgggtattgc	agatgttccc	gctgttaagc	aaacgctaaa	aagccaatca	cataacaata	5580
ttggcgaagt	agttgggaatg	ttgcctaata	aacaagattt	acagattaat	gccccgacaa	5640
agcatcaatt	tgttatgatt	gcaagatttg	cttatccaaa	attgccacaa	aatctaactg	5700
cggcaataga	gatattgaaa	ttacataaca	gtaatcatgc	gcattttaca	tttataggcg	5760
atggacctac	attaaatgat	tgtagcaaac	aagttgtaca	agctgggtta	gaaaatgatg	5820
tcacattttt	gggcaatgtc	attaatgcga	gtcatttatt	atcacaatac	gatacgttta	5880
ttttaataag	taagcatgaa	ggtttgccaa	ttagcattat	agaagctatg	gctacagggt	5940
tgctgtttat	agccagtcac	gttggcggtt	tttcagaatt	agtagctgat	aatgggtatat	6000
gtatgatgaa	caaccaaccc	gaaactattg	ctaaagtcct	ggaaaaatat	ttaatagaca	6060
gtgattacat	caaaatgagt	aatcaatcta	gaaaacgtta	tttagaatgt	tttactgagg	6120
agaaaatgat	taaagaagtg	gaagacgttt	ataattgaaa	atcaacacaa	tagtaaatta	6180
ctaacattgt	tacttatcgg	tttagcggtt	ttatttcagc	aatcttcggt	tattgccggt	6240
gtgaatgttt	ctatagctga	ctttatcaca	ttactaatat	tagttttatt	actgtttttc	6300
gctaaccatt	tattaaaggc	aatcattttt	ttacagtttt	tcattatttt	gtatacatat	6360
cgtatgatta	ttacgctttg	tttgctattt	tttgatgatt	tgatattttat	tacgggttaag	6420
gaagttcttg	catctacagt	taaatatgca	tttgtagtca	tttattttcta	tttagggatg	6480
atcatcttta	agtttaggtta	tagcaaaaaa	gtgatcggtt	cctcttatat	tataagcagt	6540
gtcactatag	gtctattttg	tattatagct	ggtttgaaca	agtccccctt	actaatgaaa	6600
ttgtttatatt	ttgatgaaat	acgttcaaaa	ggattaatga	atgaccctaa	ctatttcgcg	6660
atgacacaga	ttattacatt	ggtacttgct	tacaagtata	ttcataatta	catattcaag	6720
gtccttgcat	gtgggtatttt	gctatgggtc	ttactacaa	cgggggtctaa	gactgcgttt	6780
atcatattaa	tcgtcttagc	catttatctt	tttattaaaa	agttattttag	tagaaatgcg	6840
gtaagtgttg	tgagtatgtc	agtgattatg	ctgatattac	tttgtttttac	cttttataat	6900
atcaactact	atttattcca	attaagcgac	cttgatgcct	taccgtcatt	agatcgaatg	6960
gcgtctattt	ttgaagagg	ctttgcatca	tttaagtata	gtgggtctga	gcgaagtgtt	7020
gtatggataa	atgccatttc	agtaattaaa	tatacactag	gttttggtgt	cggatttagtg	7080
gattatgtac	atattggctc	gcaaattaat	gggtattttac	ttgttgccca	taatacatat	7140
ttgcagatct	ttgcggaatg	gggcatttta	ttcgggtgcat	tatttatcat	atttatgctt	7200
tattttactgt	ttgaattatt	tagatttaac	atttctggga	aaaatgtaac	agcaattgtt	7260
gtaatgttga	cgatgctgat	ttacttttta	acagtatcat	ttataaactc	aagatatgtc	7320
gcttttattt	taggaattat	cgtctttatt	gttcaatatg	aaaagatgga	aagggatcgt	7380
aatgaagagt	gattcactaa	aagaaaaatat	tatttatcaa	gggctatacc	aattgattag	7440



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/31, 15/66, 15/63, 1/21, C07K 14/31		A3	(11) International Publication Number: WO 00/12678 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19726 (22) International Filing Date: 31 August 1999 (31.08.99) (30) Priority Data: 60/098,964 1 September 1998 (01.09.98) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BAILEY, Camella, C. [US/US]; 1753 Kilbourne Place NW, Washington, DC 20010 (US). CHOI, Gil, H. [CN/US]; 11429 Potomac Oaks Drive, Rockville, MD 20850 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW. ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. (88) Date of publication of the international search report: 15 June 2000 (15.06.00)	
(54) Title: STAPHYLOCOCCUS AUREUS GENES AND POLYPEPTIDES			
(57) Abstract <p>The present invention relates to novel genes from <i>S. aureus</i> and the polypeptides they encode. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of <i>S. aureus</i> polypeptide activity. The invention additionally relates to diagnostic methods for detecting <i>Staphylococcus</i> nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by <i>Staphylococcus</i>.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/19726

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12N 15/31, 15/66, 15/63, 1/21; C07K 14/31 US CL : 536/23.7; 435/91.41, 320.1, 252.3, 69.1; 530/350 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.7; 435/91.41, 320.1, 252.3; 69.1; 530/350 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Genbank, Swissprot, PIR60, SPTREMBL9 search terms: sequences corresponding to SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	EP 0 843 016 A2 (SMITHKLINE BEECHAM CORPORATION) 20 May 1998, page 23 (relevant to instant SEQ ID NO:16).	1-11												
X	EP 0 811 696 A2 (SMITHKINE BEECHAM CORPORATION) 10 December 1997, page 8 (relevant to instant SEQ ID NO: 12).	1-11												
X	EP 0 826 774 A2 (SMITHKINE BEECHAM CORPORATION) 14 March 1998, Figure 1 (relevant to instant SEQ ID NO: 6).	1-11												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td>* Special categories of cited documents:</td><td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>"A" document defining the general state of the art which is not considered to be of particular relevance</td><td>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>"B" earlier document published on or after the international filing date</td><td>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>"A" document member of the same patent family</td></tr><tr><td>"O" document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>"P" document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"B" earlier document published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means		"P" document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
"B" earlier document published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family													
"O" document referring to an oral disclosure, use, exhibition or other means														
"P" document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 10 FEBRUARY 2000		Date of mailing of the international search report 06 APR 2000												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>John S. Brusca</i> JOHN S. BRUSCA Telephone No. (703) 308-0196												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/19726

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

☐
☐

- The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19726

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-11, drawn to Staphylococcal nucleic acids, proteins encoded by the nucleic acids, vectors comprising the nucleic acids, methods of making the vectors, cells comprising the vectors, and methods of expressing the nucleic acids in transformed cells.

Group II, claim(s) 12 and 13, drawn to an antibody and a cell producing an antibody, both antibodies being specific for the protein encoded by the nucleic acids of Group I.

Group III, claim(s) 16, drawn to a vaccine comprising a protein encoded by the nucleic acids of Group I.

Group IV, claim(s) 17, drawn to a method of preventing an infection by administration of a protein encoded by the nucleic acids of Group I.

Group V, claim(s) 18, drawn to a Staphylococcal nucleic acid assay using the nucleic acids of Group I as probes.

Group VI, claim(s) 19, drawn to an assay of antibodies specific for Staphylococcal proteins using proteins encoded by the nucleic acids of Group I.

Group VII, claim 20, drawn to an assay of the Staphylococcal proteins of Group I using antibodies specific for the proteins of Group I.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups II-VII constitute the third product, and the second through fifth methods of use of the products of Group I. PCT Rule 13.1 and Annex B do not show that unity of invention exists between a first and second product or method of use.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

The amino acid sequences of the polypeptides shown in Table 1.

The claims are deemed to correspond to the species listed above in the following manner:

All claims of each Group discussed above are drawn to the species indicated above.

The following claims are generic: Claims 1-20

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each species is drawn to a different amino acid sequence, and to nucleic acids encoding different amino acid sequences. There is no disclosed relationship between the sequences of each individual species disclosed in Table 1.

Restriction to a single species has been waived sua sponte and the Applicants are permitted to have ten species examined without payment of additional fees. The Applicant's representative Kenley Hoover elected telephonically on 1/27/00 to have the sequences corresponding to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 examined.

